{"infobox":{"dc_creator":"WooScraper_v1","dc_date_year":2022,"dc_description":"De minister van Volksgezondheid, Welzijn en Sport heeft op 21 december 2022 een besluit genomen op verzoeken in het kader van de Wet open overheid. Het besluit betreft openbaarmaking van documenten die betrekking hebben op informatie aangaande Vaccinaties en Medicatie over de periode februari 2021.","dc_identifier":"nl.mnre1025.2i.2022.152","dc_publisher":"mnre1025","dc_publisher_name":"Ministerie Van Volksgezondheid, Welzijn En Sport","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo","dc_title":"Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode februari 2021 |             OpenVWS","dc_type":"2i","dc_type_description":"2i - Woo-verzoek en -besluit","foi_decisionDate":"2022-12-21","foi_extraMetadata":{},"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_files":[{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108806","dc_title":"19-02-2021 1825509-218232 DL969769.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108010","dc_title":"MeldpuntTekorten2020_def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108002","dc_title":"Letterlijke tekst persconferentie minister-president Rutte en minister De Jonge (20 januari 2021) _ Mediatekst _ Rijksoverheid.nl bijlage 3.html","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107998","dc_title":"GRT-Regering-VWS-35684 2e incidentele suppletoire begroting.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118706","dc_title":"GMT-216611.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107994","dc_title":"GGD GHOR.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108990","dc_title":"20-12-07 VSO houtskoolschets acute zorg 29247 nr. 325.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1119429","dc_title":"PDC19-218074 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108970","dc_title":"2005 Par  oa SPP.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107992","dc_title":"Gezondheidsraad toezending advies COVID-19.1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118335","dc_title":"lancet psychiatry 2021, European COVID-19 exit strategy for people withsevere mental.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107976","dc_title":"brief resistente schimmels toezegging PvdD def-wijzigingen bijhouden.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107975","dc_title":"Brief aan Parlement TK 2021-02-02 10_55_53.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116827","dc_title":"FW: Indicatie COVID-19 vaccinatie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120334","dc_title":"28th WHO Regulatory Update on COVID-19_05Feb2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107949","dc_title":"Beantwoording Kamervraag 2021-02-08 13_36_27ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107947","dc_title":"Beantwoording Kamervraag 2021-02-08 13_32_10ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108788","dc_title":"2-3-2021 1829285-218543 DL970355.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107943","dc_title":"Beantwoording Kamervraag 2021-02-01 14_32_47ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120369","dc_title":"Aantekeningen 3-2.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108067","dc_title":"WJZ-217427 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108065","dc_title":"Toezending advies Ethische en juridische afwegingen COVID-19-vaccinatie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108063","dc_title":"Verzoek van SXM van 6 januari 2021ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108061","dc_title":"Toezending advies COVID-19-vaccinatie AstraZeneca-vaccin voor de CAS-landen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109230","dc_title":"RE: Bankgaranties en schenkingsovereenkomsten","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1295017","dc_title":"NoteToSFGCtte vote on vaccines.docx.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1295018","dc_title":"Vaccines implementing regulation.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135405","dc_title":"LZ-218701.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121363","dc_title":"20210204 Werkwijze uitnodigen 80-89 jarigen_v3.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134387","dc_title":"Kamervragen datalek GGD_n PDC19-217880.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107868","dc_title":"0000045A.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161158","dc_title":"9.Europol.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117367","dc_title":"flankerend beleid tbv Catshuis 7-2-2021 v4.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117551","dc_title":"EP resolutie impact covid19 op Jeugd en Sportsector.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117600","dc_title":"200205 Nieuwsbericht CONTEST onderzoek DEF.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132531","dc_title":"VWS-201231-001 029 EN.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118021","dc_title":"Spread of Canine Influenza A(H3N2) Virus, United States.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108415","dc_title":"Beantwoording Kamervraag 2021-02-25 8_24_48ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108453","dc_title":"Brief aan Parlement EK 2021-02-19 13_04_00ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127146","dc_title":"RE: N.a.v. nieuwsbericht Per Saldo","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127312","dc_title":"PDC19-217880.docx_62797b81-1b2e-4b45-aa3b-3217130a78ee.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127414","dc_title":"RE: PDC19: Reactie advies inzet AstraZeneca-vaccin tegen COVID-19","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108446","dc_title":"Brief aan Parlement TK 2021-02-18 19_09_10ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108417","dc_title":"Beantwoording commissiebrief 2021-02-18 15_37_49ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129237","dc_title":"20201210 Artikel Polack et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129241","dc_title":"2021.01.29.21250653v1.full-1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129852","dc_title":"PDC19-218150 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126106","dc_title":"RE: Discussie over vaccinatie overig zorgverlenend personeelhuisartsenzorg","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108402","dc_title":"Beantwoording commissiebrief 2021-02-18 14_55_51ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131041","dc_title":"def bericht Jan Fransoo en team adviseren RIVM NL + Engl.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131397","dc_title":"Serena frijters - VK 5-2-2021.PDF.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131527","dc_title":"FW: offerte ggd","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131637","dc_title":"stcrt-2020-66909 regeling dagbesteding.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131808","dc_title":"This_Week.full.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108382","dc_title":"218150 TK - getekende brief.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108344","dc_title":"0000065A.PDF","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107901","dc_title":"2021-02-15 Beantwoording schriftelijk overleg over het ijkpunt bestaanszekerheid Caribisch Nederland_SCHOON_gele arceringen VWS_aanpassingen na opmerkingen stas.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107933","dc_title":"Beantwoording commissiebrief 2021-02-03 16_18_43ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108762","dc_title":"1821950-217899 voordracht.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107928","dc_title":"217220 - getekende brief.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122934","dc_title":"Update_Leidraad_PBM_in_de_poliklinische_setting feb2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108756","dc_title":"1816949-217427 nader rapport.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128226","dc_title":"RE: Veiligheidsberaad","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107922","dc_title":"217143 2e Opmerkingen SVWS.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107918","dc_title":"216316 - Akkoord Min MZS.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1295009","dc_title":"POST-SUBMISSION_vaccine-DCv2-2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107895","dc_title":"1821950-217899-WJZ Nota van toelichting.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107894","dc_title":"1823124-217921-GMT Ministerieel besluit aanwijzen bevoegde autoriteit voor uitvoervergunning vaccins 03022021rc.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126940","dc_title":"Logistiek en planning van huisartsenkanaal","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125095","dc_title":"Kamerbrief LNV april 2020 over covid19 en mogelijke relatie met dieren.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125349","dc_title":"mail vaccin.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108527","dc_title":"02-03-2021 18712443-217083 DL970484.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108496","dc_title":"MCEV MJenV 3208768 Aanbieding midterm review Nationale Veiligheid Strategie (NVS).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125796","dc_title":"mantelzorg NL Blijvende+bron+van+zorg.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109686","dc_title":"COVID-19-vaccinatie+AstraZeneca-vaccin_20210204.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142949","dc_title":"4. Memo stuurgroep Audit.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150511","dc_title":"30547.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110627","dc_title":"2021 02 25 Trimbos adviezen op verhogen mentale gezondheid.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109711","dc_title":"06 Handreiking openbare manifestaties (versie voorjaar 2021).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130034","dc_title":"Nature 590 pp 371-372.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108186","dc_title":"Beantwoording Kamervraag het bericht Horizons Tepezzasupply dwindles as manufacturer Catalent pivots to Warp Speed Vaccinesocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109702","dc_title":"02082021_IDT_Vaccine Agreement_FINAL_100221.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108178","dc_title":"Basis op Orde - Verbeterplan DOTT 210215 1.0b.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153341","dc_title":"Selectie_2021-02-26.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108209","dc_title":"Brief aan Parlement TK 2021-02-12 10_18_03.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163015","dc_title":"RE: beschikbare testcapaciteit","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109680","dc_title":"012633_Uitn Zorgmedewerkers flowchart_V4_TG.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109673","dc_title":"Aanbevelingen voor een goede infectiepreventie in deverpleeghuiszorg.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109669","dc_title":"210203 Verdiepende analyse na infectiepreventiebezoeken aanverpleeghuizenHS.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165774","dc_title":"RE: Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108164","dc_title":"29 515Aanpak regeldruk en administratieve lasten.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109664","dc_title":"01-02-2021 Notaoverleg Preventie medische leefstijl su\ufffdcide en infectiepreventie VGP.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109662","dc_title":"20210202 Werkwijze uitnodigen 80-89 jarigen_v2.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112827","dc_title":"2021Z02546.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113337","dc_title":"Achtergrondinformatie digitaal bij kamervraag huisartsen niet onder deindruk.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165058","dc_title":"RE: vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149448","dc_title":".eml","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113193","dc_title":"flankerend beleid 7-2-2021 MRA.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113166","dc_title":"Brief bijwerkingen.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113010","dc_title":"210209 Subsidieregeling coronabanen in de zorg_Laatste wijzigingen SCHOON.docx_b4c781d3-ca87-4705-983c-f04a3b2cb0db.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145626","dc_title":"RE: Paar dingetjes","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112892","dc_title":"210119 - motie landelijke populatietest reactie laatste versie.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164897","dc_title":"Reg. Letter.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108253","dc_title":"Neusspray tegendepressie oude wijn in nieuwe verpakking' oude wijn in nieuwe verpakking'ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112658","dc_title":"20210201_nza_rapport_landelijk_v26_tussenrap_verwijzingen_zorgbeeld_feb_def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114996","dc_title":"Tables_Efficacy_draft.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108248","dc_title":"Ministerieel besluit 2021-02-16 11_05_50.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108235","dc_title":"kamerbrief-inzake-kabinetsappreciatie-commissie-mededeling-pakket-aanvullende-maatregelen-covid-19-en-tweede-raadsaanbeveling-gecoordineerde-aanpak.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108210","dc_title":"Brief aan Parlement TK 2021-02-15 13_31_42ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112144","dc_title":"2021 02 15 Kamervragen CDA Betrokkenheid Defensie bij bestrijdingpandemie.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111936","dc_title":"Beantwoording commissiebrief 2021-02-03 16_18_43.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108125","dc_title":"2021Z003263 Verzoek om een schriftelijke reactie te ontvangen op berichten over het (tegen de regels in) met voorrang vaccineren van personeel in zorginstellingen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109589","dc_title":"Factsheets VWS.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109575","dc_title":"Duiding Maatschappelijke impact COVID-19 nr. 20.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109488","dc_title":"3b. Bespreekpunten sheets maatregelen voor 'Catshuis'-bespreking.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109486","dc_title":"3c. Flankerend beleid.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109482","dc_title":"3a. Advies VWS na 99e OMT, deel 2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138358","dc_title":"Vertrouwen in coronabeleid op nieuw dieptepunt.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108306","dc_title":"00000559.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108127","dc_title":"2021Z03143 Verzoek om een overzicht te geven van de gewijzigde vaccinatiestrategie en een schriftelijke reactie op de uitzending van Nieuwsuur van 11 februari jl..pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109658","dc_title":"WJZ-217077 TK B.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108123","dc_title":"20210129 De Tien Punten_Openstelling Scholen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137489","dc_title":"Samenvatting ronde 9 WP3 voor beleidsrapportage.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136940","dc_title":"Voorgestelde plan om het domein Sociaal leven te heropenen.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124207","dc_title":"Re: Belevering Astra Zeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136576","dc_title":"RE: ontkrachten fabels vaccin en AZ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136568","dc_title":"FW: Vaccinatie communicatie Update -3","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108069","dc_title":"WJZ-217427 C.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165853","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109596","dc_title":"7. Brief steunpakket welzijn en leefstijl ivm COVID-19 v8 tbv overlegMVWS en SVWS.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165847","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108148","dc_title":"215875 - getekende brief.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122971","dc_title":"vaccinatie algoritme.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165848","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165849","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165851","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165852","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165855","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109660","dc_title":"WJZ-217077 EK A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165857","dc_title":"Update (social) media","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165876","dc_title":"AD Routekaart-1.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108300","dc_title":"Toelichting 2021-02-16 11_05_43.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6070","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161027","dc_title":"PEI minimum-criteria-for-rapid-sars-cov2-antigen-tests-01-12-2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1165316","dc_title":"RE: [RIJK] Verenigd Koninkrijk - Britten willen COVID consultatiesmet Den Haag","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162210","dc_title":"CoCo HERA Incubator CIE mededeling 19022021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162179","dc_title":"Press Release - New RESEMBID COVID-19 Resilience Response Facility.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162137","dc_title":"Defintieve kabinetsappreciatie VWS.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161973","dc_title":"RE: Ontvangst vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161950","dc_title":"Reflectie regiosessies 'Iedereen aan zet voor een gezondeleefstijl'.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161331","dc_title":"e-mag_Het_utrechtse_model_nov2020_def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6097","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161311","dc_title":"RE: repack details AZ-Moderna en hulpmiddelen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6095","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161297","dc_title":"2021.02.21.21252153v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6087","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161212","dc_title":"Werkinstructie 1956-1957_en_risicogroep definitief.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6082","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161137","dc_title":"OLAF.PDF","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6080","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161121","dc_title":"Lindner et al - comparison self testing vs professional testing - MedRxiv 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6077","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161079","dc_title":"Lindner et al - comparison self-collected AN swab vs professional NP swab - ERJ 2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164805","dc_title":"flowcharts 4 jan 12 jan 23 feb.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6068","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160993","dc_title":"RE: filmpje Cecile van Els over AstraZeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6064","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160884","dc_title":"Guidance_for_Vaccine_and_Pharmaceutical_Logistics_and_Distribution_Glo.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160774","dc_title":"an_het_lid_Segers_c.s._over_in_overleg_treden_met_landelijk_opererende_vrijwilligersorganisaties.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160599","dc_title":"FW: woordvoering export autorisatie vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1159257","dc_title":"FW: Export authorisation of vaccines","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160346","dc_title":"Bijlage Gepubliceerde lijst van de Wereld Douaneorganisatie; indelingen van medische voorzieningen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160030","dc_title":"Aantallen vaccinaties.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1160029","dc_title":"Kopie van 210202 Beschikbaar minus gevaccineerd versie 6 gebruikt voor Figuur 1 Kamerbrief vandaag (002).xlsx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1159685","dc_title":"FW: Overleg VWS: export verordening Covid-19 vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1159546","dc_title":"210226 PSC letter of 26 February (COVID-19 vaccines voting result).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1159495","dc_title":"210209_Cyprus SDM webstory_Crew changes solution.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1159473","dc_title":"20210216 COVID kosten ZJCN 2020 via FDC.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163645","dc_title":"RE: Let op! Deadline vervroegd: CPK-uitzetmail: Commentaar op SO ER>> deadline: vr 19 feb, 10:00 <<","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162826","dc_title":"Motie_van_het_lid_Azarkan_over_geen_coronavaccinatieplicht_.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162893","dc_title":"bijlage-1-advies-rivm-verkiezingen-en-covid-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162895","dc_title":"advies-rivm-verkiezingen-en-covid-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162903","dc_title":"kamerbrief-verkiezingen-met-inachtneming-van-covid-19 (2).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162908","dc_title":"kamerbrief-aanvullende-maatregelen-voor-de-tweede-kamerverkiezing-in-verband-met-covid-19 (2).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1162920","dc_title":"Factsheet+beschermingsmiddelen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163253","dc_title":"st05712-re01.en21.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163257","dc_title":"ST 5712 2021 REV 1.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163259","dc_title":"ST 5749 2021 INIT.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163430","dc_title":"Managementinformatie 12 2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163448","dc_title":"Safeguarding against falsified COVID-19 vaccines.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163469","dc_title":"Invitation letter 25-26 Feb. VTC Leaders.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163478","dc_title":"Letter Cssrs Johansson and Reynders Travel restrictions.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163589","dc_title":"RE: Input Ieder(in) voor coronadebat 4/2","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164634","dc_title":"Beleidsinformatiekaart-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163697","dc_title":"RE: MORGENMIDDAG van 13.15 tot 14.00 uur: overleg over flankerendbeleid ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163706","dc_title":"RE: N.a.v. nieuwsbericht Per Saldo","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163708","dc_title":"RE: N.a.v. nieuwsbericht Per Saldo","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1163711","dc_title":"RE: N.a.v. nieuwsbericht Per Saldo","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164292","dc_title":"RE: Vraag ANP over exporttoets EU","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164313","dc_title":"RE: Vraag VK ambassade over inspectie bij AstraZeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164361","dc_title":"RE: woordvoering export autorisatie vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164394","dc_title":"RE: ZJCN vervolgvragen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164553","dc_title":"vaccin gezant","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164581","dc_title":"Rapport Mensenrechtencoms RvE Protecting the Right to Health throughInclusive and Resilient Health Care for All.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.6513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1164598","dc_title":"Vraag VK ambassade over inspectie bij AstraZeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153376","dc_title":"SO ER - v2 - voor tas MP.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152849","dc_title":"Onderzoeksrapport Kantar - schattingsstudie desinfectiegebruik.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152901","dc_title":"Viral load COVID-19 and transmissability.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152923","dc_title":"012643_Griep_Covid_infographic_V1_TG.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5079","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151888","dc_title":"210226 resultaten 10e ronde gedragsonderzoek.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152965","dc_title":"Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function- A step toward personalised diabetes treatment.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152986","dc_title":"04_Handleiding huisartsenposten- COVID-19-vaccinatie kwetsbare patienten met Wlz-indicatie in instellingen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153019","dc_title":"210208_Werkinstructie COVID-19-vaccinatie HAP-BioNTechPfizer.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153039","dc_title":"20210205_summary_ERN_COVID-19_Vaccination_DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153128","dc_title":"temp kamervragen ellenmeet.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153248","dc_title":"RIVM Persupdate_20210222.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153310","dc_title":"kamerbrief-over-special-envoy-vaccins.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153329","dc_title":"Verslag stuurgroep logistiek - GGD RIVM.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153333","dc_title":"Selectie_2021-02-24.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153371","dc_title":"Selectie_2021-02-22.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152830","dc_title":"Risikogebiete_2021-02-19_en.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153384","dc_title":"Vaccineren Medewerkers Ziekenhuizen en Klinieken - 11 februari.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153394","dc_title":"Overzicht impact AZ - bewerking JWI.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153427","dc_title":"Stand_van_zaken_datalek_GGD.doc","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153437","dc_title":"Infographic RIVM vaccinatie tegen corona.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5063","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151833","dc_title":"Het testen van kinderen - vragen en antwoorden.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153439","dc_title":"Werkwijze vaccinatie zorgmedewerkers.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153445","dc_title":"Robotisering_ webversie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153547","dc_title":"Trouw20210220 Longarts Sander de Hosson Pak elkaar stevig vast en praatover de dood.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153612","dc_title":"20210212 Doelgroepbepaling voor op site _def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153642","dc_title":"1) 20210215 Leeswijzer en versieoverzicht.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5057","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151765","dc_title":"S0921_Factors_contributing_to_risk_of_SARS_18122020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153657","dc_title":"Verkiezingspaper CZ Menzis Zilveren Kruis feb 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153757","dc_title":"Duiding Weekupdate 8_v3.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152343","dc_title":"informatiememo bestuurscommissies OV en PGMZ 26-02-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152092","dc_title":"2021.02.14.21251712v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152161","dc_title":"Infographic 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152166","dc_title":"Infographic 3.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152168","dc_title":"Persbericht Intravacc  opent pilot productiefabriek en startontwikkeling grote nieuwe vaccin-productiefacililiteit_LM.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152175","dc_title":"Infographic 4.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152193","dc_title":"GMT-217601 TK A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152233","dc_title":"SARS-Cov_2 lineage B.1.526 [...]. CalTech. Feb 2021..pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152239","dc_title":"Helpt het vaccin bij mij Telegraaf 15022021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152001","dc_title":"TN294500 - SF03 Aankondiging van een gegunde opdracht20210111171045.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151998","dc_title":"TN294446 - SF03 Aankondiging van een gegunde opdracht20210111104856.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151995","dc_title":"TN299012 - SF03 Aankondiging van een gegunde opdracht20210129195303.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151991","dc_title":"TN300344 - SF03 Aankondiging van een gegunde opdracht 20210217124519(1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152247","dc_title":"Hagenaars et al. (2021) ESB te verschijnen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152259","dc_title":"Test vaccin bij kanker Telegraaf 15022021(1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153860","dc_title":"EMA SPC AstraZeneca 20210129.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152581","dc_title":"Motie_van_de_leden_Jetten_en_Segers - hoger onderwijs.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152595","dc_title":"Motie_van_de_leden_Van_der_Staaij_en_Sazias - bezoekregel.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5094","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151947","dc_title":"5_PEI_Listung_Stand_18_02_2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152602","dc_title":"Motie_van_de_leden_Pieter_Heerma_en_Dijkhoff - terrassen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5092","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151943","dc_title":"1_aktualisierte_Gebrauchsanweisung_SARS-CoV-2-RAGT_DE_markiert.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152605","dc_title":"Motie_van_de_leden_Van_der_Staaij_en_Stoffer - kopen op afspraak.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152617","dc_title":"Motie_van_het_lid_Klaver_c.s.-1- hoger onderwijs.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152621","dc_title":"Nieuwsbericht Vaccingezant.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152626","dc_title":"Motie_van_de_leden_Van_Kooten-Arissen_en_Kuzu - routekaart middelangetermijn.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152777","dc_title":"Openstaande kamervragen 25 februari 2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152778","dc_title":"Openstaande kamervragen 25 februari 2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152793","dc_title":"Testen kinderen 20210208.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1152819","dc_title":"20210208_NVK_covid 19 bij kinderen en adolescenten met een chronische ziekte of aandoening.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155867","dc_title":"BRBAfolder_01272021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157727","dc_title":"Antwoord en kamervragen daklozen febr 2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151436","dc_title":"RE: Passage in brieven aan ziekenhuizen over IC-opschaling envergoeding ZN ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157584","dc_title":"RE: e-learning astra zeneca vaccin","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157537","dc_title":"Improving_pandemic_preparedness.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157368","dc_title":"Brief aan Parlement TK 2021-02-19 13_04_00.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157363","dc_title":"210208 Werkinstructie COVID-19-vaccinatie HAP-BioNTechPfizer-def.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157307","dc_title":"Bijlage 3 Gegevens Transfer Overeenkomst tussen RIVM en Revalidatiecentrum.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154923","dc_title":"Deelname COVID-19 vaccinatie in Nederland_2021_02_16.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157253","dc_title":"Overzicht COVID-19 vaccin onderzoek RIVM en ZonMW20210211.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157198","dc_title":"st05656-re01.en21.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154936","dc_title":"webpagina Zwangerschap_20210215_DEFINITIEF.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1156193","dc_title":"Van Asten et al. Excess deaths during influenza and coronavirus disease. EID_2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1156176","dc_title":"VK.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155983","dc_title":"Fibromyalgie en het coronavirus_Fesinfo.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157782","dc_title":"object0002.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155745","dc_title":"jamainternal_harvey_2021_oi_210006_1613607951.12731.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154961","dc_title":"Duiding wekelijkse rapportage_week7_DEF.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151356","dc_title":"Interview Sanna Elkadiri Waardigheid en trots_2.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155676","dc_title":"bambra.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151347","dc_title":"IZ-218715.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154977","dc_title":"Autorisatiebesluit RvIG - VWS - RIVM.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155359","dc_title":"(INFO/ACTIE) Bilat Rutte-Netanyahu d.d. 15/2/21 (COVID-19): KortVerslag Follow Up Gesprek VWS/Dir IZ, MoH/Dir IZ en TEL d.d. 22/2/21","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155009","dc_title":"Stukje brief over motie Dijkhoff","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155293","dc_title":"Hoofdpunten uit expertgesprek LL 100221.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155286","dc_title":"Verdelen van de gezamenlijke ruimte - versie 22 feb DEF.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155219","dc_title":"paragraaf 4 verpleeghuizen.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155146","dc_title":"GMT-217219.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1155072","dc_title":"20210219 Maatschappelijke sheets 23 februari v3 12.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154676","dc_title":"210216 Nieuwsbericht 2e vaccinatie-spillage en bestellen toebehoren-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153875","dc_title":"Z-218958 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153878","dc_title":"WRR042-Houdbare+ouderenzorg-Ervaringen+en+lessen+uit+andere+landen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153908","dc_title":"def bericht Jan Fransoo en team adviseren RIVM.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153944","dc_title":"ema-combined-h-5735-nl-clean.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1153983","dc_title":"signaal over gevolgen splitsing in groepen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154096","dc_title":"Reactie discussienota NFU.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151632","dc_title":"PDC19-218497.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151604","dc_title":"1286f2a6-93ee-4fa9-ab89-b734ab2c4854.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154125","dc_title":"brief.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151574","dc_title":"PDC19-217887.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154186","dc_title":"Reactie discussienota CZ, Zilveren Kruis, Menzis.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154216","dc_title":"China nrc-handelsblad-20210206-4329629.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154350","dc_title":"RE: uitbreiding formatie kinderartsen Bonaire ivm COVID","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154648","dc_title":"210223 Nieuwsbericht 2e vaccinatie-spillage.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154743","dc_title":"210218 Werkinstructie COVID-19-vaccinatie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151506","dc_title":"Verslag RIVM VWS GGD GHOR 17-02-20201.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1158816","dc_title":"6.11 cover note Task Force AOB internal market VTC 25Feb2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1158807","dc_title":"6.10 Letter to Mr Pedro Siza Vieira.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1158556","dc_title":"06.8 xxx Bijlage VIII - Brief aan PEC van over productiecapaciteit vaccins.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154811","dc_title":"RE: Openstaande vragen n.a.v. controle contracten en kamerbrieveninzake vaccins - Vertrouwelijk!","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151460","dc_title":"Hoe verder in 2021 DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154813","dc_title":"RE: Openstaande vragen n.a.v. controle contracten en kamerbrieveninzake vaccins ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1154814","dc_title":"RE: nog meer uit een flacon","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1158483","dc_title":"RE: repack details AZ-Moderna en hulpmiddelen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1158090","dc_title":"Standpunt Vaccinatie tegen COVID-19 rondom zwangerschap en kraambed versie 18 februari 2021 definitief.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157969","dc_title":"SB_TheFutureHERA.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115046","dc_title":"communicable-disease-threats-report-5-feb-2021-restricted.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115000","dc_title":"02-COVID-Douoguih.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115002","dc_title":"03-COVID-Gargano.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115008","dc_title":"3. CRAMER_Clin Dev Pathway New Variants_2021-02-18.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143282","dc_title":"First dose vaccine effect Israel Lancet 18 Feb 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115014","dc_title":"2. JOHANSEN_ALM_RAPID RISK ASSESSMENT_18FEB.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143271","dc_title":"PIIS2666776220300211.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143263","dc_title":"Vaccine linked to reduction in risk of COVID-19 admissions to hospitals - News - Public Health Scotl.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143249","dc_title":"Science news dec 18  on COVID19 in Down syndrome.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143193","dc_title":"Letter to SofS - JCVI advice on COVID-19 vaccination in people with learning disabilities.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143135","dc_title":"Samenvattende conclusies gesprek CIO consensus 23-2.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115035","dc_title":"04-COVID-Oliver.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115042","dc_title":"Wilson et al 2021 - Schepen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143286","dc_title":"COVID-19_vaccine_effectiveness_surveillance_report_February_2021 FINAL.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115048","dc_title":"Rapport Uitval reguliere zorg door COVID-19 bij de jeugdgezondheidszorg.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143076","dc_title":"Agenda BO Cli\ufffdntenorganisaties vaccinatiestrategie 2-3-2021 versie 17.52.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143061","dc_title":"PDC19-217186.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143055","dc_title":"2e incidentele suppletoire wet op de begroting van VWS.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143024","dc_title":"PDC19-218218.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142984","dc_title":"2020 An mRNA-1273 Vaccine against SARS-CoV-2  Preliminary Report.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142953","dc_title":"PDC19-218217.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142947","dc_title":"3. Memo stuurgroep GGD datalek bespreken opdrachtverstrekkingvervanging HPZone 25 febr 2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116621","dc_title":"Bijlage 3 - Bijlage bij brief TK Nationaal Programma Funderend Onderwijs.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116434","dc_title":"Advies 99e OMT deel 2.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116432","dc_title":"Advies AP amvb raadpleging EPD ivm corona 20210225.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107957","dc_title":"Bijlage 2 Verslag EU gezondheidsraad van 2 december 2020 (videoconferentie).docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109887","dc_title":"Report Ventilation and air cleaning to limit aerosol particleconcentrations in a gym.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109858","dc_title":"03022021 Oplegger en begeleidend schrijven artikel aerosolen TUe.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109741","dc_title":"04-02-2021 Plenair debat ontwikkelingen Covid-19  PDC19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109717","dc_title":"06a Bijlage - Nomogram demonstraties.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109713","dc_title":"04b Bijlage - Kamerbrief steunpakket welzijn en leefstijl ivmCOVID-019.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108408","dc_title":"Beantwoording Kamervraag 2021-02-24 12_01_21ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108406","dc_title":"Accepted_paper_Blocken_et_al.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108404","dc_title":"Beantwoording commissiebrief 2021-02-26 12_49_58ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108083","dc_title":"000004CB.PDF","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108054","dc_title":"Toelichting 2021-02-01 8_21_07.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108034","dc_title":"Oplegbrief Eerste Kamerocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108001","dc_title":"Kamerbrief initiatiefnota Diertens - met wijzigingen.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115896","dc_title":"Bijlage 1 - notitie Sociaal Werk NL - zorgvoordejeugd en corona.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107953","dc_title":"Beantwoording Kamervraag 2021-02-08 13_40_09ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107945","dc_title":"Beantwoording Kamervraag 2021-02-08 10_45_27ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107941","dc_title":"Beantwoording Kamervraag 2021-02-02 6_48_50ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107939","dc_title":"Advies van de Denktank Coronacrisis Perspectief op Herstel.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107937","dc_title":"217557 - Opmerkingen aanpassingen Stas VWS.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114988","dc_title":"CAVALERI_Documentation of COVID-19 vaccines.pptx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114992","dc_title":"Jean Baptiste et al. Measles Outbreak in complex emergency estimating VE BMC Public Health 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107935","dc_title":"Beantwoording commissiebrief 2021-02-03 8_55_22ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115195","dc_title":"2020.11.18.20233122v2.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107907","dc_title":"210209 Subsidieregeling coronabanen in de zorg_Laatste wijzigingen SCHOON.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114998","dc_title":"Table_baseline_characteristics_draft.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120686","dc_title":"20210204_DeutscherEthikrat_ad-hoc-empfehlung-besondere-regeln-fuer-geimpfte.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1158015","dc_title":"Factsheet_-_EN.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1157530","dc_title":"Nazending printbare versie van de infosheet AstraZeneca ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151824","dc_title":"Procedure voor ontheffing voor antigeen sneltest als zelftest.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150779","dc_title":"RE: Praktijkhandleiding huisartsenposten","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141977","dc_title":"00-Dr. Peter Borger_expert PCR.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137512","dc_title":"Samenvatting ronde 8 WP3 voor beleidsrapportage.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135206","dc_title":"FW: Vaccinatiebereidheid, input op landelijke campagne, korte deadline","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129170","dc_title":"check testbeleid.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126618","dc_title":"Nota van toelichting 2021-02-02 7_04_57.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122222","dc_title":"PDC19-218150TK B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121629","dc_title":"WJZ-217427TK A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120955","dc_title":"PDC19-217604 F.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1300015","dc_title":"20210204 PPT TB 11.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127148","dc_title":"RE: N.a.v. nieuwsbericht Per Saldo","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117873","dc_title":"Het jaar van COVID-19_11_2_2021.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115797","dc_title":"Brief steunpakket welzijn en leefstijl ivm COVID-019 120221 DEF.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115795","dc_title":"Wekelijkse rapportage COVID-19 Vaccinatiegraad_Externe versie 2_2_2021_definitief_2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115788","dc_title":"210215 Vaccinatiestrategie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115780","dc_title":"Deelname COVID-19 vaccinatie in Nederland_2021_02_02.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115769","dc_title":"FW: Belgian law makes it harder for EU to enforce vaccine contract,say experts","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115744","dc_title":"Rapportage vaccinatiebereidheid zorgmedewerkers VVT algemeen - januari 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115708","dc_title":"PDC19-216642.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115673","dc_title":"FW:  Reisrestricties UK en gevolgen voor vaccinbedrijven metvestiging in Nederland","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115627","dc_title":"Overview-of-COVID-19-vaccination-strategies-deployment-plans-in-the-EU-EEA.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115197","dc_title":"Presentatie inschalingssystematiek en routekaart GGD uitwisselingsoverleg.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115089","dc_title":"kamerbrief-over-aankoop-covid-19-vaccins (5).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115097","dc_title":"Adviesaanvraag-Gezondheidsraad-inzake-ethisch-kader-uitgebreid-testprogramma-20201217.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115124","dc_title":"Deelname COVID-19 vaccinatie in Nederland_2021_02_23.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115658","dc_title":"1993 Farrington Screening method IJE.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114997","dc_title":"Tables_Safety_draft.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114356","dc_title":"beantwoording-commissiebrief-tweede-kamer-inzake-verzoek-van-de-commissie-vws-om-een-spoedige-kabinetsreactie-op-de-initiatiefnota-over-een-tijdelijke-testsamenleving.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114252","dc_title":"Israel 1st dose VE cohort.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114250","dc_title":"Deelname COVID-19 vaccinatie in Nederland_2021_02_09.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113360","dc_title":"kamerbrief-inzake-stand-van-zaken-datalek-ggd.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113137","dc_title":"2021.02.05.21251197v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112433","dc_title":"2021020 - CELEX_52020PC0726_EN_TXT Netherlands versie.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111943","dc_title":"2021Z01777 Verzoek om documenten inzake communicatie over hetcoronatest-IT-systeem van de GGD.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109905","dc_title":"flowchart-vaccins.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111099","dc_title":"NVS19_Midterm.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111089","dc_title":"Advies 17 Vaccinatie- en Testbewijs.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110124","dc_title":"2021 0079 DK Medische hulpmiddelen en beschermingsmiddelen.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109710","dc_title":"PDC19-217134.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108798","dc_title":"2.5 11feb21-ESI-CA-Meeting-Giuseppina.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108521","dc_title":"02 20.Finddx-Joysbio-Swiss-Public-Report_v1_20210211.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108249","dc_title":"LZ-218408 C - Nieuwe versie  Rapport DSP-groep_Ondersteuning op maat voor mensen met een beperking en hun naasten (005).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108160","dc_title":"217738 - Aanpassingen Min VWS.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1108154","dc_title":"216869 - Akkoord Stas VWS.pdfocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107955","dc_title":"Beantwoording commissiebrief 2021-02-05 13_02_09ocr.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1107890","dc_title":"1821950-217899-WJZ AMvB.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.40","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114210","dc_title":"210210 nieuwsbericht COVID-19-vaccinatie bewoners HAP's-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111972","dc_title":"FEITENRELAAS_def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111968","dc_title":"2021Z02546 - CU_D66_DvB.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.30","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114270","dc_title":"Beantwoording Kamervraag 2020-12-23 14_17_59.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111965","dc_title":"210202-Tijdlijn GGD.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111950","dc_title":"2021Z02378 Verzoek om een reactie op de brief inzake 2 x 900 vaccinsvoor vaccinatiestudie bij kanker.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.33","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116099","dc_title":"Factsheet vaccineren 27-1-2021 IGJ.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.34","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116383","dc_title":"COVID-19_Campagnemonitor_AlleenSamen_feb2021 (1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111939","dc_title":"2021Z02192 Verzoek om vaccinatieschema naar de Kamer te sturen.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.36","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1161005","dc_title":"RE: Stukken tbv MCC","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111938","dc_title":"2021Z01993 - Bergkamp.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111930","dc_title":"2021Z 03054 Vaccintekorten Covid-19 C-Tap.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111911","dc_title":"2021Z01806 - Veldman_pk-skp+IE (003).docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.27","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118066","dc_title":"object0003.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.41","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114294","dc_title":"Beantwoording Kamervraag 2021-01-06 12_56_07.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111910","dc_title":"2021Z02176.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.43","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114320","dc_title":"29th WHO Regulatory Update on COVID-19_19Feb2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111905","dc_title":"2021Z01993 - Bergkamp.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111421","dc_title":"5. Verbeterplan DOTT fase 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111416","dc_title":"GMT-215919.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.47","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114361","dc_title":"Initiatiefnota tijdelijke testsamenleving (1) GroenLinks.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111395","dc_title":"PDC19-216361.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111388","dc_title":"210212 Vaccinatiestrategie afb 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111234","dc_title":"20210215 omt advies 100.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111203","dc_title":"210131DEF-Kamervragen2.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112841","dc_title":"2021Z03514.docx_b8fae6f3-d60e-414e-aaf3-552e5ae106ba.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113522","dc_title":"Communicable-disease-threats-report-20-feb-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113532","dc_title":"Brauneretal_Science_2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.5","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139264","dc_title":"bijlage Informatie-over-landelijke-registratie-bij-het-RIVM (1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112889","dc_title":"210118 - Kamervragen maskergebruik ter preventie van SARS-CoV-2 infecties ziekenhuiszorg DENK GB (002).docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.7","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139914","dc_title":"RE: graag jullie akkoord op kamervragen ellenmeet over de publicatievan de scorekaart van Farma ter Verantwoording","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.8","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139939","dc_title":"voortgang sectorplan GHZ: lezen jullie mee?","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112854","dc_title":"2021Z03661.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.10","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140833","dc_title":"218576 opm min mzs.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112847","dc_title":"20210212 getekende opdrachtbrief LNAZ fase-3.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.12","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142359","dc_title":"210222 wijzigingsregeling 23 februari met avondklok - schoon.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.13","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142529","dc_title":"RE: volgende versie DO nota verplichte quarantaine","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.14","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143029","dc_title":"BPZ-216797.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109908","dc_title":"PDC19-212509.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112836","dc_title":"2021Z02656.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112834","dc_title":"2021Z03442.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112829","dc_title":"2021Z01993.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112828","dc_title":"2021Z02547.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112532","dc_title":"RE: alarmerend bericht bijwerkingen AstraZeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112441","dc_title":"2021020 - CELEX_52020PC0726_EN_TXT Netherlands versie.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112171","dc_title":"GRT-Regering-VWS-35684 2e incidentele suppletoire begroting.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112149","dc_title":"2021 02 08 Kamervragen CDA Betrokkenheid Defensie bij bestrijdingpandemie.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112002","dc_title":"24c14bc5-a563-4c01-9bfe-c38d4949aea3 (3).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111997","dc_title":"21.02.05 Overkoepelende brief - adviezen commissie WiZ 2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111975","dc_title":"2021Z02547 - SPv2_AZ.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110138","dc_title":"Nota van toelichting.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.77","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114600","dc_title":"Oran 2021 The Proportion of SARS-CoV-2 Infections That Are Asymptomatic.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.78","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114602","dc_title":"Duiding wekelijkse rapportage_week7_v4.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.79","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114605","dc_title":"Deelname COVID-19 vaccinatie in Nederland_2021_02_16___versie 12.53uur.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110455","dc_title":"20210204 Vaccinatiestrategie afbeelding 2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110450","dc_title":"VK - COVID Update 03/02","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110376","dc_title":"FW: ZJCN vervolgvragen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110348","dc_title":"Stand_van_zaken_datalek_GGD.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110234","dc_title":"Adviezen+Zelfstandig+Wonende+Ouderen+281020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110205","dc_title":"2020208 FINAL BioNTech-Pfizer-EU PA for signature top up contract.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110201","dc_title":"2020208 FINAL BioNTech-Pfizer-EU PA for signature.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110164","dc_title":"Regeling 1829285-218543-WJZ.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111165","dc_title":"Brief prog dir ZJCN omtrent reizen 2 februari 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110125","dc_title":"2021 0080 DK Desinfecteermiddelen van productsoort\ufffd1 en productsoort\ufffd2.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110123","dc_title":"2021 0078 DK Mondmaskers, Covid-19.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110122","dc_title":"2021 0070 DK Geneesmiddelen.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110121","dc_title":"2021 0041 B Volksgezondheid.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110120","dc_title":"2021 0012 F Volksgezondheid vaccins.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110076","dc_title":"2020.06.22.20136309v3.full.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110074","dc_title":"20200520 Beeld BTCb 20 mei_bijalge 3 Flitspeiling Coronavirus 7-meeting.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110063","dc_title":"20200526 Beeld BTCb 26 mei.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110002","dc_title":"2020 0847 F Vaccins, producten en vereiste diensten voor de vaccinatie COVID-19-epidemie.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109990","dc_title":"1823124-217921-GMT Ministerieel besluit aanwijzen bevoegde autoriteitvoor uitvoervergunning vaccins 03022021rc.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1109953","dc_title":"PDC19-217737.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110458","dc_title":"20210204 Vaccinatiestrategie afbeelding 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111188","dc_title":"Bijlage Factsheet IGJ.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1111024","dc_title":"Advies 16 Veiligheid Covid-19 test en vaccinatiedata.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110970","dc_title":"20210208 210119 - motie testen sequencen Laatste versie.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110961","dc_title":"20210205 kamerbrief datalek.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.57","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114434","dc_title":"PDC19-218428.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110959","dc_title":"20210204_technische_briefing_TK_vaccinatiestrategie RIVM.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110952","dc_title":"20210204 advies Gezondheidsraad.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110921","dc_title":"20210205inschalingssystematiek-bestuurdersversie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.61","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114443","dc_title":"IZ-217726TK.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.62","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114445","dc_title":"DICIO-218400.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.63","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114448","dc_title":"PG-217999.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110854","dc_title":"2021.01.29.21250653v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110833","dc_title":"20210203 -.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.66","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114492","dc_title":"210115 2e brief gedragsreflecties, avondklok-en-sociale-bubbels.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110770","dc_title":"202102 RIVM aanvullende adviezen zw ouderen.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110766","dc_title":"20210129 Vragen aan RIVM en VWS.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110723","dc_title":"20210105 motie Azarkan kst-25295-864.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.70","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114573","dc_title":"Bijlage 5 - Coronavirus anxiety workbook.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110623","dc_title":"2021 02 17 Kamervragen CDA Betrokkenheid Defensie bij bestrijding pandemie.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.72","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114585","dc_title":"Powerpoint COVID-19 webinar 17 februari 2021.final 1.0_- en Cecile.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110542","dc_title":"ECDC-weekly-policy-brief-COVID-Feb-11-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1110462","dc_title":"20210204 Voorraad en vaccinaties.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.76","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114594","dc_title":"Ren 2021 Asymptomatic SARS-CoV-2 Infections Among Persons Entering China From April 16 to October 12, 202.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130409","dc_title":"signalement 21_1.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128991","dc_title":"Stand_van_zaken_datalek_GGD.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130826","dc_title":"ZJCN-217589TK.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137497","dc_title":"Resultaten trend analyses WelzijnCGU_EM_v1.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130655","dc_title":"COVID-19-vaccinatie _ LCI richtlijnen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130537","dc_title":"Vaccinatiestrategie 5-2-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130536","dc_title":"Reactie_advies_inzet_AstraZeneca-vaccin_tegen_COVID-19.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130535","dc_title":"20210204 PPT TB 10.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130475","dc_title":"Bijlage 6A Comirnaty Instructie-klaarmaken.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129155","dc_title":"check adam test.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129161","dc_title":"check testentraceren.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128956","dc_title":"Giard 2021 Aansprakelijkheid voor vaccinatieschade.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129208","dc_title":"nejmoa2101765.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129211","dc_title":"Chang Nature 2020. Mobility network models of COVID-19 explaininequities and inform reopening.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129228","dc_title":"semi-final--respones-first-second-dose.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129233","dc_title":"Baden 2021 Efficay and safety nejmoa2035389.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129243","dc_title":"Voysey 2020 Lanceet PIIS0140673620326611.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129267","dc_title":"PIIS009167491930020X.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129275","dc_title":"UK Variant Paper AZD1222 Lancet February 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130404","dc_title":"Bijlage 5_tekst pag 5en6 uit kamerbrief verder met vaccineren 1798759-215910-PG.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130390","dc_title":"W13.21.0017_Advies.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131616","dc_title":"Stand_van_zakenbrief_COVID-19.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131997","dc_title":"Uitkomst panel zelftest quarantaine buddy..Uitkomst panel zelftest quarantaine buddy","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128861","dc_title":"SNPG DEF algemene voorwaarden ZO met Addendum en transfer versie 21-01-21.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128862","dc_title":"DEF HA Algemene voorwaarden SNPG 2021 versie 10-2-21.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131897","dc_title":"FW: Psychosociale nazorg","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131677","dc_title":"steno EK voortzetting met arceringen.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128894","dc_title":"Bijlage 2 Goed vaccinbeheer_v1.0.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131644","dc_title":"steno TK met arceringen.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131640","dc_title":"stcrt-2021-1516.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128906","dc_title":"ter info - vraag sportsector/Erik Scherder bewijs bewegen envaccinatie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131635","dc_title":"stcrt-2021-7182.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129372","dc_title":"COVID-19-vaccinatie+AstraZeneca-vaccin_20210204 (1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131483","dc_title":"RE: Claims voor ISB","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131312","dc_title":"- Acute zorg van deelbelangen naar gedeeld belang_ geel gemarkeerd.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131309","dc_title":"Sanquin 2102  Alternative Procedures for Blood and Blood Components During the COVID-1....pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131305","dc_title":"Samenvatting-Ethische-en-juridische-afwegingen-COVID-19-vaccinatie.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131205","dc_title":"object0017.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1131160","dc_title":"Supplementary Materials_v4.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130976","dc_title":"object0003.com - Rapper FLO   nogffvolhouden_v720P","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130876","dc_title":"MEVA-217688.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130833","dc_title":"Verplichte quarantaine 9-2-21.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129869","dc_title":"3a. NERVTAG Variant Note for B1.351.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129741","dc_title":"GMT-217495.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130150","dc_title":"tbed.14035.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129752","dc_title":"GMT-217232.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130143","dc_title":"COVID-19_Response_-_Spring_2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130126","dc_title":"2021.02.12.430472v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129814","dc_title":"IZ-218036TK B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129821","dc_title":"kamerbrief-over-uitbreiding-economisch-steun-en-herstelpakket-caribisch-nederland-noodpakket-40.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129824","dc_title":"2020 Artikel RNA vaccins.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130123","dc_title":"Variants_of_Concern_VOC_Technical_Briefing_6_England-1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130105","dc_title":"Quarantainegids (versie 12022021, definitief).pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129729","dc_title":"06-COVID-Shimabukuro.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130065","dc_title":"Policy-brief-39-1997-8073-eng.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129873","dc_title":"3b. NERVTAG Variant Note for B117.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129876","dc_title":"3c. NERVTAG Variant Note for 78 P.1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130032","dc_title":"Presentatie_de_heer_-_van_Delden_(programmadirecteur_vaccinatie_COVID-19_bij_het_RIVM).pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130024","dc_title":"2020 Artikel RNA vaccins KIm.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129967","dc_title":"NEJMoa2034201 janssen vaccin.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129971","dc_title":"anaphylaxie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129998","dc_title":"Productie 14 Franse avondklok heeft geen duidelijk effect NOS.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130018","dc_title":"Detection and molecular characterisation of SARS-CoV-2 Lukasz.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129507","dc_title":"Vaccinatie_Uitvraag_aantallen_hoogrisico_nierpatienten_web.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130343","dc_title":"2021_BAE_Blocken_et_al__COVID19_gym.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129377","dc_title":"Voorstel agendapunten PO FEZ/ADR 5/2","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130330","dc_title":"Press Release Statia receives 1600 vaccines (V05022021).docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130270","dc_title":"20210224 PPT v1.0.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129401","dc_title":"Update vaccinatie van medische hoog risicogroepen 20210224.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129422","dc_title":"Wat de coronavaccins ons leren over de markt voor geneesmiddelen","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129426","dc_title":"VRT.BE Correspondent Bjorn Soenens in de VS : \"Enkele langzameopmerkingen in een snelle tijd. over de covid-19 gezondsheidscrisis\"   ","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129474","dc_title":"Unterlassene Hilfeleistung.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129488","dc_title":"Zur Not mit Zwang.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128787","dc_title":"Autorisatiebesluit RvIG - VWS - RIVM.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130264","dc_title":"FDPGO210218.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129511","dc_title":"IngridNEJMoa2035389 Moderna.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129534","dc_title":"Samenvatting vragen webinar 3 feb_TWK_GdB_ls_pE.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130219","dc_title":"Publication Roche SD Biosensor Q Validation NL.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130203","dc_title":"Publication BD Veritor Validation NL.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130192","dc_title":"2021.01.29.21250653v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129695","dc_title":"Afbeelding 9  Flowchart plus leveringsoverzicht V1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1130187","dc_title":"Publication Abbott Validation NL.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1129712","dc_title":"COVID-19-vaccinatie+AstraZeneca-vaccin_20210204.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135148","dc_title":"PDC19-218593 F.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3058","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133931","dc_title":"Kopie van Moties debat 3 feb GGD datalek.xlsx.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3062","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133946","dc_title":"Kopie van Toezeggingen debat 3 feb GGD datalek.xlsx.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3065","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134000","dc_title":"Willekeur bij uitkering zorgbonus pakt duur en pijnlijk uit - Follow the Money - Platform voor onderzoeksjournalistiek.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3067","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134050","dc_title":"VWS koopt ondermaatse sneltesten en houdt betere testen buiten de deur - Follow the Money - Platform voor onderzoeksjournalistiek.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3069","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134068","dc_title":"2021 02 28 Rapportages vph vanaf week 44 2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3076","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134324","dc_title":"Ap over vaccineren en werkgevers_werknemers febr21.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3080","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134354","dc_title":"Brief datalek GGD_n PDC19-217930.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128239","dc_title":"RE: Verlenging Tijdelijke wet maatregelen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1134878","dc_title":"Volgen en duiden sociale impact corona in het sociaal domein.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128244","dc_title":"RE: Verplichte quarantaine 9-2-21 voorstel BWO 004 (003).pptx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3054","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133847","dc_title":"17.02.2021 brief RONAZ aan minister De Jonge overvaccinatiestrategie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135158","dc_title":"4_update3_2021-Wynants-BMJ-COVID19review.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135164","dc_title":"PDC19-218593 E.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135177","dc_title":"PDC19-218593 G.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135185","dc_title":"PDC19-218593 I.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135198","dc_title":"PDC19-218593 N.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135204","dc_title":"PDC19-218593 M.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135209","dc_title":"PDC19-218593 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135214","dc_title":"PDC19-218593 D.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135227","dc_title":"PDC19-218593 P.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133719","dc_title":"218232 getekende regeling en toelichting.pdf.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133415","dc_title":"W13.21.0028.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133418","dc_title":"WJZ-1821950-217899 voordracht.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133435","dc_title":"2021-02-03 kamer debat Stand_van_zaken_datalek_GGD.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133465","dc_title":"RE: aansluiting COVID-19 tabel en kasrealisatie en verplichtingen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133524","dc_title":"210108_Verwachte voorraadanalyse PBM - Update jan v1.0.pptx.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133634","dc_title":"210209 Subsidieregeling coronabanen in de zorg_Laatste wijzigingen SCHOON.docx_09c37fbc-c6e6-4d80-ba11-d9c491fc76ad.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133642","dc_title":"210223 Vaccinatiestrategie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133308","dc_title":"AMvB 2021-02-02 7_04_39.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133689","dc_title":"210223 Kamerbrief ICT.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133714","dc_title":"210219 Subsidieregeling coronabanen in de zorg_Staatscourant.pdf_ae09315e-e198-43f3-b295-b28cbba783dc.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135305","dc_title":"RE: Update from vaccine planning","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133721","dc_title":"Artikel via RIVM mbt contaminatie Analysis of Inactivation of SARS-CoV-2 by Specimen Transport.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133746","dc_title":"Brief Impact overgang nieuw ICT-systeem.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133769","dc_title":"artikel via RIVM Methods of inactivation of SARS-CoV-2 for downstream 1 biological assays.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133289","dc_title":"Amvb.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3049","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133797","dc_title":"BTCImpactAssessmentOPC_21_01_2021_EN.doc.doc","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3051","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133811","dc_title":"Avondklok Hof Den Haag 26febr21.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133282","dc_title":"Advies Raad van State.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3052","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133836","dc_title":"BTCtargetedconsultation_01_02_2021_EN_clean.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3053","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1133838","dc_title":"1722021MCCfactsheetsT&T.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132618","dc_title":"Voorstel verordening voor EU4Health programma.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132802","dc_title":"_de_heer_-_van_Dissel_(directeur_van_het_Centrum_voor_Infectieziektebestrijding_van_het_RIVM).pdf_f955d7d6-1f76-461a-8a1f-827e7082ff48.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136982","dc_title":"Beleidsverslag inleiding en H1 covid Audit Committee.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137026","dc_title":"regie gezondheidsdata HFD_20210218_0_025_003.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137096","dc_title":"210222 4e brief gedragsreflecties maatregelenpakket-defVWS.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137125","dc_title":"210205.Toelichting juridische grondslag gegevensverstrekking aan RIVM.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137159","dc_title":"210205.Toelichting juridische grondslag gegevensverstrekking aan RIVM v1.0.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132661","dc_title":"Z-205656 A.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132629","dc_title":"WJZ-1821950-217899 amvb en nvt.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137404","dc_title":"210223 Nieuwsbericht spillageprotocol BioNTech-Pfizer-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136898","dc_title":"210218 Nieuwsbericht 2e vaccinatie-spillage.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137409","dc_title":"210223 Nieuwsbericht spillageprotocol Moderna-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132495","dc_title":"VWS-201231-001 028 EN.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132481","dc_title":"VSO 22112 Vier fiches EU-Gezondheidsraad totaal.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132384","dc_title":"memo meerkosten en mail kostenposten","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128753","dc_title":"20210216 -RED-210202 SARS-CoV-2 variants of concern_final_EV_BV .docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132334","dc_title":"Volgorde vaccinatie voor mensen die niet in de zorg werken.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128763","dc_title":"SNPG DEF algemene voorwaarden ZO met Addendum en transfer versie 19-02-2021_SR.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132083","dc_title":"Vaccinatie tegen corona _ Autoriteit Persoonsgegevens.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132064","dc_title":"uitvoeringsverordening EU 2021-111 uitvoervergunning vaccins.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136381","dc_title":"Cairney2020_Article_TheUKGovCOVID-19Policy.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135470","dc_title":"Steunpakket welzijn en leefstijl","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135492","dc_title":"Briefadvies Planbureaus voor herstelbeleid: een doorstart van de samenleving","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135841","dc_title":"SCP-2021 309 betrekken maatschappelijke effecten bij toets mogelijke maatregelen Covid-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135887","dc_title":"Webstatistieken coronadashboard half jan - half feb","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1135903","dc_title":"vaccinatiestrategie (4).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132946","dc_title":"5.1 SEROLOGY DIAGNOSIS 2020 IGG RESULT BIOMERICA.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136054","dc_title":"Onepager Lieve Mark.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136379","dc_title":"20210225 R10 vragenlijstonderzoek resultaten Definitief.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132937","dc_title":"5. SEROLOGY BIOMERICA EVAL COMPARISON.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136389","dc_title":"20210224 Welbevinden en leefstijl _ RIVM.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1128484","dc_title":"RE: vragen ivm vervoer naar vaccinatielocaties","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136412","dc_title":"adviesvraag SER denktank2.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136475","dc_title":"OCW rapport pilot Praktijktesten 19feb21.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136625","dc_title":"GMT-218319.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136639","dc_title":"10-02-2021 Notaoverleg initiatiefnota GL tijdelijke testsamenleving PDC19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136762","dc_title":"RE: Tekst Vaccin in het kort AstraZeneca, graag reactie ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1136824","dc_title":"14-16_ICT&health_nr1_2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1132833","dc_title":"_de_heer_-_van_Dissel_(directeur_van_het_Centrum_voor_Infectieziektebestrijding_van_het_RIVM).pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127915","dc_title":"terugkoppeling BWO","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121971","dc_title":"210202 Persbericht Meer dan 75.000 gevaccineerden in 1 week inverpleeghuizen en instellingen gehandicapten.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2060","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124386","dc_title":"hoe_verder_in_2021_def.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2075","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124545","dc_title":"Initiatiefnota Klaver en Kr\ufffdger Tijdelijke testsamenleving TK35653.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121951","dc_title":"Erik Scherder artikel.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127959","dc_title":"Motie_van_het_lid_Dijkhoff_c.s. - ruimte en sectoren.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127955","dc_title":"Motie_van_het_lid_Ploumen_c.s. - jeugd.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127953","dc_title":"Motie_van_het_lid_Wilders_over_alleen_vrijwillige_vaccinatie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127951","dc_title":"Motie_van_het_lid_Segers_c.s. - herstelplannen.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121881","dc_title":"regeling verlenging afstandsonderwijs vo en ho versie 2.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127949","dc_title":"Motie_van_het_lid_Pieter_Heerma_c.s. - vaccinatiegezant.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121877","dc_title":"Brief onderwijs EK in format.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121876","dc_title":"Brief onderwijs TK in format.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121873","dc_title":"PDC19-217809.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127933","dc_title":"Sheets MCC_LS.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2057","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124362","dc_title":"RE: Brief steunpakket welzijn en leefstijl ivm COVID-19 v1","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124894","dc_title":"RE: Tesktvoorstel Werking en bijwerkingen vaccinatie ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i Concept","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121850","dc_title":"Motie Veldman 21-01-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121832","dc_title":"HSC_Common RAT list and common dataset for COVID-19 testresults_final_clean.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121830","dc_title":"TRP-20210115-1555 TO SANTE.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127855","dc_title":"nrc-next-20210202-4328210.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127717","dc_title":"RE: Question re. export authorisation - URGENT","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127708","dc_title":"RE: Question re. export authorisation - URGENT","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127666","dc_title":"Kortje medische indicatie v1.4_DEF.DOCX","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127571","dc_title":"Motie Marijnissen en Jetten.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127553","dc_title":"Briefing_EU_Funding_for_Health.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127462","dc_title":"Briefadvies Planbureaus voor herstelbeleid_DEF.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127460","dc_title":"Study.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127440","dc_title":"Annex.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127437","dc_title":"tabel flankerend beleid.xlsx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123362","dc_title":"IGJ-218278 A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122215","dc_title":"PDC19-218150TK A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122325","dc_title":"Doorst:  houdbaarheid astrazeneca vaccin na aanprikken","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122380","dc_title":"Re: SAS Webinar Covid & PID 3 februari jl","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122421","dc_title":"PDC19-216869.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122585","dc_title":"Murbe 2021 preprint. Aerosol emission is increased in professional singing.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122789","dc_title":"GMT-217054 G.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122188","dc_title":"Stand_van_zakenbrief_COVID-19_ 03022021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122187","dc_title":"Stand_van_zakenbrief_COVID-19 (1).docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122937","dc_title":"Dagblad adv 12-02 - geredigeerd versie 5 cs_cdj2 cs_cdj_schoon_1.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122986","dc_title":"Toestemmingsformulier+wettelijk+vertegenwoordiger.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123242","dc_title":"Epidemiological and public health requirements COVID-19 tracing apps.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123249","dc_title":"ec_rtd_he-partnerships-health-system-transform.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123273","dc_title":"ciab100(1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123279","dc_title":"Damialis_MainManuscript_FINAL.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121726","dc_title":"WJZ-217427TK C.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123382","dc_title":"IGJ-218278 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122100","dc_title":"PDC19-218037.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123398","dc_title":"Evaluatie mass testing.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123468","dc_title":"FD artikel.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123538","dc_title":"TK Stand_van_zakenbrief_COVID-19 20210202.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123543","dc_title":"european-union-medicines-agencies-network-strategy-2025-protecting-public-health-time-rapid-change_en.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123646","dc_title":"ZJCN-217589TK.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123949","dc_title":"GMT-1823124-217921.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1122037","dc_title":"nota ligt nu bij jou! RE: reactie gevraagd FW: 210126 Nota pre ordermogelijke COVID behandeling AZ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i Concept","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1123957","dc_title":"GMT-217219.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124046","dc_title":"PDC19-214293.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1124047","dc_title":"PDC19-215019.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121985","dc_title":"Brief schoolbesturen pilot Praktijktesten v.1.0 + bijlage 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126683","dc_title":"OMT advies 15 februari 100e.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125293","dc_title":"Letterlijke tekst persconferentie 2 februari_verlenging lockdown.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125294","dc_title":"Letterlijke tekst persconferentie 20 januari_invoering avondklok.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126904","dc_title":"Flaxmanetal_Nature_2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126893","dc_title":"20210218_High SARS-CoV-2 attack rates following exposure during singing events in the Netherlands, SeptemberOctober 2020.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126837","dc_title":"P2-VIJFD.PDF.PDF","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125308","dc_title":"Liverpool,Community,Testing,Pilot,Interim,Evaluation.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126811","dc_title":"2021.02.06.21251283v1.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125332","dc_title":"Machinekamer+van+de+coronacrisis_SCP.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126808","dc_title":"741.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126791","dc_title":"The COVID-19 Vaccine Communication Handbook.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126789","dc_title":"2020 Artikel RNA vaccins.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126783","dc_title":"20210225 Vaccinatiebereidheid _ RIVM.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126763","dc_title":"Overzicht van intentingen doelgroepen.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126692","dc_title":"OMT advies 30 januari 98e deel 1.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126689","dc_title":"ongecorrigeerd verslag stas.html.html","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126906","dc_title":"NIVEL onderzoek 2021.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125395","dc_title":"kamerbrief-inzake-stand-van-zaken-covid-19 - 23 feb 2021.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126681","dc_title":"COVID-19 Vaccine_Guide for members of the Public_NL Final.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126501","dc_title":"d41586-021-00396-2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126275","dc_title":"opgave aantallen.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126254","dc_title":"RE: graag jullie reactie RE: Inschatting aantallenantilichaambehandeling","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125913","dc_title":"Presentatie c-VTV 2020.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125855","dc_title":"Motie_van_het_lid_Van_Esch_c.s._over_een_voorstel_om_het_preventiebeleid_op_niveau_te_houden.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121346","dc_title":"Verslag koepeloverleg LZ Corona 0202.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121342","dc_title":"Notulen koepeloverleg LZ Corona 2601.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125825","dc_title":"Voysey et al Single Dose AZD1222 Lancet Feb 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125785","dc_title":"AZD1222_Ph3 primary_CBR_ FINAL.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125734","dc_title":"Lidocaine & Inflammation HvK 2-2-2021 final v2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125710","dc_title":"RE: Contract 2021 Fundashon Mariadal getekend","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125645","dc_title":"PDC19-218290.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126928","dc_title":"Stand_van_zaken_digitale_ondersteuning_pandemiebestrijding (1).docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127378","dc_title":"RE: Overleg cli\ufffdntenorganisaties VV","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125030","dc_title":"Kamerbrief 16 februari over gebruik foetale cellijnen bij ontwikkeling vaccins.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127367","dc_title":"RE: Optimale doseringsinterval COVID vaccinaties","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127332","dc_title":"PDC19-216877TK A.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127324","dc_title":"PDC19-217604 A.docx_03524e7f-b81e-43ee-ae09-2e7de310592f.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127317","dc_title":"PDC19-218428.docx_9c28338f-a8bc-485b-bfa3-c05d2a66eb2a.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127313","dc_title":"PDC19-217930.docx_014792c8-fd37-4b7f-bebb-77909c496c1e.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127303","dc_title":"PDC19-217814 A.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127269","dc_title":"peds.2020-048090.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127201","dc_title":"RE: Nieuwe versie actielijnen vwsflankerend beleid  en terugkoppelinggesprek VNG","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127165","dc_title":"infectivity-manuscript-20210119-merged.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125119","dc_title":"Jong Pit Corona-effecten-analyse.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125121","dc_title":"kamerbrief-over-informeren-zoonosenbeleid-waaronder-instelling-expertgroep.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121610","dc_title":"210212 Vaccinatiestrategie afb 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127161","dc_title":"RE: nieuwe aankopen vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127155","dc_title":"pcr_profile_preprint-2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121594","dc_title":"20210205_summary_ERN_COVID-19_Vaccination_DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1125162","dc_title":"kamerbrief-over-reactie-advies-inzet-astrazeneca-vaccin-tegen-covid-19.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127051","dc_title":"Campagnestrategie coronavaccinatie_totaal.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127035","dc_title":"nature nieuwe varianten.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127020","dc_title":"Powerpoint COVID-19 webinar 17 februari 2021.final 1.0_CvE.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127010","dc_title":"Powerpoint COVID-19 webinar 17 februari 2021.final 1.0.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121509","dc_title":"ECDC_RRA_SARS-CoV-2 and increased circulation of variants of concern inthe EU EEA and vaccine rollout, update 14_12-02-2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126964","dc_title":"BP_ibi_Vaccine_Management_E-book_2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121489","dc_title":"Verslag koepeloverleg LZ Corona 0902.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1126956","dc_title":"20210224 PPT TB .pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.2447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1127436","dc_title":"JUISTE TABEL Brief steunpakket welzijn en leefstijl ivm COVID-019210211_03.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151155","dc_title":"Een jaar met corona.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150645","dc_title":"RE: communicatie naar huisartsen over Astra Zeneca vaccin","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150669","dc_title":"Versie 7 230221 Stand van zakenbrief COVID-19.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150761","dc_title":"WHO Manifesto for a healthy recovery from COVID-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150773","dc_title":"RE: Informatieavond Covid-19 vaccinatie Zeeland Limburg Noord-Brabant.pptx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150872","dc_title":"RE: communicatie naar huisartsen over Astra Zeneca vaccin","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150979","dc_title":"EU Ombudsman - ECDC communicatie - document_en_137815.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150992","dc_title":"Factsheet IGJ toezicht op vaccineren.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151003","dc_title":"Factsheet+toezicht+op+vaccineren.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145946","dc_title":"RE: Programma Sociaal Domein | Terugkoppeling programmaraad 08februari ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151090","dc_title":"Features Constituting Actionable COVID-19 Dashboards Ivankovic et alJMIR 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151150","dc_title":"Flowcharts 4 jan, 12 jan, 5 feb.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150542","dc_title":"COVID-crisis of COVID-kans.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151193","dc_title":"W13.21.0028_Advies.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1151251","dc_title":"Field lab experimenten.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1148226","dc_title":"RE: Vraag FIN over realisatiecijfers vaccineren ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1147408","dc_title":"RE: Voorstel quarantaineplicht en afstemming departementen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1147235","dc_title":"210210_2020_in_volgelvucht_definitief-.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1147228","dc_title":"RE: Verzoek aanvulling ppt DO-R en BWO","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1146676","dc_title":"RE: Uitbreiden lijst uitgezonderde contactberoepen: graag zsm reactie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1146603","dc_title":"RE: Testen en vaccineren","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1146553","dc_title":"RE: terugkoppeling interdep overleg testbewijzen hedenmiddag ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1146037","dc_title":"FW: Audiciens overige zorgmedewerkers","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149947","dc_title":"bmg_plakat_impfstoffe.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1148989","dc_title":"Advies AP amvb raadpleging EPD ivm corona 20210225.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1148993","dc_title":"Verslag evaluatiemoment werkgroep coronabeleid luchtvaart d.d.2-2-2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149171","dc_title":"FW: Antw:  AZ vaccin: bewaren na aanprikken","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149278","dc_title":"Agendapunt 5 Bijlage 6  -kamerbrief-over-steunpakket-sociaal-en-mentaal-welzijn-en-leefstijl.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149761","dc_title":"SPLAV-2021.11-LvD - Bijgesteld Protocol COVID-19 Testen van VliegendPersoneel v1.0 (27FEB20).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149786","dc_title":"Bijage 1 - Kamerbrief PDC19-218593 A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149797","dc_title":"Bijlage 2 - overzicht onderzoeken naar impact van COVID19 opjongeren.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149914","dc_title":"VNG Dashboard Sociale Impact Corona.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149927","dc_title":"Memo zestien stedelijke vernieuwingsgebieden.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1149938","dc_title":"Bijlage bij memo zestien stedelijke vernieuwingsgebieden.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150029","dc_title":"Brief aan Parlement TK 2021-02-19 13_04_00.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150150","dc_title":"RE: Melding nr. M2102 11388 onderwerp: houdbaarheid na aanprikken AstraZeneca vaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150167","dc_title":"Brief verzoek TB.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150178","dc_title":"EK brief - Een farmaceutische strategie voor Europa.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150191","dc_title":"Brief van IGJ aan FMS en KNMG inzake Draaiboek Triage.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150264","dc_title":"ColumnMontesqieuBeleidsdepartement.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145896","dc_title":"RE: Principenotitie toegangstesten - ACC 1 maart 2021","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150421","dc_title":"RE: Update COVID-19-vaccinatie medische hoogrisicogroepen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150466","dc_title":"HERA_BiodefencePreparednessProgramme_v8 (003).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150485","dc_title":"covid Hera COM 78 final.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1150513","dc_title":"30547.full.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117345","dc_title":"Eerste leveringen COVID voor CAS en BES - namens vierlanden DEF zonderwijzigingen.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1052","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116543","dc_title":"Artikel 1 Volksgezondheid 2020.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1053","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116603","dc_title":"Brief gezondheidsraad Astra Zeneca vaccinatie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1056","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116630","dc_title":"Bijlage 4 - Handvaten crisisstadia verpleeghuis en wijkverpleging V&VN.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1058","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116683","dc_title":"Bijlage1_Indicatiestellingdef2021.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1061","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116753","dc_title":"210112 Vaccinatiestrategie Afb 1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1062","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116757","dc_title":"Stand van zakenbrief digitale ondersteuning pandemiebestrijdingv0.8.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1081","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116843","dc_title":"FW: invite met webex details TCF Roland - Bart FEB 1: J&J AnnouncesTopline Phase 3 Data for COVID-19 Vaccine","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117124","dc_title":"Notf\ufffdlle \ufffdberall.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117131","dc_title":"Der Lack platzt ab.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117133","dc_title":"Die dritte Welle.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117203","dc_title":"brief resistente schimmels toezegging PvdD def-schone versie.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117222","dc_title":"bron VK verpleeghuizen vaccinatie effect.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117223","dc_title":"BWBR0044416-geldend_van_30-01-2021_tm_heden_zichtdatum_04-02-2021.rtf.rtf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117247","dc_title":"Briefadvies-Covid-19-Overleg-Planbureaus-Aandachtspunten-voor-een-herstelbeleid.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1048","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116517","dc_title":"Algemene+informatie+over+coronavaccinatie+in+Nederland.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117403","dc_title":"digital_solution_covid19.016b74c0.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117479","dc_title":"CoronaDashboard_Ronde_6_Rapport.pdf_cb4c8dca-184f-49e3-84fe-1177d14b68e5.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117484","dc_title":"COVID-19-vaccinatie+AstraZeneca-vaccin_20210204.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117488","dc_title":"covid-19-vaccinatie-astrazeneca-vaccin.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117544","dc_title":"persbericht  campagne nogffvolhoudenDEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117554","dc_title":"20210205 EU COVID19 Scientific Advice Platform - flash report.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117557","dc_title":"OMT-adviezen rondom Testen vanaf januari 2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117574","dc_title":"Coronavirus__preparing_Europe_for_the_increased_threat_of_variants.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117583","dc_title":"communication-hera-incubator-anticipating-threat-covid-19-variants_en.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117598","dc_title":"Document3.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117607","dc_title":"GR advies AstraZeneca_20210204.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117666","dc_title":"Variant_of_Concern_VOC_202012_01_Technical_Briefing_5_England.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117902","dc_title":"FW: ZJCN vervolgvragen","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115967","dc_title":"annurev-virology-012420-022445.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114278","dc_title":"Beantwoording Kamervraag 2021-02-02 13_27_20.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114285","dc_title":"RoundTableReport_20210208.pdf","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115150","dc_title":"Reizen Zweden.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115816","dc_title":"2020 Logunov - Sputnik V vaccine safety and efficacy - Lancet 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115829","dc_title":"Backer Eurosurv 2021. Impact of physical distancing measures against covid-19 on contacts and mixing pattterns_Pienter Corona.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121254","dc_title":"PDC19-218600TK B-100eOMT.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115878","dc_title":"S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115899","dc_title":"Bijlage 3 - Kamerbrief PDC19-218150TK A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115906","dc_title":"Brief aan de Minister - Raad van Ouderen vaccinatie covid 19 - februari2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115943","dc_title":"Variants_of_Concern_VOC_Technical_Briefing_6_England-1 c.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115957","dc_title":"PlosOneReinman_humidity_schools.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115961","dc_title":"Stand_van_zakenbrief_COVID-19 (1).docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115965","dc_title":"210115 2e Brief Gedragsreflecties avondklok en sociale bubbels.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117953","dc_title":"COVID-19_vaccine_effectiveness_surveillance_report_February_2021_FINAL.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1115995","dc_title":"2eKamer.04.02.2021.JaapVanDissel.v1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116045","dc_title":"1613081256621.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116140","dc_title":"FW: BO - en uitvoerende partijen 04/02 (wordt geannuleerd)","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116170","dc_title":"210203 Visual vaccinatietempo.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116224","dc_title":"PDC19-218113 A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116235","dc_title":"90e advies OMT_4 dec 2020.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116311","dc_title":"98e advies OMT deel 1_29 jan 2021.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116315","dc_title":"aanbieding-advies-interval-biontechpfizer.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116318","dc_title":"Aanbiedingsbrief EK.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116357","dc_title":"Catshuis.08.02.2021.JaapVanDissel.v1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116366","dc_title":"Advies 98ste OMT Covid-19 Deel1.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116391","dc_title":"PDC19-217842 A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1116488","dc_title":"Advies-Ethische-en-juridische-afwegingen-COVID-19-vaccinatie.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120397","dc_title":"Advies aan VWS na 100e OMT definitief.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120967","dc_title":"PDC19-217604 J.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120965","dc_title":"PDC19-217604 K.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120963","dc_title":"PDC19-217604 I.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120882","dc_title":"Samenvatting 210108_Verwachte voorraadanalyse PBM - Update janv1.0.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120750","dc_title":"RE: inschatting kosten vaccinatie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120725","dc_title":"ECDC weekly policy brief COVID Feb 4 2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120634","dc_title":"217843 getekende brief min VWS.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120612","dc_title":"jama_gottlieb_2021_oi_210002_1611174299.56557.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120597","dc_title":"Re: Opzet presentatie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120594","dc_title":"RE: Opzet presentatie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.1d;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120592","dc_title":"BLAZE 1 NEJM.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120589","dc_title":"BLAZE-1_4_Topline.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120415","dc_title":"Advies 17 Vaccinatie- en Testbewijs.doc","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121037","dc_title":"PDC19-217604 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120382","dc_title":"advertentie zat 12-2 geredigeerd door corrector.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120374","dc_title":"Advies 16 Veiligheid Covid-19 test en vaccinatiedata.doc","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120342","dc_title":"28th WHO Regulatory Update on COVID-19_05Feb2021_with revision.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120308","dc_title":"kamerbrief-over-stand-van-zakenbrief-digitale-ondersteuning-pandemiebestrijding.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120306","dc_title":"bevindingen-red-team-bij-systemen-ggd.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120289","dc_title":"Derde evaluatie Embryowet III webversie def..Derde evaluatie Embryowet III webversie def","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1120197","dc_title":"RE: spreeklijn kroketten-vaccin","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1119373","dc_title":"PDC19-217880.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1119363","dc_title":"Data sharing in dementia research - the EU landscape_Alzheimer Europe.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1119270","dc_title":"Deelname RVP ten tijde van COVID-19, HPV-vaccinatie, Lareb en Waterpokken.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1119138","dc_title":"d66_verkiezingsprogramma_een_nieuw_begin_2021_2025.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1119122","dc_title":"RE: Afbakening zorgmedewerkers","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118915","dc_title":"FW: vaccinatiestrategie ACC/MCC","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121248","dc_title":"PDC19-218615EK A-100eOMT.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117977","dc_title":"Vaccine hesitancy_social_media BMJ global health.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117987","dc_title":"FINAL__20210225_Workshop_Slide_Materials_ji3RPmR.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1117997","dc_title":"briefing_Netherlands.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118003","dc_title":"PDC19-217604 G OMT-advies.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118063","dc_title":"object0002.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118114","dc_title":"Brussel hoopte met gezamenlijke vaccininkoop te schitteren maar dit project verloor snel zijn glans 29 jan","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118126","dc_title":"Minister De Jonge: vaccinatietempo omlaag door minder leveringen - 26 jan","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118293","dc_title":"Geen Onderwerp.eml_23de2399-6347-452b-9935-64bc2a4b4b67.eml","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118343","dc_title":"Persbericht: Meer dan 75.000 gevaccineerden in 1 week inverpleeghuizen en instellingen gehandicapten ","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118441","dc_title":"Vaccins i.r.t. zuid-afrikaanse variant en andere mutaties","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118447","dc_title":"Toezending advies Ethische en juridische afwegingenCOVID-19-vaccinatie ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118613","dc_title":"Farmaceut kan het land in \ufffd\ufffdn maand vaccineren - Skipr","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112949","dc_title":"Persbericht_Vaccinatie van risicopati\ufffdnten in de huisartsenpraktijk halveert de kans op ziekenhuisopnamen en overlijden door COVID.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112974","dc_title":"210202 Toelichting wijzigingsregeling 2 februari.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121246","dc_title":"PDC19-218600TK A-100eOMT.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121214","dc_title":"PDC19-218113 C.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121212","dc_title":"Factsheet+beschermingsmiddelen_versie+1.1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121210","dc_title":"bijlage-1-advies-rivm-verkiezingen-en-covid-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121193","dc_title":"PDC19-218113 D.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121190","dc_title":"advies-rivm-verkiezingen-en-covid-19-1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121188","dc_title":"PDC19-218113 B.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121105","dc_title":"RE: SPOED Re: vaccinatie (zorg)personeel IC's - zuurstof, beademing,thuisdialyse etc","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121066","dc_title":"PDC19-217604 C.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121047","dc_title":"PDC19-217604 E.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1118712","dc_title":"PDC19-216414.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121041","dc_title":"PDC19-217604 L.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.1635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1121039","dc_title":"PDC19-217604 N.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113516","dc_title":"Q1 - Increases in Loneliness Among Young Adults During the COVID-19 Pandemic and Association With Increases in Mental Health Problems.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113564","dc_title":"Scanned from a Xerox Multifunction Printer.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113555","dc_title":"Haugetal_NatureHumanBehaviour_2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114200","dc_title":"Petts 2004 MMR risk discussion.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114073","dc_title":"210109_advertentie_264x390mm_2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113545","dc_title":"ERRAZE@WUR FEB2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113536","dc_title":"Q1 Rapid Systematic Review- The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113524","dc_title":"Q1 - Estimation of US Childrens Educational Attainment and Years of Life Lost Associated With Primary School Closures During the Coronavirus Disease 2019 Pandemic.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114094","dc_title":"210211 Nieuwsbericht selectie HAP's.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113185","dc_title":"Hall 2021. Effectiveness of vaccine against infection and coverage in HCW in England_SIREN study.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113230","dc_title":"History of Medicine vaccinating children against COVID-19.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113237","dc_title":"30th WHO Regulatory Update on COVID-19_05Mar2021.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113509","dc_title":"Statement of the Twenty-Seventh Polio IHR Emergency Committee.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113460","dc_title":"Brief steunpakket welzijn en leefstijl ivm COVID-019 210211_07.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113336","dc_title":"SV Yesilg\ufffdz-Zegerius inzake bericht huisartsen niet onder de indruk van brief Viruswaarheid.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114129","dc_title":"Social science policy brief_Vaccination_v6.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114102","dc_title":"210208 Vaccin Vragen A4_DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113601","dc_title":"210225 - wijziging Wpg sluitingsbevoegdheid - -.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114241","dc_title":"210210 Werkinstructie COVID-19-vaccinatie HAP-Moderna-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1112992","dc_title":"210202 wijzigingsregeling 2 februari versie Staatscourant.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113002","dc_title":"210209 Advies 17 Test- en vaccinatiebewijzen.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113865","dc_title":"26-02-2021 1812477-217082 DL970477.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113742","dc_title":"217604 - getekende brief.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113739","dc_title":"24-02-2021 Plenair debat ontwikkelingen Covid-19  PDC19 - Minister MZS.pdf.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113008","dc_title":"210209 Subsidieregeling coronabanen in de zorg_Laatste wijzigingen SCHOON - DEF.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113141","dc_title":"NEJM BNT162b2 mRNA Covid-18 vaccine in a nationwide mass vaccination setting[1].pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1114224","dc_title":"210210 Werkinstructie COVID-19-vaccinatie HAP-BioNTechPfizer-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113600","dc_title":"210223 wijzigingsregeling 23 februari met avondklok - versie MCC.docx.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1113135","dc_title":"Early reductions in COVID in Israel_Lancet.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145652","dc_title":"RE: passage kamerbrief","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139257","dc_title":"Bijlage Vaccin+in+het+kort+voor+Moderna+tegen+COVID-19_Test_ (1).pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139305","dc_title":"210217 Werkinstructie COVID-19-vaccinatie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139313","dc_title":"Infographic RIVM vaccinatie tegen corona_TG-bev.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139348","dc_title":"2021 02 05 NL Wegwijzer vragen COVID19-vaccinatieprogramma zorgmedewerkers.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139350","dc_title":"210210 Werkinstructie COVID-19-vaccinatie HAP-Moderna-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139355","dc_title":"210210 Werkinstructie COVID-19-vaccinatie HAP-BioNTechPfizer-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139359","dc_title":"20210209 Werkwijze vaccinatie zorgmedewerkers versie 3.0.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139366","dc_title":"20210209 Werkwijze vaccinatie zorgmedewerkers versie 3.1.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139391","dc_title":"210204 Werkinstructie COVID-19-vaccinatie HAP-BioNTechPfizer-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139395","dc_title":"Beschrijving werkwijze uitnodigen 80-89.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139397","dc_title":"210208 Werkinstructie COVID-19-vaccinatie HAP-Moderna-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139245","dc_title":"Ministerieel besluit 2021-02-16 11_05_50.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139412","dc_title":"012633_Uitn Zorgmedewerkers flowchart_V5_TG.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139437","dc_title":"20210120 COMPLETE UITNODIGINGSSET DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139442","dc_title":"012633_Uitn Zorgmedewerkers flowchart_V4.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139460","dc_title":"012633_Uitn Zorgmedewerkers flowchart_V3.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139516","dc_title":"20210119_Toelichting registratie-DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139588","dc_title":"COVID-19-vaccinatie+AstraZeneca-vaccin_20210204.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139622","dc_title":"Rose 2013 AJE Mortality Risk Score Prediction in an Elderly Population Using Machine Learning.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139625","dc_title":"Hu 2020 IJE Early prediction of mortality risk among patients with severe COVID-19, using machine learning.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139663","dc_title":"Beschrijving werkwijze uitnodigen 80-89.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139739","dc_title":"09022021 Notitie vaccineren van vaccinerend zorgpersoneel om spillage op locatie te minimaliseren.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139773","dc_title":"Infographic RIVM vaccinatie tegen corona_TG.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138821","dc_title":"200225 nb Ronde 10 versie 4a.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138322","dc_title":"FW: stukken koepeloverleg corona & ggz 20 januari 2021: updatevaccinatie","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138374","dc_title":"FW: Testen en vaccineren","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138397","dc_title":"Sage_S0922_EMG_and_SPI-B_-_Mitigating_risks_of_SARS-CoV-2_transmission_associated_with_household_social_interactions_BUBBLES PARAGRAAF D OVER COMMUNICATIE.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138401","dc_title":"Sage_S0356_SPI-B_Behavioural considerations_Well-being_and_Household_Connection_bubbles.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138409","dc_title":"Sage_S0357_SPI-M-O_Statement_on_Bubbles.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138499","dc_title":"FW: Agenda Koepeloverleg 22-2-21","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138510","dc_title":"20210217 Geannoteerde agenda BO MVWS - -'en 17 februari 2021.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138512","dc_title":"RE: Signaal: Imago AstraZeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138646","dc_title":"Wallinga (2010) PNAS.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138815","dc_title":"DPV_231 Toelichting juridische grondslag gegevensverstrekking aan RIVM v1.1.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138819","dc_title":"FW: Voorstel agendapunten PO FEZ/ADR 24/2","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139799","dc_title":"Factsheet medische indicatie COVID-19 vaccinatie v1.7.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138879","dc_title":"Lunn_etal_2020_social distancing covid-19 communication.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1138883","dc_title":"FW: vraag vaccinaties","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139059","dc_title":"Instructie-klaarmaken-Moderna.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139061","dc_title":"Instructie-klaarmaken-AstraZeneca.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139087","dc_title":"20210208_weekly update tekst_definitief.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139089","dc_title":"20210208 covid update nieuwsbericht.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139217","dc_title":"210223 Nieuwsbericht 2e vaccinatie-spillage.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139220","dc_title":"210223 Werkinstructie COVID-19-vaccinatie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139224","dc_title":"012675_A5 Flyer Q&A priklocaties_V2.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139243","dc_title":"AstraZeneca_COVID-19_01 meegeef bijsluiter.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142402","dc_title":"Bijlage 3 - Medisch beleid Fase 3 code zwart .docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141252","dc_title":"PRO/AH/EDR> COVID-19 update (81): transmission, reinfection,\tvaccine and case severity, WHO","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141258","dc_title":"PRO/AH/EDR> COVID-19 update (80): vaccine, USA variants, comments,\tWHO, global","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142648","dc_title":"1-s2.0-S266637912100015X-main.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141266","dc_title":"PDC19-217738.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141273","dc_title":"3.a. Oplegger organogram datalek GGD v0.8.docx","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142550","dc_title":"Motie_van_het_lid_Kuik_over_een_Nederlandse_Global_Health_Strategie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142507","dc_title":"Heederik et al COVID-19 ERJ 2020.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142504","dc_title":"Niuewe radiocommercials","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137667","dc_title":"FW: Griepvaccins","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e;buiten verzoek","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137665","dc_title":"Verwijzingen_ggz_20210215.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142409","dc_title":"Voortgangsbrief 23-02.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142789","dc_title":"Overzicht adviezen Raad van State 2021","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137659","dc_title":"20210215_nza_rapport_landelijk_v28_tussenrap_verwijzingen_zorgbeeld_feb_def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142345","dc_title":"210223 Vaccinatiestrategie.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142325","dc_title":"FW: 20210125 Terugkoppeling overleg registreren vaccinatie werknemersnav BO","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137650","dc_title":"2020 Vaccine Schoch-Spana et al The public's role in COVID-19 vaccination Human-centered recommendations to enhance pandemic vaccine awareness access and acceptance in the US.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141375","dc_title":"FW: Advies over amvb raadpleging EPD ivm corona","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141386","dc_title":"RE: graag je reactie op een paar vragen uit Bonaire","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142259","dc_title":"03 - Infographic RIVM - Vaccinatie tegen corona.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1142248","dc_title":"210210_VRAGENLIJST coronavirus COHORT ronde 10 RIVM en GGD_DEF.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141799","dc_title":"Bijlage 3 - Bijlage bij brief TK Nationaal Programma FunderendOnderwijs.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141786","dc_title":"De+coronacrisis+-+de+zorg+en+jeugdhulp+blijvend+onder+druk.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141724","dc_title":"RE: ProMED Digest, Vol 104, Issue 53","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140842","dc_title":"24-02-2021 Plenair debat ontwikkelingen Covid-19  PDC19 - MinisterVWS.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139814","dc_title":"20210128_nieuwsbericht aandachtspunten werkinstructie en wijzigingen-def.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139819","dc_title":"FW: Versie 0.4 afwegingskader","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137833","dc_title":"RE: Ter info: griepachtige klachten na AstraZeneca","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1139839","dc_title":"20210209-2.2 Beleidsreactie VWS op uitrol NPPV PG-215910 A.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137820","dc_title":"RE: Agenda Koepeloverleg 22-2-21","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145472","dc_title":"RE: nota_commentamas","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140024","dc_title":"20210218 Bijlage 2b Factsheet 4e coronaquickscan+Jeugdautoriteit.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140089","dc_title":"20210218 Bijlage 2a 4e coronaquickscan Jeugdautoriteit.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140317","dc_title":"RE: twijfelgevallen vaccinatie groep zorgmedewerkers","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140799","dc_title":"24-02-2021 Plenair debat ontwikkelingen Covid-19  PDC19 - MinisterMZS.docx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140806","dc_title":"23-2-2021 plenair debat TwM Covid-19 en Voortduringswet artikel 8 Wbbbg(Eerste Kamer) WJZ.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141050","dc_title":"210216 Vaccinatiestrategie tijdschema.pdf","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4078","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145166","dc_title":"RE: ISB posten / beleidsuitgangspunten CPB","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1137772","dc_title":"PLATO-#4184965-v1-COVID-19__Campagnemonitor_Vaccinaties_rapportage_jan_2.._.pptx","dc_type":"URL","foi_doc_missing":0,"foi_valuation":"Reeds openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.4069","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1145031","dc_title":"RE: input crisisstaf - graag aandacht situatie in de noodopvang","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1140442","dc_title":"RE: Effectieve mondneusmaskers voor (kwetsbaar) publiek","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143741","dc_title":"RE: Agenda + stukken stuurgroep 25/2  Opvolging debat datalek ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1141232","dc_title":"RE: Vraag FIN over realisatiecijfers vaccineren ","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143609","dc_title":"RE: acties naar aanleiding van besluiten minister mbt opschaling","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e","foi_valuation":"Deels openbaar"},{"dc_identifier":"nl.mnre1025.2i.2022.152.doc.3901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/document/VWS-WOO-17-1143514","dc_title":"RE: 3 dingen over pg-covid","dc_type":"URL","foi_doc_missing":0,"foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/decision/download","dc_title":"besluit","dc_type":"besluit","foi_doc_missing":0,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"decision-3478791-1040904-pdo.pdf","foi_nrPages":13},{"dc_format":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/inventory/download","dc_title":"inventarislijst","dc_type":"inventaris","foi_doc_missing":1,"foi_fileName":"inventarislijst-3478791-1040904-pdo.xlsx"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106859","dc_title":"vaccinatiebewijs: wat inleesstukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106859","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106870","dc_title":"RE: KWALITEITSHANDBOEK VOORZIENING EN BEHEER COVID19 VACCINS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106870","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106879","dc_title":"FW: HERA Incubator Eerste appreciatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1106879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106883","dc_title":"FW: RIVM WI's + FO's - comment SS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106883","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106907","dc_title":"Terugkoppeling IPCR rondetafel, 15 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106907","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106913","dc_title":"FW: DEFINITIEVE instructies Coreper II // woensdag 3 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106913","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106920","dc_title":"FW: Comit\ufffd bouwkundige aanpassingen IC-opschaling ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106920","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106947","dc_title":"PFIZER- RE: Powerpoint presentatie vervolgsessie, exceloverzicht aanleveren aantallen en communicatiebericht toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106947","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106948","dc_title":"Quote van - van Dissel bij overhandiging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106948","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106950","dc_title":"RE:  COVID vaccin BES CAS -WEEK 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106950","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106972","dc_title":"19022021_19 februari 2021_COVID19 vaccinaties_Plan van Aanpak_opschaling (002).ppt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106972","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106993","dc_title":"AW: Follow-up MoH Netherlands","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106993","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1106998","dc_title":"Update werkinstructies ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1106998","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107004","dc_title":"EU Health Research Update | Week 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107004","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107008","dc_title":"EU Health Research Update | Week 8","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107008","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107011","dc_title":"Re: wijziging Spg ivm vaccinatie corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107011","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107015","dc_title":"RE: Tweede prik voorbereidingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107015","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107024","dc_title":"seniorenoverleg 05/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107024","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107049","dc_title":"Info mail aan leden met verzoek om datum en plaats","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107049","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107051","dc_title":"Convenant ROAZ apotheken: traject 1b","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107093","dc_title":"RE: ter meelezen: geannoteerde agenda ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107093","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107095","dc_title":"RE: Reactie DR op Jaarrapportage Toprisico's Organisatieontwikkeling & Onvoldoende financiele middelen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107107","dc_title":"RE: concept voorstel COMPLEX over sociaaleconomische gezondheidsverschillen en COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107108","dc_title":"RE: Antw: concept voorstel complex","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107110","dc_title":"Documenten COVID-19 sociaaldemografische determinanten vanuit data gezond en gelukkig Den Haag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107119","dc_title":"RE: MLS 4410002775 (ww 1100232051)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107119","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107134","dc_title":"FW: Medlab bericht voor positieve testuitslagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107136","dc_title":"FW: Update vaccinatie van klinische MSR-pati\ufffdnten en hun medewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107136","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107142","dc_title":"RE: Winkelwagen HIS Offertes deel 4/9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107142","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107158","dc_title":"RE: vraag van MN over toestemmingsformulier vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107158","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107169","dc_title":"RE: omgaan met spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107169","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107187","dc_title":"PLEASE REVIEW: draft allocation tables MODERNA TOP UP, NOVAVAX,VALNEVA ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107187","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107197","dc_title":"RE: Update plaatjes t/m week 13","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107197","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107212","dc_title":"RE: Aanbiedingsbrief extra beveiliging opslaglocaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107212","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107234","dc_title":"aanpassingen aan document 'goed vaccinbeheer' *please review*","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107236","dc_title":"FW: SLA Movianto - RIVM versie 1 *Graag laatste blik en fiat voor tekenronde* ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107236","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107244","dc_title":"RE: GGZ en kleine hoeveelheden AZ, status?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107244","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107266","dc_title":"FW: opzet SNPG-lijst + aantallen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1107266","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107284","dc_title":"FW: 15 min","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107316","dc_title":"Bureaukaart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107316","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107325","dc_title":"Verminderde levering AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107325","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107345","dc_title":"RE: blokjes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107345","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107346","dc_title":"FW: SO ER - vragen Halix","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107346","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107351","dc_title":"RE: Opzet HAP Moderna/BF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107351","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107442","dc_title":"RE: Minirsterie proof antwoord aandachtspunten COVID-lucht onderzoeksprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107442","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107626","dc_title":"RE: 2021-02-22 V5 vaccins voor voortgangsbrief (002) NT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107626","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107818","dc_title":"00000392.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107818","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107850","dc_title":"000003E4.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107850","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107852","dc_title":"000003E5.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107852","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107854","dc_title":"000003E6.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107854","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107888","dc_title":"1821950-217899-WJZ Memo KvdK.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107888","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107892","dc_title":"1821950-217899-WJZ voordracht.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107892","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107902","dc_title":"20210117 Saba Stas - Brief bevindingen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107902","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107951","dc_title":"Bevestiging afspraken met NKR tav H. Veerdig.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107951","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1107959","dc_title":"Bijlage 1 studies.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1107959","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108012","dc_title":"Nota brief vaccinatiestrategie COVID-19.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108012","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108015","dc_title":"Nota ter beslissing - overleg werkgeversorganisaties bonus 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108015","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108018","dc_title":"Nota ter beslissing 2021-02-03 15_47_48.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108018","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108019","dc_title":"Nota ter beslissing 2021-02-04 8_46_54.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108019","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108021","dc_title":"Nota ter beslissing Aanwijzing IGJ exportverbod Covidvaccins.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108021","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108026","dc_title":"Nota ter informatie 2021-02-03 10_02_14.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108026","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108027","dc_title":"Nota voorbereiding overleg 2021-02-01 16_31_33.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108027","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108031","dc_title":"Nota voorbereiding overleg 2021-02-05 8_17_53.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108031","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108038","dc_title":"Oplegnota 2021-02-01 14_32_40.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108038","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108039","dc_title":"Oplegnota 2021-02-02 13_27_14.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108039","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108041","dc_title":"Oplegnota 2021-02-03 8_55_17.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108041","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108043","dc_title":"Oplegnota 2021-02-08 13_32_02.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108043","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108055","dc_title":"RE_ Volume Increase under Dutch EU JP Procurement Contract for Pandemic Influenza Vaccine .pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108055","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108057","dc_title":"Toezending advies Interval BioNTech-Pfizer.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108057","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108071","dc_title":"000004B8.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108071","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108073","dc_title":"000004C1.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108073","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108077","dc_title":"000004C7.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108077","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108079","dc_title":"000004C0.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108079","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108093","dc_title":"0000052B.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108093","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108105","dc_title":"00000547.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108105","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108109","dc_title":"00000548.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108109","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108115","dc_title":"00000552.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1108115","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108119","dc_title":"2021-02-05 - alternative protocol FedEx (NL) (update - signed black field).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108119","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108131","dc_title":"210122 DEF Haaglanden MC advies IC Comiteocr.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108131","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108139","dc_title":"210211 IC advies Flevo zkhsocr.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108139","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108141","dc_title":"210211 voortgangsnota wob corona.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108141","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108158","dc_title":"218603 Brief offerteverzoek voor de productie en levering van FFP2 mondneusmaskers in Nederland EU geproduceerd.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108158","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108170","dc_title":"218902 AFPRO Brief offerteverzoek voor de productie en levering van deze gecertificeerde FFP2 mondneusmaskers in Nederland EU geproduceerd.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108172","dc_title":"218606 Brief offerteverzoek voor de productie en levering van deze gecertificeerde FFP2 mondneusmaskers in Nederland EU geproduceerd.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108172","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108176","dc_title":"Antwoord brief Thuisarts.nl.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108188","dc_title":"Bijlage 2 procedure toewijzen vaccin voor onderzoek.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108188","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108198","dc_title":"Brief 2021-02-10 15_17_54.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108198","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108258","dc_title":"Nota ter beslissing 2021-02-12 14_04_51.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108258","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108262","dc_title":"nota aan MVWS DOC 11 februari inzet testbewijs_uivraag MvP.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108262","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108263","dc_title":"Nota ter informatie 2021-02-17 6_15_33.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108263","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108265","dc_title":"Nota ter beslissing 2021-02-16 11_05_36.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108265","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108267","dc_title":"Nota voorbereiding overleg 2021-02-16 12_13_41.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108267","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108270","dc_title":"Ondertekende opdrachtbrief Tekst van Kerbert.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108270","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108272","dc_title":"offerte aanbieding brba componenten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108272","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108288","dc_title":"Oplegnota het bericht Horizons Tepezzasupply dwindles as manufacturer Catalent pivots to Warp Speed Vaccines.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108296","dc_title":"PA Consulting Services BV - opdrachtbevestiging datagedreven vaccineren.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108296","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108312","dc_title":"Voorstel evaluatie testbeleid bij uitbraak in de verpleeghuizen versie 4 in brief__BB.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108312","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108336","dc_title":"000005EE.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108336","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108338","dc_title":"000005F8.PDF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108338","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108386","dc_title":"218771 - Akkoord Min MZS.pdfocr.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108386","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108390","dc_title":"3. nota moeilijk bereikbare groepen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108390","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108411","dc_title":"bijlage Nota Informeel EU Ministers van Volksgezondheid 1 maart 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108411","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108412","dc_title":"Brief 2021-02-18 12_43_38.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108412","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108448","dc_title":"Brief aan Parlement TK aankoop optionele doses BiontechPfizer.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108448","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108513","dc_title":"001 voorlopige opgave meerkosten corona decemb.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108513","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108536","dc_title":"FW: Centraal register COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108536","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108552","dc_title":"RE: stukken ter voorbereiding op ons tweede overleg ggz en vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108552","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108591","dc_title":"FW: mijn reactie op het stuk van het RIVM mbt opschalingsscenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1108591","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108596","dc_title":"FW: Uitnodigingsbrief GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108596","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108599","dc_title":"FW: versterking vaccin NL. EU en Internationaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108601","dc_title":"FW: Vraag vanuit Intravacc om snel 1,2 miljoen vrij te spelen enoverleg Intravacc-PD-C19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108601","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108642","dc_title":"opdrachtbrief LHV en financiele punten voor LHV en HAP (Ineen).","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108642","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108758","dc_title":"1828329-218469-PG brief aan Lamboo Medical betreft vergunning continuiteit werkzaamheden bij COVID-19.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108758","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108771","dc_title":"FW: 15022021_OpschalingScenarios.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108771","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108773","dc_title":"RE: opschaling brainstorm en verder","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108773","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108790","dc_title":"2. Verslag 23 februari 2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108790","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108791","dc_title":"2. Presentatie - Desinformatie.pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108791","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108792","dc_title":"2.2 CCP B&BC,2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108792","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108794","dc_title":"2.1 NCA Update B&BC- T&C 2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108794","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108800","dc_title":"2.3 EC_H2020_ CCP R&I_NCA meeting_11 Feb 21.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108800","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108804","dc_title":"2.6 EMA Supply of PDMP 11Feb21.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108804","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1108837","dc_title":"FW: Voorstel Bonaire voor quarantainewet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1108837","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109022","dc_title":"FW: mijn reactie op het stuk van het RIVM mbt opschalingsscenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109059","dc_title":"200910 Verslag begeleidingscommissie 10 september.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109059","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109106","dc_title":"RE: spoed: vaccinbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109106","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109110","dc_title":"Nieuwe versie brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109126","dc_title":"FW: Uitgangspunten beleidskader fase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1109126","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109127","dc_title":"FW: verzoek afstemming voor bestuurlijk overleg Spoor 2a as vrijdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109127","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109146","dc_title":"200924 Verslag begeleidingscommissie 24 sept 2020.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109146","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109165","dc_title":"RE: Verlenging Tijdelijke wet maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109165","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109205","dc_title":"FW: verslag wekrgroep veiligheidsbewaking","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109205","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109206","dc_title":"FW: Overleg Bonaire - VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109206","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109234","dc_title":"Ter informatie: Overzicht Europese landen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109234","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109243","dc_title":"FW: Factsheet medische risicogroepen t.b.v. PO - morgenochtend","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109243","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109259","dc_title":"20210209 Geannoteerde Agenda VC ministeroverleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109259","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109298","dc_title":"RE: 20210211 medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109298","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109301","dc_title":"Hoe nu verder? Meerkosten uitvoering ggz vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109301","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109324","dc_title":"RE: check Kamervragen Bergkamp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109324","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109339","dc_title":"Update intravacc:  PPS plannen intravacc voor bouwproductie-faciliteit en overige zaken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109339","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109351","dc_title":"FW: Input Ieder(in) voor coronadebat 4/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109351","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109390","dc_title":"RE: aanpassing in brief nodig: HPZone niet al per 1 maart vervangen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109390","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109421","dc_title":"201119 Verslag begeleidingscommissie 19 november.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109421","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2h;buiten verzoek","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109422","dc_title":"201126 Verslag begeleidingscommissie 26 november.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109422","foi_groundsOfRefusal":"5.1.2a;5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109438","dc_title":"RE: Vaccinatie update ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109438","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109451","dc_title":"RE: Nota inkoop COVID behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109451","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109452","dc_title":"RE: 210209_Nota order mogelijke COVID behandelingen_v0.1_YdK HK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109452","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109467","dc_title":"RE: Stand van zakenbrief digitale ondersteuning pandemiebestrijding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109467","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109477","dc_title":"Uitvoering motie Segers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109477","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109595","dc_title":"5. Nota besluitvorming fase 0 toegangstesten spoor 2a - DOC -10-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109595","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109612","dc_title":"Bijlage 2_20210127_Nota BZK (CZW)_Test-vaccinatiesamenleving enbijlage.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109612","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109619","dc_title":"Bijlage 1_20210203_Nota BZK_Vastlegging Covid-vrij zijn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109619","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109622","dc_title":"4. Vaccinatiebewijs interdepartementale afstemming.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109622","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109637","dc_title":"2.2.1 Nota ter informatie BRBV - vitaliteit en jongeren def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109637","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109640","dc_title":"2.a.1 PG - Verslag vraaggesprek staatssecretaris Paul Blokhuis 'Nl nade crisis' 09022021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109640","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109668","dc_title":"20210205 Communicatie publicatie IGJ infectiepreventieverpleeghuizen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109668","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109677","dc_title":"Versterking vaccin keten NL.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109677","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109683","dc_title":"02-02-2021 notitie Multipurpose vaccinfaciliteit Proposal .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109683","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109695","dc_title":"Voorbereiding Intern Gesprek VWS Intravacc 10_2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109695","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109700","dc_title":"04 Oplegnotitie Kwetsbare groepen - in het bijzonder jongeren.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109700","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109706","dc_title":"04a Bijlage - Notitie Flankerend beleid kwetsbare groepen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109706","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109708","dc_title":"06b Bijlage - Handreiking demonstraties.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109708","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109724","dc_title":"signalen 1 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109724","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109734","dc_title":"05022021 verslag seniorenoverleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109734","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109738","dc_title":"2020-05-19 Aanvullend budget COVID-19 Onderzoeksprogramma.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109738","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109778","dc_title":"FW: fisches in lijn brengen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109778","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109804","dc_title":"Instructiemail notaoverleg 11 feb 12.00-14.00u - in ibabs donderdag11 feb 12u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109804","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109832","dc_title":"4-kantsoverleg woensdag 030221 verslag ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109832","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109838","dc_title":"RE: reactie op fiche leveringszekerheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109838","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109852","dc_title":"2020-04-29 COVID-19 Onderzoeksprogramma.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109852","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109889","dc_title":"11 02 2021 Concept verslag BO - en uitvoerende partijen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109889","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109896","dc_title":"12-2-2021 Verslag brainstorm opschaling.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109896","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109901","dc_title":"12022021 verslag senioren.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109901","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109902","dc_title":"11 februari BRBV stukken.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109902","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":50,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109909","dc_title":"FW: te plannen sessie VWS/RIVM volgende week m.b.t. opschalenvaccinatiestrategie Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109909","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109920","dc_title":"13 02 2021 Opschaling vaccinatie strategie rev1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109920","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109939","dc_title":"stand van zaken overzichten_overig.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109939","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109963","dc_title":"1e voorlopige opgave meerkosten Covid-19 GGD Hollands Noorden 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109963","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109965","dc_title":"20210212_aanbiedingsbrief covid 19 meerkosten ministerie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109965","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109974","dc_title":"1822599-217984-PG Brief aan ActiZ Jeugd betreft Declaratie meerkostenCovid19.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109974","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109987","dc_title":"Breathomix - Neuzen_Opdrachtverlening.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109987","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1109991","dc_title":"Overeenkomst VNO-NCW.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1109991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110005","dc_title":"2020 01 tm 12  GGD Zeeland.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110005","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110014","dc_title":"2020-11 en 2020-12 GGD Amsterdam meerkosten corona.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110014","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110016","dc_title":"2020-11-25 Publieke herstelzorg.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110016","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110017","dc_title":"2020-12 GGD IJsselland aanvullende.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110017","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110019","dc_title":"2020-11 en 2020-12 GGD Flevoland.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110019","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110021","dc_title":"2020-12 Zuid-Limburg meerkosten.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110021","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110023","dc_title":"2020-05-27 Bruikleenovereenkomst VWS.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110023","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110027","dc_title":"2020.01.03 FG Advies als bijlage bij DPIA CIMS 31 december 2020 versie 1.0 defintief.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110031","dc_title":"2020.02.17 FG Advies als bijlage bij DPIA CIMS Selecteren en Oproepen.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110031","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110036","dc_title":"2020.02.22 FG Advies bijlage DPIA CIMS 1.0 fase v en vii.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110036","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110049","dc_title":"20200402 Sitrap 51- Nieuw coronavirus_bijlage 2.pdf_fabcda14-5946-4ba9-8f0f-66ecc0f59c81.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110049","foi_groundsOfRefusal":"5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110055","dc_title":"20200520 Beeld BTCb 20 mei.docx_fdc2ab0e-999b-48ae-9ce8-1e1583039ef7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110055","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110072","dc_title":"20201012 melding door Amstelring middels meldformulier.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110072","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110105","dc_title":"20201208 Brief SPP vervolgopdracht_V3.1_schoon.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110105","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110115","dc_title":"20201223 RE_ Passage voor in brief reactie GR-advies.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110115","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110117","dc_title":"20201231 Verslag strategisch overleg vaccinatie met MVWS concept.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110117","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110118","dc_title":"20201231 Verslag BO - en uitvoerende partijen 31122020 - aangepaste versie.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110118","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110130","dc_title":"2021 01 31 Budgettaire plaat DGCZ.xlsx.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110130","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110132","dc_title":"Nota LHV opdrachtbrief definitief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110132","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110134","dc_title":"Nota ter beslissing 2021-02-18 19_09_03.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110134","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110136","dc_title":"nota ter beslissing.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110136","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110144","dc_title":"Nota ter beslissing 2021-02-26 8_11_58.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110144","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110145","dc_title":"Nota zuurstofvoorziening en naalden.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110148","dc_title":"Nota ter beslissing 2021-02-19 13_03_53.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110148","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110154","dc_title":"Oplegnota 2021-02-18 15_37_41.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110154","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110155","dc_title":"Offerte COVID vaccinatie kliniekmedewerkers ZBC.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110155","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110158","dc_title":"Oplegnota 2021-02-18 14_55_43.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110158","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110168","dc_title":"ter beslissing_brief msd.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110168","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110170","dc_title":"Uitvoeringsplan v1.3 coordinatie registratie en communicatie HISen EVS en cal plan 09022021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110170","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110199","dc_title":"20201202_Offerte 2021 P19 COVID-19.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110199","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":76,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110203","dc_title":"Situatie Beroepschauffeurs NIJPEND.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110203","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110214","dc_title":"FW_ Onderbouwing spoedbetaling GGD GHOR 21_12_2020 en vervolg.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110214","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110223","dc_title":"Kopie van Map3.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110223","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110311","dc_title":"informatief memo tbv CIO-Raad VWS mbt hotspot en verantwoordingCOVID-19 DEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110311","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110315","dc_title":"1. defintief verslag CIO raad 14 januari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110315","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110327","dc_title":"8ai. Course of action -  voor besluit naarstuurgroep_mondspoeling_covitact.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110327","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110331","dc_title":"6. Factsheet_DOTT_week05_LCT.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110331","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110333","dc_title":"5. Sneltesten onderwijs - LCT 04022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110333","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110335","dc_title":"7. Pilot Bunschoten - benodigdheden.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110335","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110338","dc_title":"8. Voortgangsrapportage stuurgroep sneltesten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110338","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110340","dc_title":"7. Grootschalig risicogericht testen - voortgangsrapportage_LCT.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110340","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110350","dc_title":"8ai. Validatie Novogenia mondspoelkit en Covitact - pilotbunschoten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110350","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110375","dc_title":"FW: SAGE werkgroep over AstraZeneca ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110375","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110393","dc_title":"2021-02-11 Minutes Cross-Border Taskforce Corona - Key Figures.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110401","dc_title":"2021-ERN COVID-19 vaccination.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110406","dc_title":"20210204 Geannoteerde Agenda VC Gezaghebbers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110406","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110407","dc_title":"20210121 Verslag VC Gezaghebbers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110407","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110410","dc_title":"RE: vaccinatie Defensie-personeel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110410","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110413","dc_title":"20210128  Verslag strategisch overleg vaccinatie met MVWS def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110413","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110419","dc_title":"20210122 Besluitenlijst Vaccinatieregister.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110419","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110424","dc_title":"20210203 Memo analyse HIS-offertes COVID-19 vaccinaties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110424","foi_groundsOfRefusal":"5.1.1c;5.1.2b","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110425","dc_title":"20210129 - DOTT Basis op orde 0.9.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110425","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110429","dc_title":"Factsheet_Follow-up_risicoanalyse_week05.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110429","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110431","dc_title":"Management samenvatting Werkgroep Burgerperspectief Testen 27 januari2021 versie 2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110431","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110433","dc_title":"Annotatie scenario opschaling RIVM.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110433","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110440","dc_title":"20210204 Beeld BTC19 4 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110440","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110442","dc_title":"Hyperimmuun globuline in studieverband","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110442","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110443","dc_title":"FW: Afwegingskader MU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110443","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110451","dc_title":"20210131 verslag PO MinVWS 20.45u - 22u def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110451","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110457","dc_title":"NCTV uitvraag Coronavirus 4 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":80,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110469","dc_title":"FW: 20210204 : Lithuania : The acceleration modelling showed thatopening schools and elections were mass spreading events. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110469","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110471","dc_title":"Presentatie DOC 3 februari 2021 V3_def.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110473","dc_title":"Compacte weergave scenario's positief neutraal negatief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110473","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110477","dc_title":"2. Verslag MT DGLZ breed 11 januari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110477","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110479","dc_title":"20210204 Scenario VWS IC-capaciteit.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110479","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110490","dc_title":"Memo onderbouwing pandemielabs.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110490","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110492","dc_title":"2020-10-13 174-2020 DG VWS Sonnema Facturatie Pandemielabs (002).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110492","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110524","dc_title":"20210211 Duitse RDI-ontwikkelingen t.a.v. coronavirus.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110524","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110530","dc_title":"20210211 Internationale factsheet_ 11 februari.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110530","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110618","dc_title":"2021 02 11 Notities clusteroverleg MOR 11 februari.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110618","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110655","dc_title":"2021-01 GGD Amsterdam Amstelland juiste adres cfm bankafschrift.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110655","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110661","dc_title":"2021-01 GGD Groningen meerkosten corona.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110661","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110674","dc_title":"2021-01 GGD IJsselland.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110674","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110676","dc_title":"2021-01 GGD Zeeland meerkosten corona.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110676","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110679","dc_title":"2021-01 GGD Zuid Limburg 20210203 meerkosten corona .pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110679","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110681","dc_title":"2021-01 GGD Zeeland meerkosten corona vaccinatie GEWEIGERD.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110681","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110687","dc_title":"2021-01-28 Goedkeuring programmavoorstellen vervolg COVID-19, behandeling en vaccinstudies.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110687","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110695","dc_title":"2021-02 GGD Hollands Noorden meerkosten.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110695","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110697","dc_title":"2021-01-29 Definief verslag BR 29 januari 2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110697","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110699","dc_title":"2021-02 GGD IJsselland.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110699","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110707","dc_title":"FW: Concept fiches spoor 2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110707","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110708","dc_title":"2021-02-04 Beslisnota BR investeringsvoorstellen RRFv3.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110708","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110720","dc_title":"20210211 Beeld BTC 11 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110720","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110725","dc_title":"20210103 FW_ concept teksten voor brief verzenddatum 04 01 2020_ goedgekeurd door LHV.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110725","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110736","dc_title":"20210112  Verslag strategisch overleg vaccinatie met MVWS def.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110736","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110740","dc_title":"20210111 Verslag strategisch overleg vaccinatie met MVWS def.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110740","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110742","dc_title":"20210122 Terugkoppeling wekelijks overleg met CBG IGJ RIVM.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110742","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110744","dc_title":"20210121 BO MinMZS, CRM inbreng Corona, monitor FN.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110744","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110759","dc_title":"20210128 verslag overleg VWS_CvB_NPG_concept.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110759","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110764","dc_title":"20210129 GGD-issues-vgl-met-RIVM-na mondelinge toelichting.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110764","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110779","dc_title":"20210202 brief ZN meerkosten gewijzigd.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110779","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110823","dc_title":"20210202 Tweede opdrachtbrief GGD GHOR inzake covid-19 vaccinatie.pdf_4324a4cc-70ea-469e-a6ce-9ba81b460081.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110823","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110834","dc_title":"20210203 nota ter beslissing bij reactie op brief pharos.dotx.dotx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110834","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110841","dc_title":"20210203 Internationale factsheet_ 3 februari.pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110841","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110842","dc_title":"20210203_Artikel_voorraad_vaccins.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110842","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110844","dc_title":"20210203_Offerteaanvraag.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110844","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110846","dc_title":"20210203_Opdrachtverlening CleverFranke.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110846","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110872","dc_title":"2021-02-04 Minutes Cross-Border Taskforce Corona - Key Figures.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110872","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110886","dc_title":"20210202 Sitrap COVID19 ACS CN.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110886","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110897","dc_title":"20210209 Corona Actualiteiten Rapportage 21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110902","dc_title":"20210209 Periodiek beeld 25 jan. - 7 feb_definitief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110902","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110928","dc_title":"20210210 Verslag strategisch overleg vaccinatie met - def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110928","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110929","dc_title":"2020211 Bespreekdocument sessie opschaling vaccinatiecampagne Q2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110929","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110930","dc_title":"20210202 Corona Actualiteiten Rapportage 20.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110930","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110944","dc_title":"20210204_Notulen Co\ufffdrdinatorenoverleg.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110944","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110947","dc_title":"20210204-Presentatie VWS - Rioolwaterprogramma_inclNotes.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110947","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110971","dc_title":"20210205_AQ prestatieverklaring en uren januari 2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110971","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110975","dc_title":"20210208 inbreng nieuwe vragen website.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110975","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110981","dc_title":"20210208_Nota opzeggen SP.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110981","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1110997","dc_title":"20210210 Brief NVIB reactie brandbrief.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1110997","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111005","dc_title":"20210210 Internationale factsheet_ 10 februari.pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111005","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111008","dc_title":"20210211 agenda stuurgroep bekostiging corona -.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111008","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111022","dc_title":"20210209 Sitrap COVID19 ACS CN.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111079","dc_title":"Factsheet_App_week07.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111079","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111082","dc_title":"Factsheet_Spoor2 IT_week07.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111082","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111084","dc_title":"Factsheet_Follow-up_risicoanalyse_week07.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111084","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111154","dc_title":"20210208 Advies SG nav suggestie FEZ voor besparing op MDT.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111154","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111162","dc_title":"TCB- Adely-Brief ministerie antigeentest.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111164","dc_title":"20210208 Verslag Werkgroep voorbereiding veiligheidsbewaking vaccinCOVID.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111164","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111167","dc_title":"20210209 Beeld BTC 9 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111167","foi_groundsOfRefusal":"5.1.2d","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111168","dc_title":"Procuratie_VWS_Corona_vaccinatie_13_02_2021_PRINT_.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111168","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111170","dc_title":"57836 Ministerie van VWS - Corona Vaccin - Dagbladen Hele Pagina13-02-2021 Materiaalspecificaties v1.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111175","dc_title":"p&a-2021000364.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111175","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111177","dc_title":"TCB- Adely-Brief gezaghebber antigeentest_laatste versie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111179","dc_title":"20210202 Beeld BTC19 2 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111179","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i OMT","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111184","dc_title":"2021 verslag koepeloverleg (002).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111184","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111192","dc_title":"2021 verslag koepeloverleg 0302.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111198","dc_title":"2021-01-19 Notities ketenpartners.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111198","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111220","dc_title":"210203 Visual vaccinatietempo.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111220","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111248","dc_title":"20210216 Governance RIVM-extern-EvL.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111248","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111251","dc_title":"20210216_Dagstart.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111251","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111252","dc_title":"20210217 - Ontwikkeling dashboard - Sprint 16.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111252","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111253","dc_title":"20210217 4kantsoverleg.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111253","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111261","dc_title":"20210217 Brief VNG bestuurlijk commitment vaccinatiegegevens naar PGO januari 2021_FL.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111268","dc_title":"20210217_Dagstart.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111268","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111309","dc_title":"20210222 - Ontwikkeling Dashboard - Sprint 17.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111309","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111321","dc_title":"20210223 Agenda stuurgroep Corona pgb aant JG.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111321","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111327","dc_title":"20210223 Corona Actualiteiten Rapportage 23.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111327","foi_groundsOfRefusal":"5.1.2a;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111328","dc_title":"20210223 Uitvoer monsters COVID vaccin.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111328","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111336","dc_title":"20210224 Notitie ter voorbereiding op Bestuurlijk overleg, Ieder(in).docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111336","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111341","dc_title":"20210224_Evaluatie_vraagprognose.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111341","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111345","dc_title":"20210225 Notulen PO PDC VWS - GGD GHOR 25 februari.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111345","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111347","dc_title":"20210225_Notulen Co\ufffdrdinatorenoverleg.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111347","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111350","dc_title":"20210225_Verslag meedenkgroep.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111350","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111370","dc_title":"210212 Uitleg vaccinatiestrategie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111370","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111403","dc_title":"Presentatie basisscenario met conclusies.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111403","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111419","dc_title":"8. Factsheet_DOTT_week06_LCT.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111419","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111435","dc_title":"Kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111435","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111436","dc_title":"5. Verbeterplan DOTT fase 1 - BIJLAGE fiches.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111436","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":28,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111438","dc_title":"210201 Aanscherping communicatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111438","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111439","dc_title":"2020-12-04 214490 Schenkingsovereenkomst Bravis Ziekenhuis -getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111439","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111442","dc_title":"2020-12-02 Schenkingsivereenkomst Deventer Ziekenhuis - door VWS en DZgetekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111442","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111444","dc_title":"2020-12-04 215137 Schenkingsovereenkomst Amphia - getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111444","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111446","dc_title":"2020-12-15 Schenkingsovereenkomst Alrijne Ziekenhuis - tweezijdiggetekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111446","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111448","dc_title":"2020-12-23 Schenkingsovereenkomst De Tjongerschans - getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111448","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111450","dc_title":"2020-12-21 Schenkingsovereenkomst Martini Ziekenhuis - getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111450","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111452","dc_title":"2021-01-05 Schenkingsovereenkomst Reinier de Graaf Groep -getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111452","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111454","dc_title":"2020-12-14 Schenkingsovereenkomst MUMC v2 - getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111454","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111456","dc_title":"2020-12-22 Schenkingsovereenkomst Radboud UMC - Getinge apparatuur -getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111456","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111458","dc_title":"2020-12-16 Schenkingsovereenkomst Medisch Spectrum Twente - tweezijdiggetekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111458","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111464","dc_title":"201210 getekende schenkingsovk Saxenburgh deel 2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111464","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111466","dc_title":"201210 getekende schenkingsovk Saxenburgh deel 1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111468","dc_title":"2021-01-24 Schenkingsovereenkomst Rijnstate ziekenhuis - getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111468","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111470","dc_title":"2021-01-14 Schenkingsovereenkomst Radboud UMC - Philips apparatuur -getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111470","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111484","dc_title":"RE: Verzoek doorgifte CoronIT nummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111489","dc_title":"RE: Dwarsverband C19v","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111489","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111490","dc_title":"Re: FW: VE after one dose","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111490","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111491","dc_title":"Re: FW: VE after one dose","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111491","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111493","dc_title":"RE: Concept rapportage uit CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111493","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111494","dc_title":"RE: samenwerkingsovereenkomst UMCU-RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111494","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111496","dc_title":"RE: Evidence mbt risico's van uitstellen 1e prik bij reeds geinfecteerden?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111496","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111497","dc_title":"RE: samenwerking op deelprogramma epidemiologie en transmissie van COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111497","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111506","dc_title":"FW: huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111506","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111508","dc_title":"RE: Memo met impactanalyse m.b.t. niet aanleveren van geanonimiseerde vaccinatiedata","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111508","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111513","dc_title":"RE: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111513","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111514","dc_title":"RE: vragen van VWS over \ufffd\ufffdn dosis/leeftijd AZ/doorgemaakte infectie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111514","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.696","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111520","dc_title":"Fw: Advies Vaccinatieprogramma_Feb 2021_concept_0.6","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111520","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.697","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111521","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1111521","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.698","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111540","dc_title":"RE: Memo met impactanalyse m.b.t. niet aanleveren van geanonimiseerde vaccinatiedata","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111540","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111549","dc_title":"RE: Vraag over aantallen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111549","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111561","dc_title":"RE: Feedback procesplaat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111561","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111563","dc_title":"RE: Aantal positieve testen naar leeftijd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111563","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111572","dc_title":"RE: Eerste effecten vaccinatie zichtbaar onder bewoners verpleeghuizen_V4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111572","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111580","dc_title":"RE: Overzicht start- en einddatums vaccinatie per doelgroep","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111580","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111581","dc_title":"RE: Vraag voor Dwarsverband: Adviesvragen mbt vanuit VWS voor deze week: GRAAG CONCEPT LEZEN DAT OM 15 UUR WORDT GESTUURD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111581","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111588","dc_title":"bestand LCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111588","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111597","dc_title":"Re: VERTOUWELIJK - Mogelijk wijziging in vaccinatiestrategie: 1 dosis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111597","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111602","dc_title":"RE: figuren voor VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111602","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111603","dc_title":"RE: Dashboard vaccinaties RIVM/VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111603","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111613","dc_title":"RE: uitdraai R script osiris - aanpassingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111613","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111614","dc_title":"FW: Vraag voor Dwarsverband: Adviesvragen mbt vanuit VWS voor deze week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111614","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111616","dc_title":"Antw: Vraag voor Dwarsverband: Adviesvragen mbt vanuit VWS voor deze week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111616","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111618","dc_title":"RE: RIVM advies wijzigingen vaccinatieprogramma  - concept","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111618","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111630","dc_title":"RE: Vaccinatie-impact op COVID-19 meldingen: uitgesplitst naar instellingen en elders.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111630","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111631","dc_title":"RE: aantekeningen bij opdrachtbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111631","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111636","dc_title":"RE: Screening method - deze week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111636","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111643","dc_title":"RE: Vaccinatieprogramma vragen voor OMT vrijdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111643","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i OMT","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111644","dc_title":"RE: rapport modellering COVID-19 vaccinatie, concept versie die we op willen sturen naar VWS en GR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111644","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111650","dc_title":"RE: nieuwsbericht: Eerste effecten vaccinatie zichtbaar onder bewoners verpleeghuizen en zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111650","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111655","dc_title":"FW: Terugkoppeling rapport Uitval reguliere zorg door COVID-19 bij jeugdgezondheidszorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111655","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111676","dc_title":"RE: EUROPEAN COMMISSION - NEW REQUEST ON VACCINE ROLL OUT DATA ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1111676","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111680","dc_title":"Concept productenkalender tbv Jaarrapportage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111680","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111681","dc_title":"RE: EUROPEAN COMMISSION - NEW REQUEST ON VACCINE ROLL OUT DATA ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111681","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111688","dc_title":"Publication of vaccine data - The Vaccine Tracker and the weekly report","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111688","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111689","dc_title":"For action by NFPs for HAIs:  TESSy can now receive aggregate, national, weekly, retrospective & prospective LTCF COVID data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111689","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111703","dc_title":"Afspraken na promotie-overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111703","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111788","dc_title":"RE: Vaccinatie rapportages BES CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111788","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111794","dc_title":"RE: Nieuwsbericht 24-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111794","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111816","dc_title":"FW: Concept pdf wekelijkse rapportage deelname COVID-19-vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111816","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111819","dc_title":"RE: Concept pdf wekelijkse rapportage deelname COVID-19-vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111819","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111826","dc_title":"RE: Concept pdf wekelijkse rapportage deelname COVID-19-vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1111826","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111865","dc_title":"RE: ICT voorwaarts concept verslag 19 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111865","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111867","dc_title":"RE: uitbraak covid Catarina ziekenhuis ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111867","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111868","dc_title":"RE: Aantallen CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111876","dc_title":"FW: uitbraak covid Catarina ziekenhuis ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111876","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111879","dc_title":"Doorst: Slides vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111892","dc_title":"RE: uitbraak covid Catarina ziekenhuis ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111892","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111900","dc_title":"RE: Debat voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1111900","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111918","dc_title":"RE: dashboard morgen: huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1111918","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111924","dc_title":"2021memo meerkosten vaccinatie RvE2 rg met opmerkingen (002).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111924","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111927","dc_title":"RE: impact grafieken voor OMT?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111927","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111933","dc_title":"6e voorlopige opgave meerkosten Covid-19 GGD Hollands Noorden.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111933","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111956","dc_title":"Inf@ct: COVID-19 (nieuw coronavirusinfectie) (99)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111956","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111957","dc_title":"memo GGD duiding en achtergrond.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111957","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111974","dc_title":"210215 Memo Jeugdjournaal definitief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111974","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111982","dc_title":"RE: HAPs Moderna","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111982","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1111986","dc_title":"21-0656 Input Ieder(in) voor coronadebat 4 februari.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1111986","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112012","dc_title":"RE: nota GMT inkoop mogelijk COVID-19 behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112012","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112025","dc_title":"217719 akkoord min MZS op nota.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112025","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2b;5.1.2e;5.1.5","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112053","dc_title":"FW: Hulp van het leger ... pak op die handschoen.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112053","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112056","dc_title":"FW: ambulancezorg en fase 3 voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112056","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112070","dc_title":"RE: COVID-VE studie protocol","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112070","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112077","dc_title":"RE: pdf vaccinatie-deelname 16-02-2021 concept 2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112077","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112093","dc_title":"FW:  [ CIMS- fase vii evaluatie, monitoring, rapportage enz.] herleidbaarheid tabel anonieme import in de BI-CIMS database","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112093","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112107","dc_title":"RE: Begroting BU 2021-2022 en begroting COVID ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112108","dc_title":"RE: pdf vaccinatie-deelname 16-02-2021 concept 1 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112112","dc_title":"FW: Maandverantwoordidng COVID gedeelte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112112","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112118","dc_title":"Dod tomorrow: modelling covid-19 vaccination strategies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112118","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112119","dc_title":"RE: pdf vaccinatie-deelname 16-02-2021 concept 1 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112119","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112123","dc_title":"RE: input t.b.v. dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112123","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112146","dc_title":"1-2-2021situatievaccinatieoncologie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112146","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112158","dc_title":"GGD-Inf@ct: COVID-19 (nieuw coronavirusinfectie) (97)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112158","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112159","dc_title":"RE: A new issue of Eurosurveillance has been published","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112159","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112164","dc_title":"RE: Vaccinaties per leeftijdsgroep voor intern gebruik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112164","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112173","dc_title":"Notitie tbv IRF over stavaza maatschappelijk steunpakket v4.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112197","dc_title":"RE: issue voortgang BSN en osiris-nummer mee te leveren met positieve testgegevens","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112197","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112198","dc_title":"RE: College rivm: Nu al 527 deelnemers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112198","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112200","dc_title":"[Spam] RE: Epidemiologic Methods for Evaluating Vaccination Programmes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112200","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112202","dc_title":"No Subject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112206","dc_title":"RE: incidentie naar leeftijd per week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112206","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112213","dc_title":"RE: Scenario's interviews CGU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112213","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112218","dc_title":"RE: Update: CoronIT data in CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112218","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112225","dc_title":"FW: Melding nr. M2102 1122 onderwerp: FW: SNPG algemene voorwaarden inclusief Addendum en transfer-overeenkomst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112225","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112229","dc_title":"RE: Info Jacco tav Zuid Afrikaanse variant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112229","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112231","dc_title":"RE: DPIA fase vii/ monitoring & evaluatie / CIMS BI omgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112231","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112234","dc_title":"RE: EPI deelname werkgroep versoepelingen na vaccinatie in langdurige zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112234","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112235","dc_title":"FW: Advisering anonimiteit geanonimiseerde vaccinatie data [ TER INFORMATIE, vragen uitgezet op 9.2.2021]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112235","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112236","dc_title":"RE: nieuw overzicht vaccinatie osiris","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112236","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112244","dc_title":"RE: Update pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112244","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112245","dc_title":"RE: Bullet-points","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112245","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112263","dc_title":"Aantal door fabrikanten aan Nederland geleverde doses COVID-19-vaccin, per week: graag zo spoedig mogelijk reactie!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112263","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112268","dc_title":"FW: Privacy toets aanlevering anonieme vaccinatiegegevens aan RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112268","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112272","dc_title":"Aanpassing SOP ivm dataa anlevering corona dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112272","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112278","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112278","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112280","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112280","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112284","dc_title":"RE: gezette vaccinaties tot en met 4 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112284","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112285","dc_title":"Registratie vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112285","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112291","dc_title":"RE: Visualisatie sterfte vs vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112291","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112293","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112293","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112297","dc_title":"RE: Visualisatie sterfte vs vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112297","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112301","dc_title":"RE: FW: Vaccinatievragen CoronIT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112301","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112305","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112305","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112315","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112315","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112329","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112329","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112338","dc_title":"2701 Voorstel VWS.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112338","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112342","dc_title":"29012021 Verslag seniorenorganisaties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112342","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112347","dc_title":"217568 opmerkingen min VWS op nota.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112347","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112427","dc_title":"conceptverslag Afstemmingsoverleg 2 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112445","dc_title":"20210201 Verslag strategisch overleg vaccinatie met MVWS def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112445","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112452","dc_title":"20210208 Verslag strategisch overleg vaccinatie met MVWS def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112452","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112453","dc_title":"20210210 Aanscherping communicatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112453","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112455","dc_title":"Oplegger MCC mbt inschalingssystematiek routekaart enafschalingsstrategie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112455","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112509","dc_title":"RE: instellen expertgroep risicoanalyse zoonosen FW: Aanbieding afschrift verzamelbrief SARS-CoV-2 bij dieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112509","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112510","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112510","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112513","dc_title":"Nota ter voorbereiding briefing GR COVID-19 030221v2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112513","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112525","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112525","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112535","dc_title":"RE: PANDEM-2 RIVM-Radboudumc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112535","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112538","dc_title":"RE: COVID Vaccine Reaction Can Mimic Breast Cancer Symptoms","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112538","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112549","dc_title":"FW: adverse events cohort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112549","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112552","dc_title":"FW: extra sessie communicatie in coronacrisis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112552","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112557","dc_title":"RE: Antw:  Elimination strategy HSC discussion paper_25.02.21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112557","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112571","dc_title":"RE: instellen expertgroep risicoanalyse zoonosen FW: Aanbieding afschrift verzamelbrief SARS-CoV-2 bij dieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112571","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112581","dc_title":"Oplegger_MT_Communicatie Strategie CoronaMelder 2021_v1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112581","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112593","dc_title":"RE: update variants uit de  Uk incl B.1.1.17 met E484K","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112593","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112600","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112600","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112607","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112607","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112630","dc_title":"3. Format MT RRF voorstel arbeidsmarkt.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112630","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112632","dc_title":"RE: definitieve pdf 'Deelname CIVID-19 vaccinatie in Nederland' 2-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112651","dc_title":"nazending Scenario Britse variant 090221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112651","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112661","dc_title":"3a 210208_LCPS weekrapportage.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112661","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112669","dc_title":"20210211 verslag stuurgroep corona.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112669","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112705","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112705","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112712","dc_title":"RE: Doorst: Update vacc Ggz","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112712","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112717","dc_title":"20210212 - Brief minVWS.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112717","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112720","dc_title":"RE: Verzoek om intern overleg/besluitvorming","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112720","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112721","dc_title":"FW: Update claims FIN en overig ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112721","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112729","dc_title":"RE: Aantallen CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112729","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112755","dc_title":"RE: Aantallen CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1112755","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112795","dc_title":"FW: Debat voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1112795","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112814","dc_title":"RE: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112814","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112825","dc_title":"Monitor Zorgcontinu\ufffdteit week 6 landelijk beeld.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112825","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112844","dc_title":"RE: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112844","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112853","dc_title":"RE: Maandverantwoordidng COVID gedeelte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112859","dc_title":"FW: samenvatting gesprek vorige week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112859","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112896","dc_title":"FW: Snotterende kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112896","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112918","dc_title":"210111_MSZ 21 Regeling tbv VWS overleg 2 februari 2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112918","foi_nrPages":20,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1112934","dc_title":"RE: Antw: instellen expertgroep risicoanalyse zoonosen FW: Aanbieding afschrift verzamelbrief SARS-CoV-2 bij dieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1112934","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113006","dc_title":"210209 Notulen MT PG_definitief.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113006","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113085","dc_title":"FW: notitie tbv TO aarly warning system","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113085","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113117","dc_title":"Coronavaccinatie campagnes.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113117","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113120","dc_title":"COVID EWA datastromen 18.2.21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113120","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113122","dc_title":"tabel_impact_omt20210225.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113122","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113132","dc_title":"20210212 project Early Warning Systeem ROAZ NH-FL 12022021 def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113132","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113146","dc_title":"overeenkomst mw. Bouten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113146","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113150","dc_title":"overeenkomst mw. Lantinga.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113150","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113152","dc_title":"overeenkomst mw. Morauw.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113152","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113169","dc_title":"20210225 RIVM Communicatiebulletin.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113169","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113173","dc_title":"Bijwerkingen poster.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113173","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113183","dc_title":"Update vaccinatie registratie: CIMS en anonieme data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113184","dc_title":"FW: Anon. dataset vacc. CoronIT - issues/actielijst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113184","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113199","dc_title":"FW: gezette vaccinaties tot en met 3 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113199","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113201","dc_title":"RE: gezette vaccinaties tot en met 7 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113201","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113207","dc_title":"20210114 Verslag PO VWS - NZa.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113207","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113208","dc_title":"20200207 NCTV Inventarisatie data naleving corona maatregelen7-2-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113208","foi_nrPages":25,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113216","dc_title":"RE: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113221","dc_title":"FW: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113221","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113222","dc_title":"FW: Verschil Excel-data vandaag en gisteren?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113222","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113223","dc_title":"FW: SPOED Besluit gevraagd over aanpassing in de geanonimiseerde data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113224","dc_title":"FW: goed opbouwen van clienthistorie in (een laag van) CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113224","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113225","dc_title":"CBM Form B 2020 -.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113225","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113232","dc_title":"1Mar2021_Overview of VE after one dose of COVID19 vaccine.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113232","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113239","dc_title":"Natuurlijke infectie en COVID vaccinatie_EV.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113239","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113263","dc_title":"20210204 Annotatie beeld ACC 8 februari (003).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113263","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113288","dc_title":"FW: Brief Impact overgang nieuw ICT-systeem","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113302","dc_title":"FW: VERSIE 13.30U RE: Brief inzet AstraZeneca VERSIE 23.00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113302","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113312","dc_title":"FW: Brief inzet AstraZeneca VERSIE 23.00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113312","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113343","dc_title":"Bijlage3-3feb_20210127 preop PCR pos beleid_.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113343","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113344","dc_title":"Bijlage2-3feb_20210128_Beleidsadvies_tav_varianten_Beleidscommissie_SARS-CoV-2IS - (003).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113344","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113348","dc_title":"Inventarisatie PBM ROAZ NH Flevoland dinsdag 2 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113348","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113351","dc_title":"Bijlage4-3feb_Crisiszorg - voorbereiding in de acute keten ROAZ NH enFlevoland v1.1 20210201.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113351","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113363","dc_title":"FW: MORGENMIDDAG van 13.15 tot 14.00 uur: overleg over flankerendbeleid ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113363","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113372","dc_title":"RE:  bespreken plan zichtbaarheid steunpakket welzijn en leefstijl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113372","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113376","dc_title":"FW: nieuwe brief over steunpakket ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1113376","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113393","dc_title":"FW: Brief steunpakket welzijn en leefstijl ivm COVID-19 v1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113398","dc_title":"FW: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113398","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113406","dc_title":"FW: Brief steunpakket welzijn en leefstijl ivm COVID-19 v8 tbvoverleg MVWS en SVWS -  ek az","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113406","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113409","dc_title":"FW: Brief mentaal en sociaal en leefstijl ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113409","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113413","dc_title":"RE: Commitment van VNG inzake PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113413","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.7047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113428","dc_title":"nieuwe versie bronbestand 11.9 definitief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113428","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113459","dc_title":"nota continu\ufffdteitsafspraken Valys V BJR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113459","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113461","dc_title":"Nota ter beslissing 2021-01-27 9_19_12.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113461","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113468","dc_title":"Verslag Bestuurlijk Overleg 5 februari 2021 vaccinatiestrategieAstraZeneca.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113468","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113474","dc_title":"Nota testen in het vo, mbo en hox.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113474","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113488","dc_title":"PresentatieLCC_Dashboard_20210225.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113488","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113508","dc_title":"22-02-2021 notulen wrapup.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113508","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113549","dc_title":"VE Covid South Africa","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113549","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113602","dc_title":"210301 Annotatie Preventie en Jeugdstaf.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113602","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113623","dc_title":"21122020.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113623","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.5","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113631","dc_title":"217403 akkoord min VWS op nota en brief.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113631","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113643","dc_title":"217513 akkoord min MZS op nota.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113643","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113668","dc_title":"217767 akkoord - op nota Addendum opdrachtbrief Loveland.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113668","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113670","dc_title":"217835 getekende brief DGLZ.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113670","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113678","dc_title":"217921 opmerking min VWS op nota.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113696","dc_title":"218164 getekende brief - LHV.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113696","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113771","dc_title":"FW: betreft ondersteunende casu\ufffdstiek MEE Mantelzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113771","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113788","dc_title":"Woordvoeringslijn rapportage meldpunt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113788","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113793","dc_title":"FW: catshuisfiche leefstijl 2.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113793","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113806","dc_title":"Claims team vaccins concept definitief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113806","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113823","dc_title":"FW: zoals zojuist besproken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113823","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113836","dc_title":"CONCEPT antwoord: Uitvraag input Monitors CUR/AUA/SXM vanuit VWS/ZJCN","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113836","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113853","dc_title":"RE: concept nota aan ACC inzet testbewijs ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113862","dc_title":"GRAAG PRINTEN VOOR TJIMKJE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113862","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113864","dc_title":"FW: Follow-up consultatie MP - PM Australie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113864","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113877","dc_title":"Bijlage 1_ Procedure opdracht ander departement.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113877","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113878","dc_title":"Bijlage 2 Overzicht Covid-19 buiten programma 19.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113878","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113915","dc_title":"3. Uitkomst ROAZ GHOR Strategisch Kernteam COVID-19 d.d. 10 februari 2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113915","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1113997","dc_title":"CORRECTIE!! RE: nav jouw vraag voor persmoment","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1113997","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114005","dc_title":"RE: Vraag NOS: Geld voor Halix??","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114005","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114024","dc_title":"Kosten G4S voor de 13 regio's.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114024","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114039","dc_title":"FW: Overleg COVID antilichamen VWS/RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114039","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114059","dc_title":"Verslag Stuurgroep VGL 21 januari 2021 concept.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114085","dc_title":"Key Opinion formers vaccinatiestrategie -top 10 ambassadeurs.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114085","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114088","dc_title":"210208 Voorstel contact medische KOF's.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114092","dc_title":"210206 Laatste gedragsinzichten Avondklok en breder  tbvCatshuisoverleg .pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114092","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114108","dc_title":"Bijlage 2 procedure toewijzen vaccin voor onderzoek.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114109","dc_title":"ExportPoeReport_202102260637.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114109","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114114","dc_title":"Contributionaef4c455-ca4d-4833-b62b-5557b571d126.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114114","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114116","dc_title":"DIR-2021-OUT-0766-AACrDr.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114116","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.28","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114147","dc_title":"Search ZA variant.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114147","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.29","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114151","dc_title":"RoundTableReport_20210212.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114151","foi_groundsOfRefusal":"5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114155","dc_title":"Vaccine Roll Out Overview 02022021.html","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114155","foi_nrPages":22,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114162","dc_title":"2021-01-26 vph verslag.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114166","dc_title":"communicable-disease-threats-report-13-feb-2021-restricted.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114166","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114171","dc_title":"20210211_Webinar deel Cecile van Els v2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114171","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.37","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114180","dc_title":"RoundTableReport_20210211.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114180","foi_groundsOfRefusal":"5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.38","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114184","dc_title":"Report from the NFP webinar on 28 January 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114184","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114186","dc_title":"ECDC-JRC Response Measure Database.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114186","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114193","dc_title":"Ireland update_28012021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114193","foi_nrPages":21,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114195","dc_title":"Lecture Vaccine effectiveness 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114195","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":49,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114197","dc_title":"RRA update-variants.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114197","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":20,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.39","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114203","dc_title":"20210113_Webinar RIVM 11 feb 2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114215","dc_title":"20210205 RIVM advies anonimiseren BI.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114215","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114217","dc_title":"20210211_Webinar RIVM_PresentatieVaccinatiestrategie_SusanHahne.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114217","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114222","dc_title":"RoundTableReport_20210210.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114222","foi_groundsOfRefusal":"5.1.2a;5.1.5;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114226","dc_title":"20210211_Webinar RIVM_LogistiekCOVID-19-vaccins_ClaudiaVonk.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114226","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114229","dc_title":"DPV_210 Aanlevering geanonimiseerde vaccinatiedata  v1.2.2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114229","foi_groundsOfRefusal":"5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114231","dc_title":"20210204 Borging anonimiteit bij geanonimiseerde vaccinatiedata RIVM met opm.1.0.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114231","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114233","dc_title":"besluitvorming doelgroepen 120221.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114233","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114248","dc_title":"RoundTableReport_20210209.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114248","foi_groundsOfRefusal":"5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114265","dc_title":"Tussen Rapportage VWS Covid Hulpverlening 2020 2021 periode tot en metdec 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114265","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114275","dc_title":"Advies prioritering medische hoogrisicogroepen voor COVID-19-vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114275","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.42","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114295","dc_title":"beantwoording nadere vragen inzake Intravacc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114295","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.44","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114325","dc_title":"Debatdossier notaoverleg definitief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114325","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.45","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114339","dc_title":"Financiering Covid testen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114339","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.46","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114345","dc_title":"FW: Oplossingsrichting","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114345","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.48","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114415","dc_title":"FW: vervolg Security aspecten app3 https://meet.hack42.nl/hack3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114415","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.49","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114419","dc_title":"Digitale Flip Dagstart | 10 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114419","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.50","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114423","dc_title":"Digitale Flip Standup | 1 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114423","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.51","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114426","dc_title":"digitale flip dagstart | 2 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114426","foi_groundsOfRefusal":"5.1.2e;5.1.2i OMT;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.52","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114427","dc_title":"Overzicht Pfizer bestellingen_150221.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":48,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.53","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114429","dc_title":"Digitale flip dagstart | 5 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114429","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.54","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114431","dc_title":"Digitale Flip Stand-up | 15 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114431","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.55","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114432","dc_title":"Digitale Flip Dagstart | 12 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114432","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.56","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114433","dc_title":"Digitale Flip Standup | 8 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114433","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.58","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114435","dc_title":"Digitale flip dagstart | 3 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114435","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.59","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114438","dc_title":"VAP update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114438","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.60","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114439","dc_title":"Digitale Flip Standup | 11 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114439","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.64","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114460","dc_title":"RE: Aanbieding offerte voor dataverzameling onderzoek coronavaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114460","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.65","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114477","dc_title":"DOC 3 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114477","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.67","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114500","dc_title":"RE: BCO Scholen, opstellen 'gerechtvaardigd belang' voor AP FW: GGD-Inf@ct: COVID-19 (nieuw coronavirusinfectie) (97)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114500","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.68","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114510","dc_title":"210125_Offerte_Campagne vaccinatie deel 3.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114510","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.69","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114569","dc_title":"AP4a - Deltaplan Framework Template1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114569","foi_nrPages":18,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.71","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114582","dc_title":"20210218-verslag Dwarsverband WP7-C19v.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114582","foi_groundsOfRefusal":"5.1.2e;5.1.2i OMT","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.73","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114589","dc_title":"20210218 Weekafronding PT.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114589","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.74","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114592","dc_title":"20210216 Dagafronding PT.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.75","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114593","dc_title":"20210211-verslag Dwarsverband WP7-C19v_sh.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114593","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.80","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114609","dc_title":"COVID-19_burden_by_agegroup_occupation_15-2-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114609","foi_nrPages":19,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.81","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114677","dc_title":"FW: 1613081256621.pdf brief die verzonden is naar OCW door Amsterdamse en Rotterdamse schoolleiders","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114677","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.82","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114688","dc_title":"SV: Minutes TC on integrating the reviews","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114688","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.83","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114711","dc_title":"FW: Landelijk BCO-beleid bij reisgeschiedenis hoogrisicoland VOC ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114711","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.84","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114730","dc_title":"GGD-Inf@ct: COVID-19 (nieuw coronavirusinfectie) (97)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114730","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.85","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114737","dc_title":"deltaplan pandemic preparedness + appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114737","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.86","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114753","dc_title":"RE: Antw:  VITAL Scientific periodic report year 2 final review","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114753","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.87","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114755","dc_title":"RE: Antw:  VITAL Scientific periodic report year 2 final review","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114755","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.88","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114757","dc_title":"RE: graag verzoek aan literatuurclubje ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114757","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.89","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114761","dc_title":"Laatste versie vragenlijst vaccinatiebereidheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114761","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.90","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114772","dc_title":"Re: Overleg Aura & Bas","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114772","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.91","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114776","dc_title":"FW: 210119 - motie testen sequencen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114776","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.92","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114777","dc_title":"FW: punt voor MT CiB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114777","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.93","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114810","dc_title":"RE: 20210202wekelijksnieuwsberichtV4_AT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114810","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.94","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114821","dc_title":"RE: Update overleg CGU/vaccinatieprgramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114821","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.95","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114840","dc_title":"RE: 20210201_V0_PANDEM-2 project: BELANGRIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114840","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.96","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114846","dc_title":"FW: concept persbericht PANDEM-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.97","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114853","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.98","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114855","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114855","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.99","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114856","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114856","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114860","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114860","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114868","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1114868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114869","dc_title":"Fw: Verzoek om commentaar voor zondag 28 februari 2021 20.00 uur VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114869","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114893","dc_title":"RE: onafhankelijk arts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114893","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114897","dc_title":"Re: feedback overleg 4 feb koppeling databases progressie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114897","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114899","dc_title":"FW: Revised budget VASCO study","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114899","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114906","dc_title":"RE: COVID VE studie ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114906","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114922","dc_title":"RE: COVID VE studie ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114922","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114925","dc_title":"FW: CID revisie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1114925","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114928","dc_title":"RE: VASCO protocol","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114928","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114930","dc_title":"FW: Bijeenkomst Dwarsverband 18-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114930","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114932","dc_title":"FW: data LCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114933","dc_title":"RE: search mbt vaccins ZA variant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114933","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114938","dc_title":"FW: Informatie bovengrens influenza vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114938","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114940","dc_title":"RE: Vaccin Data tm 01-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114940","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114943","dc_title":"FW: Eerste opzet rapportage gevaccineerde cases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114943","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114948","dc_title":"RE: mRNA-vaccins versus AstraZeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114948","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114962","dc_title":"15-02-2021 notulen wrapup.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114962","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114980","dc_title":"Dagafronding VKA - RIVM 15-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114980","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114984","dc_title":"WP7-Monitoring Brainstorm 20210210 CONCEPT.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114984","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114994","dc_title":"forest_plot_1 (003).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114994","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114995","dc_title":"Risk_of_bias_Moderna_draft.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114995","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1114999","dc_title":"GRADE_COVID_Moderna_22_12_20 (003).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1114999","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115012","dc_title":"4. ZAMBON_ECDC CoV VACCINE STRAIN SELECTION v1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115012","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":20,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115016","dc_title":"GR vraag 1 en 2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115016","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115017","dc_title":"7. VAN DEN STEEN_2021-02-18 RRF.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115017","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115019","dc_title":"6. HYPPONEN_ Vaccination Certificates - Introduction 2021-02-18.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115019","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115023","dc_title":"Timeline NL measures and advices.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115023","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":23,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115024","dc_title":"17-02-2021 notulen wrapup.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115024","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115051","dc_title":"20210128-verslag Dwarsverband WP7-C19v.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115053","dc_title":"RoundTableReport_20210205.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115053","foi_groundsOfRefusal":"5.1.5;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115055","dc_title":"Reactogeniciteit COVID-19 vaccins.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115055","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115057","dc_title":"WP7-Monitoring Brainstorm 20210203 CONCEPT-HM.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115057","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115061","dc_title":"RoundTableReport_20210204.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115061","foi_groundsOfRefusal":"5.1.5;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115064","dc_title":"GENOV_Overview of safety monitoring for COVID-19 vaccines_4 Feb 2021_2.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115064","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115066","dc_title":"EVENSEN_21020204_ECDC_Monitoring safety.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115066","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115067","dc_title":"COHET_Observational COVID-19 vaccine safety studies  04FEB21.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115067","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115070","dc_title":"20210203_Protocol Cohort VE COVID - v1.1 - INGEDIEND METC.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115070","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":35,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115078","dc_title":"RE: uitbraak covid Catarina ziekenhuis ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115078","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115086","dc_title":"LAW_SPEAC COVID AESI list  related resources_BLaw for_EU_EEA NITAG Collaboration Webinar Feb4_2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115086","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":34,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115132","dc_title":"20210223 Inhoudelijke Vooruitblik.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115132","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115141","dc_title":"210206 Laatste gedragsinzichten Avondklok en breder  tbv Catshuisoverleg .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115141","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115152","dc_title":"Tussentijdse evaluatie (proxy) vaccinatiegraad - januari 2021 (inclusief analyse effect coronacrisis) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115152","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115160","dc_title":"object0002.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1115160","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115162","dc_title":"FW: Verzoek doorgifte CoronIT nummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115168","dc_title":"RE: First impact figures Netherlands","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115168","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115176","dc_title":"RE: Eerste concept procesplaat Rapporteren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115185","dc_title":"BIJLAGE Wegwijzer richtlijnen wijzigingen COVID-19 v 1.0.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115185","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115189","dc_title":"FW: VERTOUWELIJK - Mogelijk wijziging in vaccinatiestrategie: 1 dosis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115194","dc_title":"RE: Endnote","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115194","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.31","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115205","dc_title":"RE: Vragen in RIVM stuk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115205","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.32","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115219","dc_title":"RE: Nieuwsbericht 24-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115219","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115220","dc_title":"RE: vaccinatie start data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1115220","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115223","dc_title":"RE: waar op webex? RE: Nieuwsbericht impact van vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115223","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115233","dc_title":"RE: Update verschillenanalyse","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115233","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115248","dc_title":"RE: vaccinatie start data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115248","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115249","dc_title":"RE: Nieuwsbericht impact van vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115249","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115257","dc_title":"RE: Presentatie webcollege ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115257","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115287","dc_title":"FW: planning overleg a.s. maandag vaccinatie prioritering","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115287","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115297","dc_title":"Vragen vanuit VWS voor de GR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115297","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115300","dc_title":"FW: HSC audio meeting 10/02/21 14.00: Summary of the view of all ERNs on priorities and contra-indications for COVID-19 vaccinations ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115300","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115302","dc_title":"Fw: Brief Federatie Medisch Specialisten fasering vaccinaties ziekenhuispersoneel aan NVZ, NFU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115302","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115311","dc_title":"Wegwijzer richtlijnen wijzigingen COVID-19.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115311","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115337","dc_title":"RE: re-infection manuscript v4.1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115367","dc_title":"Donderdag 11 februari van 11 tot 13 uur InterdepartementaalTestoverleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115367","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115371","dc_title":"FW: Procuratie & materiaalbon voor 13 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115371","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115412","dc_title":"FW: Vraag of blootstelling aan boompollen de gevoeligheid voor COVID-19 vergroot?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115424","dc_title":"Antw:  VITAL periodic report year 2 Summary ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115424","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115440","dc_title":"RE: Eerste leveringen COVID voor CAS en BES - namens vierlanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115440","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115443","dc_title":"RE: FOR AF REVIEW: ECDC Guidance - Use of face masks in the community ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115443","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115447","dc_title":"FW: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115447","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115449","dc_title":"FW: Eerste leveringen COVID voor CAS en BES - namens vierlanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115449","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115459","dc_title":"Voorstel doorontwikkeling Covid-19 governance structuur GGD GHOR met betrekking tot kennis en expertise IZB professionals 8 feb 2021 2200_RJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115459","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115466","dc_title":"RE: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115481","dc_title":"RE: Antw:  Terugkoppeling Bestuurlijk overleg PG d.d. 14-01-2021 --> vraag van - Brug in je cc map","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115481","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115489","dc_title":"RE: Antw: een verzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115489","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115518","dc_title":"01-02-2021 notulen wrapup.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115524","dc_title":"Verslag Stuurgroep Covid-19-vaccinatie 28-01-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115524","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115530","dc_title":"RoundTableReport_20210202.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115530","foi_groundsOfRefusal":"5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115536","dc_title":"Ernstige beveiligingsincident GGD Ghor Kennisnet website ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115536","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115540","dc_title":"EURO2020 Covid-19 Coordination Group","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115540","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115541","dc_title":"Export licentie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115541","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115543","dc_title":"extra QAs kinderpersconferentie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115543","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115544","dc_title":"Extra QenA debat 09-02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115544","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115560","dc_title":"FDA emergency use authorization (EUA) for bamlanivimab and etesevimab","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115560","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115583","dc_title":"aangevuld en nieuw: trajecten richting 23 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115583","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115590","dc_title":"flankerend beleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115590","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115591","dc_title":"FW: Advisering anonimiteit geanonimiseerde vaccinatie data [ TER INFORMATIE, vragen uitgezet op 9.2.2021]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115591","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115599","dc_title":"FW: Agenda werkgroep kwetsbare groepen 4-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115601","dc_title":"COVID-19 casu\ufffdstiek voortgang en bewaking Wegwijzer 20210201.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115601","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115612","dc_title":"ECDC_RoundTableReport_20210201.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115612","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115655","dc_title":"RE: Verantwoording meerkosten gemeenten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115655","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115656","dc_title":"vaccinaties 20210106 - 20210201.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115656","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":90,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115667","dc_title":"20210208 Analyse J07BX & epilepsie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115667","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115674","dc_title":"FW: (snel)testen ME personeel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115674","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115681","dc_title":"FW: 20210131 grafiek vaccinaties en voorraad BP.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115681","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115687","dc_title":"FW: aanpassing vliegverbod","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115687","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115696","dc_title":"FW: aantekeningen gesprek zojuist tbv verslag en spoorboekje komendedagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115696","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115697","dc_title":"FW: Aantekeningen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115697","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115698","dc_title":"FW: Actiepunten dagstart --PDC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115698","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115699","dc_title":"FW: actiepunten n.a.v. overleg stavaza vaccins LZ/CZ/DMO/J","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115699","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115702","dc_title":"FW: advies aan MinVWS over vijfhoek nationaal programma onderwijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115702","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115715","dc_title":"FW: afspraak over vaccinatie LT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115715","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115747","dc_title":"FW: antwoordlijn vaccineren tegen COVID-19 zonder toestemming of bijverzet: reactie graag uiterlijk maandag 1-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115747","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115773","dc_title":"FW: berekening/argumentatie CZ voor Medewerkers crisisdiensten ondergroepje ggz medewerkers - spoed","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115773","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115775","dc_title":"FW: berekening/argumentatie CZ voor Medewerkers crisisdiensten ondergroepje ggz medewerkers - spoed","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115775","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115776","dc_title":"FW: bespreekpunten voor onze sessie bijpraat pandemic preparedness,dinsdag 2 feb in de middag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115776","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115777","dc_title":"FW: bespreekpunten voor onze sessie bijpraat pandemic preparedness,dinsdag 2 feb in de middag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1115777","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115793","dc_title":"Brief prog dir ZJCN omtrent reizen 3 februari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115793","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115805","dc_title":"20210201 Toets dataset geanonimiseerde data v1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115805","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115808","dc_title":"Tabel_gezondheidsstatus_veiligheidsregio_week20210201_1259.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1115808","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115818","dc_title":"VE against infection and transmission_15feb2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115818","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115837","dc_title":"Budget sheet RIVM COVID-19 VE Study V2.0_26 Feb 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115837","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115844","dc_title":"Budget sheet RIVM COVID-19 VE Study V1.0 _08 Feb 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115844","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115850","dc_title":"[Spam] Executive COVID-19 Briefing: EURO Region + the Netherlands","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115850","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115851","dc_title":"Opmerkingen Budgetvoorstel VASCO RIVM 16-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115851","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115856","dc_title":"Budget sheet RIVM COVID-19 VE Study V2.0_26 Feb 2021_split by year.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115856","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115890","dc_title":"Brief reactie consultatie verlengingsbesluit 2-2-21 def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115890","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115898","dc_title":"Bijlage 2 - AKJ - 210208 voorstel perspectief voor jongeren incoronatijd.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115898","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115900","dc_title":"brief bijstandsaanvraag vaccinatie v 1 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115900","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115901","dc_title":"bijlage bijstandsaanvraag vaccinatie v 1 februari .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115901","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115908","dc_title":"Brief Aan de minister van VWS reactie VOICE studie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115908","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115910","dc_title":"Beschikbaarheid Spuiten en naalden irt vaccins - update 20210127.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115910","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115916","dc_title":"Bijlage bij notitie - registratietarief voor de huisarts ROAZNH-FL.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115916","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115918","dc_title":"TO notitie - early warning system 04022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115918","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115920","dc_title":"Bijstand voor Sal\ufffd pa Tur 20210203134057.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115920","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115948","dc_title":"20210209 Agenda 68e RT COVID-19.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115948","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115953","dc_title":"Verslag Stuurgroep Covid-19-vaccinatie 04-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115953","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115954","dc_title":"Weather_and_Covid_Short2.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115954","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":23,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115977","dc_title":"Notulen RVP 16-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115977","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115979","dc_title":"Notulen RVP 02-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115979","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1115985","dc_title":"Definitieve Besluitenlijst Directieraad 2021-02-16.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1115985","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116015","dc_title":"3. 20210216 Governance RIVM-intern-EvL.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116015","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116023","dc_title":"Definitieve Besluitenlijst Directieraad 2021-02-09.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116023","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116031","dc_title":"Bell's Palsy after vaccination.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116031","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116088","dc_title":"Concept verslag BO - en uitvoerende partijen 21012021 -aangepast.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116089","dc_title":"6. NVO.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116089","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116095","dc_title":"Concept verslag BO - en uitvoerende partijen 28012021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116138","dc_title":"FW: Bijpraten / Vaccinatie, testen en maatregelen vs mlt teambuitenlandse vakantiereizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116138","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116143","dc_title":"FW: BO - en uitvoerende partijen vaccinatiestrategie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116143","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116157","dc_title":"210202 Verzoek Nictiz realisatie gegevensdienst Covid-19.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116157","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116173","dc_title":"217143 Opmerkingen SVWS.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116173","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116212","dc_title":"FW: Briefing testen icm quarantaine","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116212","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116223","dc_title":"FW: BUZA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116247","dc_title":"FW: Casus op afstand stemmen voor jongeren in de risicogroep (18+)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116247","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116249","dc_title":"FW: check op persbericht ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116249","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116251","dc_title":"210205 Communicatie vaccinatie COVID-19 tbv NKC.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116251","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116259","dc_title":"FW: Communicatie huisartsenbericht positieve testuitslagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116259","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116264","dc_title":"FW: Concept beantwoording Kamervragen predikanten ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116264","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116265","dc_title":"FW: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116265","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116267","dc_title":"FW: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116267","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116268","dc_title":"FW: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116268","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116287","dc_title":"FW: covid-19: verzoek goedkeuring Zero Residual Spuiten en Naalden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116287","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116288","dc_title":"FW: Coronacommunicatie richting jongeren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116290","dc_title":"FW: dat dus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116290","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116309","dc_title":"A) Afwegingskader Code zwart scenario VVT (ve.docx.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116309","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116320","dc_title":"Aantal zorgmedewerkers langdurige zorg.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116320","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116323","dc_title":"Aantalprikkenperdag_aanleveringpfizer_2402.xlsx.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116323","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116337","dc_title":"Aantekeningen overleg werkgeversorganisaties bonus 2021 10-02-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116340","dc_title":"Aanvullende brief GGD GHOR aan DPGen - aanvullende informatie meerkosten op brief 20 juli 2020.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116340","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116346","dc_title":"Actielijst 8 februari.docx_adced78a-4d01-45f4-aea7-06355f3b2276.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116346","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116348","dc_title":"Actielijst dashboard nav gebruikersonderzoeken.xlsx.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116348","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116350","dc_title":"Acties crisisoverleg VWS-clientenorganisaties 16-2-2021.xlsx.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116350","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116356","dc_title":"PLATO-#4186970-v2-COVID-19_externe_peilingen_corona_feb.DOCX","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116356","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116416","dc_title":"Nota_BO_ESF_15feb.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116436","dc_title":"Agenda 16 februari.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116436","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116477","dc_title":"Brief aan Ministerie van VWS09022021143414.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116477","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116512","dc_title":"Akkoord.pdf_b668f410-70ac-4e0a-bbd7-825ccdb46578.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116512","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1049","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116521","dc_title":"Annotatie bespreking Budgetrapport in BR.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116521","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1050","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116527","dc_title":"annotatie strategiedag topteam 20210209FINAL_plus notities.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116527","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1051","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116541","dc_title":"Akkoord op de facturen.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116541","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.5","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1054","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116608","dc_title":"Bijlage 1. Samenvating werkgroep geneesmiddelentekorten 19 januari.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116608","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1055","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116627","dc_title":"Annotatie Agenda Stuurgroep CdKNL 10 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116627","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1057","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116652","dc_title":"Brief aan Min van VWS.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116652","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1059","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116701","dc_title":"Verslag contacten met GGD Zeeland.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116701","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1060","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116712","dc_title":"Principe verzoek v2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1116712","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1063","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116765","dc_title":"FW: Distributie covid vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116765","foi_groundsOfRefusal":"5.1.2e;5.1.2f","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1064","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116773","dc_title":"FW: EC joint procurement covid behandelingen - reactie WJZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1116773","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1065","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116778","dc_title":"FW: Eerste resultaten in concept van de 7e meetronde WP11","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116778","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1066","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116784","dc_title":"20210204 Duitse RDI-ontwikkelingen t.a.v. coronavirus.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116784","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116790","dc_title":"FW: Enkele take aways uit de WHO EURO meeting van vanochtend","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116790","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1067","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116791","dc_title":"FW: Eindrapporten 'eerste golf' ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116791","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1068","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116798","dc_title":"FW: Follow up van onze meeting van vandaag 01022021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116798","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1069","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116800","dc_title":"FW: Kamervragen predikanten ziekenhuizen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116800","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1070","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116804","dc_title":"FW: Gefaseerd uitnodigen zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116804","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1071","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116806","dc_title":"FW: graag jullie reactie inz covid behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116806","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1072","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116807","dc_title":"FW: graag jullie reactie inz covid behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1116807","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1073","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116809","dc_title":"FW: Hand aan de Kraan overleg 15 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116809","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1074","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116815","dc_title":"FW: Heb jij het agendapunt al wel aangemeld bij Jet Beaumont voor destuurgroep?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116815","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116819","dc_title":"FW: Hosting coronaconflict.nl ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116819","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1075","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116822","dc_title":"FW: Implementatie Vo. exportcontrole Covid 19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116822","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1076","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116829","dc_title":"FW: Informatie en conceptantwoorden per cluster","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116829","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1077","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116832","dc_title":"FW: Input BO met cli\ufffdntenorganisaties handicap","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116832","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1078","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116833","dc_title":"FW: Informatie voor opstellen DVO's op herhaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116833","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1079","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116838","dc_title":"FW: input video -","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116838","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1080","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116839","dc_title":"FW: Input steunpakket mentaal welzijn jeugd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116839","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1082","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116845","dc_title":"FW: Inzet MHC personeel bij vaccinatie Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116845","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1083","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116855","dc_title":"FW: Kamerbrief v0.6","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116855","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1084","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116857","dc_title":"FW: Kamerbrief v0.7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116857","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1085","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116873","dc_title":"FW: Kernpunten alert-overleg | 11 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116873","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1086","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116875","dc_title":"FW: Kernpunten overleg Cur 3 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116875","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1087","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116876","dc_title":"FW: Kernpunten alert-overleg | 4 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116876","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1088","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116879","dc_title":"FW: lhv ervaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1089","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116882","dc_title":"FW: leveringen per week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116882","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1090","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116897","dc_title":"COVID_narratief_TZ5.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116897","foi_nrPages":22,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1091","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116901","dc_title":"Review sessie testbewijsapp.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116901","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":18,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1092","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116927","dc_title":"COVID-19__rapport_metrixlab_coronadossier_gebruikerstest.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116927","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":23,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1093","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116935","dc_title":"FW: Logistiek Covid vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116935","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1094","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116938","dc_title":"FW: Mail namens Margreet de Graaf: definitieve monitor versie 1februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116938","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1095","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116951","dc_title":"FW: Monitoring COVID-19 vaccination progress across Europe: New ECDCdashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116951","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116956","dc_title":"FW: mogelijk zinvol materiaal GGD casus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116956","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1096","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1116975","dc_title":"FW: nav jouw vraag voor persmoment","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1116975","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1097","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117006","dc_title":"FW: NVZ-reactie op VWS-notitie inzake Uitgangspunten beleidskaderfase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117006","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1098","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117016","dc_title":"FW: offerte Corona_vaccinatie_BKB_deel3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117016","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1099","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117035","dc_title":"FW: onderbouwing maatschappelijk pakket flankerend beleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117035","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117041","dc_title":"FW: Onderzoeksvragen COVID Directie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117041","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117047","dc_title":"FW: Opmerkingen feedback MZS - Deadline 12:30 - Stavaza covid 2februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117047","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117049","dc_title":"FW: organogrammen, laatste (definitieve) versies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117049","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117108","dc_title":"FW: Positief advies St. Eustatius. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117108","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117175","dc_title":"Brief COA-Opdracht ten aanzien van gegevensdeling in het kader van vaccinatieprogramma COVID-19 voor asielzoekers.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117175","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117183","dc_title":"BM2020.0911 LiveNation - onderzoek risico COVID-19 aerosol overdracht - AFAS Live  Ziggo Dome_DEF.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117183","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":41,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117198","dc_title":"Brief Opdrachtbrief_20201210_ObservationeleStudie_SPP.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117198","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117353","dc_title":"Format moties Marijnissen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117353","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117356","dc_title":"FW: prikken van deel huisarts personeel door GGD in maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117356","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117363","dc_title":"FW: Punten BTC actualiteit ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117363","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117387","dc_title":"FW: reactie AD website ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117387","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117390","dc_title":"FW: RE: Vaccinatie VS en PA in de eerstelijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1117390","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117393","dc_title":"FW: Recente versie rapport en document tbv overleg met VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117394","dc_title":"FW: Referentie: 4184659 / Projectnummer: EP050482 OpdrachtvoorstelVWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117394","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117423","dc_title":"FW: selfiehoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117423","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117426","dc_title":"FW: Spoed: 'Aankoop Covid-19 Vaccin - Moderna, Valneva, Novavax(zaaknummer: 217568)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117426","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117427","dc_title":"FW: SIgnaal LNAZ Naalden tekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117427","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117437","dc_title":"FW: Stand van zakenbrief 02/02 - conceptversie #4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117437","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117453","dc_title":"FW: Stavaza brief concept 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117453","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117467","dc_title":"Coronabanen functies taakvoorbeelden - akkoord Kirsten.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117467","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117512","dc_title":"FW: ter informatie; oproep aangaande vaccinatie kat covid-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117512","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117516","dc_title":"FW: Terugkoppeling  Catshuis en bestellingen Hugo","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117516","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117547","dc_title":"EP plenair debat impact van Covid.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117547","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117570","dc_title":"Communicatieschema Vaccinatie covid-19-vragen 20210210 2.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117570","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117581","dc_title":"Datatable Non_pharm interventions versie februari 2021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117581","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":59,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117615","dc_title":"Definitieve Besluitenlijst Directieraad 2021-01-26.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117615","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117626","dc_title":"03-02-2021 notulen wrapup.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117626","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117651","dc_title":"Invloed coronacrisis op deelname Rijksvaccinatieprogramma_situatie 20210209.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117651","foi_nrPages":12,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117681","dc_title":"FW: tv - vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117681","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117725","dc_title":"FW: Urgent: vervoer vanuit Shanghai naar AMS van naalden en spuiten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117725","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117736","dc_title":"FW: Vaccinatie in relatie tot verwachte weersomstandigheden.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1117736","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117740","dc_title":"20210201 Brief FMS fasering vaccinaties ziekenhuispersoneel aan NVZ, NFU.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117740","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117750","dc_title":"FW: Vaccinatieoverleg 17u 5 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117750","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117787","dc_title":"FW: verzoek met oog op vaccineren pati\ufffdntvertrouwenspersonen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117787","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117790","dc_title":"FW: Voorgenomen bezoek beveiligingsautoriteit RIVM aan Sint Eustatius+ verzoek akkoord inreizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117790","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117799","dc_title":"FW: Verzoek van Marjolijn voor gesprek MVWS vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117799","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117813","dc_title":"FW: vraag mbt prio vaccineren KMar","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117813","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117865","dc_title":"Document2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117865","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117880","dc_title":"Nivel consumentenpanel: aanvraag UM vragenlijst over behandelkeuzediabetes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117880","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117896","dc_title":"FW: weergave informeel overleg vrijdag 22/1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117896","foi_groundsOfRefusal":"5.1.2b;5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117903","dc_title":"FW: Written Procedure: Implementation of ECDC Work Programme 2021(Financing Decision)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117903","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117915","dc_title":"Fwd: Goed nieuws over langere tijd tussen prime-boost + reductie van transmissie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117915","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117938","dc_title":"RE: bericht RIVM: Bpf in kleinschalige woonvormen via mobiele teams","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117938","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117943","dc_title":"RE: presentatie flankerend beleid maatschappelijk pakket plusonderbouwing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117943","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117975","dc_title":"Timen_11_maart_2020.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117975","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117976","dc_title":"object0001.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117976","foi_nrPages":12,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117984","dc_title":"20210129 Verslag PO - 29 jan def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117984","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117995","dc_title":"Reactie Motie Veldman.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117995","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117996","dc_title":"oplegvel handreiking kernoverleg 05-02.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1117999","dc_title":"Conceptverslag hand aan de kraan overleg 1 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1117999","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118007","dc_title":"Bijlage 4. 210201 Factsheet RAV's NW6 Corona-COVIDambulance-inzetten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118007","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118009","dc_title":"Bijlage 5. Overzichten VVT tbv Bestuurlijk Crisis ROAZ-02-02.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118009","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118011","dc_title":"Monitor Zorgcontinu\ufffdteit week 5 landelijk beeld.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118011","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118016","dc_title":"20210216-Notulen bespreking Control 3e projectgroepvergadering.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118016","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118019","dc_title":"10430022010022_CONTROL_Report_20210212_SARS-CoV-2 Symptoms.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118019","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118028","dc_title":"RE: Vaccinatie uitrol andere EU landen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118028","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118030","dc_title":"Verslag Ketenwerkgroep voorbereiding Crisiszorg ROAZ NH en Flevoland20210202.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118030","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118032","dc_title":"RE: Terugkoppeling afstemmingsoverleg RIVM GGD VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118032","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118034","dc_title":"RE: Pati\ufffdnten klinische revalidatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118034","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118037","dc_title":"Agenda en presentatie ketenwerkgroep voorbereiding Crisiszorg20210202.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118037","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":22,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118048","dc_title":"RE: Overleg cli\ufffdntenorganisaties VV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118048","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118054","dc_title":"RE: overleg lhv","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118054","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118071","dc_title":"object0002.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118071","foi_nrPages":18,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118075","dc_title":"object0001.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118075","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118088","dc_title":"RE: Update vaccinatiestrategie 5 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118099","dc_title":"RE: terugkoppeling PO DMO VNG ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118099","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118103","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118103","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118112","dc_title":"Graag jullie akkoord","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118112","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118131","dc_title":"RE: Agenda en stukken LCT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118131","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118132","dc_title":"FW: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118132","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118139","dc_title":"RE: Korte vraag over data safety","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118139","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118147","dc_title":"RE: Notitie Waddeneilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118147","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118163","dc_title":"RE: Afstemmingsoverleg gisteren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118163","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118164","dc_title":"RE: Uitwisselingsoverleg actielijst en presentaties van 22-02-21 en 100e OMT advies openbaar.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118164","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118170","dc_title":"RE: Korte vraag over data safety","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118176","dc_title":"FW: BCO Scholen, opstellen 'gerechtvaardigd belang' voor AP FW: GGD-Inf@ct: COVID-19 (nieuw coronavirusinfectie) (97)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118179","dc_title":"RE: Afbakening zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118179","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118188","dc_title":"FW: Brief inzet AstraZeneca VERSIE 23.00 cs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118188","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118190","dc_title":"FW: Ter informatie/vooraankondiging: artikel aerosolen is geaccepteerd voor publicatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118190","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118191","dc_title":"Vaccinatie cli\ufffdnten in instellingen onder huisartsenzorg door huisartsenposten (HAP) met Moderna en BioNTech/Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118191","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118194","dc_title":"RE: Agenda en stukken voor overleg OCW/VWS/RIVM over pilots onderwijs MBO/HBO/WO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118194","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118196","dc_title":"RE: Webinar GGD artsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118196","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118197","dc_title":"RE: varianten vaccinatie AZ 03022021 drie varianten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118197","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118201","dc_title":"FW: Beschermende middelen verkiezingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118201","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118208","dc_title":"RE: COVIg-product SPP - clarification meeting - case 858779","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1118208","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118224","dc_title":"FW: OECD questionnaire on long-term care and covid-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118224","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118237","dc_title":"RE: Annotatie vaccins DOC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118237","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118239","dc_title":"RE: concept agenda inschalingsoverleg 22-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118239","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118240","dc_title":"FW: Verslag koepeloverleg 26/01 en 02/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118240","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118242","dc_title":"RE: concept agenda inschalingsoverleg 22-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118242","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118258","dc_title":"FW: de opties op een rij","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118258","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118261","dc_title":"RE: afspraak nav RTL berichtgeving over vaccinatie bij Argos/conforte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118261","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118263","dc_title":"RE: Vraag vanuit Rapid Response Team Testen en thuisblijven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118263","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118269","dc_title":"RE: Professionele ruimte huisarts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118269","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118275","dc_title":"FW: vaccinatiebewijzen: procesdocument voor het DOC morgen 10februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118275","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118279","dc_title":"Inhoud brief TK 5 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118279","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118281","dc_title":"RE: Gespret met Marcel en Roland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118284","dc_title":"RE: sneltest niet in BCO verwerkt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118284","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118288","dc_title":"FW: Vaccinatie vrijwilligers palliatieve zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118292","dc_title":"RE: Vraag uitnodigen medewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118292","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118299","dc_title":"RE: Aanscherping communicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118324","dc_title":"RE: Brief aan Ministerie van VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118324","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118338","dc_title":"RE: Vaccin-procedure overleg 12/02/2021 (vertrouwelijk)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118338","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118339","dc_title":"RE: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118339","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118340","dc_title":"FW: Nieuwe versie flowchart + uitleg strategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118340","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118345","dc_title":"RE: Terugkoppeling afstemmingsoverleg RIVM GGD VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118345","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118346","dc_title":"RE: uitwerking opdracht motie Vaccin-gezant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118346","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118349","dc_title":"RE: Uitkomst juristen VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118349","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118350","dc_title":"RE: vraagstelling aan NCTV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118350","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118372","dc_title":"notaoverleg 10/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118372","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118380","dc_title":"RE: input kosten vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118380","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118381","dc_title":"RE: Updatemail LZ corona 12/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118381","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118391","dc_title":"Gebruikte sheet voor het plaatje","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118391","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118399","dc_title":"RE: Brief inzet AstraZeneca VERSIE 23.00 cs lz ek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118399","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118401","dc_title":"RE: Vraag betreffende verzoek van Sourcing Partner - Pfizer Bion Techkanaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118404","dc_title":"RE: update deelname vaccinatieteam","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118404","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118418","dc_title":"FW: LAREB gegevensuitwisseling wettelijke grondslag ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1118418","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118421","dc_title":"RE: contact RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118421","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118423","dc_title":"RE: 4.0. Beslisnota BR investeringsvoorstellen Recovery andResilience Facility (RRF).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118423","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118454","dc_title":"RE: vaccinaties en inspectie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118454","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118475","dc_title":"Terugkoppeling DOC vrijdag 5 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118475","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118481","dc_title":"FW: Confidential: update AZ vaccin leveringen februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118481","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118484","dc_title":"RE: Onderzoeksrapport","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118506","dc_title":"RE: spoednota","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118506","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118507","dc_title":"RE: Rapportage vaccinatiegezant Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118507","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118508","dc_title":"RE: Brief Mentorschap NL over de cruciale beroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118508","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118510","dc_title":"FW: mail aan ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118510","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118516","dc_title":"RE: Verslag koepeloverleg 26/01 en 02/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118516","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118518","dc_title":"RE: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118524","dc_title":"verslagje debat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118524","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118535","dc_title":"internationale prio's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118535","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118546","dc_title":"RE: koffiemomentje, OMT en overdracht Ton","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118546","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118552","dc_title":"RE: VERZOEK MEELEZEN: Advisering scholenteams","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118552","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118553","dc_title":"Re: VERZOEK MEELEZEN: Advisering scholenteams","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118553","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118555","dc_title":"RE: Percy Thio status","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118555","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118561","dc_title":"RE: huidige definitie op website VWS en vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118561","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118573","dc_title":"RE: Agenda en stukken LCT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118573","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118583","dc_title":"RE: Brief viruswaarheid vaccinatiecampagne","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118583","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118594","dc_title":"RE: Antw:  BCO DJI en advies GGD Utrecht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118594","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118595","dc_title":"RE: Plaat hoeveel er in hoeveel er uit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118595","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118596","dc_title":"RE: Laatste opmermingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118596","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118605","dc_title":"RE: Stand_van_zakenbrief_COVID-19 (1)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118605","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118616","dc_title":"RE: Signaal LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118616","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118617","dc_title":"RE: Ook voor po -; vaccineren gevangenen/DJI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118617","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118619","dc_title":"RE: Stand_van_zakenbrief_COVID-19 (1)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118619","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118620","dc_title":"RE: Opmerkingen MZS - Gebruik PBM in de zorg - deadline 12:30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118620","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118638","dc_title":"FW: afspraken regiegroep","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118644","dc_title":"FW: VASCO vingerprik tijdspunten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118644","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118647","dc_title":"RE: Opf\ufffdlgning: Nederlandene - interesse i dansk vaccinationsstrategi","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118647","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118660","dc_title":"FW: Dashboard en ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118660","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118676","dc_title":"RE: OMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118676","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118680","dc_title":"RE: Communicatie website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118680","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118690","dc_title":"RE: opdrachtbrief bijgewerkt na overleg gisteren..","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118690","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118693","dc_title":"RE: Percy Thio status","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118693","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118718","dc_title":"RE: OMT slides","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118718","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118725","dc_title":"FW: Programma 19 COVID19 Leefomgeving 2021 onderdeel Binnenmilieu","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118725","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118747","dc_title":"Format fiche spoor 2 IC-opschaling na verwerking opm CZ-WJZ-DUSI.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118747","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118758","dc_title":"Vaccineren bij oudere stellen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118758","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118761","dc_title":"RE: aanpassing flowchart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118761","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118763","dc_title":"Operational Conclusions - IPCR Roundtable 8 February COVID-19_.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118763","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118765","dc_title":"RescEU aanbesteding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118765","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118777","dc_title":"RE: Woordvoeringslijn pollen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118777","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118778","dc_title":"RE: extra update prognoses","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118778","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118782","dc_title":"FW: Aantallen overzicht GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118782","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118807","dc_title":"RE: overleg van daarnet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118807","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118818","dc_title":"RE: TKN vervoer tussen instellingen via apotheker","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118818","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118821","dc_title":"RE: Tabelletje varianten gebruikt voor modellering","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118821","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118825","dc_title":"RE: overleg gisteren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118825","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118831","dc_title":"RE: VK artikel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118832","dc_title":"RE: Uitvraag over testbewijzen in Europa","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118832","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118834","dc_title":"FW: Expertgroep zoonosen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118834","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118840","dc_title":"RE: vraag grote studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118840","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118842","dc_title":"RE: Snotterende kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118842","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118845","dc_title":"RE: werkgroepen HPZone transitie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118845","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118846","dc_title":"FW: Halma bericht vanuit VWS ontvangen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118850","dc_title":"RE: Advisory Agreement COVID-RED","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118850","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118857","dc_title":"brieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118857","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118864","dc_title":"Antw: extra update IC prognoses","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118864","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118865","dc_title":"RE: Antw: beoordeling manuscript","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118865","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118867","dc_title":"RE: samenwerking op deelprogramma epidemiologie en transmissie van COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118867","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118870","dc_title":"FW: Pollen voor LuVo stuurgroep","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118870","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118872","dc_title":"RE: Gebruik anti-COVID-19 immunoglobuline product `CoVIg-19\ufffd  in onderzoeks-setting - Case number 797445","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118872","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118876","dc_title":"FW: Brief Mentorschap NL over de cruciale beroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118876","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118882","dc_title":"RE: redeneerlijn ME","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118882","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118895","dc_title":"RE: Call Vaccin Gazant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118895","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118896","dc_title":"RE: spreeklijn op verhaal zelf afspraak maken dove /zieke 90+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118896","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118899","dc_title":"RE: Gezondheidsraad, planning deze week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118899","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118910","dc_title":"RE: Overleg cli\ufffdntenorganisaties VV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118910","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118920","dc_title":"Onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118920","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118921","dc_title":"Antw:  Damialis_MainManuscript_FINAL.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118921","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118925","dc_title":"FW: Antw: tussentijdse update/contact nav gesprek 29 januari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118925","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118938","dc_title":"RE: Concept-verslag QuickScan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118938","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118942","dc_title":"RE: Acties t.b.v. DOTT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118942","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118943","dc_title":"RE: Schatting reproductiegetal en aantal besmettelijke personen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118943","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118949","dc_title":"RE: Concept jaarrapportage - deadline voor evt opmerkingen: 10 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118949","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118953","dc_title":"RE: OMT brief nummer 99","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118953","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118958","dc_title":"RE: OMT brief nummer 99","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118958","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118961","dc_title":"NCTV wrap-up terugkoppeling | 4 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118961","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118964","dc_title":"RE: Eerste concept persconferentie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118964","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118965","dc_title":"RE: 10.00-10.15u Zwartste scenario","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118965","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118966","dc_title":"RE: rapport over modellering van covid-19 vaccinatie, eerste versie die we willen delen met GR en VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118966","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118976","dc_title":"RE: Leveringen AstraZeneca vaccin Q1/Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118976","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118977","dc_title":"RE: Nieuwe versie brief: datum 1 februari nog niet aangepast","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118977","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118985","dc_title":"RE: svz akties Covid lucht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118985","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118991","dc_title":"Geen verlenging bevel testlab meer nodig","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118992","dc_title":"RE: Wens voor de brief van mp/hugo","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118992","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118998","dc_title":"RE: vraag nav DR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118998","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1118999","dc_title":"RE: Aantallen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1118999","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119002","dc_title":"RE: Antw: Test-negative COVID-19 VE study","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119002","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119005","dc_title":"RE: brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119005","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119009","dc_title":"FW: Innovatie voor traceren uit Quebec / COVID","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119009","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119025","dc_title":"RE: deze sheet gaat - in het Veiligheidsberaad presenteren, kunnen wij daar iets mee in het nieuwsbericht? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119025","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119026","dc_title":"FW: Sinovac vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119026","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119034","dc_title":"RE: Input voor nieuwsbericht, begin volgende week?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119034","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119037","dc_title":"FW: Tweede rapportage van de vaccinatiegezant over Curacao","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119037","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119040","dc_title":"RE: Uitvraag agendapunten PO MVWS 5 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119040","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119042","dc_title":"RE: Levering vaccin 10 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119042","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119045","dc_title":"RE: accoord VWS op aanbestedingsstukken rescEU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119045","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119048","dc_title":"RE: Vaccin gezant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119048","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119049","dc_title":"RE: TER INFORMATIE Informatiepakket coronavaccinatie via de HAPs metModerna","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119049","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119053","dc_title":"RE: tekst kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119053","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119064","dc_title":"RE: bp bij kleinschalige woonvormen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119064","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119066","dc_title":"RE: Vraag (niet urgent) over samenhang maatregelen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119066","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119070","dc_title":"RE: nieuwe versie persbericht; graag zsm check","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119070","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119071","dc_title":"RE: Q&A Uitstel RVP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119071","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119075","dc_title":"RE: COVIg-product SPP - clarification meeting - case 858779","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119075","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119079","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119079","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119084","dc_title":"Dagafsluiting verslag 18-2-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119084","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119085","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119085","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119093","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119093","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119100","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119100","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119112","dc_title":"RE: vraag over Phizer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119112","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119113","dc_title":"FW: definitieve nota DOC 11 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119113","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119116","dc_title":"RE: doelgroepennotitie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119116","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119131","dc_title":"RE: SPOED: concept nota DOC 11 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119131","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119134","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119141","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119141","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119145","dc_title":"RE: Info vaccingesprek CBG 050221 (vertrouwelijk)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119160","dc_title":"FW: zuid afrikaanse variant en astrazeneca en de aantallen virusvarianten in Nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119160","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119164","dc_title":"RE: Verslag koepeloverleg 09/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119164","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119170","dc_title":"RE: Visuals tbv PO MVWS 5 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119173","dc_title":"Antw: instellen expertgroep risicoanalyse zoonosen FW: Aanbieding afschrift verzamelbrief SARS-CoV-2 bij dieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119175","dc_title":"RE: Verzoek: concrete tekstvoorstellen opschalingsdocument [deadline donderdag 4 maart]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119175","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119179","dc_title":"FW: astra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119179","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119186","dc_title":"RE: Antw:  covid-19: verzoek goedkeuring Zero Residual Spuiten enNaalden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119186","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119191","dc_title":"RE: covid stand up 9 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119191","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119192","dc_title":"FW: Uitzoekpunt cijfers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119195","dc_title":"RE: van VWS-net","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119195","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119203","dc_title":"RE: [Spam] RE: CID MS CID-106552","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119205","dc_title":"RE: eerste levering AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119205","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119209","dc_title":"RE: varianten vaccinatie AZ 03022021e","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119209","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119211","dc_title":"RE: nota ter voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119211","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119217","dc_title":"FW: Scenarios","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119217","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119226","dc_title":"RE: Schermen van webinar vrijdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119226","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119234","dc_title":"RE: Pollen voor LuVo stuurgroep","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119234","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119235","dc_title":"RE: For your review: Risk of death for healthcare workers from COVID-19 manuscript","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119235","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119236","dc_title":"RE: Schermen van webinar vrijdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119236","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119241","dc_title":"RE: Antw: tussentijdse update/contact nav gesprek 29 januari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119241","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119249","dc_title":"RE: Vervolg vaccinatie BW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119249","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119250","dc_title":"RE: Snotterende kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119250","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119256","dc_title":"Debat_over_de_ontwikkelingen_rondom_het_coronavirus_(ongecorrigeerd_stenogram) d.d. 09-12-20.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119256","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":159,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119258","dc_title":"RE: Oplossingsrichting","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119258","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119290","dc_title":"RE: PGB zorgmedewerkers ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119290","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119293","dc_title":"RE: Aanlevering CoronIT-nr. RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119293","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119296","dc_title":"RE: Directeurenoverleg/Strategiesessie (on)mogelijkheden en wenselijkheid van vastlegging covid-vrij zijn - 03/02 14.00 - 14.30 uur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119296","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119298","dc_title":"RE: Debatdossier 09-02 concept 0.1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119298","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119301","dc_title":"FW: Vraag Iederin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119301","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119312","dc_title":"delphi 12 februari.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119312","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119317","dc_title":"delphi 25 februari.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119317","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119323","dc_title":"Delphi 19 februari 2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119323","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119326","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119326","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119327","dc_title":"Deltaplan Jeugd tbv stuurgroep 11 feb.pptx_9432c8e6-e4de-4817-9037-7d96ee6f16d6.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119327","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119330","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119330","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119344","dc_title":"RE: PDC19: Toezending voorlopige resultaten grootschalig testen in degemeente Lansingerland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119344","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119350","dc_title":"RE: nabrander op de brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119350","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119367","dc_title":"op afroep VRIJDAG 5 februari om 11.30 uur vaccinatieoverleg terugkoppeling MCC over inzet AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119367","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119391","dc_title":"RE: Prognoses","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119391","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119395","dc_title":"Demo Sprint 16.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119395","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119397","dc_title":"RE: Infectieradar: covid-19 achtige klachten en ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119397","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119399","dc_title":"Demo sprint 13.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119399","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119401","dc_title":"Demo sprint 15.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119401","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119403","dc_title":"Demo sprint 14.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119403","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119409","dc_title":"agenda straks","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119409","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119413","dc_title":"update concept rapport modellering COVID-19 vaccinatie strategieen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119413","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119416","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119462","dc_title":"Kick off meeting kwaliteitsevaluatie AG-sneltesten  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119462","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119464","dc_title":"FW: PNAS artikel mogelijk morgen al online en FAQ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119464","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119481","dc_title":"Operationeel projectleider","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119481","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119482","dc_title":"RE: Rapport en tijdschriftartikel veehouderij en effecten op volksgezondheid en milieu","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119482","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119494","dc_title":"Prognoses","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119494","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119498","dc_title":"FW: HCW Manuscript Draft #2 and disclosure of interest form","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119498","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119512","dc_title":"RE: vraag mbt prio vaccineren KMar","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119512","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119527","dc_title":"RE: Uitvraag FFP2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119527","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119530","dc_title":"FW: SOP Pfizer BioNTech Vaccine","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119530","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119533","dc_title":"FW: Vaccinatie Beschermd Wonen en GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119533","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119541","dc_title":"RE: Noodsignaal Amarant Brabant en verzoek vaccinatiestrategiemedewerkers GHZ ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119541","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119542","dc_title":"RE: TK-vraag over R-waarde / grootschalig testen (tbv stuurgroep morgen)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119542","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119559","dc_title":"AANPASSING: Vaccinoverleg morgen, donderdag 11 februari, vindt plaatsvan 15.30 tot 17.15 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119559","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119562","dc_title":"RE: Productie Janssen Vaccin in Nederland / urgent","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119562","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i;5.1.2i Concept;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119563","dc_title":"FW: signalen vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119563","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119564","dc_title":"RE: Brief inzet AstraZeneca VERSIE 23.00 cs lz","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119564","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119566","dc_title":"Vraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119566","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119570","dc_title":"RE: nav jouw vraag voor persmoment","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119570","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119591","dc_title":"RE: Concept Persbericht -  Eerste leveringen COVID voor CAS en BES -namens vierlanden maandagavond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119591","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119592","dc_title":"Studies met Nanogam-COVIg mogelijk maken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119592","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119597","dc_title":"RE: Kamervragen vaccinatie: ouder- en /of familie-initiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119597","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119598","dc_title":"RE: zorgen vanuit EZK over export beperkende maatregelen rondomvaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119598","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119599","dc_title":"RE: Check FW: Vraag webcare","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119599","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119601","dc_title":"RE: aantallen vaccinaties langdurige zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119601","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119603","dc_title":"FW: Test- en vaccinatiebewijzen DOC-19 dinsdag en ACC-19 donderdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119603","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119620","dc_title":"RE: Stroomschema bewoners irt vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119620","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119622","dc_title":"FW: Kamervragen vaccinatie: ouder- en /of familie-initiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119622","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119626","dc_title":"RE: spreektekst debat morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119626","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119639","dc_title":"RE: Update ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119639","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119652","dc_title":"RE: Onderzoeksvragen COVID Directie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119652","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119655","dc_title":"RE: input kosten vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119655","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119671","dc_title":"FW: PvA en voortgang forensisch onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119671","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119675","dc_title":"RE: Stand van zaken Kamervragen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119675","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119676","dc_title":"RE: Call Vaccin Gazant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119676","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119687","dc_title":"RE: Test- en vaccinatiebewijzen DOC-19 dinsdag en ACC-19 donderdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119687","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119693","dc_title":"RE: vaccinatie 11.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119693","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119694","dc_title":"RE: CONCEPT 210209 nota onderzoek zonmw met bijlagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119694","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119697","dc_title":"RE: Informatie website coronavaccinatie n.a.v. afstemmingsoverleginhoud  Q&A's COVID vaccinatie 2/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119697","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119699","dc_title":"FW: Vragen zijn aan PDC19 gesteld ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119699","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119704","dc_title":"Re: polio en corona vaccinaties ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119704","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119705","dc_title":"RE: gedoe met vervoer van vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119705","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119714","dc_title":"RE: varianten voor AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119714","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119715","dc_title":"RE: Mondkapjes en hielprikscreening","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119715","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119723","dc_title":"RE: Mondkapjes en hielprikscreening","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119723","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119727","dc_title":"RE: Verzoek Telegraaf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119727","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119728","dc_title":"FW: Actiepunten n.a.v.  overleg stavaza vaccins LZ/CZ/DMO/J","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119728","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119735","dc_title":"RE: review testbewijsapp ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119735","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119742","dc_title":"RE: Vraag uitnodigen medewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119742","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119762","dc_title":"RE: Nieuw middel Israel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119762","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119763","dc_title":"RE: Naaldenprobleem","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119763","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119768","dc_title":"Prognoses: vreemde resultaten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119768","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119772","dc_title":"RE: Snotterende kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119772","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119783","dc_title":"RE: rapport over modellering van covid-19 vaccinatie, eerste versie die we willen delen met GR en VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119783","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119789","dc_title":"Advies voor aanvullende tests op alle informatiesystemen t.b.v. covidbestrijding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119789","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119793","dc_title":"Re: geldigheidsduur testuitslag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119793","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119795","dc_title":"RE: metadata testbereidheid en overheidsbeleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119795","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119803","dc_title":"RE: aanpassing toestemmingsformulier vaccinatie onder huisarts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119803","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119806","dc_title":"RE: Input Ieder(in) voor coronadebat 4/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119806","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119809","dc_title":"RE: HEDENAVOND om 20.00 uur! vaccinatieoverleg inzet AZ n.a.v. GR-advies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119809","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119812","dc_title":"RE: GRAAG EVEN KIJKEN HIERNAAR EERNST - VERSIE 13.30U RE: Brief inzetAstraZeneca VERSIE 23.00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119812","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119821","dc_title":"RE: Update ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119821","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119824","dc_title":"RE: wie kan deze motie op zich nemen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119824","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119842","dc_title":"FW: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119842","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119847","dc_title":"FW: Opdrachtverstrekking dossieronderzoek tbv audit EY","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119847","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119864","dc_title":"RE: Antw:  verdeling epidemiologische ruimte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119864","foi_groundsOfRefusal":"5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119868","dc_title":"RE: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1119868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119869","dc_title":"Overleg morgenochtend","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119869","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119870","dc_title":"RE: Concept verslag Inhoudelijke vooruitblik RIVM/VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119870","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119876","dc_title":"FW: Landelijke stuurgroep GRT: agenda en stukken vergadering 24/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119876","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119894","dc_title":"RE: Inf@ct 97 en handreiking privacy PO- en VO-raad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119894","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119897","dc_title":"FW: Werkwijze vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119897","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119904","dc_title":"FW: CIB overleg 11/2 vervalt | Schriftelijke mededelingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119904","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119907","dc_title":"RE: ter bespreking sneltest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119907","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119917","dc_title":"FW: TF Covid rl: update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119919","dc_title":"RE: Melding nr. M2102 3224 onderwerp: GGD Limburg Noord - Kwetsbaarheid binnen supermarkten ontdekt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119919","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119923","dc_title":"FW: vers uit het BAO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119923","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119936","dc_title":"RE: Retourpost 217770 - Voorraad FFP2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119936","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119938","dc_title":"FW: graag verzoek aan literatuurclubje ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119938","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119946","dc_title":"meesturen met de notulen vd wrap up morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119946","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119956","dc_title":"RE: Versie voor op de website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119956","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119959","dc_title":"RE: Update ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119959","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119972","dc_title":"RE: Snotterende kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119972","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119973","dc_title":"RE: varianten voor AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119973","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119980","dc_title":"RE: Updatemail LZ corona 12/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119980","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1119996","dc_title":"RE: 2 oversterfte geatllen noemen? ( Bericht oversterfte week 4)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1119996","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120007","dc_title":"RE: overzicht aantal zorgmedewerkers LZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120007","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120008","dc_title":"RE: VTC ER 25-26/2 - concept-verklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120008","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120012","dc_title":"RE: Prognoses en scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120012","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120013","dc_title":"RE: Uitvraag FFP2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120013","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120017","dc_title":"FW: Samenvatting mails","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120017","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120023","dc_title":"RE: Planning gezamenlijke factsheet: deadline donderdag 4 februari15.30 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120023","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120026","dc_title":"RE: Kamervragen vaccinatie: ouder- en /of familie-initiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120026","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120033","dc_title":"HSC MT comments","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120033","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120049","dc_title":"RE: Nieuwe versie flowchart + uitleg strategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120049","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120054","dc_title":"RE: Nieuwe versie brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120054","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120068","dc_title":"Re: Ter info - FW: URGENT | EMA vaccin validatie proces voor Sinovac","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120068","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120076","dc_title":"RE: twee kleine groepjes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120076","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120084","dc_title":"Aantal voorkomen infecties door de avondklok ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120084","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120092","dc_title":"RE: Data prognose mutant tbv wetenschapsartikel?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120092","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120099","dc_title":"RE: cijfers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120099","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120102","dc_title":"FW: Antw: Test-negative COVID-19 VE study","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120102","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120114","dc_title":"Leveringen AstraZeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120114","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120133","dc_title":"lijn naalden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120133","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120138","dc_title":"RE: media offensief tbv sneller vaccineren thuiszorg medewerkersmorgen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120138","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120140","dc_title":"RE: Nieuw: visual vaccinatiestrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120140","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120142","dc_title":"RE: SAS Webinar Covid & PID 3 februari jl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120142","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120157","dc_title":"overleg communicatie en proces hoog risicogroepen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120157","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120176","dc_title":"RE: prioritering medische risico groepen en ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120183","dc_title":"FW: wetsvoorstel testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120185","dc_title":"RE: Werkwijze uitnodigen 80-89 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120185","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120187","dc_title":"Overleg KNMP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120187","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120198","dc_title":"RE: Tweede rapportage vaccinatiegezant Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120198","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120201","dc_title":"RE: prioritering COVID19 vaccinatie transplantatiepatienten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120201","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120206","dc_title":"FW: nota aan MVWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120206","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120208","dc_title":"RE: AANGEPASTE DATUM! overleg over Covid-vaccinatie op vrijdag 5februari om 15.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120208","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120214","dc_title":"RE: Vaccinatie vrijwilligers palliatieve zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120214","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120215","dc_title":"RE: aanpassing LCI handleiding covid vaccinatie immuungecompromitteerde patienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120215","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120222","dc_title":"volgorde en planning zorgmedewerkers voor verzending","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120222","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120223","dc_title":"Ge\ufffdntegreerd IT-platform voor Vaccinatie Management","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120232","dc_title":"Vraagstuk CoronaMelder.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120232","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120234","dc_title":"Zuid-Afrikaanse variant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120236","dc_title":"RE: Doorst: Fwd: South+Africa+suspends+use+of+AstraZeneca\ufffds+COVID-19+vaccine+after+it+fails+to+clearly+stop+virus+variant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120236","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120237","dc_title":"gesprek 2 met Jan Fransoo (TU Eindhoven) en Paul Enders (ASML)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120237","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120239","dc_title":"Vraagstuk Retail.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120239","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120261","dc_title":"RE: passage brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120273","dc_title":"vrijgifte goederen Janssen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120273","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120275","dc_title":"Kosten vaccinatie via de HAP (de 'Moderna-route').docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120275","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120278","dc_title":"Update Beveiliging en bewaking Vaccins_2021_02_15.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120278","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2h","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120281","dc_title":"RE: Allergie Corona vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120284","dc_title":"RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120305","dc_title":"Geannoteerde agenda directeurenoverleg beveiliging COVID-19 vaccins16_02.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120305","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120310","dc_title":"FW: Proces inschaling per 2 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120310","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120318","dc_title":"RE: vraag ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120318","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120321","dc_title":"PLATO-#4184126-v1-Rekenmodule_Corona_Vaccinatie_jan_feb_2021.XLS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120321","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120327","dc_title":"RE: Vaccin voor onderzoek vertrouwelijk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120327","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120357","dc_title":"V-Trace Commercial Presentation - Jan 21 QC gvt.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120357","foi_nrPages":32,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120362","dc_title":"RE: SAS Webinar Covid & PID 3 februari jl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120362","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120366","dc_title":"Fw: Antw:  mix COVID vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120366","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120367","dc_title":"Memo Mentale Gezondheid en bestaandszekerheid jongeren.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120367","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120372","dc_title":"Aantallen_actueel.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120372","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120390","dc_title":"RE: observatietijd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120390","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120407","dc_title":"Format fiche spoor 2vaccins_HB 04022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120407","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120424","dc_title":"RE: Antw:   Covid19 vaccinatie piloten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120424","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120425","dc_title":"RE: vraag over individuele afweging ouderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120425","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120427","dc_title":"Antw:   Covid19 vaccinatie piloten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120431","dc_title":"nieuwe versie richtlijn en instructie AZ vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120431","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120434","dc_title":"RE: Overleg Pfizer - RIVM 1 februari 2021: Beantwoording vraag naaldlengte bij obesitas","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120434","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120438","dc_title":"FW: overleg vanmiddag om 14.30 over de richtlijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120438","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120453","dc_title":"RE: Begroting COVID-15, 16, 17 2021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120453","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120473","dc_title":"Terugkoppeling SBI teamoverleg 1 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120473","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120488","dc_title":"RE: Doorst:  Vraag AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120488","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120498","dc_title":"RE: afstemming communicatie en follow up","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1120498","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120510","dc_title":"RE: Gedragsinterventies ter verhoging vaccinatiebeleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120510","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120519","dc_title":"RE: Gebruikerstest Clientenportaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120519","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120528","dc_title":"RE: Vraag aan - van Vliet, Programmamanger COVID-19 vaccinatie, betr. Webinar 17 febr. 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120528","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120552","dc_title":"FW: laatste versie en akkoord met versturen van deze brief vandaag naar NFU en NVZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120552","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120562","dc_title":"Flyer voor na de vaccinatie, graag uiterlijk maandag reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120562","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120565","dc_title":"RE: Plan Janssen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120565","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120573","dc_title":"RE: Vraag voorichters BZ247 Sneltest na vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120573","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120582","dc_title":"Bamlanivimab info.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120582","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120595","dc_title":"GGD GHOR corona monitor definitief 08-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120595","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":32,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120610","dc_title":"RE: Gevaccineerd en de website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120610","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120633","dc_title":"graag check: Q&A PGB ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120633","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120649","dc_title":"FW: Doorst: 20210216_weekly update tekst_DEFINITIEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120649","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120670","dc_title":"RE: inzet opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120670","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120673","dc_title":"RE: inzet opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120673","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120680","dc_title":"FW: Review vaccinatieprogramma en RGW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120680","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120683","dc_title":"Annotatie 4 feb.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120683","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120685","dc_title":"Verslag brieding GR advies ethische en juridische aspecten 3 feb.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120685","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120695","dc_title":"RE: Waarom nog gedragsregels gelden na vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120695","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120700","dc_title":"RE: Notulen Bijeenkomst Vaccinatieprogramma & Gedrag 05/02 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120700","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120713","dc_title":"RE: Optimale doseringsinterval COVID vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120713","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120748","dc_title":"Verslag WG Grensproblematiek donderdag 4 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120748","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120756","dc_title":"RE: Lijst met pati\ufffdnten die volgens de experts voorrang zouden moeten krijgen bij vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120756","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120764","dc_title":"RE: Stavaza covid 23 februari- deadline aanlevering donderdag 10:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120764","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120775","dc_title":"RE: hulpvraag tbv. vaccineren pati\ufffdntvertrouwenspersonen Stichting PVP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120775","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120789","dc_title":"Doorst:  Covid19 vaccinatie piloten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120789","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120800","dc_title":"RE: Pagina volgorde vaccinatie zorgmedewerkers bijgewerkt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120800","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120811","dc_title":"po - vaccinaties 0203- agendapunt BW- uitvoering.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120811","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120818","dc_title":"RE: Bijpraten lange termijn scenario","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120818","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120827","dc_title":"nav PO -","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120827","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120832","dc_title":"intern  weekoverzicht Lareb van de meldingen op Covid vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120832","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120840","dc_title":"RE: Fwd: FW: Databron vraag Corona. Meldingnummer: M2011 5453","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120840","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120885","dc_title":"overzicht gegeven aan aankomende presentaties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120885","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120899","dc_title":"Nota ter informatie medische risicogroepen COVID-19 vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120899","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120904","dc_title":"RIVM+FMS-Bijlage - Risico op gecompliceerd beloop COVID-19 enprioritering COVID-19-vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120904","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120908","dc_title":"217832 getekende brief -.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120908","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120915","dc_title":"Agenda afstemmingsoverleg CIB Gedragsunit 180221_v2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120915","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120917","dc_title":"210204  Taak bevoegdheid en uitvoering crisisorganisatie RIVM voor Rec_concept_80%_vs 3.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120917","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120918","dc_title":"Gepoolde reactie Taskforce Diagnostiek LCI GRT.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120918","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120919","dc_title":"210218 Bespreekpunten vervolgoverleg over eerste producten R&V team.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120919","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120920","dc_title":"Reactie LCI GRT.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120920","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120922","dc_title":"Gedragsinterventies voor Thuisblijven en Testen vanuit RRT - Check & Test OnePager - versie 20210217.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120922","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120927","dc_title":"FW: Agenda overleg VWS RIVM GGD GHOR 24/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120927","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120933","dc_title":"FW: VOPG: Update GOR-propositie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120933","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120934","dc_title":"FW: Begroting COVID-15, 16, 17 2021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120934","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120954","dc_title":"FW: Tweede Kamer - update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120954","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120970","dc_title":"Doorst:  ODP brief ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120970","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120979","dc_title":"fiches voor Recovery and Resilience Fund van de EC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120979","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120980","dc_title":"Re: COVID 19 vaccinatie rollout & capacity planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120980","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120982","dc_title":"RE: medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120982","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120984","dc_title":"Kinderen en COVID_samenvatting_v11.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120984","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":42,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1120991","dc_title":"RE: Vraag mbt Dekkingsgraad vaccinaties DVHN","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1120991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121002","dc_title":"RE: Email n.a.v. overleg van vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121002","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121014","dc_title":"Impactanalyses nav GR-advies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121014","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121020","dc_title":"FW: Agenda vaccinatie overleg - 26 februari 15.15u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121020","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121024","dc_title":"RE: Concept vrijdag sessie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121024","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121030","dc_title":"Vaccine Management Platform - Automation","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121030","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121045","dc_title":"Sint Maarten beoordeling randvoorwaarden Covid-19 vaccinatiems40221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121045","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121052","dc_title":"Voorstel huisartsen_20210202_LK_MV.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121052","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121054","dc_title":"Voorstel partyline en proces FEZ covidmand.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121054","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121070","dc_title":"RE: Vaccinatie VS en PA in de eerstelijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121070","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121071","dc_title":"Verslag WG Grensproblematiek donderdag 11 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121071","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121082","dc_title":"RE: Hoogrisicogroep en start vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121082","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121083","dc_title":"RE: berekening/argumentatie CZ voor Medewerkers crisisdiensten ondergroepje ggz medewerkers - spoed","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1121083","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121085","dc_title":"RE: prikken van deel huisarts personeel door GGD in maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121085","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121090","dc_title":"VWS  Corona Dashboard - Vaccinaties versie 2-LQ.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121090","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121092","dc_title":"RE: Laatste versies visuals + PPT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121092","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121097","dc_title":"RE: Proces inschaling per 2 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121097","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121120","dc_title":"Bijlage (uitgangspunten en voordelen gegevensdienst COVID-19vaccinaties).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121120","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121124","dc_title":"RE: Update plaatjes t/m week 13","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121124","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121128","dc_title":"RE: Doorst:  opzet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121128","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121135","dc_title":"Realisatie PGO gegevensdienst vaccinatiegegevens RIVM GKIRG0202102.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121135","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121145","dc_title":"No Subject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121147","dc_title":"RE: Update en vervolgstappen covid dataplatform en dashboards","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121147","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121151","dc_title":"RE: Vijf doelstellingen vandaag (19-02) 2.5m schaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121151","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121161","dc_title":"RE: pb leveringen AZ_YW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121161","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121172","dc_title":"Antw: opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121172","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121176","dc_title":"RE: Actie | Actie | Notitie Operationele Planning AstraZeneca week 7 t/m 14 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121177","dc_title":"RE: Actie | Actie | Notitie Operationele Planning AstraZeneca week 7 t/m 14 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121179","dc_title":"RE: Actie | Notitie Operationele Planning Pfizer week 7 t/m 14 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121179","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121182","dc_title":"Notulen afstemmingsoverleg CIB Gedragsunit 180221_def...docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121182","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121192","dc_title":"RE: hulpvraag tbv. vaccineren pati\ufffdntvertrouwenspersonen Stichting PVP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121202","dc_title":"MWM2 - Onderzoeksrapport - Informatie over vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":29,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121220","dc_title":"Overzicht te actualiseren onderdelen COVID RL .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121220","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121221","dc_title":"Actiepunten GGD overleg inschaling.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121221","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121222","dc_title":"tabel_gezondheidsstatus_veiligheidsregio_week20210222_1119.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121222","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121223","dc_title":"210215_Lansingerland_vgemeente_EwoutFenoy_GGDRotterdam.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121223","foi_nrPages":13,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121225","dc_title":"Inschalingsoverleg Epi verloop_20210215.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121225","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121227","dc_title":"Presentatie inschalingssystematiek en routekaart-2_SabienaFeestra210222.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121227","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121230","dc_title":"Input CAK en ZiNL | RE: Filmpjes | Input PUR en voorbeelden ZonMW |RE: Input voor filmpjes vanuit pSG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121230","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121234","dc_title":"Input AO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121235","dc_title":"Input AO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121235","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121239","dc_title":"WOB PROCEDURE INTERNATIONALE KENNISGEVING? / FW: Korte terugblikvaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121239","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121253","dc_title":"RE: uitzonderlijke situatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121253","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121257","dc_title":"FW: COVID-19 vaccinatie & patienten met kanker","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121257","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121260","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121260","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121271","dc_title":"FW: Vertrouwelijk, Wekelijks overzicht infectieziektesignalen 25 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121271","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121272","dc_title":"FW: Actie | Alleen 1e prikken zetten | Vergelijking base case (huidige planning) tov Scenario (alleen maar 1e prikken)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121272","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121276","dc_title":"RE: Antw:  mix COVID vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121276","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121294","dc_title":"RE: Doorst: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121294","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121297","dc_title":"RE: Antw:  Debat voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1121297","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121305","dc_title":"RE: Doorst:  Vraag AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121305","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121314","dc_title":"RE: Vaccins - verzoek Libra instelling gebruik vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121314","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121326","dc_title":"GGD GHOR corona monitor definitief 01-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121326","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":32,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121331","dc_title":"RE: GR-advies versus OMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121332","dc_title":"RE: inzet opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121332","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121335","dc_title":"RE: Vragen over naalden en vriezers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121335","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1696","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121349","dc_title":"RE: Preconclusies bestuurlijk overleg toegangstesten 5 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121349","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1697","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121373","dc_title":"21_02_01_brief_ministerie_vws.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121373","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1698","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121376","dc_title":"Reactie op uw brief prioritering politiepersoneel binnendoelgroepenbele.._.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121376","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121378","dc_title":"RE: Verzoek om onderzoeksvoorstel even snel te beoordelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121378","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121381","dc_title":"20210209 Uitnodiging-vaccinatie-Rijksambtenaren-in-het-buitenlandfinaal.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121381","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121395","dc_title":"RE: COVID-19 vaccins Moderna ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121395","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121398","dc_title":"FW: Conceptverslag overleg Movianto-LCC ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121398","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121401","dc_title":"Antw:  t.i. nieuwste versie nota na verwerken opmerkingen mt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121404","dc_title":"Madurodamplan, nog op- of aanmerkingen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121404","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121414","dc_title":"RE: Doorst: opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121422","dc_title":"Antw: Doorst: opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121422","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121428","dc_title":"RE: Cov19 vacc Voorbereiding CvT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121428","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121433","dc_title":"Antw:  Antw:   Doorst:  Doorst: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121433","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121434","dc_title":"RE: Opschaling 2.5 miljoen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121434","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121440","dc_title":"FW: laatste opmerkingen op presentatie ter voorbereiding op sessie vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121440","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121445","dc_title":"RE: 210205 afstemming communicatie verhaal frame logistiek tbv video ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121445","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121446","dc_title":"RE: akkoord allocatie versnelde traject zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121446","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121447","dc_title":"RE: overleg CBG irt EMA, vaccingoedkeuring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121447","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121462","dc_title":"FW: verslag bezoek CAS/BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121462","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121466","dc_title":"FW: Bijlage 3 Opschaling uitwerking ideeen uit verleden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121467","dc_title":"Optimale doseringsinterval COVID vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121467","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121471","dc_title":"RE: Actie | Governance Structuur Tactische Planning | Voorzet ontwerp en vervolgstappen - resourcing nodig om structuur op te zetten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121473","dc_title":"FW: Uitwisselen vaccins onderling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121473","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121478","dc_title":"Verslag 10 februari ggz BW MO jeugd.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121478","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121479","dc_title":"Verslag vaccinatieoverleg 30012021 cs.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121479","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121480","dc_title":"RE: contact RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121480","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121503","dc_title":"FW: Brede blik sessie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121503","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121543","dc_title":"RE: Tekst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121543","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121554","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121554","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121568","dc_title":"FW: Uitzetmail Q&A's kinderpersconferentie 16 februari 2021 - deadline: 15.30 u vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121568","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121577","dc_title":"Re: Werksessie PLanning en modellering - slides en conciusies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121577","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121591","dc_title":"20210202_Format Uitnodiging bewoners instellingen_GGZ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121591","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121597","dc_title":"20210202 GGZ overleg verslag.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121597","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121601","dc_title":"20210202_Standaard uitnodigingsbrief zorgmedewerkers_GGZ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121601","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121612","dc_title":"Geplande vaccinaties 05022021 v2.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121612","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121616","dc_title":"Verslag RIVM VWS GGD GHOR 100221.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121616","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121620","dc_title":"210205 Memo vaccinatieregister en vaccinatiebewijs Def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121620","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121622","dc_title":"Price quote_Job 210078 -Coronavaccinatie_vaccinatiehallen_selfiehoek_banieren.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121622","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121626","dc_title":"Verslag CCT LZ 3 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121626","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121628","dc_title":"Annotatie koepeloverleg LZ Corona 0202.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121628","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121650","dc_title":"Doorst: Visuals tbv PO MVWS 5 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121650","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121651","dc_title":"toelichting foutieve data op dashboard (2e paragraaf)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121651","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121654","dc_title":"RE: Start regio pfizer- 4000 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121654","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121669","dc_title":"overleg over dagbetsteding op 25 februari a.s.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121669","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121687","dc_title":"locaties zoeken irt opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121687","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121698","dc_title":"RE: kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121698","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121702","dc_title":"FW: Cijfers vandaag GGD + LNAZ + instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121702","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121706","dc_title":"Antw:  Pot","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1121706","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121717","dc_title":"RE: bericht over dubbeltelling, graag akkoord","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121717","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121731","dc_title":"RE: 20210131 grafiek vaccinaties en voorraad BP.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1121731","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121740","dc_title":"overige zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121740","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121746","dc_title":"RE: Terugkoppeling uit overleg met CBG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1121746","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121751","dc_title":"update Nanogam met anti-covid antistoffen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121751","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121754","dc_title":"Fw: overleg overlijden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121754","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121772","dc_title":"RE: vraag over individuele afweging ouderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121772","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121779","dc_title":"RE: polio en corona vaccinaties ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121779","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121783","dc_title":"RE: conceptverslag regieteam 1 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121783","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121784","dc_title":"Adviesaanvraag 2e Kamer aan AIV over Global Health","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121784","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121797","dc_title":"RE: Doorst:  Doorst:  Antw: Campagne Gezondheid Preventie - Financieel Dagblad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121797","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121853","dc_title":"Nota ter voorbereiding briefing GR ethisch afwegingskader 3 febdef.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121865","dc_title":"tabel_gezondheidsstatus_veiligheidsregio_week20210215_1259.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121865","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121867","dc_title":"201218 overeenkomst Halma Solutions - VWS getekend en geparafeerd doorbeide partijen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121867","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121879","dc_title":"Voorstel praktijktesten voortgezet onderwijs sheets_V3.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121879","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121882","dc_title":"20210203 Verslag strategisch overleg vaccinatie met - def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121882","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121910","dc_title":"RE: nota ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121910","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121937","dc_title":"RE: Nanogam - opzet nota voor minister - graag je reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121937","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5;buiten verzoek","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121946","dc_title":"Notulen afstemmingsoverleg CIB Gedragsunit 040221_def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121946","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121948","dc_title":"Mededelingen overleg CIB Gedragsunit 110221_MJ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121948","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121957","dc_title":"Presentatie inschalingssystematiek en routekaart GGD uitwisselingsoverleg - Sabiena Feenstra.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121957","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121964","dc_title":"vaccinatie verpleeghuizen def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121964","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121977","dc_title":"Brief MECVS pt.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121977","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121988","dc_title":"2.e.0. Nota MT - Prioritering farmastrategie_2021 02 12.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121988","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121989","dc_title":"Annotatie koepeloverleg LZ Corona 0902.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121989","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1121996","dc_title":"Stas Bevinding tav voortgang vaccinatieprogramma Sint Maartenms040221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1121996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122052","dc_title":"Technische briefing 4 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122052","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122056","dc_title":"20210209 Inhoudelijke Vooruitblik.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122056","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122059","dc_title":"nota aan MVWS DOC 11 februari inzet testbewijs definitief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122075","dc_title":"Nieuwe opdrachtbrief RIVM.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122075","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122080","dc_title":"Brief PM Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122080","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122086","dc_title":"RE: agenda voor het overleg over dagbesteding op 28 januari van 14.00uur tot 15.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122086","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122106","dc_title":"PvA VWS Kennisnet V2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122106","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122109","dc_title":"O2_grafieken_week3_2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122109","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122155","dc_title":"Notulen gesprek VWS en Leon van Toorn | 4 feb 2021 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122155","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122167","dc_title":"bijlage3_notulen_vaccinatiejourney.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122167","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122169","dc_title":"Bijlage1_Antwoord_RTT effectiviteit maatregelen 260121 (002).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122169","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122173","dc_title":"Uit Stavaza brief VWS aan 2e kamer030221 onderwijs en testbeleid.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122173","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122178","dc_title":"210201 Protocol BCO.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122178","foi_groundsOfRefusal":"5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122184","dc_title":"Offerte techniek livestream islamitische netwerken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122184","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122192","dc_title":"Voortgangsrapportage Curacao Stas ms080221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122192","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122196","dc_title":"Curacao voortgang Minister  ms080221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122196","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122203","dc_title":"SOP Pfizer BioNTech Vaccine.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122203","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122206","dc_title":"20201202_Offerte 2021 P19 COVID-19 (1).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122206","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":76,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122213","dc_title":"FW: houdbaarheid astrazeneca vaccin na aanprikken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122213","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122219","dc_title":"Declaratie kosten januari screening Schiphol.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122219","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122247","dc_title":"RE: artikel over covid-19 Vaccin Moderna","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122247","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122254","dc_title":"RE: Antw:  werkwijze doortrekken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122254","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122268","dc_title":"Re: aanpassing LCI handleiding covid vaccinatie immuungecompromitteerde patienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122268","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122272","dc_title":"reactie op Moderna vaccin bij mensen die reeds Covid hebben doorgemaakt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122272","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122283","dc_title":"RE: Verzoek tot aanvullend budget 10430012010017 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122283","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122290","dc_title":"RE: selectie hematologische patienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122290","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122291","dc_title":"Nieuwe publicatie Lancet AstraZeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122291","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122300","dc_title":"OMT Epi verloop_20210225.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122300","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":23,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122307","dc_title":"-20201204.04a - Governance Covid-19 GGD GHOR Nederland.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122307","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122310","dc_title":"RE: DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122310","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122316","dc_title":"Factuur 20200596 Totaal Mondkapjes.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122316","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122332","dc_title":"Re: prioritering van hoogrisicopati\ufffdnten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122332","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122353","dc_title":"gesprek bestuurders verpleeghuizen britse virus 3 feb 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122353","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122356","dc_title":"RE: DBC-codes patienten nefrologen: nabrander","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122356","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122366","dc_title":"RE: DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122366","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122367","dc_title":"rectificatie figuur 1 TK-brief 20210202.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122367","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122369","dc_title":"20210201 verslag overleg CVRR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122369","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122371","dc_title":"notitie DOC 11 februari afbakening voorzieningen bij inzet testbewijsdef (003).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122371","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122400","dc_title":"RE: Definitie hoog risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122400","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122401","dc_title":"Moties en Toezeggingen COVID-19 debat 04022021 PB.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":21,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122416","dc_title":"Brief CIO Toegang pastores tot ziekenhuizen enzorginstellingen-11-02-21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122427","dc_title":"RE: Vaccinatie medisch geprioriteerde doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122427","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122428","dc_title":"Fw: nieuwe tekst voor enkele dosis vaccin na eerdere ernstige bijwerkingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122428","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122429","dc_title":"RE: COVID vaccinatie pati\ufffdnten uit medische risicogroepen in het ziekenhuis? Ziekenhuis Rijnstate in Arnhem","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1122429","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122440","dc_title":"Vaccinatiestrategie 12022021 def met nummering (002).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122440","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":41,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122442","dc_title":"RE: BO toegangstesten op vrijdag 5 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122442","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122444","dc_title":"RE: Antw:  Fwd: Vaccinatie-uitvraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122444","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122461","dc_title":"Brief ziekenhuisbesturen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122461","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122502","dc_title":"Ontvangen Covid-mutaties ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122502","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122504","dc_title":"Re: gaarne nieuwe versie handleiding online","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122504","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122506","dc_title":"covid vaccinatie 16-18 jr?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122506","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122525","dc_title":"Registratie software =alternatief?=","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1122525","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122527","dc_title":"Oplossingsrichting Sint Eustatius","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122527","foi_groundsOfRefusal":"5.1.2e;5.1.2i Toelichting","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122540","dc_title":"RE: vandaag reactie- meelezen overeenkomst taxivervoer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122540","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122548","dc_title":"Terugkoppeling GGD datalek debat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122548","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122552","dc_title":"RE: Verzoek agendapunten voor PO IZ en PG ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122552","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122566","dc_title":"RE: Question concerning co-editor role  Frontiers Medical Technology article collection on COVID-19 therapeutics? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122566","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122603","dc_title":"Re: selectie van hoog risico neurologische patienten voor vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122603","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122609","dc_title":"RE: prioritering van immuundeficientie patienten voor covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1122609","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122617","dc_title":"Gespreksnotitie Versnellingsimpuls tbv overleg 080221 def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122617","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122619","dc_title":"RE: vaccinatiebewijs planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122619","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122630","dc_title":"Persoonlijke beschermingsmiddelen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122630","foi_nrPages":19,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122632","dc_title":"RE: Antw: overleg rivm fms","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1122632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122633","dc_title":"RE: Ter info WHO SAGE recommendations on use of AZD1222 & persrelease long term supply","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122633","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122638","dc_title":"Annotatie versnellingsimpuls 2021 VWS - zvz ZN NZa ZiNl 080221.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122656","dc_title":"RE: Doorst: [Spam] Reminder: SAGE extraordinary meeting on COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122656","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122665","dc_title":"RE: update protocol heftige reacties na vaccinatie - eindelijk!!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122665","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122672","dc_title":"RE: WORLD-FIRST COVID-19 ALTERNATING DOSE VACCINE STUDY LAUNCHES IN UK - EMBARGOED UNTIL 00.01 THURSDAY 4 FEBRUARY 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122672","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122686","dc_title":"RE: Antw:  Herziene Stuk Reactie Motie Veldman","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122686","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122695","dc_title":"011-2021 Verzoek van RIVM tot aanlevering CoronIT nrs.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122695","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122698","dc_title":"011-2021 Verzoek van RIVM tot aanlevering CoronIT nrs..docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122698","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122705","dc_title":"RT Epi verloop_20210223.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122705","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122706","dc_title":"FW: 23 02 2021 Notitie LHV tweede kwartaal rev","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122706","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122708","dc_title":"RT Epi verloop_20210223.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122708","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122710","dc_title":"RE: opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122710","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122711","dc_title":"Grafieken_Overzicht_Britse_variant_inclusief_NL20210218_1712.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122711","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122715","dc_title":"RE: kies niet voor de Elfstedentocht maar kies voor de uitermate effici\ufffdnte en wendbare 5000 huisartsenpraktijken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122715","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122718","dc_title":"FW: 1 A4 plan samenvatting voor maandag 12:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122718","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122719","dc_title":"RE: medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122719","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122720","dc_title":"RE: [External] - hoe gaat het","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122720","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122726","dc_title":"Doorst:  Email t.b.v. informeren ziekenhuisbestuur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122726","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122729","dc_title":"FW: Actie | Alleen 1e prikken zetten | Vergelijking base case (huidige planning) tov Scenario (alleen maar 1e prikken)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122729","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122744","dc_title":"RE: LNAZ opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122744","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122749","dc_title":"FW: [PERSCO] Uitvraag Q&As persco dinsdag 23 februari - deadline 16:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122749","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122754","dc_title":"RE: verklaring leveringen en uitleveringen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122754","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122765","dc_title":"FW: Antw: concept aantekeningen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122765","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122766","dc_title":"FW: Opschaling 2.5 miljoen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122766","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122774","dc_title":"RE: Vijf doelstellingen vandaag (19-02) 2.5m schaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122774","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122783","dc_title":"RE: pb leveringen AZ_YW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122783","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122791","dc_title":"FW: Aangepaste levering Astra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122791","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122792","dc_title":"RE: Actie | Noitie Operationele planning AZ - Concept ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122792","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122797","dc_title":"RE: levering week 8","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122797","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122808","dc_title":"RE: Vijf doelstellingen vandaag (19-02) 2.5m schaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122808","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122819","dc_title":"RE: Actie | Actie | Notitie Operationele Planning AstraZeneca week 7 t/m 14 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122819","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122827","dc_title":"FW: Update: schaling 2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122827","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122844","dc_title":"RE: t.i. nieuwste versie nota na verwerken opmerkingen mt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122844","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122846","dc_title":"FW: Doorst:  communicatie frame logistiek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122858","dc_title":"RE: Antw:   RTL interview","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122858","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122871","dc_title":"RE: verzoek om brief naar ziekenhuizen over optimale ondersteuning covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122871","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122882","dc_title":"RE: akkoord allocatie versnelde traject zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122882","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122883","dc_title":"RE: Afspraak Opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122883","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122885","dc_title":"RE: Antw:   Doorst:  Doorst: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122885","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122897","dc_title":"FW: 210205 afstemming communicatie verhaal frame logistiek tbv video ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122899","dc_title":"FW: Antw: Telco Ernst Kuipers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122899","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122930","dc_title":"RE: Moderna - doorrekening verlaagde toelevering in week 8","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122930","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122940","dc_title":"RE: scenarios","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122940","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122957","dc_title":"FW: Actie | Governance Structuur Tactische Planning | Voorzet ontwerp en vervolgstappen - resourcing nodig om structuur op te zetten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122957","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122961","dc_title":"RE: voorstel LHV voor vaccinatie AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122961","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122976","dc_title":"Antw:   Laatste AZ leverschema met verdeling?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122976","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1122980","dc_title":"RE: Vaccinatie pati\ufffdnten in de revalidatiesector","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1122980","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123015","dc_title":"20210128 LCG overleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123015","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123041","dc_title":"RE: URGENT graag akkoord van RIVM op spreeklijn AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123041","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123042","dc_title":"FW: COVID 19 vaccinatie rollout & capacity planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123042","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123060","dc_title":"RE: Slots","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123060","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123065","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123065","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123068","dc_title":"df","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123068","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123088","dc_title":"RE: Vragen Nieuwsuur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123088","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123090","dc_title":"FW: Doorst: Herziene Stuk Reactie Motie Veldman","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123090","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123110","dc_title":"RE: leuk ideetje voor jou?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123110","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123112","dc_title":"RE: Doorst:  tekst kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123112","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123117","dc_title":"FW: voorstel huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123117","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123118","dc_title":"FW: Input agenda 03/02 VWS RIVM GGD GHOR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123118","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123122","dc_title":"RE: Berekening gevaccineerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123122","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123124","dc_title":"RE: Antw:  vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123124","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123128","dc_title":"FW: tekst kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123128","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123129","dc_title":"RE: Besluit veegactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123129","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123205","dc_title":"Duiding VWS 26 feb 2021.docx_78d81a91-616f-481e-bc26-15da7f46e2e5.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123205","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123217","dc_title":"DVO Stichting PAMM 2 zijdig .pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123217","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123244","dc_title":"EU Health Union.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123244","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123248","dc_title":"Evaluatie CoronaMelder GGD Huisartsen ronde2_final.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123248","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123295","dc_title":"Schema overzicht maatregelen timing en monitoring nationaal plan povo.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123295","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123296","dc_title":"paar vragen van NJi","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123296","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123302","dc_title":"Uitkomsten Brainstorm perspectief voor jongeren (4 februari 2021).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123302","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123453","dc_title":"Factsheet vaccinatie Wlz en niet Wlz in vph-ghz.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123453","foi_groundsOfRefusal":"5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123455","dc_title":"RE: Press Release Statia receives 1600 vaccines (V04022021) ms050221","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123455","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123470","dc_title":"FW: Arguments regarding 3 or 6 weeks interval between 1st and 2nd ofPfizer vaccination on Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123470","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123481","dc_title":"DRAFT Arguments regarding 3 or 6 weeks interval between 1st and 2ndof Pfizer vaccination on Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123481","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123547","dc_title":"RE: stukken stuurgroep seqnet 25 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123547","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123548","dc_title":"RE: stukken stuurgroep seqnet 25 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123548","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123557","dc_title":"COVID-19_WebSite_rapport_wekelijks_20210203_1144.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123557","foi_nrPages":76,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123573","dc_title":"Re: stukken stuurgroep seqnet 25 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123573","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123579","dc_title":"RE: nav stuurgroep van gisteren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123579","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123585","dc_title":"RE: verslag 1e vergadering stuurgroep sequencing netwerk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123585","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123603","dc_title":"RE: voor ons overleg morgen.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123603","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123604","dc_title":"RE: OGZ en sequencing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123604","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123605","dc_title":"RE: OGZ en sequencing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123605","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123620","dc_title":"Re: regio ams","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123620","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123649","dc_title":"Veiligheidsberaad 25 januari 2021 - zorgcontinuiteit_ (002).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123649","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123669","dc_title":"Union Budget 2021-22.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123669","foi_nrPages":24,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123696","dc_title":"RE: draft invitation ECDC se-epi studies contract","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123696","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123713","dc_title":"EQA update and shipping addresses","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123713","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123732","dc_title":"RE:  berekening/argumentatie CZ voor Medewerkers crisisdiensten ondergroepje ggz medewerkers - spoed","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1123732","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123734","dc_title":"RE:  FW: Overleg Bonaire - VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123734","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123744","dc_title":"Geannoteerde agenda DOC 10 februari.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123744","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123745","dc_title":"RE:  verbreding reischeck naar Q algemeen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123745","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123760","dc_title":"RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123760","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123787","dc_title":"RE: 2021memo meerkosten vaccinatie RvE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123787","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123818","dc_title":"RE: 210209_Nota order mogelijke COVID behandelingen_v0.1_YdKHK_JC_FJ_YdK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123818","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123820","dc_title":"RE: 220202_Uitwerking mogelijke intensiveringen DMO 4 febr 1700  FvdW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1123820","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123822","dc_title":"RE: 220202_Uitwerking mogelijke intensiveringen DMO 4 febr 1700  FvdW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123822","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123829","dc_title":"RE: aanbod voor hulp bij vaccinatieprogramma : scenarioplanning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123829","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123831","dc_title":"RE: 220202_Uitwerking mogelijke intensiveringen DMO 4 febr 1700  PG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123834","dc_title":"RE: 220202_Uitwerking mogelijke intensiveringen DMO 4 febr 1700  PG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123834","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123868","dc_title":"RE: aanschaf antilichamen behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123874","dc_title":"RE: Aanvraag alternatief protocol Vereniging NederlandseVerkeersvliegers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123874","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123875","dc_title":"RE: Aantal gezette prikken tm 8-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123875","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123877","dc_title":"RE: aantallen delen met pfizer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123877","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123887","dc_title":"RE: Advies 16 Veiligheid COVID-19 Test- en Vaccinatiedata","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123887","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123894","dc_title":"RE: Vaccinatie en elispot data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123894","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123906","dc_title":"RE: Advies 17 Vaccinatie- en/of Testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123906","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123912","dc_title":"Fw: Agenda werkgroep zelftesten 16-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123912","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123919","dc_title":"RE: afbakening doelgroep uitzonderingen-hardheidsclausule","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123919","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123927","dc_title":"RE: Afspraak M MZS met werkgeversorganisaties over bonus 2021 d.d. 10februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123927","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123932","dc_title":"Gecoordineerde factsheets MCC 22.02 (002).pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123932","foi_nrPages":41,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123935","dc_title":"RE: Afstemmen brief korpschef ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123954","dc_title":"RE: Agenda Directeurenoverleg desinformatie 04-02-2021 - in ibabs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123954","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123962","dc_title":"RE: Kamerbrief varianten deadline 18 februari 10:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123962","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123976","dc_title":"RE: Agenda en stukken overleg Nationaal Programma Onderwijs na Corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123976","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123977","dc_title":"RE: Agenda en stukken overleg Nationaal Programma Onderwijs na Corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123977","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123987","dc_title":"RE: Agenda koepeloverleg 02/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123987","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1123991","dc_title":"Re: Agenda overleg VWS-cli\ufffdntenorganisaties, dinsdag 16-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1123991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124003","dc_title":"RE: Agenda werkgroep kwetsbare groepen 4-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124003","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124009","dc_title":"RE: Agenda werkgroep kwetsbare groepen 4-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124009","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124012","dc_title":"RE: Agenda werkgroep kwetsbare groepen 4-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124012","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124017","dc_title":"RE: Agendapunten voor gezamenlijk MT PG met MT PDC-19 / vandaag 1530u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124017","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124019","dc_title":"RE: akkoord met deze tekst voor de Kamerbrief? graag reactie voor14.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124019","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124023","dc_title":"RE: akkoord met deze tekst voor de Kamerbrief? graag reactie voor14.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124023","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124029","dc_title":"RE: AKKOORD? Proces weekcijfers op Dashboard ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124029","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124031","dc_title":"FW: Overzicht NIVEL COVID-19.xlsx - sequencing voor I-MOVE COVID-19 project","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124031","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124034","dc_title":"RE: Akkoord? Route BW-clienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124034","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124039","dc_title":"RE: Akkoord: Update SG: sneeuwpret!   ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124039","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124042","dc_title":"RE: Eerste opzet concept Plan van Aanpak voor Medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124042","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124043","dc_title":"RE: Akkoord? Route BW-clienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124043","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124045","dc_title":"FW: Antw:  Eerste opzet concept Plan van Aanpak voor Medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124045","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124060","dc_title":"RE: Annotatie DOC item NOS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124060","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124063","dc_title":"RE: Antilichaam therapie\ufffdn werken matig tegen varianten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124063","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124070","dc_title":"RE: Antw: overleg rivm fms","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124070","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124072","dc_title":"RE: Antw:  covid-19: verzoek goedkeuring Zero Residual Spuiten enNaalden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124072","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124075","dc_title":"RE: Antw:   ServiceNow Vaccinatie Management Platform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124075","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124076","dc_title":"RE: Antwoorden IRF ISB 4_HB_DEF ZONMW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124076","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124085","dc_title":"RE: Appreciatie Verenigd Front","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124085","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124098","dc_title":"RE: prioritering van hoogrisicopati\ufffdnten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124098","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124100","dc_title":"RE: Eerste opzet volgende nieuwsbrief COVID-19-vaccinatie voor professionals","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124100","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124107","dc_title":"RE: DBC-codes patienten nefrologen: nabrander","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124109","dc_title":"FW: prioritering van hoogrisicopati\ufffdnten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124109","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124113","dc_title":"Doorst:  DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124113","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124115","dc_title":"RE: Definitie hoog risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124115","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124121","dc_title":"RE: Update COVID-19-vaccinatie medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124121","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124122","dc_title":"RE: FAQs medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124122","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124125","dc_title":"FW: DBCs hemato","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124125","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124149","dc_title":"FW: Vragen tool wanneer ben ik aan de beurt?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124149","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124158","dc_title":"FW: brief aan NFU en NVZ over hoog risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124158","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124160","dc_title":"RE: update on the COVID vaccination program, priorities for specific patients with rare diseases","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124160","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124168","dc_title":"RE: Verzoek RvB i.v.m. hoog risico groepen Covid-19 vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124168","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124169","dc_title":"RE: Antw: akkkord met versuren van deze brief vandaag naar NFU en NVZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124169","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124179","dc_title":"FW: laatste versie en akkoord met versturen van deze brief vandaag naar NFU en NVZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124179","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124183","dc_title":"RE: feedback tekst prioritering website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124189","dc_title":"FW: Debat voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124190","dc_title":"RE: astra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124190","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124191","dc_title":"RE: astra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124191","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124194","dc_title":"FW: Vraag voorichters BZ247 Sneltest na vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124194","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124198","dc_title":"RE: prioritering medische risico groepen en ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124198","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124202","dc_title":"RE: nieuwe Handleiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124210","dc_title":"RE: aanpassing tekst uitvoeringsrichtlijn nav eerdere COVID ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124210","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124212","dc_title":"RE: Stroomschema verwijderingsverzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124212","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124213","dc_title":"FW: prioritering COVID19 vaccinatie transplantatiepatienten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124213","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124215","dc_title":"FW: prioritering van immuundeficientie patienten voor covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124215","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124222","dc_title":"RE: Berichtenbundel Covid-19 IAN Frankrijk dd 29/01//2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124222","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124227","dc_title":"RE: Bespreekversie Kamerbrief Flankerend Beleid voor 13.15 -14.00 |toevoeging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124227","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124228","dc_title":"FW: covid vaccinatie prioritering zeer hoog risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124228","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124229","dc_title":"RE: Bespreekversie Kamerbrief Flankerend Beleid voor 13.15 -14.00 |toevoeging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124229","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124231","dc_title":"FW: prioritering van immuundeficientie patienten voor covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124231","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124233","dc_title":"FW: Antw: Dringende vraag voor VOICE studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124233","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124234","dc_title":"RE: overleg CBG irt EMA, vaccingoedkeuring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124242","dc_title":"RE: Antw: Dringende vraag voor VOICE studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124242","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124247","dc_title":"FW: Antw: Dringende vraag voor VOICE studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124247","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124252","dc_title":"FW: covid vaccinatie prioritering zeer hoog risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124252","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124257","dc_title":"RE: Bespreekversie Kamerbrief Flankerend Beleid voor 13.15 -14.00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124257","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124264","dc_title":"RE: vaccinatiebewijs planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124264","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124271","dc_title":"RE: bijeenkomst opschaling vaccinaties volgende week dinsdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124271","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124275","dc_title":"RE: Bijstand Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124275","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124280","dc_title":"RE: zuid afrikaanse variant en astrazeneca en de aantallen virus varianten in Nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124280","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124288","dc_title":"RE: zuid afrikaanse variant en astrazeneca en de aantallen virus varianten in Nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124290","dc_title":"RE: Bijstandsverzoek Salu pa tur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124290","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124293","dc_title":"RE: aanwezigheid bij overleg farmaceuten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124293","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124297","dc_title":"RE: Terugkoppeling uit overleg met CBG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124297","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124305","dc_title":"RE: bijstandsverzoek Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124305","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124306","dc_title":"RE: vraag over individuele afweging ouderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124306","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2048","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124310","dc_title":"RE: vraag vanuit voorwacht tav RL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124310","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2049","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124321","dc_title":"RE: Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124321","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2050","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124323","dc_title":"RE: Bijeenkomst Scenarioverkenning Corona: vandaag van 13.00 tot15.30 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124323","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2051","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124324","dc_title":"RE: BIJSTANDSVERZOEK TBV SALU PA TUR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124324","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2052","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124333","dc_title":"FW: 20210201_weekly update tekst_eindconcept.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124333","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2053","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124344","dc_title":"RE: Brief inzet AstraZeneca VERSIE 23.00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124344","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2054","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124346","dc_title":"RE: Brief mentaal en sociaal en leefstijl ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124346","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2055","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124349","dc_title":"RE: Brief PM Rhuggenaath aan Rutte en Blokhuis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124349","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2056","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124356","dc_title":"RE: Brief steunpakket welzijn en leefstijl ivm COVID-019 ek (003)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124356","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2058","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124373","dc_title":"RE: brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124373","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2059","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124383","dc_title":"FW: afvaardiging richtlijn COVID-19 vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124383","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2061","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124388","dc_title":"RE: stukken stuurgroep seqnet 25 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124388","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2062","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124389","dc_title":"RE: CAS BES en betalingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124389","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2063","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124404","dc_title":"RE: Amendment no 1 to ECD.11508 (id 23673) - Request for Offer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124404","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2064","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124429","dc_title":"RE: Catshuissessie: veerkracht ondernemers/ weerbare werknemers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124429","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2065","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124431","dc_title":"RE: check reactie: NPPU support en evaluatie request.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124431","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2066","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124436","dc_title":"RE: Check op catshuisstukken FW: Link stukken Catshuis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124436","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2067","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124450","dc_title":"RE: Chronisch zieke ouders, en het heropenen van de scholen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124450","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2068","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124452","dc_title":"RE: Chronisch zieke ouders, en het heropenen van de scholen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124452","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2069","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124468","dc_title":"RE: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124468","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2070","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124469","dc_title":"RE: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124469","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2071","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124470","dc_title":"RE: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124470","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2072","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124472","dc_title":"RE: concept kamerbrief maatschappelijk pakket","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124472","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2073","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124479","dc_title":"RE: Concept Persbericht -  Eerste leveringen COVID voor CAS en BES -namens vierlanden maandagavond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124479","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2074","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124492","dc_title":"RE: concept-nota DOC 11 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124492","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2076","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124601","dc_title":"RE: AD en virus isolaten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124601","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2077","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124615","dc_title":" sequencing support offered by ECDC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124615","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2078","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124648","dc_title":"RE: P.1.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124648","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2079","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124651","dc_title":"RE: Vraag VWS ZA en Manaus varianten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124651","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2080","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124657","dc_title":"FW: ECDC technical report on the Member States Sequencing capacities","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124657","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2081","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124680","dc_title":"RE: Landelijke inventarisatie sequence capaciteit: graag een reactie voor 17/1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124680","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2082","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124683","dc_title":"FW: Sequence netwerk overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124683","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2083","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124690","dc_title":"FW: Finale versie NTMM artikel: De opkomst van variants of concern van SARS-CoV-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124690","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2084","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124696","dc_title":"FW: typeringsnetwerk SARS-CoV-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124696","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2085","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124697","dc_title":"RE: Landelijke inventarisatie sequence capaciteit: graag een reactie voor 17/1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124697","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2086","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124699","dc_title":"RE: Eerste opzet concept Plan van Aanpak voor Medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124699","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124700","dc_title":"FW: prioritering van hoogrisicopati\ufffdnten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124700","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2087","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124702","dc_title":"RE: DBC-codes patienten nefrologen: nabrander","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124702","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2088","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124710","dc_title":"RE: Antw:  Berichtgeving aan leden van werkgroep COVID-19-vaccinatie van immuungecompromitteerde pati\ufffdnten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124710","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2089","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124713","dc_title":"RE: Vragen van HA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124713","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2090","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124719","dc_title":"FW: zuid afrikaanse variant en astrazeneca en de aantallen virus varianten in Nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124719","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2091","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124727","dc_title":"RE: Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124727","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2092","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124728","dc_title":"FW: Doorst: Fwd: Vaccinatie-uitvraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124728","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2093","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124732","dc_title":"FW: Doorst: vaccinatie van neurologische patienten via de huisarts?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124732","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2094","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124736","dc_title":"1. Agenda overleg medische advisering RVP 16-2-21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124736","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2095","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124737","dc_title":"5  DVP_SOP_0804 - Afhandelen verzoek om informatieverstrekking RVP_20210203.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124737","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2096","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124739","dc_title":"3. 20210113 Invloed coronacrisis op deelname Rijksvaccinatieprogramma_situatie 20210113.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124739","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2097","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124741","dc_title":"2. Notulen overleg medische advisering RVP 19-01-21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124741","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2098","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124759","dc_title":"RE: kamervragen en -brief RE: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124759","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2099","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124781","dc_title":"Doorst: Placeholder - Extraordinary NFP for Microbiology meeting, 11 March at 15:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124781","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124786","dc_title":"RE: Vraag VWS omtrent Kiemsurveillance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124786","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124793","dc_title":"Doorst:  HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124793","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124811","dc_title":"FW: Terugkoppeling overleg corona-varianten 09-02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124811","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124818","dc_title":"RE: COVID-19 protocol 06-282/E - wijziging 03-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124818","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124823","dc_title":"FW: reactie op Moderna vaccin bij mensen die reeds Covid hebben doorgemaakt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124823","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124829","dc_title":"RE: sequence strategie in denemarken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124829","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124831","dc_title":"FW: RAT in Europe: updated overview & list of COVID-19 rapid antigen tests","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124834","dc_title":"RE: RAT in Europe: updated overview & list of COVID-19 rapid antigen tests","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124834","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124836","dc_title":"RE: RAT in Europe: updated overview & list of COVID-19 rapid antigen tests","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124836","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124852","dc_title":"RE: Vaccinatiebewijs - juridische grondslagen voor data ontsluiting scenarios vanuit het RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124852","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124859","dc_title":"RE: Vaccinatiebewijs - document ter bespreking","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124859","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124874","dc_title":"RE: concept-Verslag risico's dataplatform logistiek vaccins 23-02-21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1124874","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124878","dc_title":"RE: Memo toezending aan RIVM geanonimiseerde vaccinatiedata","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124878","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124889","dc_title":"KAB 1.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124889","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124904","dc_title":"KAB 2.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124904","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124919","dc_title":"RE: Financiele verantwoording vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124919","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124924","dc_title":"RE: Graag je feedback - Concept notitie vaccinatiebewijs_stuurgroep COV-19 vaccinatie programma -AANVULLING","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124924","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124928","dc_title":"RE: dPIA CIMS rapportage - voorgenomen live gang 25.2.2021- Verzoek advies. [ TER INFO]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124928","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124932","dc_title":"FW: Graag je feedback - Concept notitie vaccinatiebewijs_stuurgroep COV-19 vaccinatie programma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124932","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124941","dc_title":"RE: dPIA CIMS rapportage - voorgenomen live gang 25.2.2021- Verzoek advies. [ TER INFO]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124941","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124944","dc_title":"FW: Besluit livegang Rapportage Tooling ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124944","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124951","dc_title":"terugkoppeling HIS-overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124951","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124959","dc_title":"RE: variant UK E484K mutatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124959","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124963","dc_title":"RE: variant UK E484K mutatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124963","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124984","dc_title":"RE: Cov19 vacc Voorbereiding CvT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124984","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1124989","dc_title":"RE: Update en hulpvraag m.b.t. dataplatform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1124989","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125042","dc_title":"RE: akkoord allocatie versnelde traject zorginstellingen | voorraadstand ter info","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1125042","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125046","dc_title":"RE: Besluit livegang Rapportage Tooling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125046","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125063","dc_title":"RE: Doorst:  bericht huisartsen en hoog-risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125063","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125067","dc_title":"RE: Waddeneilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125067","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125092","dc_title":"RE: Doorrekening extra 10kd doses Pfizer - instellingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125092","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125104","dc_title":"RE: Overeenkomst ROAZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125104","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125105","dc_title":"RE: Bespreekpunten en stukken regiegroep vaccinatie zorgmedewerkers 08-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125105","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125110","dc_title":"RE: Antw:  Doorst: DPIA fase vii/ monitoring & evaluatie / CIMS BI omgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125114","dc_title":"FW: Doorst: DPIA fase vii/ monitoring & evaluatie / CIMS BI omgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1125114","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125129","dc_title":"Vraag ggd v01","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125129","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125155","dc_title":"RE: TKN | FW: update Vaccinatiebewijs ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125155","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125170","dc_title":"Werkwijze en planning vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125177","dc_title":"RE: Antw:  Onderzoeksvragen RIVM ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125227","dc_title":"RE: Doorst:  BO - en uitvoerende partijen 04/02 (wordt geannuleerd)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125227","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125249","dc_title":"FW: QA 7 doses","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125249","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125260","dc_title":"RE: presentatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125260","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125262","dc_title":"FW: 20210204 PPT TB concept 0.4.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125262","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125268","dc_title":"Aanvullende stukken Stuurgroep 4/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125268","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125281","dc_title":"RE: Voor VWS overleg vanmiddag: initiele inventarisatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125284","dc_title":"RE: Factcheck presentatie technische briefing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125285","dc_title":"RE: Factcheck presentatie technische briefing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125285","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125296","dc_title":"RE: Factcheck presentatie technische briefing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125296","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125298","dc_title":"RE: Doorst: Herziene Stuk Reactie Motie Veldman","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125298","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125307","dc_title":"FW: Om te checken: weekupdate 5 vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125307","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125318","dc_title":"RE: Doorst:  Operationele planning - urgent ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125318","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125334","dc_title":"RE: naalden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125334","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125353","dc_title":"C-ARVE update januari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125353","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125361","dc_title":"Terugkoppeling apothekers please","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125361","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125365","dc_title":"FW: De getallen rond vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125384","dc_title":"RE: Vertrouwelijkheid en integriteit data covid vaccinatieprogramma - LCC gerelateerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1125384","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125386","dc_title":"RE: Antw: Ter check: Offerte en overeenkomst realiseren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125389","dc_title":"RE: Update en vervolgstappen covid dataplatform en dashboards","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125389","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125393","dc_title":"RE: Antw: operationele plantool","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125398","dc_title":"gap analyse CIMS en proxi op basis van uitgereden vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125398","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125400","dc_title":"FW: PID LCC Dashboard ManInfo Vaccinleveringen v02 md","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125400","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125401","dc_title":"Doorleveringen ROAZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125402","dc_title":"RE: COVID 19 vaccinatie rollout & capacity planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125402","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125404","dc_title":"RE: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125404","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.2h","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125408","dc_title":"RE: Parameters dashboard.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125408","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125409","dc_title":"Reactie  m.b.t. offerte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125409","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125413","dc_title":"SPOED: Reactie naar VD&D m.b.t. offerte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125413","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125414","dc_title":"RE: Argumentatie programma gebruik dwingende spoed proces","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125415","dc_title":"FW: Uitleveringen aan huisartsen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125415","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125416","dc_title":"RE: Vervolgstappen dataplatform en gerelateerde acties.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1125416","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125421","dc_title":"FW: Voorstel incl op te leveren KPI's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125421","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125456","dc_title":"RE: Coronastrategie 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125456","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125457","dc_title":"Input voor technische briefing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125470","dc_title":"RE: concept-Verslag bijeenkomst m.b.t. risico's dataplatform logistiek vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125470","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125471","dc_title":"Ter info: Vertrouwelijkheid en integriteit data covid vaccinatieprogramma - LCC gerelateerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125499","dc_title":"FW: Doorst:  Doorst: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1125499","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125510","dc_title":"RE: Doorrekening extra 10kd doses Pfizer - instellingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125510","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125538","dc_title":"LCC parameters in programma dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125538","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125539","dc_title":"RE: risico's m.b.t. vertraging op dataplatform en plantool","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125539","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125550","dc_title":"RE: VKA - tussenstand procesplaten COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125550","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125565","dc_title":"RE: Risico rondom het operationeel planningstool","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125565","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125577","dc_title":"info en korte toelichting op het LCC-Dataplatform mbt architectuur en security ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125577","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125608","dc_title":"RE: Vervolgstappen dataplatform en gerelateerde acties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125608","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125647","dc_title":"Price quote_Job 210088 - Corona_vaccinatie_HvdM_PR werkzaamhedenfebruari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125647","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125650","dc_title":"Price quoteJob 210099 - Corona_vaccinatie_dagblad ad 1502.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125650","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125654","dc_title":"Price quote_Job 210074 - Corona_vaccinatie-aanscherpen concept tbv testen vervolg op test.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125654","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125656","dc_title":"Price quote_Job 210030 - Coronavaccinatie_ divers_ tm middelen tbv PRwerkzaamheden.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125656","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125660","dc_title":"quote-Coronavaccinatie_social en native ads.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125660","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125664","dc_title":"Doorst:  akkoord allocatie versnelde traject zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125664","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125666","dc_title":"quote_Coronavaccinatie_Dagblad ad 2912 + engelstalige ads.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125666","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125674","dc_title":"pre COVID pandemic preparedness overview.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125674","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125678","dc_title":"Price quote_Job 210092 - Corona_vaccinatie_social_ambassadeurs.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125678","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125688","dc_title":"PDC19-217990 B.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125688","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125691","dc_title":"RE: Contactgegevens Nicole","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125691","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125692","dc_title":"Correcties nodig in berekeningen van besmettingsgraden en R-waarden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125692","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125694","dc_title":"Doorst: Verminderde levering AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125694","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125721","dc_title":"AstraZeneca_V1_NKRW.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125721","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125732","dc_title":"20210202_FS+PLIS_CNLD.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125732","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":37,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125755","dc_title":"RE: Antw: Schalingsvraagstuk - ziekenhuizen & DVP levering","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125755","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125756","dc_title":"RE: Jaarlijkse IHR vragenlijst en additionele IHR COVID-19 vragenlijst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125756","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125757","dc_title":"RE: Antw: Schalingsvraagstuk - ziekenhuizen & DVP levering","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125757","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125760","dc_title":"Handreiking Checklist Ambulancezorg - AZN.versie3.bv.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125760","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125768","dc_title":"AZN-Preparatie-ambulancezorg-COVID-19-crisis-fase-3 def-bv.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125768","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125787","dc_title":"RE: Covid-uitgaven tot nu toe","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125787","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125788","dc_title":"FW: Korte vraag over data safety","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125788","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125806","dc_title":"RE: Covid19 vaccinatie piloten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125806","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125831","dc_title":"Memo kennismakingsgesprek Adnan Tekin MBO Raad 18022021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125831","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125832","dc_title":"Memo FAQs 03 02 2021 vanuit BIPC.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125832","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125873","dc_title":"MedicatieOverdracht_Presentatie_KerngroepIB_20200126.pdf_3ec8b1c7-e340-42b5-948b-e4354e0b30cf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125873","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125916","dc_title":"Commercial MTA for EVAg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125916","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125918","dc_title":"RE: Afspraken RIVM - DJI: addendum AV SNGP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125918","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125923","dc_title":"FW: Aansluiting Piva BES/CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125923","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125935","dc_title":"RE: Revalidatiecentra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125950","dc_title":"RE: Schriftelijke bevestiging RIVM standup vaccinatiebewijsuitgifte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125950","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125965","dc_title":"algemene voorwaarden HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125965","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125983","dc_title":"check: juridisch advies project PGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125983","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1125992","dc_title":"FW: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1125992","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126000","dc_title":"RE: Tekst citaat Van Dissel 98%","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126000","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126012","dc_title":"FW: Dienstverleningsovereenkomst ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126012","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126018","dc_title":"RE: Lang transport en productkwaliteit COVID-vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126018","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126019","dc_title":"Factsheet debat _ definitief.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126019","foi_nrPages":15,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126020","dc_title":"Factuur St Afuk (Fries).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126020","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126023","dc_title":"Factsheet epi-beeld tbv debat 4 febr  (003).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126023","foi_nrPages":17,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126027","dc_title":"Hernieuwde aanstelling Begeleidingscommissie D10.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126028","dc_title":"RE: Data velden/tabellen afstemmen - link, toelichting en def.tijd wordt aangevuld [ PSEUDONIMISERINGSOPLOSSING CIMS] ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126028","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126029","dc_title":"RE: de opties op een rij","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126029","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126030","dc_title":"FW: Onrust over vaccinatiebewijs en vaccinatiepaspoort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126030","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126061","dc_title":"FW: Verwijderingsverzoeken GGD'en: consequenties voor RIVM?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126061","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126063","dc_title":"RE: declaratie screeningswerkzaamheden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126063","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126077","dc_title":"RE: controversiele onderwerpen demissionair kabinet deel 2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126077","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126080","dc_title":"RE: DEZE verzie gebruiken - nog iets gewijzigd.:","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126080","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126096","dc_title":"RE: Directeurenoverleg/Strategiesessie (on)mogelijkheden en wenselijkheid van vastlegging covid-vrij zijn - 03/02 14.00 - 14.30 uur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126096","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126105","dc_title":"Overzicht cohort studies.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126105","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126108","dc_title":"ZonMW cohortstudies.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126119","dc_title":"Price quote_Corona_vaccinatie_BKB_deel3.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126119","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126124","dc_title":"RE: doelgroepen nota ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126124","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126126","dc_title":"RE: Doorbraak proposities voor versnelling productie corona vaccinsin Europa","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126126","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126143","dc_title":"RE: EC joint procurement covid behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126143","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126145","dc_title":"RE: Eerste antwoorden op jullie vragen van woensdag 10 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126145","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126150","dc_title":"RE: eerste tabel aansluiting kasrealisatie COVID-19 tabel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126150","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126152","dc_title":"RE: Eerste leveringen COVID voor CAS en BES GJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126152","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126155","dc_title":"Offerte SP Cloudservices - W2102 011_v0.3.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126155","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126165","dc_title":"15.02 AZD1222 Status Update for EUC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126165","foi_groundsOfRefusal":"5.1.1c;5.1.2a","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126175","dc_title":"RE: Eindrapporten 'eerste golf' ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126175","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126183","dc_title":"RE: Ernstige beveiligingsincident GGD Ghor Kennisnet website ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126183","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126184","dc_title":"RE: Ernstige beveiligingsincident GGD Ghor Kennisnet website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126184","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126189","dc_title":"RE: EU en Corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126190","dc_title":"Re: EWS NHFL / iets voor Hand ad Kraan?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126190","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126192","dc_title":"RE: factsheet medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126197","dc_title":"RE: EZK, terugmelding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126197","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126202","dc_title":"RE: FAQ vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126216","dc_title":"RE: fisches in lijn brengen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126218","dc_title":"RE: Filmpjes | Input PUR en voorbeelden ZonMW | RE: Input voorfilmpjes vanuit pSG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126218","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126220","dc_title":"RE: fisches in lijn brengen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126220","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126222","dc_title":"RE: fisches in lijn brengen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126222","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126223","dc_title":"RE: fisches in lijn brengen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126224","dc_title":"RE: fisches in lijn brengen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126224","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126225","dc_title":"RE: flankerend beleid op leefstijl 1.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126225","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126227","dc_title":"RE: flankerend beleid op leefstijl 1.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1126227","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126230","dc_title":"RE: flankerend beleid op leefstijl 1.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1126230","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126231","dc_title":"RE: Flits IPCR rondetafel, 28 januari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126231","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126233","dc_title":"RE: Format fiche spoor 2 IC-opschaling - nieuwe versie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126233","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126234","dc_title":"RE: Format fiche spoor 2 IC-opschaling - nieuwe versie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126234","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126243","dc_title":"RE: Fwd: POST: 2021-02-10 NVZ - URGENT! COVID-19 vaccinatiestrategieopgeven aantal overige zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126243","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126266","dc_title":"RE: Grens","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126266","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126267","dc_title":"RE: helpende hand ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126267","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126272","dc_title":"RE: Herverdeling IC-bedden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126272","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126283","dc_title":"RE: huidige definitie op website VWS en vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126283","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126285","dc_title":"RE: Ideeen voor gedragsinterventies voor Vaccineren vanuit RRT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126285","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126288","dc_title":"RE: inbreng notaoverleg d66 + cda","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126292","dc_title":"RE: Veegronde","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126292","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126318","dc_title":"FW: Concept DR-nota aanpassingen interne organisatie Covid-vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126318","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126334","dc_title":"FW: Onderzoeksvragen RIVM ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126334","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126340","dc_title":"Doorst: Vraag COA voor strategisch crisisberaad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126340","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126363","dc_title":"RE: Voorstel Menno de jong, onderzoek vaccin respons na COVID ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126363","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126386","dc_title":"FW: Agenda en stukken PO - 3-2-2021 10.30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126390","dc_title":"Routekaart Amarant code rood en zwart concept DEF 4-2-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126390","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126397","dc_title":"RE: Input Ieder(in) voor coronadebat 4/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126397","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126402","dc_title":"RE: input kosten vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126402","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126405","dc_title":"RE: inschatting kosten vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126405","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126412","dc_title":"RE: ISB Coronagerelateerde mutaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126415","dc_title":"RE: inzet stas urgentie leefstijlcampagne","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126415","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126422","dc_title":"Samenvatting voor RVP nieuwsbrief 20210128 - V3.1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126422","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126425","dc_title":"Antw:  Doorst: DPIA fase vii/ monitoring & evaluatie / CIMS BI omgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126425","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126430","dc_title":"RE: Kamerbrief v0.7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126430","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126431","dc_title":"RE: Kamerbrief v0.7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126431","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126432","dc_title":"RE: Kamerbrief v0.7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126432","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126433","dc_title":"Highlights kamerstukken week 8 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126433","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126437","dc_title":"RE: Kamerbrief v0.7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1126437","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126439","dc_title":"RE: kamervragen datalek GGD 20, 116, 177, 178, 275, 276","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126439","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126442","dc_title":"RE: Kamerbrief v0.9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126442","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126444","dc_title":"RE: Kamervragen predikanten ziekenhuizen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126444","foi_groundsOfRefusal":"5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126471","dc_title":"RE: kamervragen scorekaart Farma ter Verantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126472","dc_title":"Concept Brief RIVM RvB ziekenhuizen faciliteren prioritering vaccinatie 16 feb 2021 (005).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126472","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126479","dc_title":"RE: kamervragen scorekaart Farma ter Verantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126479","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126483","dc_title":"Afspraken overleg LHV VWS RIVM 7 feb 2021 def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126483","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126485","dc_title":"C19 2021 1001 NFU hoog risicogroepen (002).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126485","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126489","dc_title":"RE: kennisbank vaccins en moeders van morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126489","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126500","dc_title":"madurodam.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126500","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126561","dc_title":"Vragen nav COVID webinar vaccinatie eerstelijn beantwoord.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126561","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126568","dc_title":"NL-NPS-0221-00014 Reliable Supply Messaging Final February 01 2021-final.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126568","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126590","dc_title":"Nota ter beslissing 2021-02-18 13_53_19.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126590","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126597","dc_title":"RE: Kernpunten overleg SXM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126597","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126599","dc_title":"Nota ter beslissing 2021-02-23 13_43_30.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126599","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126627","dc_title":"Nota voorbereiding overleg 2021-02-25 6_29_38.docx_79913a6e-ba8b-4de6-bcc6-5cf38896632e.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126627","foi_groundsOfRefusal":"5.1.2e;5.1.2f","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126638","dc_title":"Notitie ter voorbereiding op Bestuurlijk overleg, Iederin, Versie 25-2-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126638","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126652","dc_title":"NZa 20210201 Voortgangsrapportage week 4.pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126652","foi_nrPages":15,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126694","dc_title":"cancer.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126694","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126703","dc_title":"Opdracht intensivering hulp GGD bij privacy en informatieveiligheid.docx_3c3cf5e8-a371-4d9c-ab4d-75a000e60341.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126703","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126712","dc_title":"Opdrachtbevestiging PA Consulting.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126712","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126743","dc_title":"Overzicht 03 feb 2021 Defensie.pdf_8b0b9639-0a74-40e3-add4-6685a91869ff.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126743","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126768","dc_title":"Ovk Lareb - RIVM getekend.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126768","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126770","dc_title":"covid vaccinatie selectie en tweede dosis 9 feb AM Vollaard.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126770","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126775","dc_title":"9-2-2021 Vaccinatie. intro lieke 3.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126775","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126778","dc_title":"17022021 Notitie uitzonderingsgevallen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126778","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126794","dc_title":"LCI organisatie_def.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126794","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126806","dc_title":"Aanbiedingsbrief_definitief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126806","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126823","dc_title":"Projectie COVID-19 25-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126823","foi_nrPages":23,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126825","dc_title":"010-2021 brief concept rapport modellering COVID-19 vaccinatie voor VWS en GR.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126825","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126839","dc_title":"DPV_213 Hoofdpuntenrapportage Landelijke Registratie 20210225.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126839","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126840","dc_title":"DPV_234 b Aanvraagformulier risicoacceptatie CIMS Rapportage 210222.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126840","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126842","dc_title":"DPV_246a PIA Vaccinatieregister COVID -19  selecteren-oproepen_FdC opm JK - final-reviewed.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126842","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126844","dc_title":"DPV_246 Oplegnotitie livegang CIMS 2. 0  v1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126844","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126846","dc_title":"DPV_234 d  Memo Livegang BI-CIMS- privacy aspecten.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126848","dc_title":"011-2021 Verzoek van RIVM tot aanlevering CoronIT nrs_.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126848","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126859","dc_title":"M01-22-02-21-0.8-JEST bijlage bij de oplegnotitie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126859","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126863","dc_title":"20210217_ verslag landelijke stuurgroep.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126863","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126865","dc_title":"factsheet pilots.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126865","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126868","dc_title":"DPV_195 Use Case covidvaccinatie versie 1.1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":37,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126877","dc_title":"20210216 concept verslag MT Uitvoering.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126877","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126881","dc_title":"Bijl. 4.1 Procesoverzicht MT Uitvoering COVID-19 RIVM_20210218 RR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126881","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126899","dc_title":"008-2021 brief concept rapport modellering COVID-19 vaccinatie voor VWS en GR.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126899","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126910","dc_title":"SOA afdelingsdag 2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126910","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126919","dc_title":"20210216_ Agenda stuurgroep GRT 17-02.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126919","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126932","dc_title":"COVID-19 non-wmo protocol versie 1 definitief.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126935","dc_title":"PrognosesLCPS15022021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126937","dc_title":"Projectie COVID-19 12-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126937","foi_nrPages":30,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126963","dc_title":"20210223 Dagafronding PM.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126963","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126969","dc_title":"Scanned from a Xerox Multifunction Printer.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126969","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126991","dc_title":"19-2-2021 definitief tekst akkoord JvDBrief RIVM RvB ziekenhuizen faciliteren prioritering vaccinatie (005).ls.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126994","dc_title":"20210219_Programma Dashboard.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126994","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.2h","foi_nrPages":34,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126998","dc_title":"20210216 Dagafronding PM.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126998","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1126999","dc_title":"DPV_166 Verslag stuurgroep covid-registratie 20210211 versie 1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1126999","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127000","dc_title":"20210215 Dagafronding PM.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127000","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127011","dc_title":"uitrol proces doortrekken versie 0.3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127011","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127017","dc_title":"Vraag ggd v01.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127017","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127018","dc_title":"20210113_Presentatie - van Vliet_Cecile van Els (webinar huisartsen)_v5.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127018","foi_nrPages":16,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127022","dc_title":"Notulen_050221_Vaccinantieprogramma_def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127025","dc_title":"4.1 Verslag Overkoepelend uitvoeringsoverleg 4 februari 2021 versie 0.2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127025","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127031","dc_title":"20210205 Dagafronding PM.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127031","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127032","dc_title":"Operatie Steepen the Curve - JvD 8 feb 21.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127032","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127041","dc_title":"20210202 Dagafronding PM.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127041","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127046","dc_title":"Notulen afstemmingsoverleg Vaccinatie 290121_def..docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127046","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127047","dc_title":"20210201 Dagafronding PM.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127047","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127056","dc_title":"Relatie_schoolgaande_kinderen_symptomen_positief.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127056","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127059","dc_title":"005-2021 brief concpt rapport modellering COVID-19 vaccinatie voor VWS en GR.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127061","dc_title":"RE: leefstijl campagne tbv brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127061","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127071","dc_title":"RE: lijstje te vaccineren medewerkers site lhv","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127071","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127092","dc_title":"RE: mail aan IRF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127092","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127100","dc_title":"RE: Map Vaccins voor medewerkers buiten PDC-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127100","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127110","dc_title":"RE: Masterclass NieuweZorg 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127115","dc_title":"RE: Meedoen aan validatie ademtest als grote VG organisatieNoord-Oost Nederleand","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127115","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127125","dc_title":"Maatregelen compact overview.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127125","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127132","dc_title":"RE: mijn bezoek aan twee priklokaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127132","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127135","dc_title":"Selectie uit vragenlijst CONTEST studie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127135","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127138","dc_title":"RE: Micha de Winter","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127138","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127141","dc_title":"Bijlage I - GGD contact _svz en mogelijke toekomst.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127141","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127149","dc_title":"PrognosesLCPS08022021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127149","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127153","dc_title":"Re: Nav suggestie privacy / fraude in community te bespreken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127153","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e;5.1.2h;5.1.2i","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127158","dc_title":"RE: Naaldenprobleem","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127158","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127162","dc_title":"Projectie COVID-19 04-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127162","foi_nrPages":26,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127168","dc_title":"Rt_estimation_NICE_Osiris_5feb2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127168","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127171","dc_title":"Relatie_verkouden_COVIDpositief_kinderen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127171","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127173","dc_title":"RE: nieuwe aankopen vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1127173","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127180","dc_title":"RE: nieuwe berekening reactie gevraagd RE: graag jullie reactie RE:Inschatting aantallen antilichaambehandeling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127180","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127183","dc_title":"RE: Nieuwe versie actielijnen vwsflankerend beleid  en terugkoppelinggesprek VNG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127183","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127197","dc_title":"Projectie COVID-19 03-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127197","foi_nrPages":26,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127199","dc_title":"RE: Nieuwe versie brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127199","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127203","dc_title":"Projectie COVID-19 03-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127203","foi_nrPages":25,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127227","dc_title":"RE: Nota doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127227","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127228","dc_title":"RE: Noodtoelating mogelijk voor verschillende COVID therapie\ufffdn? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127228","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127239","dc_title":"RE: Nota inkoop COVID antilichaambehandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127239","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127245","dc_title":"RE: Nota ter bespreking in Afstemmingsoverleg morgen  : punten voorErnst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127245","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127250","dc_title":"RE: Notaoverleg testsamenleving - (verouderde?) conceptmoties GLnotaoverleg testsamenleving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127250","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127251","dc_title":"RE: Notaoverleg testsamenleving - (verouderde?) conceptmoties GLnotaoverleg testsamenleving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1127251","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127275","dc_title":"RE: Offerteaanvraag flitspeiling naam app","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127275","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127278","dc_title":"20210129_Verslag COVID-VZ programma_thema 14 tm 18.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127278","foi_groundsOfRefusal":"5.1.1a;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127285","dc_title":"2eKamer.04.02.2021.JaapVanDissel.v2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127285","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":33,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127287","dc_title":"RE: onderbouwing maatschappelijk pakket flankerend beleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127287","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127289","dc_title":"RE: Onderwijsregeling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127289","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127314","dc_title":"RE: Ook voor po -; vaccineren gevangenen/DJI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127314","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127325","dc_title":"RE: openstaande vraag richting RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127325","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127360","dc_title":"RE: Opmerkingen MZS - Gebruik PBM in de zorg - deadline 12:30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127360","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127373","dc_title":"RE: organogrammen, laatste (definitieve) versies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127373","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127375","dc_title":"RE: orienterend voor op de MT agenda misschien?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127375","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127376","dc_title":"RE: Overdracht poliodossier ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127376","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127381","dc_title":"RE: Overleg cli\ufffdntenorganisaties VV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127381","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127383","dc_title":"RE: Overleg cli\ufffdntenorganisaties VV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127383","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127385","dc_title":"RE: Overleg communicatie arbeidsmarkt morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127385","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127393","dc_title":"RE: Overzicht covid (gerelateerde) dossiers (graag donderdag reactie) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127393","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127402","dc_title":"RE: Pandemic preparedness en leefstijl - in ibabs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127402","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127409","dc_title":"RE: passage brief testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127409","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127410","dc_title":"RE: passage Kamerbrief bescherming chirurgische masker IIR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127410","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127433","dc_title":"RE: PERSCO uitvraag | deadline 16:00 vanmiddag!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127433","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127444","dc_title":"Inrichting NKC Covid 20210210.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127444","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127456","dc_title":"Inbreng-NVZ-t.b.v.-consultatie-discussienota-Zorg-voor-de-Toekomst-inclusief-bijlage.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127456","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127463","dc_title":"Schets huidige situatie gedragsunit.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127463","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127464","dc_title":"Pilot_vaccinatiebereidheid_belangrijkste_determinanten_MdV_V2_-.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127464","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127466","dc_title":"Briefadvies Planbureaus.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.35","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127501","dc_title":"RE: Praktijktest onderwijs VO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127501","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127520","dc_title":"RE: Priktempo GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127520","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127537","dc_title":"Lijst van afspraken overleg 210128 nr. 2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127537","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127570","dc_title":"Startnotitie  250221.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127570","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127614","dc_title":"RE: Priktempo GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127614","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127673","dc_title":"Punten Corona overleg VWS.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127673","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127680","dc_title":"Annotatie gezamenlijk MT LZ RIVM 20200304 def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127680","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127688","dc_title":"RE: Q&A's persconferentie 2 februari 2021 - deel VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127688","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127691","dc_title":"RE: Q&A voor debat straks","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127691","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127692","dc_title":"RE: Q&A's persconferentie 2 februari 2021 - deel VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127692","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127693","dc_title":"Verwerkersovereenkomst_RIVM_ABNAMRO Arbo Services_getekend _beide.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127693","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127703","dc_title":"RE: Q&A's persconferentie 2 februari 2021 - deel VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127703","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127704","dc_title":"RE: Q&A's persconferentie 2 februari 2021 - deel VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127704","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127706","dc_title":"RE: QenA voor notaoverleg preventie 1 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127706","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127707","dc_title":"RE: QenA voor notaoverleg preventie 1 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127707","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127711","dc_title":"NVZ-reactie op aanscherping tijdelijk beleidskader.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127711","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127713","dc_title":"Opdrachtvoorstel 3 VWS vaccinatie COVID-19.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127713","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127727","dc_title":"RE: Reactie brandbrieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127727","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127738","dc_title":"RE: reactie NCSC advies merking/rubricering risico analyse","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127738","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127746","dc_title":"RE: Reactie_advies_inzet_AstraZeneca-vaccin_tegen_COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127746","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127755","dc_title":"RE: Request from Dutch government to prepare for questions fromParliament around site selection","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127755","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127768","dc_title":"RE: Retourpost 217719 - Inkoop mogelijke COVID-19 behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127768","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127778","dc_title":"RE: Revisie Nationaal Actieplan Rode Kruis - verzending aan DG's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127778","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127791","dc_title":"RE: Set Jetten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127791","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127792","dc_title":"RE: Set Van Gerven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127792","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127804","dc_title":"RE: SPOED deadline 9:45u extra Q&A kinderpersco","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127804","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127805","dc_title":"RE: Spoed 11u: akkoord bullets BTC actualiteit ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127805","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127806","dc_title":"RE: Spoed: 'Aankoop Covid-19 Vaccin - Moderna, Valneva, Novavax(zaaknummer: 217568)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127806","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127809","dc_title":"RE: SPOED: aanvulling nav contact VNG in brief steunpakket welzijn enleefstijl ivm COVID-019 210211_07 incl opm MCC en VNG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127809","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127812","dc_title":"RE: SPOED: Q&A social media HdJ algemene vragen over snelheid,effectiviteit en uitnodiging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127812","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127820","dc_title":"RE: SPOED: verzoek s.v.z. 'zwarte scenario' corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127820","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127821","dc_title":"RE: SPOEDvragen Webcare n.a.v. weersomstandigheden en inzet AstraZeneca ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127821","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127822","dc_title":"RE: SPOED REACTIE VOOR EINDE DAG verzoek akkoord geen bestellingeuropese gezamenlijke inkoop","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127822","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127829","dc_title":"RE: stand van zaken overzichten ADR vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127829","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127843","dc_title":"PLATO-#4185154-v1-Verslag_VoRa_28_januari_2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127843","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127869","dc_title":"RE: Stand van zakenbrief 02/02 - conceptversie #4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127869","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127875","dc_title":"RE: Stand van zakenbrief 02/02 - conceptversie #4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127875","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127876","dc_title":"RE: Stand van zakenbrief 02/02 - conceptversie #4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127876","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127891","dc_title":"RE: Stand van zakenbrief digitale ondersteuning pandemiebestrijding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127891","foi_groundsOfRefusal":"5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127920","dc_title":"Motie Marijnissen (SP) afvullen Janssen vaccin binnen Europa.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127920","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127957","dc_title":"Nota ter beslissing 2021-01-21 9_21_28.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127957","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1127997","dc_title":"RE: Steunpakket welzijn en leefstijl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1127997","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128008","dc_title":"RE: Stroomschema bewoners irt vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128008","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128016","dc_title":"RE: Stukken tbv budgethoudergesprek SG ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128016","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128019","dc_title":"RE: Stukken tbv budgethoudergesprek SG ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128019","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128040","dc_title":"RE: suggestie passage in de covid brief om op te schieten!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128040","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128046","dc_title":"RE: Svp reactie: toezeggingen T03018, T03020, T03022","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128046","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128066","dc_title":"RE: tekort aan optrek naalden voor de ect, door beleid vws","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128066","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128077","dc_title":"RE: Ter akkoord: Blauwe mail verlenging en aanpassing vliegverboden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128077","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128079","dc_title":"RE: Ter info: laatste versie vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128079","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128081","dc_title":"RE: ter info - mhoo discussie over 'prik-paspoort': Hongarije ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128081","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128082","dc_title":"RE: Ter check. FW: Deadline 12 feb 12:00 FW: Vraag via Webcare teamHdJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128082","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128096","dc_title":"RE: Terugkerende aanbesteding risico's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128096","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128098","dc_title":"RE: ter voorbereiding van een overleg fractie blauw","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128098","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128099","dc_title":"RE: Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)donderdag 4 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128099","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128111","dc_title":"RE: Terugkoppeling DOC-19 11 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128111","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128113","dc_title":"RE: Test- en vaccinatiebewijzen DOC-19 dinsdag en ACC-19 donderdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128113","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128114","dc_title":"RE: Test- en vaccinatiebewijzen DOC-19 dinsdag en ACC-19 donderdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128114","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128117","dc_title":"RE: Testen en vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128117","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128120","dc_title":"RE: terugkoppeling Taskforce bevordering naleving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128120","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128123","dc_title":"RE: Testen en vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128123","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128126","dc_title":"RE: Testbewijs en vaccinatiebewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128126","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128127","dc_title":"NCTV en NKC toets- band op afstand DEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128127","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128130","dc_title":"RE: Toepassing Coronavirus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128130","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128134","dc_title":"RE: Toepassing Coronavirus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128137","dc_title":"RE: Tijdelijke stop uitrol Covid-19 ademtest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128137","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128145","dc_title":"RE: uitnodiging deelname gesprek over mogelijke betekenis Britsevariant corona Virus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128145","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128149","dc_title":"RE: Uitgangspunten beleidskader fase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128149","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128154","dc_title":"RE: Uitwerking DMO op mentaal welbevinden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128154","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128157","dc_title":"RE: uitwerkingsafspraken steunpakket welzijn en leefstijl: graagreactie  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128157","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128172","dc_title":"RE: Update intravacc: afdoen motie SP en PPS plannen intravacc voorbouw productie-faciliteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128172","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128183","dc_title":"RE: Update vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128184","dc_title":"RE: Update voorbereiding COVID19 vaccinatie programma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128184","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128191","dc_title":"RE: URGENT  stand van zaken vaccinatie Covid Statia ne bezoek opdinsdag 16 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128191","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128193","dc_title":"RE: Vaccin advertentie 28 januari - niet geplaatst in ReformatorischDagblad.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128193","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128199","dc_title":"RE: vaccinatie in relatie tot de verwachting weersverwachtingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128199","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128205","dc_title":"RE: Vaccinatie Beschermd Wonen en GGZ - aantallen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128205","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128208","dc_title":"RE: Vaccineren groepen met sterk verhoogd risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128208","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128210","dc_title":"RE: vandaag reactie- meelezen overeenkomst taxivervoer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128210","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128211","dc_title":"RE: vaccinverlies travel clinics","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128211","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128216","dc_title":"RE: Vanochtend in ACC: Presentatie sociaal mentaal welzijn kwetsbaregroepen + leefstijl ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128220","dc_title":"RE: VAL staffing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128220","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128233","dc_title":"RE: Verkenning vaccinatiestelsel voor donderdag a.s.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128233","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128237","dc_title":"RE: Verbreding reischeck naar Quarantainecheck","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128237","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128242","dc_title":"RE: Verlenging Tijdelijke wet maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128242","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128245","dc_title":"RE: VERSIE 13.30U RE: Brief inzet AstraZeneca VERSIE 23.00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128245","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128271","dc_title":"RE: vertrouwelijk:  acc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128271","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128285","dc_title":"RE: Vervolg vaccinatie BW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128285","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128288","dc_title":"RE: Vervolg vaccinatie BW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128288","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128290","dc_title":"RE: Vervolg vaccinatie BW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128290","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128312","dc_title":"RE: Vijfde addendum Valys/doelgroepenvervoer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128312","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128314","dc_title":"RE: Voorbereiding overleg VWS-VIG 18 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128314","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128317","dc_title":"Memo Gevolgen oordeelsonthouding 2020 voor vierkantsoverleg 17 feb2020.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128317","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128366","dc_title":"RE: Voorstel covidmand partyline + proces + planning ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128366","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128375","dc_title":"RE: voorstel huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128375","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128377","dc_title":"RE: voorstel huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128377","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128399","dc_title":"RE: voortgang opschaling ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128399","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128402","dc_title":"RE: Vraag (niet urgent) over samenhang maatregelen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128402","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128416","dc_title":"RE: Vraag EK inzake stand van zaken toezegging T03019","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128416","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128420","dc_title":"RE: Vraag over bedrijven in covid keten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128420","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128438","dc_title":"FW: niet-mobiele ouderen vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128438","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128443","dc_title":"RE: Vraag over vaccin groep 1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128443","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128446","dc_title":"Sequencing netwerk voor DT webinar.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128446","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128457","dc_title":"RE: Vraag over vaccin groep 1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128460","dc_title":"RE: Vraag over vaccin groep 1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128460","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128474","dc_title":"RE: Vraagje n.a.v. punt dagstart over maken afspraak vaccinatie meten zonder uitnodiging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128474","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128480","dc_title":"RE: Vraag: ZIN-advies vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128480","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128493","dc_title":"06.078-21 Tussentijdse evaluatie WHO Partnerschapsprogramma.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128493","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":27,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128565","dc_title":"RE: weekbericht Rien over verplichte vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128565","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128567","dc_title":"RE: weergave informeel overleg vrijdag 22/1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128567","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128568","dc_title":"03.112n-21 P22 DVP Jaarrapportage 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128568","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128570","dc_title":"RE: VVVV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128570","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128596","dc_title":"RE: zaken waarvoor dI de Landsadvocaat heeft ingeschakeld","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128596","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128598","dc_title":"RE: Wil je meedenken met Kamervragen scorekaart Farma terVerantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1128598","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128600","dc_title":"RE: woordvoering vaccinatie ggz patienten / TBS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128600","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128616","dc_title":"RE: zinvolle aanvulling op testbeleid COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128616","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128623","dc_title":"Re: Zorg voor de Jeugd en corona: agenda overleg 4 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128623","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128630","dc_title":"RE: zoals net met Herbert besproken: KLM persbericht met quote stas.Lezen jullie mee?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128630","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128636","dc_title":"RE: [retour voor 11:00] Vragenset schriftelijke vragen ICT datalekbij GGDen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1128636","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128638","dc_title":"RE: aanvulling: besluitvorming routekaart heropening sectoren (motieDijkhoff) en scenario's (motie Segers)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128642","dc_title":"RE: [retour voor 11:00] Vragenset schriftelijke vragen ICT datalekbij GGDen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128642","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128649","dc_title":"RE: [WARNING :  MESSAGE ENCRYPTED]FW: 3e brief met gedragsreflectiesop bestaande en beoogde maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128649","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128668","dc_title":"04.118-21 Vastlegging en openbaarmaking adviezen mbt COVID-19 pandemie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128668","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128677","dc_title":"FW: update richtlijn ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128677","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128684","dc_title":"Pros and Cons 3 - 6 weeks interval.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128684","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128700","dc_title":"Ter info[Wg vaccineren/testen/maatregelen] Reactiemogelijkheid mbtscenario's tot 11.15 uur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128700","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128713","dc_title":"06.128-21 VWS, goedkeuring offerte vaccinimplementatie COVID-19.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128713","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128716","dc_title":"Mandaat 6-447 1 RIVM- Input voor vaccinatie COVID19.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128716","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128743","dc_title":"Vergoeding sequencing 01022020.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128743","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128748","dc_title":"signalen en tips uit het seniorenoverleg op vrijdagochtend","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128748","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128758","dc_title":"Signalen/punten Ieder(in) voor Overleg dinsdag 9 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128758","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128773","dc_title":"Sequence netwerk 04022021 _1e overleg.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128773","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128781","dc_title":"VOOR AKKOORD - Stand van zakenbrief COVID-19 d.d. 2 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128781","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128852","dc_title":"stuurgroep corona dus..","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128852","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128888","dc_title":"quote_Corona_vaccinatie_ conuitw dagblad ad 14.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128888","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128890","dc_title":"quote_Conceptontwikkeling en strategie_vaccinatieprogramma.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128890","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128897","dc_title":"quote_Corona_vaccinatie_poster zorgmedewerkers + banners tbvtoolkit.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128897","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128905","dc_title":"tekstje ernst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128905","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128916","dc_title":"Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)dinsdag 2 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128916","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128917","dc_title":"Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)woensdag 3 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128917","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128920","dc_title":"Terugkoppeling DOC-19 1 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128920","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128922","dc_title":"Terugkoppeling gesprek IGJ, onderwerp vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128922","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128923","dc_title":"Bijlage 1 Position paper Implementatie COVID-19 vaccins Caribische delen van het Koninkrijk.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128923","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128926","dc_title":"terugkoppeling mtdgv","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128926","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128927","dc_title":"terugkoppeling overleg met ADR (Monica) over de  punten  +garantieverplichtingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128927","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128929","dc_title":"Terugkoppeling koffie-MT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128929","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128935","dc_title":"Terugkoppeling --overleg 2 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128935","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128950","dc_title":"twee punten uit crisisoverleg gehandicapten en clientonrganisaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128950","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1128952","dc_title":"triagisten HAP, onderdeel van de vaccinatie medewerkers huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1128952","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129008","dc_title":"Opslag en Distributie Overeenkomst met ziekenhuisapotheek  AmsterdamUMC - RIVM.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129008","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129020","dc_title":"RE: Bekijken + akkoord vaccinatie-document o.b.v. Kamerbrieven/brondocument","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129020","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129025","dc_title":"vaccinatiebewijs interdepartementale afstemming","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129025","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129029","dc_title":"RE: varianten vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129029","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129036","dc_title":"varianten vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129036","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129142","dc_title":"Koepeloverleg 11-2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129142","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129189","dc_title":"Verslag CCT LZ 10 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129293","dc_title":"Verzoek om tabel Astra feb voor TK brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129293","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129362","dc_title":"Corona_update 20210129.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129362","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129374","dc_title":"Voor DO desinformatie: info punt 5 - in ibabs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129374","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129390","dc_title":"COVID-19-vaccinatie-handreiking-beoordelen-allergische-reacties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129390","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129392","dc_title":"Overleg prioritering covid19 vaccinatie 15 feb 2021 21u Hemato.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129392","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129509","dc_title":"C19 2021 1001 NFU hoog risicogroepen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129509","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129645","dc_title":"Roche List of Comments on Framework Contract.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129645","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2c;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129653","dc_title":"covid vaccinatie 9 feb AM Vollaard.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129653","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129687","dc_title":"Aantal zorgmedewerkers langdurige zorg vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129687","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129710","dc_title":"Cover letter offer amendment antigenic characterization_CR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129710","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129747","dc_title":"Offerte techniek livestream islamitische netwerken.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129747","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129790","dc_title":"Verslag 4 februari ggz BW MO jeugd.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129790","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129794","dc_title":"Goedkeuringsbrief offerte vaccinimplementatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129794","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129845","dc_title":"Operatie Steepen the Curve - Slides Programma Bureau 2.5m.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129845","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129855","dc_title":"Oplegnotie Snaptest 17112020-1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129855","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129872","dc_title":"Typerings netwerk SARS-CoV-2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129872","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129889","dc_title":"PLATO-#4188423-v1-Verslag_VoRa__11_februari_2021.DOCX","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129889","foi_groundsOfRefusal":"5.1.2e;5.1.2i Eenheid kabinet;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1129960","dc_title":"20210203_ RIVM  PID Presentatie 03 feb 2021 (def)_.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1129960","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130121","dc_title":"object0002.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130121","foi_groundsOfRefusal":"5.1.2c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2696","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130163","dc_title":"Evaluation SD Biosensor F-Covid-19 Ag.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130163","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2697","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130171","dc_title":"Evaluation Biosynex SARS-CoV-2 Ag test_Final (2).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130171","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2698","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130176","dc_title":"Evaluation Clinitest SARS-CoV-2 Ag test(2).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130178","dc_title":"Evaluation Healgen SARS-CoV-2 Ag test(2).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130178","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130184","dc_title":"ChildrenJaapVanDissel.v1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130184","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130223","dc_title":"20210215 Stuurgroep Programma Covid 19 Vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130231","dc_title":"Coronastrategie 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130231","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130234","dc_title":"input - voor 24 februari 2021 def.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130234","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130236","dc_title":"Verslag Overkoepelend uitvoeringsoverleg 25 februari 2021 versie 0.1 jvd.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130236","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130243","dc_title":"Vragen AP ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130243","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130244","dc_title":"FW: Centraal register COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130244","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130251","dc_title":"20121092v1.0-RIVM-Pentest SNPG Webapp.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130251","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130255","dc_title":"DPV_211e Besluitnota risicoacceptatie IBP bestelproces Covid-vaccins 25-02-2021 v0.1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130255","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130261","dc_title":"Aanvraagformulier risicoacceptatie 20210225 bestelproces Covid vaccins_v1.1b.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":20,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130347","dc_title":"FW: vaccinaties asielzoekers/ mail RIVM/ SPOED","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130347","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130373","dc_title":"Privacylek GGD TK-debat 3-2-21 (ongecorrigeerd_stenogram).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130373","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":98,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130385","dc_title":"FW: Aanvullende eisen RIVM bij  verwerkersovereenkomst getekend 502599-003. [Advies over aan Xerox te stellen eisen in verband met verwerken oproepbrieven COVID-19]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130385","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130387","dc_title":"20210211_Advies Voorraad.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130387","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130391","dc_title":"Bijlage 1_toelichting PGO.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130391","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130393","dc_title":"20210209 Memo SNPG 0.1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130399","dc_title":"20210210_Notitie PGO.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130399","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130420","dc_title":"DPV_230 Memo communicatie burgers cli\ufffdntenportaal.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130420","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130429","dc_title":"COVID Vaccinatie Sal\ufffd pa Tur.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130429","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130430","dc_title":"20210205_Actiekalender CIMS.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130430","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130433","dc_title":"20210205 Besluitenlijst Vaccinatieregister.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130433","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130437","dc_title":"Planning vaccinatie zorgmedewerkers, opzet.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130437","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130441","dc_title":"Bijlage 5 spuiten en naalden COVID-19-vaccinatie _ LCI richtlijnen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130441","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130443","dc_title":"Factsheets v3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130443","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130473","dc_title":"20210208 Agenda centrumoverleg 3_EB.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130473","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130510","dc_title":"Bijlage 4a -Nieuwsbericht vaccinatie_LP.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130510","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130513","dc_title":"statusrapportage 2 Coronavaccinatieprogramma VKAdef.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130513","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2f","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130517","dc_title":"Anaplan_Vaccines_Capacity Planning_Overview_01182021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130517","foi_nrPages":13,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130522","dc_title":"20210114 Verslag PO VWS.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130522","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130527","dc_title":"20210204 PPT TB concept 0.4_Slides GGD GHOR NL v2.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130527","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130539","dc_title":"Aanbevelingen RIVM tav ketenplanning.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130539","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":21,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130559","dc_title":"DPV_223 Datakwaliteit signalering CIMS.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130559","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130568","dc_title":"Nota batchreview.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130568","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130570","dc_title":"DPV_160 Agenda Stuurgroep COVID-registratie 20210204 v1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130570","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130571","dc_title":"20200305 Verslag PO VWS def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130571","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130573","dc_title":"Agenda tactisch crisisberaad 2 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130573","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130605","dc_title":"varianten vaccinatie 03022021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130605","foi_groundsOfRefusal":"5.1.1c;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130635","dc_title":"Vaccinatie locatie - versie 5.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130635","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130668","dc_title":"Verplichte quarantaine 9-2-21 voorstel BWO 005.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130668","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130686","dc_title":"Verbreding_Q_003.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130686","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130688","dc_title":"Waardebrief PBMs BON vlucht 09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130688","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130693","dc_title":"Waardebrief PBMs SXM vlucht 09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130693","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130694","dc_title":"Waardebrief PBMs EUX vlucht 09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130694","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130695","dc_title":"Waardebrief PBMs AUA vlucht 09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130695","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130701","dc_title":"Waardebrief PBMs SAB vlucht 09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130701","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130708","dc_title":"Dagafsluiting verslag 10-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130708","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130709","dc_title":"Waardebrief PBMs CUR vlucht 09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130709","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130720","dc_title":"Verbreding_Q_def (002).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130720","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130726","dc_title":"PresentatieLCC_Dashboard_20210214.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130726","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130728","dc_title":"PresentatieLCC_Dashboard_20210205.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130728","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130733","dc_title":"PresentatieLCC_Dashboard_20210223.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130733","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130734","dc_title":"PresentatieLCC_Dashboard_20210219.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130734","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130739","dc_title":"PresentatieLCC_Dashboard_20210222.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130739","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130741","dc_title":"PresentatieLCC_Dashboard_20210220.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130741","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130749","dc_title":"Overeenkomst Viqtor Davis RIVM 27022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130749","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130757","dc_title":"2021.02.05  terugkoppeling Dagstart LCC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130757","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130758","dc_title":"PresentatieLCC_Dashboard_20210209.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130758","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130769","dc_title":"2021.02.01 Dagstart LCC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130769","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130773","dc_title":"2021.02.03 Terugkoppeling Dagstart LCC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130773","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130795","dc_title":"Offerte - Data Platform LCC-RIVM (v2.2) - VQD DN.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130795","foi_nrPages":31,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130805","dc_title":"verslag CN 2 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130805","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130814","dc_title":"Verslag FIO 4 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130814","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130817","dc_title":"210219_notitie repack covid-19 vaccins v1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130817","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130819","dc_title":"Verslag CCT LZ 10 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130819","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130821","dc_title":"Ppt RIVM vaccinatie dashboard.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130821","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130829","dc_title":"2021.02.11  terugkoppeling Dagstart LCC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130829","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130836","dc_title":"2021.02.12 Terugkoppeling Dagstart LCC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130836","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130918","dc_title":"20210126 Gouvernance EvL RR.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130918","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130920","dc_title":"PresentatieLCC_Dashboard_20210222.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130920","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130921","dc_title":"PresentatieLCC_Dashboard_20210223.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130921","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130930","dc_title":"PresentatieLCC_Dashboard_20210224.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130930","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130937","dc_title":"PresentatieLCC_Dashboard_20210221.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130937","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130945","dc_title":"PresentatieLCC_Dashboard_20210212.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130945","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130946","dc_title":"PresentatieLCC_Dashboard_20210210.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130946","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130947","dc_title":"PresentatieLCC_Dashboard_20210220.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130947","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130951","dc_title":"PresentatieLCC_Dashboard_20210218.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130951","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130954","dc_title":"PresentatieLCC_Dashboard_20210216.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130954","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130958","dc_title":"PresentatieLCC_Dashboard_20210219.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130958","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130959","dc_title":"PresentatieLCC_Dashboard_20210217.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130959","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130977","dc_title":"PresentatieLCC_Dashboard_20210215.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130977","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130978","dc_title":"210219-back-up transport en outboundproces v1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130978","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130984","dc_title":"PresentatieLCC_Dashboard_20210222.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130984","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130990","dc_title":"PresentatieLCC_Dashboard_20210211.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130990","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1130995","dc_title":"Motivering HISen v1.0 def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1130995","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131001","dc_title":"RE: Centraal register COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131001","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131014","dc_title":"5. Notitie vaccinatiebewijs_stuurgroep COV-19 vaccinatie programma V1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131014","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131019","dc_title":"20210219_Notitie Operationele Planning Pfizer.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131019","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131033","dc_title":"6.1. DPV_213 Hoofdpuntenrapportage Landelijke Registratie 20210218.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131033","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131050","dc_title":"15022021_OpschalingScenarios_v3.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131050","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131063","dc_title":"FW: Nota multifunctionele vaccinfabriek  (MPVPP)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131063","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131067","dc_title":"GGD_roadmap2.0_vaccineren_22 01 21_final.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131067","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131070","dc_title":"Verslag Overkoepelend uitvoeringsoverleg 11 februari 2021 versie 0.1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131070","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131077","dc_title":"210217 Presentatie LCC - Movianto.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131077","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131086","dc_title":"FW: VACCINATIE SELECTIE, ANTISTOFFEN, MUTATIES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131086","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131087","dc_title":"FW: VACCINATIE SELECTIE, ANTISTOFFEN, MUTATIES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131087","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131101","dc_title":"10022020_RIVM_Opschaling2_5m_CONCEPT.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131101","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131102","dc_title":"20210219_Notitie Operationele Planning AstraZeneca.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131102","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131170","dc_title":"No Subject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131170","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2h;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131174","dc_title":"FW: concept opdrachtbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131174","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131184","dc_title":"BMC SARS-COV-2 vaccinaties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131184","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131187","dc_title":"Annotatie BMC vergadering def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131187","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131203","dc_title":"RE: Vac.bereidheid data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131241","dc_title":"FW: Aanpassing/update van meerkostenafspraak tussen GGD'en en VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131241","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131244","dc_title":"RE: Spoedvraag vandaag - Doorst:  breder beeld","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131244","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131246","dc_title":"Samenvatting Kamerbrief 23022021 stavaza COVID.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131246","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131276","dc_title":"RE: Brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131276","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131277","dc_title":"FW: Doorst:  Doorst:  Antw: Campagne Gezondheid Preventie - Financieel Dagblad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131277","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131336","dc_title":"FW: Kwalitatief onderzoek uitnodiging vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131336","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131343","dc_title":"Digitale Flip dagstart | 16 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131343","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131360","dc_title":"welbevinden voor beleidsrapportage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131368","dc_title":"Short presentation Ingrid van den Broek Min Health NL LSTMH workshop 20210211.pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131368","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131372","dc_title":"Signalen corona Mantelzorglijn- week van 1 - 5 februari 2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131372","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131403","dc_title":"FW: Deltaplan Jeugd (deelplan Welzijn Jeugd) - Sociale activiteiten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131403","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131407","dc_title":"RE: Twijfels bij zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131407","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131409","dc_title":"FW: Garantieaanvraag - ACE Pharmaceuticals","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131409","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131416","dc_title":"Stand van zaken Beleid W8.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131453","dc_title":"FW: communicatie Astra Zeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131453","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131466","dc_title":"FW: RRF-Fiche Acute Zorg ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131503","dc_title":"RE: welke data hebben wij nodig uit toekomstig 'spoor 2' Open Samenleving testprogrammas?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131503","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131505","dc_title":"RE: vaccination simulations","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131505","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131517","dc_title":"RE: RSV na coronamaatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131517","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131521","dc_title":"RE: update report, and question for the ministry","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131521","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131524","dc_title":"aanleveren vragen tbv PTO en 2e levering Zorginstituut","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131524","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131530","dc_title":"RE: rapport modellering COVID-19 vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131530","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131537","dc_title":"Definitieve offerte 2021 P5 RBB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131537","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131576","dc_title":"RE: The follow-up questions","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131576","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131583","dc_title":"RE: RIVM-scenarios (prognoses) - graag kort overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131583","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131585","dc_title":"RE: Presentatie Van Dissel MCC-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131585","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131586","dc_title":"RE: literatuur zoeken COVID-19 vaccinatie en varianten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131586","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131592","dc_title":"Stand-up verslag 15-2-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131592","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131622","dc_title":"RE: RIVM: witte vlekken overig ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131622","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131648","dc_title":"FW: Wetsvoorstel testbewijzen - deadline 3 maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131648","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131662","dc_title":"Suggesties voor Colin.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131662","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131671","dc_title":"RE: Concept gedragstoets kernpunten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131671","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131681","dc_title":"RE: Concept gedragstoets kernpunten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131681","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131682","dc_title":"storyboard dashboard.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131682","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131688","dc_title":"RE: Agenda co\ufffdrdinatorenoverleg 16-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131688","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131716","dc_title":"Teksten jaarverslag GMT.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131716","foi_groundsOfRefusal":"5.1.2b;5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131764","dc_title":"FW: tbv overleg 20.00: sheets quarantaine ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131764","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131768","dc_title":"Terugkoppeling overleg EWS 04022021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131768","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131775","dc_title":"Terugkoppeling overleg EWS 11022021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131775","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131812","dc_title":"ODP+ brief voor kabinet ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131812","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131823","dc_title":"RE: 20210216 besluitvormingsnota scenario's opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131823","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131840","dc_title":"RE: Eerste resultaten in concept van de 7e meetronde WP11","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131840","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131847","dc_title":"Britse variant op de CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131847","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131849","dc_title":"FW: Covid-19 Actualiteiten Rapportage (CAR) 22 | Nieuw coronavirus |16 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131849","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131851","dc_title":"RE: Eerste resultaten in concept van de 7e meetronde WP11","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131851","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131855","dc_title":"RE: laatste versie tbv A4 voor input Catshuis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131855","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131859","dc_title":"RE: Eerste resultaten in concept van de 7e meetronde WP11","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131859","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131862","dc_title":"Opdrachtbegroting testen - Q1/Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131862","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131877","dc_title":"RE: Debrief concepttest vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131877","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131882","dc_title":"FW: 4e brief gedragsreflecties: concept","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131882","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131883","dc_title":"FW: Stukken tbv ACC19 mbt scenario's ontwikkeling epidemie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131883","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131893","dc_title":"FW: scherpte bespreekpunt 2 > voorbereiding BWO ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131893","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131903","dc_title":"RE: briefing visualisatie basisregels","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131903","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131917","dc_title":"FW: vaccinatieruimte huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131921","dc_title":"FW: pdf met nalevingsinterventies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131921","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131929","dc_title":"RE: Meest actuele versie beleidsrapportage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131929","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131945","dc_title":"RE: vaccineren / omgevingsanalyses afspraak maken met ministeries","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131949","dc_title":"FW: cijfers avondklok / bezoekregel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131949","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131955","dc_title":"RE: samenvatting ronde 8 en 9 tbv beleidsrapportage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131955","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131958","dc_title":"FW: in/doorstroom en JZNL interviewronde op corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131958","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131959","dc_title":"ter akkoord en voorleggen aan minVWS in volgend PO: nota moeilijk tebereikbare doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131959","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1131980","dc_title":"Re: Onderzoek jongeren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1131980","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132008","dc_title":"FW: Concept game","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132008","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132016","dc_title":"FW: concept sheets catshuis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132016","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132020","dc_title":"FW: voorbereiding Catshuis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132020","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132032","dc_title":"RE: pgb zorgbonus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132032","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132036","dc_title":"agendapunten maandag 8 februari kernteam","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132036","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132053","dc_title":"FW: Conceptversie vragenlijst ronde 10 - input overleg CIB-CGU 29/01","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132053","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132059","dc_title":"Universiteit Twente_opdrachtverlening.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132059","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132066","dc_title":"Nieuwe thema's gedragsunit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132066","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132067","dc_title":"FW: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132067","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132071","dc_title":"FW: Agenda co\ufffdrdinatorenoverleg DGSC-19, RRT, NKC, NCTV, RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132071","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132081","dc_title":"UvA_ opdrachtverlening onderzoek pilot grootschalig testen.pdf_9b339de0-d78e-4e18-9d53-ea68bc747439.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132081","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132086","dc_title":"FW: spoed: ter akkoord internationale factsheet tbv ACC en MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132086","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132087","dc_title":"Urgentie van preventie_Aanvraag verzoek intentie tot financiering_DEF.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132087","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132098","dc_title":"FW: concept wetsvoorstel en toelichting testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132098","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132111","dc_title":"vaccinatiebewijs planning.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132111","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132142","dc_title":"RE: Update Hand aan de Kraan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132142","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132145","dc_title":"RE: Processchema en schermafbeeldingen cli\ufffdntportaal RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132151","dc_title":"Re: Vaccinatiebereidheid, input op landelijke campagne, korte deadline","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132151","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132153","dc_title":"RE: FW: Ontsluiting vaccinatie naar PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132153","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132195","dc_title":"RE: Graag update van ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1132195","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132199","dc_title":"verslag 16 februari 2021.docx_2ab41e75-406c-4634-b119-e61369387af7.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132199","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132204","dc_title":"verslag 2 februari 2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132204","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132206","dc_title":"RE: Vragen CoronaCheck","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132206","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132207","dc_title":"Verslag 16 februari.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132207","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132216","dc_title":"FW: [EXT] RE: check data irt Datakwaliteit barchnummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132216","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132223","dc_title":"Verslag 26 jan.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132227","dc_title":"Verslag 4 februari ggz BW MO jeugd_TW.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132227","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132230","dc_title":"Verslag 9 februari.docx_ccf44993-de16-4b16-9622-53f7e54461fe.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132230","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132238","dc_title":"RE: [brba] controle op vaccinatieregistratie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132238","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132242","dc_title":"RE: Nota ter voorbereiding stas Vaccinatiealliantie - in ibabs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132242","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132277","dc_title":"Update verschillenanalyse","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132277","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132278","dc_title":"RE: Totaal overzicht van alle bronsystemen en aan welke partijen ze gekoppeld zijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132278","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132305","dc_title":"RE: systemen brba en coronit op  elkaar afgestemd?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132305","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132331","dc_title":"RE: Wetsvoorstel Testbewijzen MBO/HO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132338","dc_title":"FW: concept fiche vaccinatieplicht kinderopvang","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132338","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132349","dc_title":"RE: Vaccinatiebewijs - vaccinatie gegevens ontsluiten vanuit het RIVM, bespreken van mogelijkheden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132349","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132353","dc_title":"voorbereiding BO 20210210 vakbonden, werkgevers, beroepsorganisaties.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132353","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132367","dc_title":"FW: Versie 0.7. afwegingskader VVT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132367","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132393","dc_title":"RE: gegevens CIMS naar PGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132394","dc_title":"RE: ZKH - opschaling naar 2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132394","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132396","dc_title":"graag reactie op onderstaande vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132396","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132450","dc_title":"VETROUWELIJK - Notulen STRIP vergadering 15-02-2021.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132450","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132457","dc_title":"FW: lockdown","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132470","dc_title":"RE: afdronk bestelling Hugo scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132470","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132480","dc_title":"FW: afdronk bestelling Hugo scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132480","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132568","dc_title":"FW: Wijziging ministeriele regeling - deadline VANDAAG COB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132568","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132587","dc_title":"RE: Niet-geverifieerde BSN en datakwaliteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132587","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132593","dc_title":"resultaten Ronde 10 gedragsonderzoek (RIVM Gedragsunit)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132593","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132595","dc_title":"Vaccinatiebewijs technische uitwerking | Slides workshop & openstaande vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132595","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132603","dc_title":"FW: Versie 27: Maatregelensheets aangepast NA besluitvorming MCC-19 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132603","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132625","dc_title":"Wijzigen in ministeriele regeling verplichte testen v2_PRO.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132625","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132749","dc_title":"FW: 23 02 2021 Notitie LHV tweede kwartaal rev reactie Paul","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132749","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132750","dc_title":"FW: 23 02 2021 Notitie LHV tweede kwartaal rev","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132750","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132755","dc_title":"FW: Doorst: 23 02 2021 Notitie LHV tweede kwartaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132755","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132762","dc_title":"FW: Nieuw stuk vaccinatiebewijs DOC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132762","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132795","dc_title":"RE: Urgente vraag voor 13:00: BRBA koppeling met CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1132795","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132824","dc_title":"FW: verzoek akkoord NB deadline 14.00 uur aanpassing tekst voor notaaan mcc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132824","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132846","dc_title":"Overeenkomst SNGP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132854","dc_title":"RE: meedoen in data validatietraject?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132854","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132874","dc_title":"FW: stuk scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132874","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132878","dc_title":"object0001.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132878","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132892","dc_title":"1. Verslag werksessie 16 feb - afwegingskader code zwart.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132892","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132895","dc_title":"RE: Uitbreiding KCC met ondersteuning App 3 en meer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132895","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132921","dc_title":"2. SEROLOGY Biomerica Evaluation UK.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132921","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132929","dc_title":"3. SEROLOGY BIOMERICA EVALUATION SCOTLAND.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132929","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132939","dc_title":"4. SEROLOGY BIOMERICA Specificity vs. Sensitivity .pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132939","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132944","dc_title":"6. SEROLOGY Declaration Biomerica COVID-19 IgG-IgM Rapid Test Nbased.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132944","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132961","dc_title":"7. ANTIGEN Presentation BIOMERICA COVID19 Test NP Rev 1_CLJan21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132961","foi_nrPages":16,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132963","dc_title":"8. ANTIGEN Declaration Biomerica N Protein.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132963","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1132982","dc_title":"RE: Lareb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1132982","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133005","dc_title":"RE: Antw:  Eerste resultaten load test Clientenportaal (acceptatie)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133005","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133046","dc_title":"RE: graag reactie: stappenplan PGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133046","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133065","dc_title":"FW: Q&A over dubbele uitnodigingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133065","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133066","dc_title":"RE: Stavaza","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133066","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133103","dc_title":"RE: Work.com for Vaccines ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133103","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133107","dc_title":"RE: Telco Ernst Kuipers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133111","dc_title":"CIO advies + visualisaties + aanpak: opleveringen week 1 team ontwerpQ reizigers ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133111","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133112","dc_title":"Beeld ISB ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133112","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133114","dc_title":"RE: ISB posten / beleidsuitgangspunten CPB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133114","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133119","dc_title":"FW: Planning uitwerking motie Dijkhoff richting 9 maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133119","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133123","dc_title":"FW: Agenda werkgroep 'Verdeling gezamenlijke ruimte'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133123","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133132","dc_title":"versies ter bespreking","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133132","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133152","dc_title":"Ter info: datakwaliteit CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133152","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133154","dc_title":"RE: meldingen over reclame-uitingen COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133154","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133158","dc_title":"RE: meldingen over reclame-uitingen COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133158","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133164","dc_title":"RE: meldingen over reclame-uitingen COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1133164","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133203","dc_title":"RE: data inlezen.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133231","dc_title":"20210111 Verslag briefing GR Moderna MVWS def.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133231","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133244","dc_title":"RE: koppeling RIVM-RECOVAC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133244","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133246","dc_title":"20210209_Dagstart.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133246","foi_groundsOfRefusal":"5.1.1d;5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133250","dc_title":"20210204_Dagstart.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133250","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133256","dc_title":"20210212_Dagstart.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1133256","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133260","dc_title":"20210210_Stavaza beleid.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133260","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133263","dc_title":"20210218_Notulen Co\ufffdrdinatorenoverleg.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133263","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133264","dc_title":"20210219 Toezegging incidenten GGD.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133264","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133269","dc_title":"20210211_Terugkoppeling vaccinatie.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133269","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133277","dc_title":"20210210_Dagstart.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133277","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133285","dc_title":"6a. Courses of action validatie ademtest.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133285","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133288","dc_title":"20210217_Overleg financi\ufffdn GGD acties en openstaande punten.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133288","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133292","dc_title":"FW: adviesvraag SER denktank","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133292","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133293","dc_title":"3. NGS.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133293","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133295","dc_title":"3.a.2. Interne COVID-organisatie VWS-Kern 22-2-21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133295","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133300","dc_title":"RE: stukken projectgroepoverleg PGO, donderdag 11 februari 15:00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133300","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133301","dc_title":"3.a.1. Memo bespreekpunt aansluiting programmadirectie covid 19_1 maart2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133301","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133304","dc_title":"Dagafsluiting verslag 9-2-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133304","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133312","dc_title":"217767 getekende brief - Opdrachtbrief Loveland.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133312","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133314","dc_title":"Epi-beeld tbv Catshuis - schoon NA.pptx.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133314","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133322","dc_title":"Brief Opdracht SBIR's monkappen en isolatiejassen.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133322","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133331","dc_title":"FW: Proces 'monitoring\t","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133342","dc_title":"Nota voorbereiding overleg 2021-02-25 12_37_28.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133342","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133365","dc_title":"Onderzoek sanquin groepsimmuniteit.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133378","dc_title":"20200402 ACE aanvraag inkoopgarantie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133378","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133383","dc_title":"20200324 Chloroquine ACE reactie minister.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133383","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133385","dc_title":"Stand-up verslag 8-2-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133385","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133396","dc_title":"FW: Reactie: agenda nota + agenda BO 2 3 2021VWS-clientenorganisaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133396","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133401","dc_title":"VERTROUWELIJK - Memo criteria robotlocaties STRIP-2 tm 6 - 07-12-2020.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133401","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133403","dc_title":"20200402 ACE communicatie achterhouden voorraad.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133403","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133421","dc_title":"1. Verslag Stuurgroep 26 Januari '21.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133421","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133424","dc_title":"1. Verslag Stuurgroep 26 Januari '21.docx_3ad839d3-c78d-4f68-a767-baa8b167f325.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133424","foi_groundsOfRefusal":"5.1.2b;5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133466","dc_title":"20210202 Opdracht opschaling testcapaciteit stichting TOMi CONCEPT.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133466","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133471","dc_title":"FW: Agenda koepeloverleg 23/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133497","dc_title":"RE: verantwoording LCPS en verzoek om voorschot","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133497","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133515","dc_title":"Bijlage III - Coronagerelateerde mutaties.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133515","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133590","dc_title":"20210223 Actualiteitenbeeld BTC 23 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133590","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133599","dc_title":"FW: Adviesvragen RIVM inzake aangepaste richtlijn type IIgroepsvervoer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133599","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133647","dc_title":"2021-02-24 IRF vragen coronaplaat.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133647","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133661","dc_title":"210226 16.55 uur Addendum Eurofins.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133661","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133681","dc_title":"4.a. Terugkoppeling GMT-MT 22-02-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133681","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133684","dc_title":"programmatje Catshuis 21 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133684","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133690","dc_title":"20210219 Besluitenlijst Vaccinatieregister.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133690","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133697","dc_title":"4.a. Terugkoppeling GMT-MT 15-02-2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133697","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133730","dc_title":"20210219 Reactie op Per Saldo.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133730","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133748","dc_title":"Korte vraag - kunnen we dit gebruiken? (ServiceNow Vaccinatie Management Platform)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133748","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133753","dc_title":"FW: Advisering anonimiteit geanonimiseerde vaccinatie data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133753","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133756","dc_title":"0. geannoteerde agenda schriftelijke BR 19-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133756","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3048","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133773","dc_title":"Certificate of Payment - getekend.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133773","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3050","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133801","dc_title":"Debatdossier GGD datalek woensdag 3 februari 2020.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133801","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3055","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133874","dc_title":"Diverse wetenswaardigheden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133874","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3056","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133886","dc_title":"RE: Antw:  Acties t.b.v. DOTT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133886","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3057","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133930","dc_title":"17 02 2021 Notitie bespreking LHVdef.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133930","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3059","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133932","dc_title":"17 02 2021 Notitie bespreking LHV.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133932","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3060","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133939","dc_title":"Memo van Afwijking AMI 9 feb 2021.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133939","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3061","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133941","dc_title":"FW: SPOED: Privacy toets aanlevering anonieme vaccinatiegegevens aan RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133941","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3063","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133983","dc_title":"Verslag Klankbordgroep 22 Januari'21.docx.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133983","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3064","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1133988","dc_title":"Format data grafiek verwachte levering.xlsx.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1133988","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3066","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134003","dc_title":"Update berggfrafiek data door RIVM 20210215_LS_V2.xlsx.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134003","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3068","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134059","dc_title":"18-02-20201 Samenvatting persconferentie Cura\ufffdao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3070","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134191","dc_title":"RE: Issues m.b.t. specificaties geanonimiseerde data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134191","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3071","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134196","dc_title":"RE: bijeenkomst morgen over Vaccinatiebewijs 14.45-15.30h","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134196","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3072","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134201","dc_title":"2021-02-18 Minutes Cross-Border Taskforce Corona - Key Figures.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134201","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3073","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134298","dc_title":"15 02 2021 planning.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134298","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3074","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134307","dc_title":"20210208 Verslag overleg CVRR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134307","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3075","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134315","dc_title":"26 02 2021 Overleg Jan Fransoo.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134315","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3077","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134328","dc_title":"20210225 Voorlopig actualiteitenbeeld BTC 25 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134328","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3078","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134340","dc_title":"Bijlage 1_20210203_Nota BZK_Vastlegging Covid-vrij zijn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134340","foi_groundsOfRefusal":"5.1.2i Eenheid kabinet","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3079","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134344","dc_title":"Bijlage 2_20210127_Nota BZK _CZW__Test-vaccinatiesamenleving en bijlage.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134344","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3081","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134380","dc_title":"16022021 Voortgangspresentatie dagstart.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134380","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3082","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134402","dc_title":"Overzicht_Evenementen_Onderwijs_Europa.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134402","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3083","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134415","dc_title":"Terugkoppeling gesprek MVWS over CoronaCheck 24febr.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134415","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3084","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134425","dc_title":"Verslag corona MO BW GGZ 21 januari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134425","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3085","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134429","dc_title":"Verslag corona MO BW GGZ 4 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134429","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3086","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134431","dc_title":"RE: Doorst:  communicatiemethoden voor ondersteunen gedrag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134431","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3087","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134442","dc_title":"Operatie Steepen the Curve - VWS update 10 feb 2021 _002_ _003_.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134442","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3088","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134463","dc_title":"VWS op het Baken 19 februari 2021 _003_ _002_.ppt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134463","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3089","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134555","dc_title":"FW: Trendbreuk bij interviewcohort => input voor beleidsrapportage?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134555","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3090","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134562","dc_title":"FW: campagnevoorstellen studenten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134562","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3091","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134691","dc_title":"Belangrijkste punten WVO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134691","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3092","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134723","dc_title":"20210209 Verslag stuurgroep Corona pgp.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134723","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3093","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134726","dc_title":"FW: Antw: sessie komende maandag??","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134726","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3094","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134733","dc_title":"20210204 Verslag VC Gezaghebbers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134733","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3095","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134734","dc_title":"20210218 Geannoteerde Agenda VC Gezaghebbers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134734","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3096","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134750","dc_title":"20210209 Verslag VC Ministersoverleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134750","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3097","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134810","dc_title":"RE: Ideeen voor gedragsinterventies voor Vaccineren vanuit RRT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134810","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3098","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134819","dc_title":"FW: Aanvullingen conceptagenda en stukken werkgroepgeneesmiddelentekorten 16 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134819","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3099","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134846","dc_title":"RE: Aanvullingen conceptagenda en stukken werkgroepgeneesmiddelentekorten 16 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134846","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134852","dc_title":"volgende week CHMP opinie art 5.3 ? RE: Akkoord en reactie ministerantilichamen nota","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134852","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134898","dc_title":"210217 wanneer is welke groep klaar op basis van flow chart.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134898","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134954","dc_title":"FW: werkinstructie huisarts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134954","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1134955","dc_title":"besmettingen in verpleeghuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1134955","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135036","dc_title":"18022021 Presentatie quarantaineplicht (versie 10.02).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135036","foi_nrPages":18,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135038","dc_title":"FW: Doorst:  ODP brief ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135038","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135070","dc_title":"FW:  Cijfers trendonderzoek gedrag - incl. avondklok 26 jan - 1 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135070","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135077","dc_title":"FW: NKC Agenda Kernoverleg 8/2 & verslag Kernoverleg 5/2 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135077","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135096","dc_title":"19022021 Verslag seniorenorganisaties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135096","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135129","dc_title":"Overzicht Parlementaire zaken.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135129","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135141","dc_title":"Verslag 2e stuurgroepvergadering 290121.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135141","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135174","dc_title":"FW: SPR voorstel ter info ivm mogelijke samenwerking Corona Gedragsunit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135174","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135193","dc_title":"FW: stukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135193","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135219","dc_title":"FW: intensivering op gezonde leefstijl en op welbevinden - RE: Nationaal Programma Onderwijs - Welbevinden ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135219","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135280","dc_title":"RE: Verdere vragen voor persconferentie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135280","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135294","dc_title":"RE: interessant onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135294","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135301","dc_title":"RE: Covid Gezondheidseconomie **update 12 december**","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135301","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135324","dc_title":"RE: Verplichtingen per 31 december 2020 inzake vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135324","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135365","dc_title":"FW: Verdeling 200 miljoen flankerend beleid voor ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135393","dc_title":"RE: vaccine planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135393","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135402","dc_title":"Marjolein CC email:","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135402","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135406","dc_title":"RE: Update from vaccine planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135406","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135418","dc_title":"Re: next generation matrices","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135418","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135447","dc_title":"RE: ME/CVS brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135447","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135455","dc_title":"FW: Vaccineren (acute) verloskunde + Audiciens","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135455","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135460","dc_title":"FW: 17 02 2021 Notitie bespreking LHV (003)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135460","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135465","dc_title":"ZonMw project SCONE: Vragenlijst eerste ronde","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135465","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135469","dc_title":"FW: Verdeling 200 miljoen flankerend beleid voor ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135469","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135477","dc_title":"RE: Correcties nodig in berekeningen van besmettingsgraden en R-waarden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135477","foi_groundsOfRefusal":"5.1.2e;5.1.2i Wetenschappelijk beraad;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135480","dc_title":"RE: part of the report for ministry and health council on deferral second dose","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135480","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135498","dc_title":"Doorst:  verzoek ter attentie van dr. Mariken Leurs, centrumhoofd Centrum Gezondheid en Maatschappij","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135498","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135531","dc_title":"RE: Uitnodiginslijst expertsessie gedragsondersteuning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135531","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135594","dc_title":"RE: ODP brief versie 14 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135594","foi_groundsOfRefusal":"5.1.2a;5.1.2e;buiten verzoek","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135608","dc_title":"FW: Presentatie Catshuis (en wat opmerkingen van mij)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135608","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135647","dc_title":"RE: Overall raamwerk van aanpak en evidentie voor beleid en communicatie over vaccinatie, maatregelen en testen. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135647","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135664","dc_title":"RE: Input LOC-C","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135664","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135691","dc_title":"FW: vertrouwlijk, interview resultaten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135691","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135707","dc_title":"RE: Literatuuronderzoek werkende interventies naleving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135707","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135714","dc_title":"FW: verzoek ter attentie van dr. Mariken Leurs, centrumhoofd Centrum Gezondheid en Maatschappij","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135714","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135736","dc_title":"RE: anonieme data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135736","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135737","dc_title":"RE: lijstje","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135737","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135740","dc_title":"RE: dPIA CIMS rapportage - voorgenomen live gang 25.2.2021- Verzoek advies.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135740","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135765","dc_title":"voorbereiding 9 feb 12.30-13.00  opzet taskforce","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135765","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135768","dc_title":"RE: tekst en bijlagen stand van zakenbrief 2-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135768","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135790","dc_title":"RE: Literatuuronderzoek werkende interventies naleving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135790","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135799","dc_title":"Conclusie & synthese interventies voor naleving 260221.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135799","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135803","dc_title":"Tabellen Interventies voor Bevordering Naleving 260221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135803","foi_nrPages":14,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135831","dc_title":"FW: nota over  testbewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135833","dc_title":"RE: uit de ochtendcall: aanpassen presentatie MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135833","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135838","dc_title":"Communicatieplan - Maat, Regels! .pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135838","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":21,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135840","dc_title":"Graag jullie akkoord: Conceptnota SG onrechtmatigheden BRBA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135840","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135848","dc_title":"Communicatieplan_Feelin'Good.Fontysstudenten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135848","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":22,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135891","dc_title":"signalen 1 maart 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135891","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135897","dc_title":"Voorschot LNAZ LCPS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135905","dc_title":"RE: Antw:  Eerste resultaten load test Clientenportaal (acceptatie)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135905","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135908","dc_title":"RE: Dashboardoverleg op 29 jan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135908","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135910","dc_title":"RE: juridisch advies project PGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135910","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135912","dc_title":"RE: Stand van zaken rondom proces \"monitoring\"","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135912","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135916","dc_title":"Correspondentie SG BZK en SG VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135916","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135947","dc_title":"FW: SO vragen RAZ -- DEADLINE vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135947","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135950","dc_title":"FW: SO vragen RAZ -- DEADLINE vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135950","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135961","dc_title":"FW: Communication adopted today by the European Commission -  HERAIncubator: Anticipating together the threat of COVID-19 variants","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135961","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135972","dc_title":"Onderzoeksrapport covid-crisis of covid-kans","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135972","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1135996","dc_title":"Korte bijdrage discussie sociale bubbel.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1135996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136048","dc_title":"20210216 Sitrap COVID19 ACS CN.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136048","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136051","dc_title":"20210222 Agenda PO PDC VWS - GGD GHOR 22 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136059","dc_title":"RE: beslissing vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136086","dc_title":"Dagverslag 16 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136086","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136091","dc_title":"RE: Definitieve cohort vragenlijst ronde 10","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136091","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136119","dc_title":"Deadline 19-2 12u Check tekst vaccinatgielogistiek ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136119","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136132","dc_title":"RE: Tekst voorstel mbt Toezending materialen kwaliteit COVID-19 PCR bepalingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136132","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136135","dc_title":"FW: Antw:  Gesprek over testen/testbeleid ikv c-ARVE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136135","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136170","dc_title":"RE: COVID dwarsthema Ouderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136177","dc_title":"voorstel Covid babies- vertrouwelijk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136177","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136191","dc_title":"Digitale Flip Dagstart | 24 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136191","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136193","dc_title":"Ter reactie: concept-presentatie voor DG-brede bijeenkomstmorgenochtend","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136193","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136194","dc_title":"FW: COVID dwarsthema Ouderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136194","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136195","dc_title":"RE: Verantwoordelijkheid inventarisatie claims covid DGCZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136195","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136202","dc_title":"Memo Redenen om niet te testen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136204","dc_title":"Digitale Flip Dagstart | 23 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136204","foi_groundsOfRefusal":"5.1.2e;5.1.2i OMT;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136206","dc_title":"Digitale Flip Dagstart | 25 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136206","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136207","dc_title":"FW: Cohort studies ZonMW vs RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1136207","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136210","dc_title":"Jaarplan Gedragsunit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136210","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136211","dc_title":"Digitale Flip Dagstart | 17 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136211","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136217","dc_title":"Digitale Flip Standup | 18 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136217","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136219","dc_title":"RE: COVID dwarsthema Ouderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136219","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136221","dc_title":"Digitale Flip Dagstart | 26 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136221","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136237","dc_title":"FW: Vaccinatiebereidheid, input op landelijke campagne, korte deadline","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136237","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136240","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136240","foi_groundsOfRefusal":"5.1.2e;5.1.2f;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136252","dc_title":"FW: Dienst Testen - webinar testlandschap","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136252","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136256","dc_title":"Door Scheper, E.Z.G. - 3.0 NSOB - essay Leven in de Curve - versie 30 januari 2021.pdf (gedeeld door Scheper, Eline).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136256","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136257","dc_title":"RE: corona-programma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136257","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136274","dc_title":"Monitoring verbeterplan DOTT 210218 - 0.9.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136274","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136275","dc_title":"Factsheet_App_week08.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136275","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136287","dc_title":"RE: Doorst:  Concept-verslag QuickScan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136287","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136288","dc_title":"Factsheet_Spoor2 IT_week08.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136288","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136306","dc_title":"20210302 Dagstart.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136306","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136312","dc_title":"20210222 Voortgangsrapportage week 8.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136312","foi_nrPages":12,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136335","dc_title":"RE: Opdrachtbevestiging voor akkoord","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136335","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136339","dc_title":"20210226 Verslag Teamoverleg Plans.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136339","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136343","dc_title":"20121088.v1.1-OFF-MinisterieVWS-Designreview+scans bij RIVM.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136343","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136345","dc_title":"20210222 PPT Interdepartementaal overleg .pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136345","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136352","dc_title":"20210310 Dagstart Plans.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136352","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136366","dc_title":"20210223 Sitrap COVID19 ACS CN.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136366","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136369","dc_title":"Aanvullende annotatie bij de slides 22-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136369","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136384","dc_title":"Duiding cijfers Caribisch Gebied voor DOC/BTC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136384","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136392","dc_title":"Duiding cijfers voor DOC/BTC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136392","foi_groundsOfRefusal":"5.1.1d;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136416","dc_title":"RE: VIDO protocol","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136420","dc_title":"FW: persbriefing txt vaccin studies Corona ouderen Doetinchem","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136420","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136429","dc_title":"Adviesvraag RIVM inzake type II mondkapjes ad_ft_ep_fg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136429","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136451","dc_title":"RE: Vervolgstappen vaccinatiebrieven & gedragstechnieken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136451","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136453","dc_title":"FW: 20210225 Concept evaluatievragen huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136453","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136455","dc_title":"RE: Vervolgstappen vaccinatiebrieven & gedragstechnieken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136455","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136456","dc_title":"RE: Vaccinatie communicatie Update - 4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136456","foi_groundsOfRefusal":"5.1.2e;5.1.2h;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136457","dc_title":"Projectie COVID-19 28-01-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136457","foi_nrPages":25,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136459","dc_title":"informatie over livegang Burgerportaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136459","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136462","dc_title":"RE: Antw: informatie over livegang Burgerportaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136462","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136474","dc_title":"RE: Antw: Filmpjes AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136474","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136484","dc_title":"FW: SCP-publicatie 'Een jaar met corona' - onder embargo tot woensdag3 maart 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136484","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136492","dc_title":"EMA heeft zonet gepubliceerd RE: mogelijke publiciteit overantilichaambehandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136492","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136494","dc_title":"RE: filmpje Cecile, graag ZSM online","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136494","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136505","dc_title":"RE: Agenda Koepeloverleg 22-2-21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136505","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136508","dc_title":"FW: videos AstraZeneca met Cecile :-)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136508","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136519","dc_title":"Post video Cecile","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136519","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136521","dc_title":"Aanpassen fouten op pagina's vaccinatie bewoners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136521","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136525","dc_title":"Nieuwsberichten en werkinstructies: vaccinatie bewoners door HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136525","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136526","dc_title":"RE: Gedragsondersteuning Vaccineren - uitnodigingen en reminders ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136526","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136529","dc_title":"FW: Interview_VWS_Schoenmakers_akv01","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136529","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136534","dc_title":"FW: Vaccinatievragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136534","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136542","dc_title":"RE: Verslag dagstart vaccanatiecommunicatie - 22 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136542","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136564","dc_title":"RE: aanvulling imm compr pt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136564","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136579","dc_title":"Fw: Doorst: Meegeef-folder bijsluiter ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136579","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136584","dc_title":"Erik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136584","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136588","dc_title":"20210225 Verslag Teamoverleg Plans.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136588","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136589","dc_title":"FW: ECDC ombudsman evaluatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136589","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136599","dc_title":"Even snel 10 punten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136603","dc_title":"20210216 memo nav voorstel anonimiseren anonieme dataset.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136603","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136604","dc_title":"210224 IB analyse koppelpunten aanleverende partijen v1.1 CIMS.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136604","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136607","dc_title":"20210225  v1.0 werkplan privacy CIMS.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136607","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":45,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136610","dc_title":"210224.Update verschillenanalyse aantal vaccinaties in CIMS vs dashboard Rijksoverheid.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136610","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136612","dc_title":"RE: mutaties virus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136612","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136614","dc_title":"RE: Beknopte briefing kwali onderzoek comm middelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136614","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136618","dc_title":"check inhoud film met Cecile!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136618","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136622","dc_title":"Toelichting fin claim voor ZonMw deelprogramma covid voor herstel ennazorg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136622","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136632","dc_title":"2. besluitvormingsnota scenario's opschaling.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136644","dc_title":"RE: actueel schema","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136644","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136655","dc_title":"4. nota ter beslissing - uitwerking COVID-19 vaccinatie groepenmedische indicatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136655","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136663","dc_title":"RE: Antw: inkorten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136663","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136668","dc_title":"RE: tekst advertentie - ingekort/geredigeerd -> nog een laatste check!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136668","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136682","dc_title":"FW: Dubbel check  medische indicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136682","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136683","dc_title":"8. Fiche Spoor 2 Ondersteuning amateursportverenigingen 0.2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136683","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136690","dc_title":"FW: Advertentietekst - aangepast","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136690","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136701","dc_title":"FW: verwarrende wegwijzer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136701","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136707","dc_title":"10. 210217 Update figuren berg en staafjes.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136707","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136709","dc_title":"20210215 Verslag strategisch overleg vaccinatie met MVWS def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136709","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136725","dc_title":"RE: brief zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136725","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136759","dc_title":"RE: Melding nr. M2102 2494 onderwerp: medicatieoverzicht en covidvaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136759","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136770","dc_title":"FW: Concept besluitenlijst DR 2 februari 2021 en vastgestelde besluitenlijst DR 26 januari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136770","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136784","dc_title":"Foutieve tekst op website VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136784","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136796","dc_title":"FW: UItnodigen waddeneilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136796","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136829","dc_title":"RE: covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136829","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136831","dc_title":"RE: foutief vermeld emailadres!!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136831","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136833","dc_title":"RE: meerdere uitnodigingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136833","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136868","dc_title":"RE: Veegsessies VVT instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136871","dc_title":"210218 communicatiesheets CH 23 feb.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136871","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136907","dc_title":"16022021 Presentatie Dagstart light versie.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136907","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136909","dc_title":"210219 Dwarsdoorsnijdende toets communicatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136909","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136910","dc_title":"RE: Antw: COVID format en offerte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136910","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136917","dc_title":"beslisnota aangaan dienstverleningsovereenkomst spoor 219-2-2021!.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136917","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136919","dc_title":"FW: Wegwijzer tussentijdse wijzigingen COVID richtlijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136919","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136945","dc_title":"20210224 Dagstart.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136955","dc_title":"FW: Fiche crisisbestendigheid ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136955","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136992","dc_title":"210203.Principes COVID vaccinatieregistratie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136992","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1136995","dc_title":"Vergelijking flowcharts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1136995","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137001","dc_title":"210217.Analyse verstrekkingen CIMS vs dashboard.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137001","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137012","dc_title":"Workshop Technische uitwerking_deel 1.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137012","foi_nrPages":23,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137037","dc_title":"20210217 Dagstart.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137037","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137039","dc_title":"FW:  FAQ vaccinatie - correctie foutieve web info","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137039","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137053","dc_title":"Vaccinatie Management Platform - overzicht v12.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137053","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137055","dc_title":"FW: Verzoek gesprek / presentatie Vaccine Administration Management ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137055","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137059","dc_title":"DPV_124 Voortgangsrapportage CIMS Functioneel 20210125 20210208.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137060","dc_title":"DPV_145 Voortgangsrapportage CIMS CP 20210121 20210104.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137060","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137063","dc_title":"DPV_164 Voortgangsrapportage CIMS API Gateway 20210123- 20210104.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137063","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137082","dc_title":"B4_Vaccinatiescenario's_Gesprekshandleiding focusgroep_DEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137082","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137084","dc_title":"B2_Terugkoppeling aanpassingen vragenlijst - 19-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137084","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137088","dc_title":"Agenda_afstemmingsoverleg230221_def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137110","dc_title":"DPV_171 Voortgangsrapportage CIMS datakoppeling GZ en VPT 20210121 20210104.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137118","dc_title":"B3_Vaccinatiescenario's_Focusgroep Corona.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137118","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137124","dc_title":"FW: Additionele peiling 1 jaar corona 17 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137124","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137127","dc_title":"20210127 Dataflow processen en CIMS.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137127","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137141","dc_title":"FW: Antw:   ServiceNow Vaccinatie Management Platform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137141","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137142","dc_title":"20210205 Teamoverleg Plans.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137142","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137146","dc_title":"FW: Apps","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137146","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137173","dc_title":"RE: communicatie naar huisartsen over Astra Zeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137185","dc_title":"RE: SPOED: visuals en animaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137185","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i Concept","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137189","dc_title":"RE: Brieven naar burgers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137203","dc_title":"RE: videos AstraZeneca met Cecile :-)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137207","dc_title":"RE: uitnodiging Webinar Goed Vaccinbeheer v0.4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137207","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137209","dc_title":"RE: Antw:  Vaccinatie telefoonlijn nog steeds flop.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137209","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137211","dc_title":"RE: vraag politie: technische briefing voor Nederlandse bevolking?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137211","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137218","dc_title":"20210223 PPT - en Victor Vaccinatiealliantie v6.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137218","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137247","dc_title":"RE: Ter info: griepachtige klachten na AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137247","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137251","dc_title":"FW: Beschikbaarheid hulpmiddelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137251","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137261","dc_title":"FW: Betreft: digitaal vaccinatie- en testbewijs zonderpersoonsgegevens (vertrouwelijk) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137262","dc_title":"FW: Bij uitzondering een persoonlijke vraag; operatieassistentenvergeten groep medewerkers in de zorg voor vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137262","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137267","dc_title":"RE: concept order (71,72,73,74 jarigen) en concept planning 65-74 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137267","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137276","dc_title":"FW: Budget voor communicatie over corona-apps","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137276","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137295","dc_title":"FW: Cluster Sitrep 16.2.2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137295","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137308","dc_title":"RE: Agenda en verslag werkgroep COVID-vaccinatie in huisartsenpraktijk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137308","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137322","dc_title":"FW: Covid-19 Vaccinatie / PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137322","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137329","dc_title":"FW: Covid-19 Vaccinatie / PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137329","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137334","dc_title":"FW: Covid-19 Vaccinatie / PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137334","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137337","dc_title":"Is aan de assistenten gedacht?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137337","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137355","dc_title":"RE: tekstvoorstellen uitnodiging en gezondheidsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137355","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137356","dc_title":"FW: DEBAT uitvraag | deadline maandag 09:00 - Even sparren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137356","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137372","dc_title":"FW: Dit is het bronbestand","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137372","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137391","dc_title":"FW: Doorst: AZ leveringen verminderd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137391","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137416","dc_title":"uitnodigingsproces 80-84 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137465","dc_title":"210319 Gedragstoets maatregelenpakket - vraag 17 februari 2021_layout.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137465","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137476","dc_title":"Briefing animaties basisregels.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137476","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137487","dc_title":"Agenda_Expertmeeting_160221_MJ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137487","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137500","dc_title":"Notulen_120221_VaccinatieprogrammaGedrag_MJ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137500","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137507","dc_title":"Bijlage 3 Rolomschrijving en werkwijze Wetenschappelijke Adviesraad Corona Gedragsunit.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137507","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137514","dc_title":"20210121 Interviews coronavaccinatie _DEF.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137514","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137519","dc_title":"Bijlage 6 Tabellen Naleving interventies.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137519","foi_nrPages":19,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137525","dc_title":"Response Team_9_2_2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137525","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137540","dc_title":"RE: 2de COVID-Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137540","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137553","dc_title":"RE: vaccinatie en immunotherapie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137553","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137561","dc_title":"Response_team_9_2_2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137561","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137563","dc_title":"FW: bespreekpunten voor casuistiek as maandag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137563","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137574","dc_title":"RE: vragen IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137574","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137578","dc_title":"RE: vragen IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137578","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137584","dc_title":"RE: vragen IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137584","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137591","dc_title":"RE: Interview_VWS_Schoenmakers_akv01","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137591","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137599","dc_title":"FW: Effectieve mondneusmaskers voor (kwetsbaar) publiek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137608","dc_title":"FW: Filtertool Wanneer ben ik aan de beurt?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137608","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137609","dc_title":"20210216 Actielijst COVID-19 vaccinatie.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137609","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137618","dc_title":"FW: FLITS onderdeel CRP  HERA INCUBATOR & Co","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137618","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137626","dc_title":"20210217 Voortgangsrapportage week 6.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137626","foi_nrPages":15,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137634","dc_title":"FW: Geef burgers regie over hun eigen gezondheidsdata","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137634","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137637","dc_title":"RE: Bericht HAP MOderna en Pfizer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137637","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137639","dc_title":"FW: gecombineerde werkgroep test- en vaccinatiebewijzen vrijdag 19feb 12-13h","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137639","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137646","dc_title":"Notulen_Expertmeeting_020221def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137646","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137656","dc_title":"FW: graag jullie akkoord op kamervragen ellenmeet over de publicatievan de scorekaart van Farma ter Verantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137656","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137657","dc_title":"CoronaGedrag_onthulling.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137657","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137661","dc_title":"Nieuwe thema's gedragsunit 2020201.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137661","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137663","dc_title":"Analyse invoering avondklok.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137663","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137678","dc_title":"FW: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1137678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137681","dc_title":"FW: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137681","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137686","dc_title":"RE: ontkrachten fabels vaccin - akkoord op uitbeelden virus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137686","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137694","dc_title":"FW: Inhoudelijke check over medische indicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137694","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137696","dc_title":"FW: Presentatie desinformatie stakeholders","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137696","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137699","dc_title":"FW: Hoe verder in 2021?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137699","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137703","dc_title":"FW: videos AstraZeneca met Cecile :-)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137703","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137717","dc_title":"FW: Call centrum en AstraZeneca.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137717","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137727","dc_title":"7 dec  Structuur gedragsaanpak.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137727","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137734","dc_title":"FW: laatste versie overzicht ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137734","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137735","dc_title":"FW: Johnson & Johnson COVID-19 Vaccine Authorized by FDA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137735","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137737","dc_title":"FW: Kosten rondom vaccineren van derden ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137737","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137739","dc_title":"21.01.15 Debrief Vaccinatiecampagne fase FB_def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137739","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137742","dc_title":"FW: Laatste versie tekst stavazabrief en twee nieuwe leden vanuit VNGen VB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137742","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137747","dc_title":"FW: Lijnen uitloop - 26 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137747","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137770","dc_title":"FW: Vaccin in het kort vervangen met PDF/A bestanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137770","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137774","dc_title":"Fabels en feiten video/animatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137774","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137779","dc_title":"FW: Melding medewerkers gemeente S\ufffddwest-Frysl\ufffdn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137779","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137781","dc_title":"RE: script Vaccinatie proces_BP_V6","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137781","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137783","dc_title":"RE: Vraag @hugodejonge","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137783","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137788","dc_title":"FW: N.a.v. telefonisch contact | casus huisarts/informedconsent/Limburg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137788","foi_groundsOfRefusal":"5.1.2d;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137793","dc_title":"FW: MvT versie 19 februari - ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137793","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137797","dc_title":"FW: Nieuwe versie scenariobeschrijvingen - verzoek vandaag tereageren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137797","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137803","dc_title":"RE: videos AstraZeneca met Cecile  -> vraag over bescherming 60-80%","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137803","foi_groundsOfRefusal":"5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137807","dc_title":"RE: Definitie hoog risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1137807","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137811","dc_title":"FW: checklist","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137811","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137824","dc_title":"FW: Nota inzet  documentatie doorgemaakte infectie voor openensamenleving opm jvh (002)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137824","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137834","dc_title":"FW: nota optreknaalden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137834","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137847","dc_title":"FW: nota","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137847","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137850","dc_title":"FW: Notitie ontwikkeling van de epidemie - namens VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137850","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137862","dc_title":"FW: Nieuwsbericht + nieuwe werkinstructie pagina bewoners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137862","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137871","dc_title":"FW: tekst voor Rijksoverheid over effectiviteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137871","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137879","dc_title":"RE: Schema niet medewerkers in de zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1137879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137883","dc_title":"RE: Bespreekpunten en stukken regiegroep vaccinatie zorgmedewerkers 08-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137883","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137897","dc_title":"FW: extra webpagina zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137899","dc_title":"RE: fotoshoot vaccinatie verpleeghuisbewoners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137899","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137921","dc_title":"RE: Mbt antwoord: Corona vaccinatie en mantelzorgers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137921","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137925","dc_title":"FW: brief wmo ondersteuning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137925","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137932","dc_title":"instructie vaccins die overblijven in verpleeghuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137939","dc_title":"RE: Melding nr. M2101 10246 onderwerp: Onbeveiligde pdf-bestanden van het RIVM en CBG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137939","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137941","dc_title":"RE: Veegsessies VVT instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137941","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137944","dc_title":"Verslag dagstart + breed overleg vaccanatiecommunicatie - 25 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137944","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137954","dc_title":"RE: vraag politie: technische briefing voor Nederlandse bevolking?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137954","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137961","dc_title":"Verslag dagstart vaccanatiecommunicatie - 9 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137961","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137970","dc_title":"FW: Ondersteuning  door apothekers van Corona-vaccinatiecampagne doorhuisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137970","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137973","dc_title":"FW: Mogelijkheden flyer bewegen en COVID-19 vaccinatie (vanuit werkgroep bewegen het nieuwe normaal)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137973","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1137979","dc_title":"FW: Spoed: kwalitatief comm onderzoek nodig voor corona vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1137979","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138016","dc_title":"tijdelijke verkorte versie nieuwsbericht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138016","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138046","dc_title":"RE: Transport vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138046","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138054","dc_title":"FW: verzoek om brief naar ziekenhuizen over optimale ondersteuning covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138054","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138068","dc_title":"FW: Lijst met pati\ufffdnten die volgens de experts voorrang zouden moeten krijgen bij vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138068","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138074","dc_title":"FW: Ter informatie: Lijst met pati\ufffdnten die volgens de experts voorrang zouden moeten krijgen bij vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138074","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138077","dc_title":"Re: Agenda werkgroep voor de COVID-19 vaccinatie bij immuungecompromitteerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138077","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138080","dc_title":"FW: Preferenti\ufffdle vaccinatie strategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138080","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138085","dc_title":"FW: Zeldzame Ziekten en prioriteit voor COVID-vaccinaties.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138085","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138087","dc_title":"FW: Overzicht TK-brieven 2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138087","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138097","dc_title":"RE: richtlijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138097","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138107","dc_title":"FW: Ter info. Maandag. Concept-publicatie cijfers aantallen mensen met med indicatie vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138133","dc_title":"FW: Pre-ABC overleg morgenochtend: Zvw actualisatiecijfers Q4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138133","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138134","dc_title":"FW: Hulp nodig: redactieslag nodig op privacyverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138136","dc_title":"FW: planning concept wetsvoorstel testbewijs ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138136","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138139","dc_title":"FW: Privacyverklaring en extra uitleg voor de rechten van betrokkenen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138139","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138147","dc_title":"RE: Gegevens aanmeldlink","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138147","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138149","dc_title":"FW: Interview Sam Schoenmakers - graag check","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138149","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138161","dc_title":"FW: QenA Vaccin transparantie tbv plenair coronadebat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138161","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138162","dc_title":"RE: Verslag dagstart vaccanatiecommunicatie - 22 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138170","dc_title":"RE: Te bestellen Vaccinatie Registratiekaarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138174","dc_title":"Infopunt in het zonnetje?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138174","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138177","dc_title":"RE: Gebruik van beeldmateriaal uit de pdf's over instructie klaarmaken covid19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138195","dc_title":"FW: Resultaten peiling corona 17 en 18 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138195","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138202","dc_title":"FW: RRF-Fiche Acute Zorg ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138203","dc_title":"RE: Q&A over dubbele uitnodigingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138203","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138216","dc_title":"FW: Tracker up to date?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138217","dc_title":"RE: overlijden na vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138217","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138221","dc_title":"FW: Ideeen voor gedragsinterventies voor Vaccineren vanuit RRT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138221","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138224","dc_title":"FW: Schriftelijke ronde overleg - 24 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138224","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138230","dc_title":"RE: Nieuwe versie uitnodiging 75-79","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138230","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138235","dc_title":"FW: Concept social media bericht LCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138235","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138236","dc_title":"RE: Melding nr. M2102 1273 onderwerp: vaccineren niet mobiele 90 plussers in de huisartspraktijk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138236","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138247","dc_title":"FW: Flyer op locatie,","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138247","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138283","dc_title":"FW: voorbereiding van veel uitnodigingsmateriaal voor prikken bij de HA.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138283","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138284","dc_title":"RE: voorbereiding van veel uitnodigingsmateriaal voor prikken bij de HA.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138308","dc_title":"FW: stukjes van de Kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138308","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138357","dc_title":"FW: T.i. Mail NKC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138357","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138373","dc_title":"FW: ter info: Horizon 2020 vaccine clinical network VACCELERATE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138373","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138377","dc_title":"FW: Testen en vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138377","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138390","dc_title":"FW: Uitbreiden lijst uitgezonderde contactberoepen: graag zsm reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138390","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138403","dc_title":"FW: Tijd tussen twee vaccinaties bij Moderna vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138403","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138415","dc_title":"FW: Agendapunten BO MVWS - -'en 17 februari - Tanja Runhaar zaljullie uitnodigen voor volgende overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138415","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138462","dc_title":"FW: Brief Eerste Kamer: vragen over de farmastrategie - Deadline 4maart 12:00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138462","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138464","dc_title":"RE: vraag politie: technische briefing voor Nederlandse bevolking?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138464","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138474","dc_title":"FW: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138474","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138481","dc_title":"RENEW projectplan def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138481","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138483","dc_title":"FW: Eerste antwoorden op jullie vragen van woensdag 10 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138483","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138484","dc_title":"RE: Verslag dagstart vaccanatiecommunicatie - 22 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138485","dc_title":"FW: Gecombineerde adviesaanvraag GR - Janssen-vaccin envaccinatiestrategie middellange termijn (versie 23-2-2021)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138485","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138486","dc_title":"RE: vraag politie: technische briefing voor Nederlandse bevolking?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138486","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138507","dc_title":"RE: ontkrachten fabels tbv social media","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1138507","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138516","dc_title":"FW: Capaciteit Corona vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138516","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138517","dc_title":"Verwachtingen tav financi\ufffdle regelingen mbt corona.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138517","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138518","dc_title":"RE: overlijden na vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1138518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138520","dc_title":"RE: Fwd: Orders > 5 mln - Sion Biotext   5 miljoen mondmaskers FFP2 (11/5)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138520","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138526","dc_title":"20-04-07 - Bijlage 1 Tabel Productieinitiatieven.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138526","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138530","dc_title":"RE: -70 leveringen  - ziekenhuisapotheken   Code  rood  beleveringen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138530","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138534","dc_title":"RE: terugkoppeling overleg VWS communicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138534","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138536","dc_title":"2020-006 Sion Biotext NL aanvullende brief VWS LCH.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138536","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138542","dc_title":"RE: -70 leveringen  - ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1138542","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138543","dc_title":"RE: Tekst bij Rijksoverheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138543","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138545","dc_title":"Bijlage 1 - nota ter beslissing - NL productie - opstartenproductielijnen 3.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138545","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138561","dc_title":"RE: SPOED: COMMUNICATIE BERICHT HAP MODERNA/ PFIZER","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138561","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138563","dc_title":"20210218 Beeld BTC 18 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138563","foi_groundsOfRefusal":"5.1.2a","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138568","dc_title":"RE: Acties en notulen CAS/BES overleg met VWS van 3 feb 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138568","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138571","dc_title":"RE: AANZET communiatiebericht- verwachtingsmanagement","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138571","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138589","dc_title":"FW: URGENT: Vaccination","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138589","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138599","dc_title":"20210218 Agenda PO PDC VWS - GGD GHOR 18 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138614","dc_title":"210225 LCPS Weekrapportage - week 8 (VWS).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138614","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138617","dc_title":"Vaccine Impact.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138617","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138618","dc_title":"20210217 Ketenwerkgroep_fase 3_planvorming v0.6 (DEF).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138618","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138633","dc_title":"FW: vaccinatie dakloze mensen + kleine groep jeugdzorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138633","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138649","dc_title":"PrognosesLCPS22022021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138649","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138653","dc_title":"Projectie COVID-19 19-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138653","foi_nrPages":43,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138654","dc_title":"FW: Vaccins ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138654","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138660","dc_title":"FW: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138660","foi_groundsOfRefusal":"5.1.2d;5.1.2e;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138666","dc_title":"FW: verklaring avondklok - psychische gesteldheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1138666","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138671","dc_title":"AZ Vaccine Allocation.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138671","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138694","dc_title":"Scenarios COVID-19 10-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138694","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138704","dc_title":"FW: Versie 4 stand van zakenbrief COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138704","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138705","dc_title":"FW: Verslag Alertoverleg 19 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1138705","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138707","dc_title":"FW: Versie 6 stand van zakenbrief COVID-19 ter akkoord MOCW en MI&W","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138707","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138711","dc_title":"Reactie RIVM op methode scenariovisualisatie interdepart. wg.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138711","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138726","dc_title":"FW: verslag van overleg gisteren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138726","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138738","dc_title":"FW: versnelling opnemen vaccinatiegegevens en vaccinatiepaspoort inPGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138738","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138763","dc_title":"Communicatiemethoden voor gedragsverandering v1.5.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138763","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138764","dc_title":"FW: Vervolgoverleg voorbespeken BO met de minister en cli\ufffdntenorganisaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138764","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138792","dc_title":"FW: Voorstel Bonaire voor quarantainewet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138792","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138794","dc_title":"FW: Voorstel quarantaineplicht en afstemming departementen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1138794","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138801","dc_title":"FW: Voorstel Besluit tav periode tussen eerste en tweede COVID Pfizervaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138801","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138807","dc_title":"210219 1e resultaten ronde 10 gedragsonderzoek_v2_MdB.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138807","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138859","dc_title":"Antwoord Rapid Response Team 240221_MJ_MM.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138859","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138870","dc_title":"FW: Vraag Gezondheidsraad vaccinatiebeleid in Versie 4 stand vanzakenbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138870","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138872","dc_title":"WP-leidersoverleg 220121.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138872","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138876","dc_title":"Sheets werkpakketten voor VWS 040221.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138876","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138877","dc_title":"Samenvatting CGU Kennisintegratie Covid onderzoeken 160221_def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138877","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138887","dc_title":"Covid Dwarsthema Ouderen .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138887","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138892","dc_title":"FW: vraag: hoe is het in de WLZ geregeld als instelling zelf prikt?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138892","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138922","dc_title":"FW: [ACTIE] Uitzetmail COVID deel VTC ER 25 februari - deadlinedonderdag 18/2 12:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138922","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138931","dc_title":"FW: [Wg vaccineren/testen/maatregelen] Scenariobeschrijvingen -->reactiemogelijkheid: vrijdag 26/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138931","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138940","dc_title":"FW: Kosten rondom vaccineren van derden ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138940","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138951","dc_title":"Uitleg getallen validatie rapport.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138951","foi_groundsOfRefusal":"5.1.2e;5.1.2f","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1138970","dc_title":"RE: Vraagje over vaccinatie jongeren onder de 18 met onderliggendeaandoeningen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1138970","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139032","dc_title":"FW: Debatvoorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139032","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139101","dc_title":"20210216 verslag sessie opschaling Q2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139101","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139111","dc_title":"Overleg CAS BES 3 feb 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139111","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139166","dc_title":"Woordvoering 80-89 jarigen_v2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139166","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139201","dc_title":"25346 - 2- Checklist brief 70+.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139201","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139215","dc_title":"217475 opmerkingen min MZS op nota.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139215","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139226","dc_title":"Desinformatie content Stakeholders.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139226","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139250","dc_title":"217219 opmerkingen min MZS op nota en brief.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139250","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139260","dc_title":"218397 akkoord min MZS op nota.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139260","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139267","dc_title":"218118 akkoord min MZS op nota.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139267","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139271","dc_title":"212221 Tekst over bijwerkingen en inzetbaarheid werknemers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139271","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139275","dc_title":"RE: Korte uiteenzetting mbt Productie.NL  inzake acocuntantscontroleLCH!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1139275","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139281","dc_title":"RE: Terugkoppeling overleg MVWS CoronaCheck","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139283","dc_title":"RE: kort verslag overleg minister - gezant, 17 februari 9.30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139283","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139288","dc_title":"FW: vraag over vaccinatie en onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139288","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139302","dc_title":"Notulen 1802 operationeel overleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139302","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139345","dc_title":"210210 nieuwsbericht COVID-19-vaccinatie bewoners HAP's-def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139345","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139353","dc_title":"210210 aanpassingen internet pagina HAP traject.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139353","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139414","dc_title":"210204 verslag werkgroep uitvoering - bewoners instellingen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139444","dc_title":"210128 verslag Werkgroep COVID-19 vaccinatie intramurale instellingen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139444","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139447","dc_title":"FW: VERTROUWELIJK Brief Veiligheidsberaad over Routekaart en Jongeren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139447","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139451","dc_title":"RE: Concept afwegingskader VVT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139451","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139458","dc_title":"uitnodiging Webinar Goed Vaccinbeheer def-rivm.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139458","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139465","dc_title":"RE: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139465","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139477","dc_title":"FW: OMT - exitstrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139477","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139489","dc_title":"Notulen groot overleg 18 feb 21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139489","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139496","dc_title":"20210216 conceptverslag WG uitvoering huisartsen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139496","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139499","dc_title":"Beknopte briefing kwali onderzoek comm middelen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139499","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139501","dc_title":"Notulen groot overleg 25 feb 21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139501","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139510","dc_title":"20210223 Agenda - WG uitvoering huisartsen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139510","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139514","dc_title":"20210402 COVID-19 dagstart _ Trello.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139514","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139523","dc_title":"RE: Verzoek om schriftelijke reactie op de berichten over het (tegende regels in) met voorrang vaccineren van personeel in zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1139523","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139534","dc_title":"012654 Uitnodigingstekst_75-79.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139534","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139545","dc_title":"RE: follow up - HiFiBiO COVID antibody","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139545","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139549","dc_title":"RE: Voorstel : Actief cohort beschermingsprogramma  COVID-19 lanceren of krachtig faciliteren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139549","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139587","dc_title":"Re: Offerteverzoek voor gecertificeerde FFP2-mondneusmaskers, inNederland/EU geproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139587","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139599","dc_title":"Geen Onderwerp.eml_4ea077b1-ceb1-46cc-944f-f74fe0502b74.eml","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139615","dc_title":"RE: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139615","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139621","dc_title":"FW: Voor intern gebruik - ontheffingsprocedure zelftesten versie 3.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139621","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139641","dc_title":"RE: Memo Mediq mbt aansprakelijkheid v2502","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139641","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139655","dc_title":"RE: graag jullie akkoord op kamervragen ellenmeet over de publicatievan de scorekaart van Farma ter Verantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139655","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139662","dc_title":"FW: Dit is het bronbestand","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139662","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139678","dc_title":"FW: terugkoppeling afwegingskader code zwart ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139682","dc_title":"RE: Verzoek woordvoeringslijn vaccinaties instellingen verpleeghuizen- 12:00 uur vandaag gereed","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139682","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139693","dc_title":"RE: Retour 218701 - Ciebrief verzoek om schriftelijke reactie  opberichten met voorrang vaccineren personeel in zorginstellignen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139693","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139700","dc_title":"FW: 23022021 concept afwegingskader versie 0.5 opmerkingen IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139700","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139704","dc_title":"RE: wetsvoorstel testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139704","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139705","dc_title":"RE: agenda en stukken PO MVWS 18 februari 15.30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139705","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139709","dc_title":"FW: nota vaccinatiebewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139709","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139723","dc_title":"Vraag GGZ financiering voor na de call als Brigitte eens ophoudt metpraten ;-))))","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139723","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139726","dc_title":"RE: nieuwe aantallen vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139726","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139735","dc_title":"Vaccine Administration Management Value Perspective Rev 1.0.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139735","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139738","dc_title":"FW: Vaccinatie knelpunten ouder- en wooninitiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139738","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139743","dc_title":"FW: Europese info zelftesten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139743","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139745","dc_title":"QA ouderen voor cli\ufffdntenorganisaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139745","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139784","dc_title":"RE: Update leveringen tot week 9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139784","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139786","dc_title":"casussen demo.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139786","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139790","dc_title":"RE: conceptnotitie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139790","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139792","dc_title":"RE: stuk vaccinatiebewijzen voor het DOC donderdag ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139792","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139803","dc_title":"218748 getekende brief -.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139803","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139840","dc_title":"FW: Verzoek tot meelezen van de concept kabinetsbrief over devoortgang toezicht op het gebruik van algoritmen door de overheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139840","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139847","dc_title":"  FW: Stuurgroep Covid-Luchtkwaliteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139847","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139856","dc_title":"Prefilled Questionnaire OECD -rhn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139856","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139889","dc_title":"FW: Memo Mediq mbt aansprakelijkheid v2502","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139889","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139892","dc_title":"RE: Sekswerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139892","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139895","dc_title":"FW: afdwingen herverdelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139895","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139896","dc_title":"FW: Kort verslag OTKP 09022021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139896","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139911","dc_title":"RE: Retour 218701 - Ciebrief verzoek om schriftelijke reactie  opberichten met voorrang vaccineren personeel in zorginstellignen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139911","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139915","dc_title":"FW: Voorlopig 2020 resultaat Z&O","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139915","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139917","dc_title":"FW: vaccinaties bewoners ouderinitiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139919","dc_title":"RE: Retour 218701 - Ciebrief verzoek om schriftelijke reactie  opberichten met voorrang vaccineren personeel in zorginstellignen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139919","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139923","dc_title":"RE: vraag over PIENTER","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139923","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139933","dc_title":"RE: Gesprek Prepardness","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139933","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139935","dc_title":"RE: Contact met LVOI over vaccinatiestrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139936","dc_title":"FW: C-ARVE update januari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139936","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139937","dc_title":"RE: DRINGEND: Gebruik COVig/Nanogam voor fase 1/2 studie waarvoor alhele tijd terug ZONMW funding werd ontvangen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139937","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139941","dc_title":"RE: nazending DR agentschapsparagraaf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139941","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139955","dc_title":"Terugkoppeling Btc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139955","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139956","dc_title":"RE: Verzoek woordvoeringslijn vaccinaties instellingen verpleeghuizen- 12:00 uur vandaag gereed","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139956","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139968","dc_title":"nieuwe versie brief met opm minister","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139968","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139982","dc_title":"FW: punt voor MT CiB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139982","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1139987","dc_title":"RE: Input voor de IV board","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1139987","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140004","dc_title":"20210225 nota moeilijk bereikbare doelgroepen versie 4.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140004","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140008","dc_title":"20210218 verslag stuurgroep corona.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140008","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140013","dc_title":"20210218 Verslag strategisch overleg vaccinatie met MVWS concept.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140013","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140035","dc_title":"20210218 Corona Crisis overleg CZ MO Jeugd.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140035","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140041","dc_title":"RE: spoedoverleg  AP-RIVM-OCW-VWS-GGDGHOR over BCO rondom scholen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140041","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140060","dc_title":"RE: RIVM persupdate","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140060","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140062","dc_title":"20210218 Bijlage 3 Uitkomsten interviewronde JN 'tweede coronagolf'def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140062","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140068","dc_title":"Leveringen AstraZeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140068","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140072","dc_title":"- en OCW: verzoek van Rien","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140072","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140073","dc_title":"Terugkoppeling VB 15 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140073","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140076","dc_title":"RE: OMT - exitstrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140076","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140077","dc_title":"RE: EU flex manufacturing pool / F-map","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140077","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140083","dc_title":"20210224 Nota ter voorbereiding staatssecretaris VierdeVaccinatiealliantie_DEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140083","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140085","dc_title":"20210223 Technische briefing - Planbureaus.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140085","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140122","dc_title":"FW: Versie 0.5 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140122","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140125","dc_title":"RE: preparedness  initiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140125","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140126","dc_title":"FW: Annotatie periodiek overleg OneMed/QRS (donderdag 25 februari'21)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140126","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140132","dc_title":"RE: CoronIT Wpg/Wgbo: alvast notitie testen aanvullen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140132","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140145","dc_title":"RE: overleg dagbesteding terugkoppeling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140145","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140146","dc_title":"RE: Retour 218701 - Ciebrief verzoek om schriftelijke reactie  opberichten met voorrang vaccineren personeel in zorginstellignen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140146","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140152","dc_title":"20210225 Verslag BTC-19 - Coronavirus.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140152","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140154","dc_title":"20210225 Actualiteitenbeeld BTC 25 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140154","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140156","dc_title":"Duiding rapportENVIv3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140156","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140177","dc_title":"20210225 geannoteerde agenda afstemmen opschaling vaccianties Q2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140182","dc_title":"20210224 Voortgangsrapportage vaccinatiegezant ms.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140182","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140192","dc_title":"RE: Effectieve mondneusmaskers voor (kwetsbaar) publiek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140203","dc_title":"RE: Vaccinatiestrategie crisisbedden ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140216","dc_title":"RE: vraag vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140218","dc_title":"RE: overleg PG/GMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140218","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140226","dc_title":"RE: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140226","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140312","dc_title":"FW: PREFINAL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140312","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140328","dc_title":"RE: EU flex manufacturing pool / F-map","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140328","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140335","dc_title":"RE: Uitvraag gecertificeerde FFP2-mondneusmaskers, in Nederland/EUgeproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140335","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140338","dc_title":"FW: Vraag korte check antwoorden webinar","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140338","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140343","dc_title":"RE: update acties lessons learned document","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140343","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140360","dc_title":"RE: Voorbereiding overleg VWS-VIG 18 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140371","dc_title":"RE: Memo - donatie PBM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140371","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140389","dc_title":"RE: 2e vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140389","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140391","dc_title":"Updates monitor sterfte en Wlz-gebruik  tm week 6","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140391","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3696","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140393","dc_title":"RE: Opzet storyline","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140393","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3697","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140405","dc_title":"RE: reactie op uw aanmelding vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1140405","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3698","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140406","dc_title":"RE: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140406","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140408","dc_title":"zojuist veldoverleg gehad over code zwart, ging ook over RTLberichtgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140408","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.9","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140409","dc_title":"RE: Memo Mediq mbt aansprakelijkheid v2502","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140409","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140420","dc_title":"RE: Debatvoorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140420","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140435","dc_title":"RE: woordvoeringslijn verkeerde zorgmedewerkers geprikt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140435","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140437","dc_title":"FW: Vaccins EU en NL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140437","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140454","dc_title":"FW: Nieuwsbericht CONTEST onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140454","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140467","dc_title":"RE: Gespreksverslag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140467","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140472","dc_title":"RE: concept wetsvoorstel en toelichting testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140472","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140476","dc_title":"RE: wetsvoorstel testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140476","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140480","dc_title":"RE: Woordvoeringslijn vaccinaties instellingen verpleeghuizen ENCOMMISSIEBRIEF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140480","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140483","dc_title":"RE: concept persbericht PANDEM-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140483","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140500","dc_title":"FW: woordvoeringslijn pollen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140500","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140511","dc_title":"RE: BCG-Corona antistofresultaten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140511","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140516","dc_title":"FW: vraag van MN over toestemmingsformulier vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140516","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140530","dc_title":"FW: registratie studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140530","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140535","dc_title":"Re: DMTA, offerte, FDI en DMTA Sublicense - Voorbereidingen opsturen serum van Lifelines deelnemers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140535","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140539","dc_title":"RE: Certificate for recovered persons - HSC maandagochtend ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140539","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140554","dc_title":"Re: VOICE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140554","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140556","dc_title":"Re: VOICE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140556","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140578","dc_title":"RE: Openen van de maatschappij m.b.v. corona-antistoftesten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140578","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140620","dc_title":"GGZ vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140620","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140622","dc_title":"RE: Agenda + stukken stuurgroep 25/2  Opvolging debat datalek ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140622","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140624","dc_title":"RE: serologische bepalingen COBRA-KAI studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140624","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140638","dc_title":"RE: COVID19 neutralisatie, hoe pakken we dit op ? voor MT IIV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140648","dc_title":"RE: BcG contract","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140648","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140652","dc_title":"help: concept inkoopprojectplan kits PIENTER studie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140652","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140661","dc_title":"RE: Handleiding invoeren papieren vragenlijsten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140661","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140663","dc_title":"RE: COVID19 neutralisatie, hoe pakken we dit op ? voor MT IIV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140663","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140682","dc_title":"Re: IDSCOVA ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140682","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140702","dc_title":"Pagina antistoffen v0.9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140702","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140710","dc_title":"RE: mazelen project","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140710","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140722","dc_title":"FW: wetsvoorstel testbewijs in tas MVWS ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140722","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140728","dc_title":"ACE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140728","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140738","dc_title":"FW: Nota ter beslissing - Gecombineerde adviesaanvraag GR -Janssen-vaccin en vaccinatiestrategie versie 26 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140738","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140743","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragenantigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140743","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140763","dc_title":"RE: Interview MASSC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140763","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140824","dc_title":"FW: Vragen en antwoorden voor FTM wil je even meelezen.?. Gr. Harald","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140824","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140840","dc_title":"25 02 2021 Notitie bespreking LHV.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140840","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140867","dc_title":"M S COVID-19 Nota ter informatie Annotatie BWO 26 febr 2021quarantaineplicht.DOCX","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140867","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140873","dc_title":"presentatie heroverweging reismaatregelen.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140873","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140875","dc_title":"Agenda Kernoverleg 5/2 & verslag Kernoverleg 3/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140875","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140879","dc_title":"RE: DMTA, offerte, FDI en DMTA Sublicense - Voorbereidingen opsturen serum van Lifelines deelnemers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140885","dc_title":"FW: FINAL FOR APPROVAL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140885","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140886","dc_title":"RE: VOICE en andere studies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140886","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140888","dc_title":"RE: serologische bepalingen COBRA-KAI studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140888","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140897","dc_title":"RE: COVID19 neutralisatie, hoe pakken we dit op ? voor MT IIV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140902","dc_title":"RE: BCG-Corona antistofresultaten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140902","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140909","dc_title":"RE: Concept-verslag QuickScan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140909","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140932","dc_title":"25022021 Presentatie quarantaineplicht versie 14.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140932","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140957","dc_title":"RE: RIVM brede communicatiestrategie COVID-19 + structuur--> hoi Remko, moet ik hier iets voor inplannen? (grt, Anja)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140957","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1140972","dc_title":"Nog een paar vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1140972","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141005","dc_title":"UV-vragen (voor behandeling in het MT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141005","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141009","dc_title":"RE: agenda en verslag mMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141009","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141012","dc_title":"210216 Nieuwe figuren en vragen Marcel v2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141012","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141037","dc_title":"RE: BMC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141037","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141055","dc_title":"signalen 15 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141055","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141066","dc_title":"210216 Corona update.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141066","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141075","dc_title":"MEMO leveringen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141075","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141095","dc_title":"RE: verslag 1e vergadering stuurgroep sequencing netwerk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141096","dc_title":"RE: sequencing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141096","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141105","dc_title":"RIVM+FMS-Bijlage - Risico op gecompliceerd beloop COVID-19 enprioritering COVID-19-vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141105","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141109","dc_title":"210216 Uitleg vaccinatiestrategie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141109","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141152","dc_title":"RE: Voor na je vakantie: outlines voor communicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141152","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141154","dc_title":"RE: graag je reactie op een paar vragen uit Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1141154","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141170","dc_title":"RE: Caribisch Nederland - Coronadashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141170","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141171","dc_title":"RE: HERA Incubator appreciatie - svp check uiterlijk 17 uur.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141171","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141173","dc_title":"RE: Caribisch Nederland - Coronadashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141181","dc_title":"RE: Versie 0.7. afwegingskader VVT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1141181","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141182","dc_title":"RE: Caribisch Nederland - Coronadashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141182","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141188","dc_title":"RE: Marcel van Raaij - opvolging telefoon gesprek: Mondkapjes die hetvirus doden en besmettingsmomenten elimineren: Biohazard prevention - Testand Compliance documents","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141188","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141194","dc_title":"opdrachtbrief VWS effectiviteits studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141194","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141202","dc_title":"RE: uitnodiging door gemeente sudwest-fryslan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141208","dc_title":"RE: Uitleg ontheffingsprocedure voor zelftesten voor publicatie oprijksoverheid.nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141208","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141222","dc_title":"RE: Verzoek n.a.v. overleg met RIVM over vaccinatie pati\ufffdnten MSRZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141222","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141224","dc_title":"RE: actiepunten n.a.v. stavaza overleg vaccins LZ/CZ/DMO/J","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141224","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141225","dc_title":"Verslag 4-kantsoverleg 170221","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141225","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141228","dc_title":"RE: Biodefence CIE-mededeling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141228","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141229","dc_title":"RE: veiligheid ondersteunend personeel ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141229","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141233","dc_title":"RE: veiligheid ondersteunend personeel ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141233","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141237","dc_title":"RE: Kosten rondom vaccineren van derden ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141237","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141243","dc_title":"RE: Communicatie input covid stand van zaken kamerbrief 23-02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141243","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141259","dc_title":"RE: Europese Commissie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141259","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141274","dc_title":"Re: samenvatting One Health and Animal reservoir SARS-Cov-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141274","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141276","dc_title":"3.c. Bijlage Organogram digitale verbeteringen GGD V0.8.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141276","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141304","dc_title":"Systeemfout/geen vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141304","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141327","dc_title":"RE: Verslag overleg RIVM VWS GGD GHOR 24.02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141327","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141347","dc_title":"RE: terugkoppeling afwegingskader code zwart ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141347","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141349","dc_title":"RE: po Stan/Marieke 1e lijn zorg - Covid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141349","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141365","dc_title":"RE: Antwoordlijn kleinschalige woonvormen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141365","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141368","dc_title":"RE: Antwoordlijn kleinschalige woonvormen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141368","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141389","dc_title":"RE: nagebeld over 102 jarige mevrouw","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141389","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141390","dc_title":"Re: Aruba - vaccinatie waarnemers die invliegen vanuit Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141390","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141398","dc_title":"Aruba","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141398","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141431","dc_title":"RE: Wekelijks TC COVID-19 Caribische regio - aanvullende stukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141431","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141435","dc_title":"FW: new proposal document - route from containment to mitigation (vaccinations)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141435","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141445","dc_title":"RE: seminar 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141445","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141465","dc_title":"RE: Caribisch Nederland - Coronadashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1141465","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141470","dc_title":"Re: Verificatiesetje varianten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141470","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141481","dc_title":"RE: Interview MASSC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141481","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141502","dc_title":"RE: [Spam] Re: [Spam] Re: Introductions and some queries","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141502","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141504","dc_title":"FW: Inreismaatregelen BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141504","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.11","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141512","dc_title":"RE: Korte follow-up bijpraten LCVI/IDS ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141512","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141513","dc_title":"RE: [Spam] Re: [Spam] Re: Introductions and some queries","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141513","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141515","dc_title":"Test-strategie BVI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141515","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141519","dc_title":"RE: aruba","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141519","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141538","dc_title":"RE: vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141538","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141597","dc_title":"RE: C-ARVE update januari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141597","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141600","dc_title":"concept persbericht vaccinatie intramurale ggz","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141600","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141603","dc_title":"RE:  ISB Coronagerelateerde mutaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141603","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141624","dc_title":"RE: Voorzet aanvullende memo COVID-lucht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141624","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141638","dc_title":"ivm PO Intravacc FW: Doorst:  Verzoek om reactie op initiatiefnotaVeldman (VVD)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141638","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141680","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141680","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141686","dc_title":"RE: UPDATED: COVID-19 Updated Information Products_26 February 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141686","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141700","dc_title":"RE: Caribisch Nederland - Coronadashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141700","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141701","dc_title":"FW: [Spam] Re: [Spam] Re: Introductions and some queries","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141701","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141703","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141703","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141715","dc_title":"RE: British Virgin Island toevoegen aan veilige landen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141715","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141721","dc_title":"RE: British Virgin Island toevoegen aan veilige landen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141721","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141722","dc_title":"FW: Voor CO LCI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141722","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141725","dc_title":"kattenbel overleg 17:00 uur verkiezingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141725","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141730","dc_title":"FW: ECDC RT Report 22 February  2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141730","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141732","dc_title":"RE: slides van afgelopen donderdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141732","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141737","dc_title":"RE: Korte trips Saba/Statia naar SXM via corridor","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141737","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141751","dc_title":"RE: Nogmaals  graag je reactie op een paar vragen uit Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141751","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141753","dc_title":"RE: maatregelen verkiezingen op Saba ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141753","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141778","dc_title":"Variant B.1.1.7 on the Dutch Caribbean Islands","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141778","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141789","dc_title":"20210212 Stand van zaken beleidskader kwaliteit en continu\ufffdteit van zorg in fase 3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141789","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141838","dc_title":"RE: 20210201 brief COVID 19 vaccinatie V5_schoon","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141838","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141843","dc_title":"Effecten opkomst nieuwe variant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141843","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141857","dc_title":"Afstemmingsoverleg ICT GGD GHOR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141857","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141940","dc_title":"21-0660 Inbreng Ieder(in), Per Saldo en Kansplus tbv coronadebat24-02.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141940","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141960","dc_title":"Re: Vaccinatiekosten schatting Parnassia Groep - Kopie.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141960","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141983","dc_title":"FW: Agenda Kernoverleg 19/2 & verslag Kernoverleg 17/2 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141983","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141986","dc_title":"2021memo meerkosten vaccinatie versie1602.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141986","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141994","dc_title":"Voorstel ondersteuning Data Gedreven Vaccineren.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141994","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1141998","dc_title":"Verzoek annotatie 3 maart interne begroting 2021 RIVM tbv PO pSG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1141998","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142025","dc_title":"FW: EC documents for OECD Health Committee  Draft \"Blueprint Framework for Safer International Travel during the COVID-19 Pandemic\"","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142025","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142028","dc_title":"FW: Antw: DG-bericht 24 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142028","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142044","dc_title":"FW: DG bericht 3 februari 2021 -  Onze basis is kennis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142044","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142097","dc_title":"RE: Offerte t.b.v. aanvullende opdracht Infectieziekten en werknemersbescherming","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142097","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142103","dc_title":"RE: Dienstverleningsovereenkomst uitvoeren groot volume labs covid-19 capaciteit - Jeroen Bosch.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142103","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142106","dc_title":"RE: Invoice 7799 from St. Maarten Laboratory Services N.V.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142106","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142110","dc_title":"Doorst: Invoice 7799 from St. Maarten Laboratory Services N.V.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142134","dc_title":"MEE NL.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142166","dc_title":"MEE West Brabant.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142166","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142200","dc_title":"maandag tussen 1 en half 3 bellen? RE: Update antilichaamtherapieCOVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142200","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142261","dc_title":"RE: instellen expertgroep risicoanalyse zoonosen FW: Aanbieding afschrift verzamelbrief SARS-CoV-2 bij dieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142275","dc_title":"RE: instellen expertgroep risicoanalyse zoonosen FW: Aanbieding afschrift verzamelbrief SARS-CoV-2 bij dieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142275","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142278","dc_title":"mening van vaccinatie gezant over AMI personeel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142278","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142294","dc_title":"mogelijke publiciteit over antilichaambehandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142294","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142323","dc_title":"RE: Doorst:  sequencing","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142323","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142324","dc_title":"RE: DEBAT uitvraag | deadline maandag 09:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142324","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142333","dc_title":"20210225 Registratie vaccinatie COVID-19 werkgevers - werknemersSCHOON.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142333","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142334","dc_title":"20210225 Uitwerking afspraken steunpakket DEFINITIEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142334","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142342","dc_title":"210221 Samenloop verlenging avondklok en verkiezingen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142342","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142355","dc_title":"RE: concepttekst DG-bericht 24 februari 2021 - graag je reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142355","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142360","dc_title":"210222 brief LNAZ kernteam voorbereiding fase 3.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142363","dc_title":"210223 Corona update.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142363","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142371","dc_title":"210219 Corona update.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142371","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142376","dc_title":"210222 bijlage 2 raakvlakken plannen fase 3.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142376","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142390","dc_title":"Ter info: Geleideformulier aanbiedingsbrief DVP 2021_1 toedieningsmateriaal, transport en transportbeveiliging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142390","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142398","dc_title":"Angst en corona communicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142398","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142430","dc_title":"NCTV dagstart terugkoppeling | 16 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142430","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142432","dc_title":"FW: WMO ondersteuning versus WMO-huishoudelijke julp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142432","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142434","dc_title":"RE: DG bericht 3 februari 2021 -  Onze basis is kennis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142434","foi_groundsOfRefusal":"5.1.2e;Wft","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142436","dc_title":"RE: reactie Jeroen ten Kroode -DG bericht 3 februari 2021 -  Onze basis is kennis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142436","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142450","dc_title":"Agenda PO dgMI met dgRIVM 2 met annotatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142450","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142500","dc_title":"FW: nota_commentamas","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142500","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142505","dc_title":"FW: Bespreken conceptnotitie q-plicht voor directeurenoverleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142505","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142562","dc_title":"FW: SPOED: Privacy toets aanlevering anonieme vaccinatiegegevens aan RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142562","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142612","dc_title":"FW: pbm voor mantelzorgers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142612","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142633","dc_title":"Stukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142633","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142656","dc_title":"Notulen 2SG & DG overleg 16 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142656","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142692","dc_title":"RE: Passage voor COVID-brief 23/02 - graag jouw reactie/fiat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142692","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142698","dc_title":"Stukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142698","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142729","dc_title":"P14 GR zonder financi\ufffdn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142729","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142739","dc_title":"Bijlage D. JAARPLAN 2021 -.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142739","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142757","dc_title":"P26 OenM zonder financi\ufffdn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142757","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":30,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142771","dc_title":"P24 DLO zonder financi\ufffdn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142771","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142778","dc_title":"P45 DCC zonder financi\ufffdn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142778","foi_nrPages":12,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142790","dc_title":"stand van zaken 23-02-21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142790","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142798","dc_title":"P11 GVW zonder financi\ufffdn.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142798","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":23,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142804","dc_title":"ter info: FW: gebruikte data voor LCC-dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142804","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142809","dc_title":"Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)Vrijdag 19 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142809","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142818","dc_title":"RE: Advies mail Victor Sannes opdracht COVID vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142818","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142838","dc_title":"RE: CoronaCheck en wetgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142838","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142858","dc_title":"Concept DR 2021-02-02.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142858","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142898","dc_title":"FW: inzet gedragsexpertise - graag overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142898","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142910","dc_title":"RE: RIVM Persupdate","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142910","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142935","dc_title":"Notulen Inhoudelijk MT 20210118.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142945","dc_title":"218792 getekende brief min VWS.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142986","dc_title":"7. Principenotitie toegangstesten - DOC-19 25 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142986","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1142993","dc_title":"6. Factsheet_DOTT_week07_LCT.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1142993","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143000","dc_title":"8ii. Voortgangsrapportage_grootschalig_risicogericht_testen_LCTweek7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143000","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143011","dc_title":"5b. Factsheet pilots sneltesten in het mbo en ho (LCT).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143011","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143017","dc_title":"5b. Pilots sneltesten mbo & hoger onderwijs.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143017","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143036","dc_title":"RE: Projectportfoliorapportage IV-Board/IV-Voorportaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143036","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143071","dc_title":"Antw:  terugkoppeling IV-Board februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143071","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143095","dc_title":"RE: Vervolgstappen dataplatform en gerelateerde acties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143134","dc_title":"RE: Vragen nav meeting Calamiteitenprocedure overleg RIVM VZVZ SC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143134","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143137","dc_title":"IV afstemming LCC DAshboard - Dataplatform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143137","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143142","dc_title":"Aanvullende sheets ter verduidelijking processen en planning - motiedijkhoff v0.5.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143142","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143155","dc_title":"Stand van zaken vaccinatiestrategie - overleg 22-2-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143155","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143176","dc_title":"FW: Persbericht Intravacc  opent pilot productiefabriek en startontwikkeling grote nieuwe vaccin-productiefacililiteit_LM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143190","dc_title":"FW: - goudsmit:  hierbij mijn stappenplan neergelegd bij de minister VERTROUWELIJK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143190","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143199","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143199","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143202","dc_title":"FW: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143251","dc_title":"Agenda expertgroep  testen 23-02 / Notulen 16-02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143251","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.15","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143291","dc_title":"ZonMW aanvraag COBRA Kai FINAL.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143291","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143295","dc_title":"RAC-overleg: Vaccinatie in VVT tijdens uitbraak","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143295","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143298","dc_title":"Verslag ketenoverleg 25 feb.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143298","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143311","dc_title":"RAC update week 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143311","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143319","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143319","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143326","dc_title":"RE: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143326","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143329","dc_title":"Resultaten publiekspeiling corona 17 en 18 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143329","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143332","dc_title":"FW: RAC update week 5","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143332","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143361","dc_title":"FW: Sant\ufffd Group Introduction","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143361","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143391","dc_title":"Inf@ct: COVID-19 (nieuw coronavirusinfectie) (95)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143391","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143397","dc_title":"Inf@ct: COVID-19 (nieuw coronavirusinfectie) (94)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143397","foi_groundsOfRefusal":"5.1.2e;5.1.2i Toelichting;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143405","dc_title":"RE: clusters scholen en kinderdagverblijven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143405","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143407","dc_title":"FW: Vragen over immuungecompromitteerden in relatie tot BCO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143407","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143413","dc_title":"RE: Inf@ct: COVID-19 (nieuw coronavirusinfectie) (93)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143413","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143425","dc_title":"RE: RVP en de coronamaatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143425","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143429","dc_title":"RE: Eerste terugkoppeling 'Gebruikerservaring Testen bij Kinderen'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143429","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143438","dc_title":"Notulen REC-overleg 11-2-2021 en enkele actiepunten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143438","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143444","dc_title":"FW: COVID vaccinaties tijdens VVT uitbraak","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143444","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143447","dc_title":"RE: verslag en nadere informatie Corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143447","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.1540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143449","dc_title":"HP-zone, vaccinatie webinar, en overig","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143449","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.2628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143461","dc_title":"RE: Pleidooi voor aanpassing richtlijn COVID wat betreft verlenging van de isolatie in het geval van symptomen op grond van vermoeden van persisteren van besmettelijkheid.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143461","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143482","dc_title":"RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1143482","foi_groundsOfRefusal":"5.1.2d;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143499","dc_title":"RE: 2021memo meerkosten vaccinatie RvE2 rg met opmerkingen (002) av(003)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1143499","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143504","dc_title":"RE: 2021memo meerkosten vaccinatie RvE2 rg met opmerkingen (002) av(003)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143504","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143525","dc_title":"RE: 210212 wijziging Spg ivm vaccinatie corona enbevolkingsonderzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143525","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143529","dc_title":"RE: Aangepaste levering Astra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143529","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143554","dc_title":"FW: Vaccineren asielzoekers I protocol I voorlichtingsmaterialen I GGD GHOR Kennisnet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143554","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143555","dc_title":"RE: Aangepaste levering Astra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143555","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143556","dc_title":"RE: aanschaf antilichamen behandelingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143556","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.16","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143563","dc_title":"RE: Notitie t.b.v. --Raad 12 februari 2021: Interne standpuntbepaling governance infectieziektecrisis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143563","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143577","dc_title":"RE: izb expertise in covid 19 governance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143577","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143590","dc_title":"RE: Aansluiting met FIN - beeld ISB ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143590","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143593","dc_title":"RE: Actiepunten stavaza bijwerken s.v.p.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143593","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143594","dc_title":"FW: Samenvatting ECDC RRA (14) 15-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1143594","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143596","dc_title":"FW: Samenvatting ECDC RRA (14) 15-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143596","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143608","dc_title":"RE: Aanvulling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143608","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143612","dc_title":"RE: 20210218 nota moeilijk bereikbare doelgroepen versie 4","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143612","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143617","dc_title":"RE: Actiepunten stavaza bijwerken s.v.p.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143617","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143622","dc_title":"taakomschrijving GGDGHOR/LOI en LCI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143622","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143632","dc_title":"RE: Landelijk geneeskundig beeld corona?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143632","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143653","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragenantigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143653","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143668","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragenantigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143668","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143669","dc_title":"RE: Bijwerkingen formulier Lareb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143669","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143670","dc_title":"RE: Spironose","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143670","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143674","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragenantigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143674","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143684","dc_title":"RE: adviesvraag SER denktank","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143684","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143694","dc_title":"RE: Inf@ct: COVID-19 (nieuw coronavirusinfectie) (93)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143694","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143703","dc_title":"RE: adviesvraag SER denktank","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143703","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143705","dc_title":"RE: adviesvraag SER denktank","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143705","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143712","dc_title":"RE: Amerikaanse guidance","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143712","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143723","dc_title":"RE: afspraken LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143723","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143725","dc_title":"RE: afwikkeling PD -ALT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143725","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143730","dc_title":"RE: Afstemming ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143730","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143747","dc_title":"RE: Agenda en stukken vaccinatie overleg - 19 februari 15.15u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1143747","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143765","dc_title":"RE: Agenda PO PDC VWS - GGD GHOR 18 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143765","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143768","dc_title":"FW: Jaarlijkse IHR vragenlijst en additionele IHR COVID-19 vragenlijst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143768","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143780","dc_title":"RE: akkoord?: geco\ufffdrdineerde factsheets voor ACC en MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143780","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.17","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143783","dc_title":"RE: Terugkoppeling eventuele grenscontroles DUI / testen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143783","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143785","dc_title":"RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143785","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143793","dc_title":"RE: Ambtelijk vooroverleg 15 feb voor BO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1143793","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.18","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143799","dc_title":"RE: Ambtelijk vooroverleg 15 feb voor BO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143799","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143802","dc_title":"RE: nasal swabs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143802","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143810","dc_title":"RE: Antw: Schriftelijke ronde overleg - 24 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143810","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143811","dc_title":"RE: Antw: niet-mobiele ouderen/door huisartsen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143811","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143813","dc_title":"RE: Antigeen testen COVID EU commissie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143813","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143818","dc_title":"RE: Apple Maps voor Covid-19 testlocaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143818","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143824","dc_title":"FW: besluiten over de richtlijn COVID-19-vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143824","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143825","dc_title":"RE: antwoord op je vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143825","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143833","dc_title":"Risicogroepen kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143833","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143836","dc_title":"RE: Art. 5(3) antilichamen: wanneer wordt uitspraak EMA verwacht?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143836","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143849","dc_title":"RE: Artikel Amigoe gister","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143849","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143860","dc_title":"RE: Attentie Team Vaccins: Vragenformulier 19-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143860","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143877","dc_title":"RE: Belangrijkste posten MU artikel 1 die geen projectbureau GGD GHORzijn.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143877","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143904","dc_title":"RE: Aantallen Alliade ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143904","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143906","dc_title":"RE: Bijlage CW 3.1 toevoegen aan volgende Kamerbrief Pallas","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143906","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143908","dc_title":"FW: Revalidatiecentra","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143908","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143912","dc_title":"RE: binnengekomen vraag bij IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143912","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143916","dc_title":"RE: bijpraten vaccinatiebewijzen klankbordgroep morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143916","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143917","dc_title":"RE: Vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143921","dc_title":"RE: Bilat Rutte-Netanyahu d.d. 15/2/21 (COVID-19): Kort VerslagFollow Up Gesprek VWS/Dir IZ, MoH/Dir IZ en TEL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143921","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143922","dc_title":"RE: Werkwijze spillage? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143922","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143932","dc_title":"Update Week 8","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143934","dc_title":"RE: Apple Maps voor Covid-19 testlocaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143934","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143948","dc_title":"FW: onderzoek naar gebruik handdesinfectie in NL door Kantar i.o.v. IenW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143948","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143972","dc_title":"RE: BRBA verkenning - ziekenhuizen en registratie/uitnodigingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143972","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1143992","dc_title":"RE: nasal swabs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1143992","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144009","dc_title":"RE: Budget voor communicatie over corona-apps","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144009","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144025","dc_title":"RE: BW-route","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144025","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3965","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144028","dc_title":"RE: check op vragen defensie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144028","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144032","dc_title":"RE: Cluster Sitrep 16.2.2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144032","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144040","dc_title":"RE: Concept conclusies DO Reizen 25/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144040","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144063","dc_title":"RE: Concept kabinetsstandpunt vaccinatiebewijs COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144063","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144068","dc_title":"RE: concept kabinetsstandpunt vaccinatiebewijzen versie 12 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144068","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144083","dc_title":"RE: Concept presentatie vaccinatiealliantie en deelnemerslijst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144083","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144089","dc_title":"RE: concept rapport modellering COVID-19 vaccinatiestrategieen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144089","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144096","dc_title":"RE: concept wetsvoorstel en toelichting testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144096","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144100","dc_title":"RE: concept opdrachtbrief GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144100","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144103","dc_title":"RE: Conceptverslag en beeld BTC-19 | 23 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144103","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144107","dc_title":"RE: Core task of VWS and Health Inspection","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144111","dc_title":"RE: Corona vaccin voor mensen met acute kanker ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1144111","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144125","dc_title":"RE: CoronaCheck en wetgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144125","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144128","dc_title":"Toegang tot richtlijnontwikkeling voor covidvaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144128","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144139","dc_title":"FW: flacons pfizer vaccin over","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144139","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.19","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144147","dc_title":"FW: Flacons over","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144147","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144160","dc_title":"RE: COVID claims: meelopen in ISB of voorjaarsnotaplaat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144160","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144172","dc_title":"RE: COVID gerelateerde uitgaven: ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144172","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144179","dc_title":"RE: Covid vaccinaties en AMI/uitzendpersoneel URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144179","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144188","dc_title":"RE: Melding dichte flacons | AGB 41412903","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144188","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144189","dc_title":"RE: COVID SO RAZ_CommAdH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144196","dc_title":"RE: Covid-19 Vaccinatie / PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144196","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144197","dc_title":"RE: Gebruik spillage voor 1e vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144197","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144224","dc_title":"2e lijn helpdesk 5","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144224","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144233","dc_title":"RE: 1 ampul vaccins over - AGB-code 41412401 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144233","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144237","dc_title":"RE: Covid-19 Vaccinatie / PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144237","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144240","dc_title":"RE: cross-border request regarding the need for doctors and nurses.Slowakije","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144240","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144243","dc_title":"FW: link voor werkinstructie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144243","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144248","dc_title":"RE: cross-border request regarding the need for doctors and nurses.Slowakije","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144248","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144249","dc_title":"FW: vaccinatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144249","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144250","dc_title":"RE: Dagverslag 16 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144250","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144251","dc_title":"RE: wijziging spillage beleid RE: Vaccinatie 2 ronde bewoners | Ananz wonen-welzijn-zorg | AGB 41412903","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144251","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144252","dc_title":"RE: Covid-19 Vaccinatie / PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144252","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144254","dc_title":"RE: Deadline: dinsdag 11:00 | Uitvraag actualiteiten en agendapuntenBTC-19 23 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144254","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.3999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144260","dc_title":"RE: Melding nr. M2102 7642 onderwerp: FW: Eerste prik door ons, tweede prik door GGD?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1144260","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144265","dc_title":"RE: Debat avondklok en tijdelijke wet 18/2 vanaf 11.00 - gelievestandby te staan voor vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144265","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144271","dc_title":"RE: Spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144271","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144274","dc_title":"RE: DEBAT uitvraag | deadline maandag 09:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144274","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144275","dc_title":"RE: Definitie overwinteraars","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144275","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144276","dc_title":"info helpdesk#5","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144276","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144278","dc_title":"RE: vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144278","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144279","dc_title":"RE: denkkracht op surplus issue einde dag: idee\ufffdn vanuit RIVM en VWS op specifieke doelgroepen wellicht?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144279","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4007","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144290","dc_title":"FW: vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144290","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144300","dc_title":"RE: vraag overgebleven (geprepareerde) COVID vaccins Pfizer/BioNTech vaccin (Comirnaty)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144300","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144315","dc_title":"RE: Doorst:  Verzoek om reactie op initiatiefnota Veldman (VVD)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144315","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144325","dc_title":"RE: Dit is het bronbestand","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144325","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144333","dc_title":"RE: Doorst: The Netherlands: Moderna Vaccine shipment #5 and #6 -March 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144333","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144335","dc_title":"RE: Dit is het bronbestand","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144335","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144379","dc_title":"Update week 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144379","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144394","dc_title":"RE: Support NPPU evaluatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144394","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144415","dc_title":"RE: Review scripts isolatie en quarantaine / COVID-19 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144415","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144452","dc_title":"FW: zuid afrikaanse variant en astrazeneca en de aantallen virus varianten in Nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144452","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144460","dc_title":"RE: Opzet webpagina virusvarianten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144460","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144475","dc_title":"RE: Klimaatfactoren in offerte Leefomgevingsfactoren COVID 19 programma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144475","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144484","dc_title":"FW: Follow-up onderzoeksplan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144484","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144493","dc_title":"RE: Projectplan Leefomgevingsfactoren voor het Coronadashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144493","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144530","dc_title":"Re: Update week 5","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144530","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144536","dc_title":"FW: Correcties nodig in berekeningen van besmettingsgraden en R-waarden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144536","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144543","dc_title":"FW: Viruswaarheid en kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144543","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144568","dc_title":"RE: Vraag m.b.t. aanvullende informatie diagnostiek COVID-19 bij de LCI-richtlijn COVID-19 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144568","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144572","dc_title":"RE: geldigheidsduur testuitslag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144572","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144592","dc_title":"RE: Coronadashboard budgetverdeling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144592","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144594","dc_title":"RE: Ter voorbereiding van ons gesprek zometeen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144594","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144595","dc_title":"RE: DG-bericht 17 februari 2021: Domeinoverstijgende samenwerking en projecten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144595","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144597","dc_title":"RE: Klimaatfactoren in offerte Leefomgevingsfactoren COVID 19 programma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144597","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144640","dc_title":"RE: Campagne-effectmonitor Alleen Samen 10 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144640","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144655","dc_title":"RE: Scholen 13-18 jaar_CONCEPT 08022021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144655","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144662","dc_title":"RE: EC joint procurement covid behandelingen - reactie WJZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144662","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144663","dc_title":"RE: HSC terugkoppeling - vaccinatie certificaten, mondmaskers, scholen, RAT, PLF, nertsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144663","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144668","dc_title":"RE: ww: 1100233162  30.200,00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144668","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144675","dc_title":"RE: vragen tav prijs en financiele bepalingen Covid 19 vaccinatie campagne","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144675","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.20","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144683","dc_title":"RE: Brief onderwijsraden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144683","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144712","dc_title":"RE: Stuk AG testen kinderen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144712","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.21","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144748","dc_title":"FW: Terugkoppeling HSC ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144748","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144753","dc_title":"RE: follow up - HiFiBiO COVID antibody","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144753","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144766","dc_title":"RE: Melding onprofessionele commerciele teststraten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144766","foi_groundsOfRefusal":"5.1.1e;5.1.2e;5.1.2i;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144769","dc_title":"RE: huisarts die vraag verklaring te tekenen voordat hij vaccin zet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144769","foi_groundsOfRefusal":"5.1.2d;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144775","dc_title":"RE: eerste versie nota Directeurenoverleg Reizigers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144775","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144777","dc_title":"RE: informatie over livegang Burgerportaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144777","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144780","dc_title":"RE: eerste versie nota Directeurenoverleg Reizigers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144780","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144786","dc_title":"RE: Eerste conceptversie Kamerbrief [morgenochtend 10:00 aanleverenbij pDGV]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144786","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144792","dc_title":"RE: Effectiveness of First Dose of COVID-19 Vaccines Against HospitalAdmissions in Scotland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144792","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144796","dc_title":"RE: Inf@ct: COVID-19 (nieuw coronavirusinfectie) (94)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144796","foi_groundsOfRefusal":"5.1.1e;5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144838","dc_title":"RE: FW: Wijzigingen in ministeriele regeling op het gebied van reizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144838","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144839","dc_title":"RE: FW: 20210222 -- NvD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144839","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4048","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144842","dc_title":"RE: Advies mail Victor Sannes opdracht COVID vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1144842","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4049","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144850","dc_title":"RE: Gesprek BZK / VWS over testbewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144850","foi_groundsOfRefusal":"5.1.2d;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4050","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144855","dc_title":"RE: Gesprek met IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144855","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4051","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144857","dc_title":"FW: Zoektermen medische gegevens","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144857","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4052","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144867","dc_title":"RE: ggz medewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144867","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4053","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144872","dc_title":"RE: goedkeuring voor 2 punten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144872","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4054","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144873","dc_title":"RE: GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144873","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4055","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144892","dc_title":"RE: graag jullie akkoord op kamervragen ellenmeet over de publicatievan de scorekaart van Farma ter Verantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144892","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4056","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144902","dc_title":"RE: Graag reactie op mijlpalen voor dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144902","foi_groundsOfRefusal":"5.1.2d;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4057","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144928","dc_title":"RE: nu met bijlagen - RE: Uitnodiging en toelichting workshops 'project PGO'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144928","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4058","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144940","dc_title":"RE: Herziening additionele offerte Covid-19 Vaccinatieprogramma (P19)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144940","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.22","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144943","dc_title":"RE: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1144943","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4059","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144952","dc_title":"Re: Historische eerste week vaccinatie!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144952","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4060","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144953","dc_title":"RE: Hi Marja, ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144953","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4061","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144962","dc_title":"FW: opmerkingen bij de eerste versie van fiches ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144962","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4062","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144971","dc_title":"RE: Inbreng Jeugd, eerste versie agenda en nota BO 2-3-2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144971","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4063","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144976","dc_title":"RE: Infectiewet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144976","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4064","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144978","dc_title":"RE: Inbreng Jeugd, eerste versie agenda en nota BO 2-3-2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1144978","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4065","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144981","dc_title":"RE: info over Sanquin aan de TK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144981","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4066","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144987","dc_title":"RE: Inkopen en aanbestedingen CPO GGD GHOR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144987","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4067","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1144990","dc_title":"EVGI workshop_Gerlofs-Nijland_210920_final version_distribution.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1144990","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":23,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4068","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145025","dc_title":"FW: Antw:   ServiceNow Vaccinatie Management Platform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145025","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4070","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145037","dc_title":"RE: input nav budgethoudersgesprek ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145037","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4071","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145047","dc_title":"FW: Doorst:  Vaccinatieregistratie kaartjes voor huisartsvaccinatie in de ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145047","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4072","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145059","dc_title":"RE: Interdepartementaal directeurenoverleg inz. beveiliging - verslag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4073","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145072","dc_title":"RE: Interview MASSC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145072","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4074","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145102","dc_title":"Doorst:  TKN : 2e vaccinatie  -  7,7 uit een dosis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145102","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4075","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145117","dc_title":"FW: communicatie frame logistiek tbv video - verzoek MinVWS - input vandaag svp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145117","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4076","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145122","dc_title":"Doorst:  Doorst:  Doorst: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145122","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.23","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145125","dc_title":"FW: Goed vaccinbeheer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145125","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.24","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145139","dc_title":"RE: introductie Marveltest en Min van VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145139","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4077","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145161","dc_title":"FW: Laatste AZ leverschema met verdeling?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145161","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4079","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145172","dc_title":"RE: Uitstellen vaccinaties ivm slecht weer_050221","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145172","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4080","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145181","dc_title":"RE: kamervragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145181","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4081","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145183","dc_title":"RE: jammer!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4082","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145188","dc_title":"FW: Slots","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145188","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4083","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145205","dc_title":"Netwerk Onderzoek en Evaluatie: inspiratiesessie 11/2 en update onderzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145205","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4084","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145208","dc_title":"Re: Vertrouwelijk: Dienstverleningsovereenkomst ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145208","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4085","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145216","dc_title":"RE: kernpunten minister","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4086","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145239","dc_title":"RE: AZ vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145239","foi_groundsOfRefusal":"5.1.2e;5.1.2i OMT","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4087","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145260","dc_title":"RE: Laatste versie Kamerbrief ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145260","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4088","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145264","dc_title":"RE: Laatste versie slides voor DOC 16/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145264","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4089","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145265","dc_title":"RE: Laatste versie scenario's Covid-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145265","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4090","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145274","dc_title":"RE: kwali corona spoedtest 09 - met 70+-ers - kunnen we die gaan opstarten?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145274","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4091","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145279","dc_title":"RE: maatregelen verkiezingen op Saba ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145279","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4092","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145291","dc_title":"vaccinatiebewijs bij 2e vaccinatie Acute zorg dooor GGD ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145291","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4093","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145295","dc_title":"5.a. Verslag MT - 15 februari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145295","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4094","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145299","dc_title":"Q&A werking vaccins.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4095","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145301","dc_title":"FW: uitzonderlijke situatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145301","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4096","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145305","dc_title":"1. Verslag Actualiteitenstaf 25 januari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145305","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4097","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145317","dc_title":"RE: liquiditeit regionale GGD-en","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145317","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4098","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145328","dc_title":"RE: Moties en toezeggingen COVID-19 debat 24/02 | goedkeuring bwp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145328","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4099","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145339","dc_title":"FW: wat te doen met de MOU met de WHO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145339","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.25","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145350","dc_title":"RE: Marjolein CC email:","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145350","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145354","dc_title":"FW: Voor vragen op social over adenovirus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145354","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145359","dc_title":"RE: medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145359","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4102","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145360","dc_title":"RE: MCC geco\ufffdrdineerde factsheets & epi-beeld","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145362","dc_title":"FW: Script AZ Cecile","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145362","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145368","dc_title":"RE: medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145368","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145383","dc_title":"FW: Referentie: 4189909 / Projectnummer: EP050472 Opdrachtvoorstel: RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145383","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145384","dc_title":"RE: Gebruik van beeldmateriaal uit de pdf's over instructie klaarmaken covid19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145384","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145398","dc_title":"RE: MvT versie 19 februari - ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145398","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145400","dc_title":"RE: nagebeld over 102 jarige mevrouw","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145400","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145401","dc_title":"RE: Nieuwe versie passage COVID-19 vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145401","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145406","dc_title":"RE: Nieuwe versie passage vaccins voor voortgangsbrief + Planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145406","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145410","dc_title":"RE: niet regulieren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145410","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145412","dc_title":"RE: Nieuwe versie scenariobeschrijving - verzoek om voor 13.00 uur tereageren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145414","dc_title":"input briefing fim cecile AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145419","dc_title":"RE: nieuwsbericht vernet over verzuim in januari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145419","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145426","dc_title":"RE: ontkrachten fabels vaccin en AZ film","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145426","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145430","dc_title":"RE: SPOED: graag wel/geen akkoord PDF en duiding vaccinatiecijfers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145430","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145450","dc_title":"RE: Gevaccineerd en de website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145450","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145455","dc_title":"RE: nota MVWS wetsvoorstel testbewijs ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145455","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145474","dc_title":"RE: notitie tbv diner LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145474","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145481","dc_title":"RE: OMT adviesaanvraag 19-2 DEF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145481","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145483","dc_title":"FW: SPOED: graag voor 14:00 uur akkoord voor publicatie 'Wekelijkse update deelname COVID-19-vaccinatie Nederland'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145483","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145505","dc_title":"RE: Concept pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145505","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145508","dc_title":"RE: Ongeregistreerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145508","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145513","dc_title":"RE: Ongeregistreerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145513","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145521","dc_title":"RE: ontheffing Sanquin voor plasmageneesmiddel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145521","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145528","dc_title":"RE: Opmerking MZS op covidbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145528","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145529","dc_title":"Redactie & afstemming","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145529","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145531","dc_title":"RE: opgave meerkosten COVID-19 GGD Hollands Noorden ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145531","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.26","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145539","dc_title":"RE: opmerkingen MMZS op svz covid brief DEADLINE 14 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145539","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145547","dc_title":"FW: zeer voorlopige pdf Vaccinatiecijfers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145547","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145549","dc_title":"RE: 20210201_Vragen en antwoorden coronavirus_INBEWERKING op R-schijf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145549","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145565","dc_title":"RE: opties testen voor mantelzorgers mensen die niet gevaccineerdkunnen worden (BO 2 maart)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145565","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145568","dc_title":"Antw: 20210201_Vragen en antwoorden coronavirus_INBEWERKING op R-schijf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145568","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145570","dc_title":"RE: Opvolging gesprek MSD/VWS [Vertrouwelijk-Confidential]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145570","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145578","dc_title":"RE: Overleg Intravacc/VWS over Multi Purpose Production Plant envoortgang COVID vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145578","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145581","dc_title":"RE: Overleg over notitie microbiologische diagnostiek as. dinsdag. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145581","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145587","dc_title":"RE: relevante passages concept-TK-brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145587","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145592","dc_title":"RE: Overleg RIVM VWS GGD GHOR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145592","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145599","dc_title":"RE: Overzicht en eenduidige lijn tav verkenningen GevolgenCoronapandemie voor Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145599","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145606","dc_title":"Doorst:  Bespreekpunten en stukken regiegroep vaccinatie zorgmedewerkers 08-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145606","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145611","dc_title":"RE: Notulen werkgroep vaccinatie zorgmedewerkers ziekenhuizen en klinieken ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145611","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145616","dc_title":"SITREP inzet RIVM [24-FEB-21]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145616","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145624","dc_title":"RE: Pakket Caribisch Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145624","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145625","dc_title":"RE: ondeugdelijk transport Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145625","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145627","dc_title":"RE: Pandemic preparedness - vaccin beschikbaarheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145627","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145629","dc_title":"RE: Overzicht en eenduidige lijn tav verkenningen GevolgenCoronapandemie voor Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145629","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145632","dc_title":"RE: passage kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145636","dc_title":"RE: Passage Cariben vaccinatie paragraaf brief TK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145636","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145661","dc_title":"RE: Actie | Leveringen AZ week 7 en 8 flink lager dan gepland | Voorstel oplossingsrichting bijgevoerd om impact te beperken ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145661","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145666","dc_title":"RE: Persbericht Intravacc  opent pilot productiefabriek en startontwikkeling grote nieuwe vaccin-productiefacililiteit_LM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145666","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145668","dc_title":"210219_notitie repack covid-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145668","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145677","dc_title":"Conceptagenda overleg Movianto-LCC ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145677","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145685","dc_title":"RE: Persbericht Intravacc  opent pilot productiefabriek en startontwikkeling grote nieuwe vaccin-productiefacililiteit_LM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145685","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145690","dc_title":"RE: Doorst:  levering extra vaccins.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145690","foi_groundsOfRefusal":"5.1.1e;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145692","dc_title":"RE: persbericht Intravacc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145692","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145697","dc_title":"RE: Antw:   ServiceNow Vaccinatie Management Platform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145697","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145710","dc_title":"Re: Actie | Leveringen AZ week 7 en 8 flink lager dan gepland | Voorstel oplossingsrichting bijgevoerd om impact te beperken (moet nog wel langs -) - Kunnen jullie dit alvast checken?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145710","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145727","dc_title":"RE: Contactpersoon voorraadbeheer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145727","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145728","dc_title":"FW: Info VebaBox","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145728","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145730","dc_title":"RE: Actie | Governance Structuur Tactische Planning | Voorzet ontwerp en vervolgstappen - resourcing nodig om structuur op te zetten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145730","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145737","dc_title":"RE: SNPG - back-up plan | SPOED","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145737","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145739","dc_title":"RE: Antw: Vervolg uitnodigingen 2 prikkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145739","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145742","dc_title":"Re: Antw: procesplaat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145742","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145747","dc_title":"RE: brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145747","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4166","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145754","dc_title":"FW: Vaccinatie Beschermd Wonen en GGZ - besluitvorming ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145754","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145764","dc_title":"FW: Gesprek VWS over Asielzoekers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145764","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145767","dc_title":"RE: Concept reminderbrief 80/90+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145767","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145769","dc_title":"RE: heli vaccinatie waddeneilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145769","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145775","dc_title":"RE: Concept order 75-79","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145775","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145777","dc_title":"RE: SNPG - back-up plan | SPOED","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145777","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145779","dc_title":"Re: Medewerkers ziekenhuis 2e vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145779","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145780","dc_title":"SITREP inzet RIVM [09-FEB-21]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145780","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145784","dc_title":"overlegstructuur GGD LCC input stuurgroep","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145784","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145790","dc_title":"20210210_Vaccinatieuitnodigingen tracker.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145790","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145801","dc_title":"RE: Voorraden vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145801","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145802","dc_title":"RE: Uitnodigen voor opschaalsessie vanavond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145802","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145804","dc_title":"Informatie mbt supply planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145804","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145807","dc_title":"Doorst: Contactpersoon voorraadbeheer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145807","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145812","dc_title":"RE: impact weersvoorspelling op GGD locaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145812","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145815","dc_title":"RE: Start regio pfizer- 4000 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145815","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145816","dc_title":"FW: Vertrouwelijk - Vaccinatie Movianto | verzoek uitwerken scenarios","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145816","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145819","dc_title":"FW: aanpassing planning v 17: SPOEDVRAAG - update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145819","foi_groundsOfRefusal":"5.1.1c;5.1.2c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145836","dc_title":"RE: Plannen overleg over inzet Logius voor Covid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145836","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145837","dc_title":"RE: Plannen overleg over inzet Logius voor Covid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145837","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145847","dc_title":"RE: Aantal 75-79 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145847","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145857","dc_title":"RE: Agenda / gesprekspunten: Inkoop/logistiek/planning RIVM & GGDGHOR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145857","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145858","dc_title":"RE: 90 plus openstaande afspraak 1e vacc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145858","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145860","dc_title":"FW: overgebleven PFizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145860","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145862","dc_title":"RE: planning morgenochtend nota MVWS wetsvoorstel ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145862","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145863","dc_title":"RE: Restanten instellingen en Haps naar GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145863","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145867","dc_title":"RE: low dead space naald uitproberen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145867","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145868","dc_title":"RE: planning morgenochtend nota MVWS wetsvoorstel ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145868","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145869","dc_title":"FW: Restanten instellingen en Haps naar GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145869","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145873","dc_title":"RE: Planning stand van zakenbrief vandaag/morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145873","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145874","dc_title":"Werkwijze / proces 2de prik via GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145874","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145875","dc_title":"RE: flacon Covid vaccin Pfizer over","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145875","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145876","dc_title":"FW: nieuw voorstel tekst webpagina","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145876","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145881","dc_title":"RE: Pos. getest achteraan?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145881","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145890","dc_title":"RE: Agendapunten uitvoeringsoverleg 11 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145890","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145891","dc_title":"RE: Principenotitie toegangstesten - ACC 1 maart 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145891","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145892","dc_title":"Doorst: Vragen vaccinatieproces Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145892","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145903","dc_title":"RE: Notulen 4-2 ziekenhuizen en klinieken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145903","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145910","dc_title":"RE: 90 plus openstaande afspraak 1e vacc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145910","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145911","dc_title":"FW: PGB-zorgverleners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145911","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145912","dc_title":"werkwijze 75-89 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145912","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145913","dc_title":"RE: werkwijze en woordvoering 75+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145913","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145919","dc_title":"RE: Uitnodiging 89-jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145919","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145924","dc_title":"RE: Checklist introductie AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145924","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145926","dc_title":"RE: wegprikken Pfizer ter voorkoming van spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145926","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145927","dc_title":"RE: Input AZ voor draaiboek GGD'en","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145927","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145929","dc_title":"RE: notitie LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145929","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145932","dc_title":"RE: Project WO-Covid19: Stappen voorwaarts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145933","dc_title":"RE: Notulen werkgroep vaccinatie zorgmedewerkers ziekenhuizen en klinieken ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145933","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145935","dc_title":"RE: Checklist introductie AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145947","dc_title":"RE: DPC ticket EM1704845 :Reactie hr. Goossens met extra informatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145947","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145969","dc_title":"RE: PvA en voortgang forensisch onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145969","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145973","dc_title":"RE: Weekupdate vaccinatie 190221","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145973","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145978","dc_title":"RE: akkoord allocatie versnelde traject zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145978","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145979","dc_title":"RE: Profielomschrijving v3 (002)_NH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145979","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145986","dc_title":"RE: Vragen over uitnodiging thuiswonende ouderen door de GGD ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145986","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145991","dc_title":"RE: QA ouderen die niet naar de prikstraat willen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145996","dc_title":"RE: QenA AP over werkgevers. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1145996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1145997","dc_title":"FW: 1102021_Notitie_2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1145997","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146003","dc_title":"RE: QenA AP over werkgevers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146003","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146004","dc_title":"FW: Verzoek afspraak met de heer Gerritsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146004","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146006","dc_title":"RE: Digitaal uitnodigingsproces/boekingsproces bij 1.5m vaccinaties per week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146006","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146018","dc_title":"RE: Uitnodigingsscenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146018","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146023","dc_title":"RE: Reactie op uw mail","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146023","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146031","dc_title":"FW: Opschaling - vraag voor GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146031","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146033","dc_title":"RE: Registratie vaccinatie werkgever-werknemer A4 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146033","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146042","dc_title":"RE: - advies vaccinatiestelsel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1146042","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146044","dc_title":"FW: Visie 2.5m opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146044","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146047","dc_title":"FW: Zinder introductie n.a.v. uw Linkedin bericht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146047","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146051","dc_title":"RE: Scenario's Corona 2021 d.d. 25.02.2021 DEF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146053","dc_title":"RE: Opschaalscenario","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146053","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146055","dc_title":"01122020-RT-teamCOVIDveehouderij, luchtkwaliteit en COVID.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146055","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146073","dc_title":"RE: Schets mogelijkheden corona-antistoftesten in relatie totvaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146073","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146075","dc_title":"RE: Scenario's Covid-19 in 2021 - reacties voor +/- 22.30 uur kan ikvandaag nog verwerken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146075","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146077","dc_title":"RE: Schriftelijke ronde overleg - 24 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146077","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146083","dc_title":"RE: SENSITIVE - please register - meeting with GSK- presenting amonoclonal antibody in development ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146083","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146085","dc_title":"RE: SENSITIVE - please register - meeting with GSK- presenting amonoclonal antibody in development ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146085","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146092","dc_title":"RE: sequencing RE: UITVRAAG KAMERBRIEF [DEADLINE WOENSDAG 12:00]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146092","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146102","dc_title":"RE: situatie Oost-Gelderland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146102","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146109","dc_title":"Veegactie-vraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146109","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146112","dc_title":"RE: sites van Rijksoverheid in verschillende talen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146112","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146114","dc_title":"RE: Voorlopige overzicht Vaccins / flacon verdeling / data 2e ronde d.d. 11 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146114","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146116","dc_title":"RE: SO vragen RAZ -- DEADLINE vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146116","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146120","dc_title":"RE: GGD/RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146120","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146125","dc_title":"RE: signaal vanuit ZIekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146125","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146130","dc_title":"RE: SPOED graag akkoord: advies door AP nodig. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146130","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146137","dc_title":"RE: SPOED graag akkoord: advies door AP nodig. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146137","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146138","dc_title":"RE: Vaccinaties ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146138","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146145","dc_title":"Antw: Filmpjes AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146151","dc_title":"RE: Vraag website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146151","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146159","dc_title":"RE: Gevaccineerd en de website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146159","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146180","dc_title":"RE: Q&A's over beschermingsmiddelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146180","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146183","dc_title":"Voorkeuren van Nederlanders voor vaccinatiebeleid ...FW: Uitnodiging EPI masterclass donderdag 18 februari 12.30-13.30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146183","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146184","dc_title":"RE: input kosten vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146184","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146192","dc_title":"RE: reactieve Q&A Astra Zeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146198","dc_title":"FW: Voorbeeld mail, excel en werkinstructies HAP Moderna/ Pfizer traject- Vaccin Makelaar","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1146198","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146201","dc_title":"RE: Uitnodigen zorgmedewerkers gehandicaptenzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146201","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146202","dc_title":"FW: goedkeuringen minister","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146202","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146205","dc_title":"FW: Medisch onderliggende vaccinatie Longziekten?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146205","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146216","dc_title":"RE: Aanpassen Q&A veel gestelde vragen zorgmedewerkers buiten het ziekenhuis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146216","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146233","dc_title":"RE: deoelgroepomschrijving 1e groep zorgmedewerkers op rijksoverheid syncen met werkwijze?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146233","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146234","dc_title":"uitzetting vreemdelingen in relatie tot vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146240","dc_title":"FW: draaiboek vaccinatie en angedanpunt voor as. dinsdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146240","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146241","dc_title":"FW: Input AZ voor draaiboek GGD'en","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146241","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146256","dc_title":"RE: Tussenstand Covid-vials Roermond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146256","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146267","dc_title":"FW: Input AZ voor draaiboek GGD'en","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146267","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146269","dc_title":"RE: Aanpassen volgorde zorgmedewerkers op website coronavaccinatie.nl ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146269","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146286","dc_title":"Re: Pfizer overdracht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146286","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146292","dc_title":"RE: Uitvraag vaccinatie klinische MSR-patienten RIVM.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146292","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146294","dc_title":"RE: Bevestiging levering BioNTech/ PFizer voor Maastricht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146294","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146295","dc_title":"RE: HAPs Pfizer over?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146295","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146300","dc_title":"RE: spoedoverleg  AP-RIVM-OCW-VWS-GGDGHOR over BCO rondom scholen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146300","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146303","dc_title":"RE: SPOED: welke landen hebben 1-prik vaccinatieschema?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146303","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146313","dc_title":"RE: Levering Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146313","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146316","dc_title":"RE: Levering Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146316","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146319","dc_title":"RE: Levering Pfizer vaccins MAASTRICHT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146319","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146321","dc_title":"RE: Levering Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146321","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146322","dc_title":"RE: Levering Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1146322","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146326","dc_title":"RE: PFIZER PRIMACURA-RE: aantallen Pfizer en bestellen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146326","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146331","dc_title":"Re: Levering Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146343","dc_title":"FW: Levering PFizer voor HAPS vaccinatie teams","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146343","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146349","dc_title":"RE: Status Nanogam-COVig","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146349","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146351","dc_title":"FW: PFIZER- Benodigd aantal Medicamus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146351","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146352","dc_title":"FW: Levering Pfizer vaccins MUMC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146352","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146356","dc_title":"RE: Statement URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146356","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146363","dc_title":"RE: Statement","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146363","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146366","dc_title":"FW: Nieuwsbericht en werkinstructie vaccinatie bewoners HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146366","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146369","dc_title":"RE: Powerpoint presentatie vervolgsessie, exceloverzicht aanleveren aantallen en communicatiebericht toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146369","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146370","dc_title":"RE: Steunpakket welzijn en leefstijl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146370","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146375","dc_title":"FW: Pfizer vaccins voor distributie via HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146375","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146377","dc_title":"RE: Powerpoint presentatie vervolgsessie, exceloverzicht aanleveren aantallen en communicatiebericht toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146377","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146378","dc_title":"Re: HAP ALMERE- PFIZER bijstelling aantal vaccins en leveringsadres HAP Almere","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146378","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146383","dc_title":"RE: Stroomschema verwijderingsverzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146383","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146386","dc_title":"RE: Vervolg BioNTech/Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146387","dc_title":"RE: Stroomschema verwijderingsverzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146387","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146400","dc_title":"RE: TER INFO: Tussenstand HAPs die gaan voor Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146400","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146420","dc_title":"RE: Suicide en huiselijk geweld","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146420","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146423","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx | versnelling vaccinatie bewoners zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146423","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146427","dc_title":"RE: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146428","dc_title":"FW: OPROEP: in aanmerking komen voor BionTechPfizervaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146428","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146430","dc_title":"FW: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146430","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146432","dc_title":"FW: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146432","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146438","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx | versnelling vaccinatie bewoners zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146438","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146440","dc_title":"No Subject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146440","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146443","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx | versnelling vaccinatie bewoners zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146443","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146444","dc_title":"RE: GRAAG REACTIE vaccineren door prikteam instellingen ipv mobiele team HAP en bestelpercentage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146444","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146453","dc_title":"RE: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146453","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146462","dc_title":"RE: tekort aan optrek naalden voor de ect, door beleid vws","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146462","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146463","dc_title":"FW: beoordeling VTGM instructie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146463","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146477","dc_title":"RE: Suicide en huiselijk geweld","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146477","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146481","dc_title":"RE: tekst inkoop griepvaccins tbv Voortgangsbrief COVID-19 dd 23/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146481","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146495","dc_title":"RE: aanpassing planning v 17","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146495","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146496","dc_title":"RE: aanpassing planning v 17","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146496","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146506","dc_title":"RE: teksten voor de beschikking","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146506","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146518","dc_title":"RE: Covid Gezondheidseconomie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146525","dc_title":"RE: Conceptrapportage VAN CORONACRISIS NAAR BEWEEGCRISIS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146525","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146534","dc_title":"thema E-health in Covid-onderzoeksprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146534","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146539","dc_title":"RE: Gezondheidseffecten en kosten van uitgestelde zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146539","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146540","dc_title":"RE: Uitnodiging EPI masterclass donderdag 18 februari 12.30-13.30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146540","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146541","dc_title":"RE: Uitnodiging EPI masterclass donderdag 18 februari 12.30-13.30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146541","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146545","dc_title":"RE: Ter voorbereiding op: Overleg inzet PG covid vaccinatie (ma 1maart 9.00u)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146545","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146548","dc_title":"RE: Conceptrapportage VAN CORONACRISIS NAAR BEWEEGCRISIS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146548","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146557","dc_title":"RE: Terugkoppeling G4 overleg MO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146557","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146564","dc_title":"RE: terugkoppeling op hoofdlijnen van het overleg met het BT JGZ 16februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146564","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146567","dc_title":"FW: Vervolg uitnodigingen 2 prikkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146567","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146569","dc_title":"RE: Terugkoppeling overleg MVWS CoronaCheck","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1146569","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146577","dc_title":"RE: Terugkoppeling Werkgroep veiligheidsbewaking COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146577","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146600","dc_title":"RE: Controleren aanmeldingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146600","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146611","dc_title":"Verslag Overleg uitwerking AZ HA | do 4-2-2021 | 15.00-16.00 uur + dynamische actielijst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146611","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146623","dc_title":"RE: Testen en vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146623","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146628","dc_title":"RE: Testen en vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146628","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146632","dc_title":"RE: Testen en vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146636","dc_title":"FW: Standaarden uitnodigingen + verwijzingen voor bijlagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146636","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146648","dc_title":"RE: transport 1-2 Comirnaty flacons Tjongerschans/MCL -> GGD Fryslan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146648","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146658","dc_title":"RE: overgebleven flacons Pfizer covid vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146658","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146692","dc_title":"RE: Tweewekelijks overleg testen LHV/GGD GHOR/VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146692","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146700","dc_title":"RE: Concept Nieuwsbrief Volksgezondheid en Zorg | februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146700","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146701","dc_title":"RE: aantekeningen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146701","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146722","dc_title":"RE: Uitbreiden lijst uitgezonderde contactberoepen: graag zsm reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146722","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146730","dc_title":"RE: Gesprek gister ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146730","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146744","dc_title":"RE: uitbreiding opdracht GGD ivm opschaling kwartaal twee","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146744","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146752","dc_title":"RE: Uitnodiging overleg publieke microbiologische diagnostiek 23februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146752","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146804","dc_title":"RE: 2de COVID-Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146804","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146805","dc_title":"RE: UITVRAAG KAMERBRIEF [DEADLINE WOENSDAG 12:00]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1146805","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146809","dc_title":"RE: uitnodiging door gemeente sudwest-fryslan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146809","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146853","dc_title":"RE: Vragen over de uitnodigingsbrief ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146867","dc_title":"RE: [vragen vanuit OCW]: Pilots coronasneltesten in het ho/mbo","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146867","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146869","dc_title":"RE: Uitzoekpunt cijfers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146869","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146877","dc_title":"RE: onvoldoende hulpmiddelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146877","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146882","dc_title":"verbeterpunten ggd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146882","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146887","dc_title":"RE: Update antilichaamtherapie COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146887","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146896","dc_title":"FW: wegprikken Pfizer ter voorkoming van spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146896","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146897","dc_title":"FW: wegprikken Pfizer ter voorkoming van spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146903","dc_title":"RE: toch al vaccinatie wmo medewerkers? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146903","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146914","dc_title":"RE: Vragen AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146914","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146923","dc_title":"FW: Definitieve versie PDF en nieuwsbericht vaccinatiegraad. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146923","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146933","dc_title":"RE: concept gesprekshandleiding focusgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146933","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146935","dc_title":"RE: Scenario's vaccinatie en maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146939","dc_title":"RE: Vaccinatie audiciens / overige zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146939","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146941","dc_title":"RE: Vaccinatie / RIVM\t","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146941","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146945","dc_title":"RE: RIVM-ers die met scenarios tijdlijnen COVID bezig zijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146948","dc_title":"Doorst:  RIVM-ers die met scenarios tijdlijnen COVID bezig zijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146948","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146949","dc_title":"RE: RIVM-ers die met scenarios tijdlijnen COVID bezig zijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146949","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146950","dc_title":"FW: Vaccin nodig?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146950","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146959","dc_title":"RE: Vaccinatie Beschermd Wonen en GGZ - besluitvorming ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146959","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146972","dc_title":"FW: communicatie Astra Zeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146972","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146974","dc_title":"RE: aangepaste wvlijn ompakken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146974","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146976","dc_title":"RE: Vaccinatie ongeregistreerden Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146976","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146977","dc_title":"RE: Marjolein CC email:","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146977","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146987","dc_title":"RE: Vaccinatie pagina | Presentatie stappenplan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146987","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1146988","dc_title":"RE: Nieuwsbericht 24-2-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1146988","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147001","dc_title":"Doorst:  Ter info: griepachtige klachten na AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147001","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147011","dc_title":"RE: Vaccins EU en NL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147011","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147016","dc_title":"RE: vaccinverlies travel clinics","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147016","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147022","dc_title":"RE: vaccinverlies travel clinics","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147022","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147027","dc_title":"RE: veiligheid ondersteunend personeel ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147030","dc_title":"RE: Berichtgeving AZ 60+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147030","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147033","dc_title":"RE: Veiligheidsberaad maandag a.s.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147033","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147038","dc_title":"RE: Verdeling 200 miljoen flankerend beleid voor ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147038","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147041","dc_title":"RE: Verdeling 200 miljoen flankerend beleid voor ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147041","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147057","dc_title":"RE: Convenant Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147057","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147061","dc_title":"RE: opdrachtbrief 9/2/21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147061","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147068","dc_title":"RE: concept gesprekshandleiding focusgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147068","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147069","dc_title":"RE: Ondersteuning  door apothekers van Corona-vaccinatiecampagne doorhuisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147069","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147090","dc_title":"FW: Brede blik sessie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147090","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147101","dc_title":"RE: Antw: Terugkoppeling gesprek VWS opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147101","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147107","dc_title":"RE: Doorst: opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147107","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4395","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147110","dc_title":"RE: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147110","foi_groundsOfRefusal":"5.1.2d;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147117","dc_title":"RE: Versie 0.4 afwegingskader","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147117","foi_groundsOfRefusal":"5.1.2d;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147123","dc_title":"RE: verklaring avondklok - psychische gesteldheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147123","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147130","dc_title":"RE: 1102021_Notitie_2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147130","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147144","dc_title":"RE: Versie 3 stand van zakenbrief COVID-19 | voorleggen aan BR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147144","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147147","dc_title":"RE: Versie 4 stand van zakenbrief COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147147","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147149","dc_title":"RE: Versie 4 stand van zakenbrief COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147149","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147150","dc_title":"RE: Programmabureau RIVM en GGD in crime","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147150","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147155","dc_title":"RE: laatste opmerkingen op presentatie ter voorbereiding op sessie vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147155","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147173","dc_title":"RE: Verslag en concept verslag DOTT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147183","dc_title":"RE: versnelling opnemen vaccinatiegegevens en vaccinatiepaspoort inPGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147183","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147194","dc_title":"RE: Planning Friese Wadden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147194","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147205","dc_title":"RE: Registratie vaccinatie werkgever-werknemer A4 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147205","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147213","dc_title":"RE: vervoer naar vaccinatielocaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147213","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147227","dc_title":"RE: Verwacht einde vaccinatie in zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147227","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147234","dc_title":"Overdracht uitzonderingssituaties vanuit programmabureau","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147246","dc_title":"RE: Verzoek aanvulling ppt DO-R en BWO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147246","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147264","dc_title":"RE: Verzoek Henri: mail BZK over CoronaCheck","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147264","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147275","dc_title":"RE: Convenant Saba","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147275","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147279","dc_title":"RE: Verzoek Minister","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147279","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147291","dc_title":"RE: Verzoek Minister","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147291","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147299","dc_title":"RE: Gepersonaliseerde data voor BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147306","dc_title":"RE: verzoek om akkoord en of aanvullingen op annotatie BO met VNO NCWas maandag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147306","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147311","dc_title":"RE: Verzoek om passage voor Covid-brief 23/02 (svp voormaandagochtend)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147311","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147319","dc_title":"Spillageprotocollen clienten instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147319","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147324","dc_title":"RE: Planning Friese Wadden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1147324","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147331","dc_title":"FW: Concept reminderbrief 80/90+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147342","dc_title":"Wadden vervolg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147342","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147353","dc_title":"RE: Donderdag 25 ipv maandag 22","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147353","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147362","dc_title":"RE: Voorbereiding debat  wat betreft Reactie op motie SP over stoppenprivatisering Intravacc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147362","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147372","dc_title":"FW: Uitvraagformulier vaccinatie PAAZ/PUK medewerkers en UCP pati\ufffdnten in umc's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147372","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147374","dc_title":"RE: [vragen vanuit OCW]: Pilots coronasneltesten in het ho/mbo","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147374","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147382","dc_title":"RE: Voorbereiding overleg VWS-VIG 18 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147382","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147389","dc_title":"RE: Short stay regeling Curacao","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147389","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147393","dc_title":"RE: Voorstel Bonaire voor quarantainewet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147393","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147394","dc_title":"RE: Vervoer priklocatie (rodekruis) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147394","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147407","dc_title":"FW: concept uitnodigingsbrief Waddeneilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147407","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147409","dc_title":"RE: Convenant CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147409","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147411","dc_title":"FW: RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147411","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147413","dc_title":"RE: Convenant CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147413","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147416","dc_title":"RE: Convenant Saba","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147426","dc_title":"FW: Contact mbt vragen registratie CAS + populatie BES en waarborgen anonimiteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147426","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147432","dc_title":"RE: Convenant Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147432","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147443","dc_title":"RE: Voorstel quarantaineplicht en afstemming departementen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1147443","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147449","dc_title":"RE: BES / CAS karakteristieken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147449","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147450","dc_title":"Update registratie BES/CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147450","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147461","dc_title":"RE: Voorstel quarantaineplicht en afstemming departementen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147461","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147462","dc_title":"RE: Contactgegevens Nicole","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":4,"v2":4},"foi_fileName":"VWS-WOO-17-1147462","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147463","dc_title":"RE: Voorstel quarantaineplicht en afstemming departementen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1147463","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147464","dc_title":"RE: Antwoorden op vragen Nicole","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147464","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147484","dc_title":"FW: Doorst: opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147498","dc_title":"FW: Visie 2.5m opschaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1147498","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147503","dc_title":"FW: scenarios","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147503","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147507","dc_title":"FW: Strategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147507","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147508","dc_title":"FW: Vaccineren groepen met sterk verhoogd risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147508","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147525","dc_title":"RE: Motie Veldman en uitwerking 2-2,5 mln scenario","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147525","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147528","dc_title":"RE: afspraken uitwerking bijzondere groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147528","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147536","dc_title":"RE: Telco Ernst Kuipers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147536","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147550","dc_title":"RE: Vraag 23 D66 over testbewijs - akkoord?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147550","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147555","dc_title":"RE: Contactgegevens Nicole","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147555","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147558","dc_title":"RE: Vraag Britse ambassade over vaccineren lokaal personeel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147558","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147568","dc_title":"RE: Doorst:  Antw: Update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147568","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147569","dc_title":"RE: Vraag Britse ambassade over vaccineren lokaal personeel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147569","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147580","dc_title":"Re: Vraag tweede vaccinatie bij ziekte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147580","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147584","dc_title":"RE: Vraag Gezondheidsraad vaccinatiebeleid in Versie 4 stand vanzakenbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147584","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147592","dc_title":"FW: FAQs medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147599","dc_title":"RE: Te beoordelen Openstaande inkoopverplichtingen en openstaandevoorschotten artikel 2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147599","foi_groundsOfRefusal":"5.1.2b;5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147619","dc_title":"RE: Bijgesteld protocol COVID-19 Testen van Vliegend Personeel KLM ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147619","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147628","dc_title":"RE: Uitzondering op sneltest voor een vlucht van Itali\ufffd naar Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147628","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147633","dc_title":"Re: adres registratiekaarten Covid-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147633","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147634","dc_title":"Re: Vragen die worden gesteld bij controleren gegevens en doorgeven inlogcode","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147634","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147640","dc_title":"RE: Antw:  Waddeneilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147640","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147652","dc_title":"RE: Update coronavirus - 108","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147652","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147656","dc_title":"FW: Overleg BES/CAS registratie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147656","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147667","dc_title":"RE: vragen over leverschema kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147667","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147674","dc_title":"RE: DVP recall procedure","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147674","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147675","dc_title":"RE: wat te doen met de MOU met de WHO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147675","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147683","dc_title":"Re: VWS en contact","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147683","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147700","dc_title":"RE: wetsvoorstel testbewijs in tas MVWS ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147700","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147706","dc_title":"Vaccin niet nodig","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147706","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147710","dc_title":"RE: Wetsvoorstel Testbewijzen MBO/HO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147710","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147712","dc_title":"RE: Wetsvoorstel Testbewijzen MBO/HO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147712","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147721","dc_title":"FW: nieuwsbericht: Eerste effecten vaccinatie zichtbaar onder bewoners verpleeghuizen en zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147721","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147730","dc_title":"RE: Wetsvoorstel Testbewijzen MBO/HO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147730","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147733","dc_title":"RE: Wetsvoorstel Testbewijzen MBO/HO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147733","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147738","dc_title":"RE: Wil je meedenken met Kamervragen scorekaart Farma terVerantwoording","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147738","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147744","dc_title":"RE: 1 miljoen mensen niet vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147744","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147747","dc_title":"Logistiek en Mexicaanse griep","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147747","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147748","dc_title":"RE: zelfstandige gezinshuize / vaccinatietraject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147748","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147767","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1147767","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147769","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147769","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147770","dc_title":"RE: Vraag Nursing-artikel AstraZeneca ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147770","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147771","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147771","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147773","dc_title":"RE: Vaccinatie communicatie Update -3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147773","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147774","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147774","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147775","dc_title":"RE: ZonMw COVID-19 deelprogramma herstel- en nazorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147775","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147779","dc_title":"RE: ZN-regeling corona MSZ 2021 - inhaalzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147779","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147787","dc_title":"RE: Zorg voor de Jeugd en corona: agenda overleg 18 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147787","foi_groundsOfRefusal":"5.1.1d;5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147797","dc_title":"RE: [21-__5b]  Waarschuwing door PSI ivm vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147797","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147803","dc_title":"RE: [ACTIE] Uitzetmail COVID deel VTC ER 25 februari - deadlinedonderdag 18/2 12:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147803","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147810","dc_title":"RE: Bevestiging levering BioNTech/ PFizer voor Primacura","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147810","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147811","dc_title":"RE: Tussenstand Covid-vials Roermond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1147811","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147825","dc_title":"FW: MODERNA Gegevens Dokterszorg Friesland Moderna Vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147825","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147826","dc_title":"RE: overzicht aantallen 088 nummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147826","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147828","dc_title":"Antw: vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147828","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147829","dc_title":"RE: Nieuwsberichten en werkinstructies: vaccinatie bewoners door HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147829","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147834","dc_title":"RE: Inzet 1ste en 2de lijn beantwoording van vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147834","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147844","dc_title":"RE: nieuw voorstel uitvraag call center","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147844","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147847","dc_title":"RE: [Scenario's] Aanpassingen + marsroute: graag spoedig jouw reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147847","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147848","dc_title":"RE: vaccinatiebereidheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147848","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147858","dc_title":"RE: analyse ook voor RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147858","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147879","dc_title":"registraties Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147885","dc_title":"RE: Bevestiging levering BioNTech/ PFizer voor Oost- Brabant ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147885","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147889","dc_title":"RE: Levering Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147889","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147891","dc_title":"RE: Temperatuur ingevroren Pfizer vaccin 19-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147891","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4513","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147895","dc_title":"nog de terugkoppeling van besluit minister over vaccins en onderzoek ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147895","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147900","dc_title":"Bevestiging levering BioNTech/ PFizer voor Medicamus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147900","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147901","dc_title":"RE: kamervraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147901","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147905","dc_title":"RE: Bevestiging levering BioNTech/ PFizer voor Primacura","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147905","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147908","dc_title":"RE: Uitnodiging EPI masterclass donderdag 18 februari 12.30-13.30","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147908","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147911","dc_title":"RE: HAP MEDRIE RE: Selectie Moderna week 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147911","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147914","dc_title":"FW: HAP MEDRIE RE: Selectie Moderna week 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147914","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147917","dc_title":"RE: Conceptrapportage VAN CORONACRISIS NAAR BEWEEGCRISIS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147930","dc_title":"RRF fiche leefstijltransitie 2.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147930","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147933","dc_title":"RE: Conceptrapportage VAN CORONACRISIS NAAR BEWEEGCRISIS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147933","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147936","dc_title":"RE: Hoe IT inrichten t.b.v  doelgroep asielzoekers en dak-en thuislozen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147936","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147947","dc_title":"RE: Opzet HAP Moderna/BF - UPDATE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147947","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147948","dc_title":"RE: Opzet HAP Moderna/BF","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147948","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147949","dc_title":"FW: Opdrachtbrief en toelichting vaccinatieprogramma tbv onderbouwingvpl in K+V administratie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147949","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147960","dc_title":"Scenario's 14/02 (basis, positief, negatief)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147960","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147973","dc_title":"LEZEN / BERICHT - / FW: toezegging scenario's ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147973","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147985","dc_title":"FW: toezegging scenario's ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147985","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1147986","dc_title":"RE: RIVM Persupdate van maandag 22 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1147986","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148030","dc_title":"RE: URGENT graag akkoord van RIVM op spreeklijn AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148030","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148038","dc_title":"FW: Vaccineren groepen met sterk verhoogd risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148038","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148048","dc_title":"FW: reactie op uw aanmelding vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148048","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148055","dc_title":"uitnodigingspakket vaccinatie Covid-19 wijkverpleging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148055","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148084","dc_title":"Stand van zaken vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148084","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148087","dc_title":"RE: Vaccinatie Beschermd Wonen en GGZ - besluitvorming ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148087","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148088","dc_title":"RE: URGENT: SARS-CoV2 en vaccinatie: De Noord-Braziliaanse variantgaat de Britse variant verdringen: Noodzaak voor aangepastevaccinatiestrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148089","dc_title":"FW: vraag hepatitis B","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148089","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148103","dc_title":"RE: begeleidende brief voor werkgevers Texel??","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148103","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148105","dc_title":"RE: Vaccinatie van uitzonderingsgroepen via de GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148105","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148112","dc_title":"RE: URGENT: SARS-CoV2 en vaccinatie: De Noord-Braziliaanse variantgaat de Britse variant verdringen: Noodzaak voor aangepastevaccinatiestrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148112","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148128","dc_title":"Re: Vaccinatie Covid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148128","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148138","dc_title":"RE: Telling - en HL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148138","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148141","dc_title":"RE: vaccinatieruimte huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148141","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148153","dc_title":"FW: GGZ uitnodigingsbrief zorgmedewerkers en bewoners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1148153","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148154","dc_title":"RE: instelling De Skuul Texel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148154","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148166","dc_title":"RE: Extra aantallen DJI/ JCvSZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148166","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148167","dc_title":"FW: meest recente versie gezondheidsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148167","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148173","dc_title":"stukken ter voorbereiding op sessie opschaling vaccinaties 16februari om 14.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148175","dc_title":"2 uitnodigingsbrieven en  flyer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148175","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148177","dc_title":"LIJST GGZ concept","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148196","dc_title":"uitzondering meenemen gesprek Laura","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148196","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148201","dc_title":"RE: Vraag Britse ambassade over vaccineren lokaal personeel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148201","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148206","dc_title":"RE: Vraag FIN over realisatiecijfers vaccineren ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148206","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148214","dc_title":"RE: mobiele vaccinatiebus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148214","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148221","dc_title":"scope en overzicht instellingen SNPG account","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148221","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148224","dc_title":"FW: Email t.b.v. informeren ziekenhuisbestuur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148224","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148227","dc_title":"RE: Vaccinatiebewijs - juridische grondslagen voor data ontsluiting scenarios vanuit het RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148227","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148237","dc_title":"FW: verslag + formats uitnodigingsbrieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148237","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148244","dc_title":"RE: Concept: risicoacceptatieformulier CIMS Rapportageomgeving","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148244","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148256","dc_title":"RE: Nieuwe versie High level design anonieme aanlevering BI-CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148256","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148261","dc_title":"RE: Aanlevering excel voor aanvullen vaccinatiestatus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148267","dc_title":"RE: PSA BI-CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148267","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148279","dc_title":"FW: [ PSEUDONIMISERINGSOPLOSSING CIMS] ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148279","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148282","dc_title":"RE: Samenvatting gesprek Diana- DPIA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148282","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148285","dc_title":"FW: Tekst stavaza brief 23 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148285","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148301","dc_title":"Re: Onze BPEL en AD meeting van as vrijdag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148301","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148303","dc_title":"RE: Written Procedure: Amendment of SPD 2021 and Supplementary andAmending Budget 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148303","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148306","dc_title":"RE: Samenvatting gesprek Diana","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148306","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148310","dc_title":"Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)maandag 22 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148310","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148313","dc_title":"Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)donderdag 25 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148313","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148329","dc_title":"Terugkoppeling communicatie overleg / dagstart kernoverleg (NKC)woensdag 24 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148329","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148331","dc_title":"terugkoppeling corona-overleg pgb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148332","dc_title":"RE: Antw:  Vaccinatie in relatie tot verwachte weersomstandigheden.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148332","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148335","dc_title":"Terugkoppeling woordvoerdersoverleg 1 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148335","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148351","dc_title":"informatiepakket tbv vaccinatie van uw zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148351","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148358","dc_title":"RE: Callcenter","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148358","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148364","dc_title":"RE: Benodigde Capaciteit Callcenter","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148364","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148378","dc_title":"FW: Agendapunt bespreking VWS - OneMed ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148378","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148381","dc_title":"Doorst:  Vervolg op BI CIMS - data/rapportageverzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148381","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148387","dc_title":"Even apart een update dashboards","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148387","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148389","dc_title":"Doorst:  voorstel datakwaliteit dashboard werkgroep verdere uitwerken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148389","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148390","dc_title":"FW: LAREB gegevensuitwisseling wettelijke grondslag ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148390","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148395","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148395","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148403","dc_title":"s.v.z. vaccinatiebewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148403","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148412","dc_title":"FW: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148416","dc_title":"RE: urgent!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148416","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148428","dc_title":"RE: [Wg vaccineren/testen/maatregelen] Scenariobeschrijvingen -->reactiemogelijkheid: vrijdag 26/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148428","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148432","dc_title":"FW: gecombineerde werkgroep test- en vaccinatiebewijzen vrijdag 19 feb 12-13h","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148432","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148435","dc_title":"interdepartementale werkgroep vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148435","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148436","dc_title":"Vaccinatiebewijs | Requierement vanuit eHealth (Europees niveau)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148436","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148449","dc_title":"RE: Memo - vaccinatie'bewijs'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148449","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148468","dc_title":"FW: inschatting vaccinatiebewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148468","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148470","dc_title":"FW: Advies 17 Vaccinatie- en/of Testbewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148470","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148472","dc_title":"FW: Inschatting realisatiegrootte RIVM scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1148472","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148474","dc_title":"RE: Doorst:  Samenvatting gesprek Diana","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148474","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148484","dc_title":"RE: Afweging pseudonimiseringsmethodes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148492","dc_title":"FW: INFO: Duitse besluitvorming vaccinatiecertificaten ihkv gecombineerde werkgroep test- en vaccinatiebewijzen morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148492","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148493","dc_title":"interdepartementale werkgroep vandaag ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148493","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148495","dc_title":"RE: Vaccinatiebewijs | Eerste analyse technische uitwerking (op hoofdlijnen)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148495","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148501","dc_title":"Korte tussentijdse update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148501","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148503","dc_title":"FW: dagafronding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148503","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148505","dc_title":"RE: Bottom-up scenario's - RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148505","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148508","dc_title":"RE: Verzoek afspraak met de heer Gerritsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148508","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148515","dc_title":"FW: Certificate for recovered persons COVID-19 for comments","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148515","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148528","dc_title":"RE: betrouwbaarheidsniveau vaccinatiebewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148528","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148532","dc_title":"Vaccinatie ongeregistreerden CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148532","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148537","dc_title":"RE: Brondocument ter check en akkoord!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148537","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148543","dc_title":"RE: Notities - Workshop vaccinatiebewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148543","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148548","dc_title":"RE: Vaccinatiebewijs - Punten waar snel antwoord op moet komen voor technische ontwikkeling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148548","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148555","dc_title":"RE: Hoog-over inschatting P&IM risico's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148555","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148556","dc_title":"RE: ZKH - opschaling naar 2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148556","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148567","dc_title":"RE: [ PROCES SELECTEREN EN OPROEPEN] RE: Aanvullende eisen RIVM bij  verwerkersovereenkomst getekend 502599-003. [Advies over aan Xerox te stellen eisen in verband met verwerken oproepbrieven COVID-19]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148567","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148569","dc_title":"RE: Datakoppeling tentatief scenario vanuit CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148569","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148570","dc_title":"RE: Aanvullende eisen RIVM bij  verwerkersovereenkomst getekend 502599-003. [Advies over aan Xerox te stellen eisen in verband met verwerken oproepbrieven COVID-19]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148570","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148571","dc_title":"RE: 200217_Concept notitie_RIVM kan niet de uitgevende instantie van het vaccinatie bewijs zijn","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148571","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148576","dc_title":"20210210_Vaccinatieuitnodigingen tracker.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148576","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148582","dc_title":"Stavaza - ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148582","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148605","dc_title":"RE: [brba] controle op vaccinatieregistratie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148605","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148610","dc_title":"RE: Bevestiging levering BioNTech/ PFizer voor HKN","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148610","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148614","dc_title":"Programmadashboard parameters","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148614","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148623","dc_title":"RE: Covid Gezondheidseconomie **update 19 december**","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148623","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148650","dc_title":"RE: Covid-19 onderzoeksprogramma thema 16 - projectplannen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148650","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.294","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148659","dc_title":"RE: rollen beheer BI CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148659","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148664","dc_title":"RE: input kosten vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148664","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148670","dc_title":"RE: Alternatieve vaccinatiestrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148670","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148673","dc_title":"FW: Aanpassing Subsidieregeling Publieke Gezondheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148673","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148678","dc_title":"RE: HA traject, drie besluiten rond besteldata en leverdata planning provincies","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148679","dc_title":"RE: Alternatieve vaccinatiestrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148679","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148685","dc_title":"RE: HIS planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148685","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148691","dc_title":"FW: AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148691","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148696","dc_title":"RE: Besluit livegang Rapportage Tooling ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148696","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148698","dc_title":"RE: Dashboardoverleg op 29 jan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148698","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148702","dc_title":"FW: uitzondering 2de prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148702","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148711","dc_title":"RE: restjes van Astra vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148711","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148715","dc_title":"FW: Overzicht GGZ, vervolgplanning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148715","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148733","dc_title":"FW: Overzicht GGZ & Moderna, wat verwacht Nils","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148733","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148738","dc_title":"Voor 17 uur aanleveren RE: Stukje voor preventiestaf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148738","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148739","dc_title":"Antw:  Temperatuur ingevroren Pfizer vaccin 19-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148739","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148750","dc_title":"RE: Temperatuur ingevroren Pfizer vaccin 19-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148750","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148761","dc_title":"RE: brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148761","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148762","dc_title":"RE: afleverdatum GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148762","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148772","dc_title":"RE: nieuwe medewerkers in iDoc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148772","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148779","dc_title":"Antw: nieuwsbericht over vervoer juist?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1148779","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148780","dc_title":"RE: Koude keten meldingen COVID-19 door huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148780","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148784","dc_title":"FW: aanpassen richtlijn vervoer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148784","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148785","dc_title":"RE: Goed vaccinbeheer v3_concept *please review*","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148785","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148786","dc_title":"RE: transport instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148786","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148814","dc_title":"RE: Medisch Centrum Twente","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148814","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148817","dc_title":"FW: Batchreview","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148817","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148841","dc_title":"RE: Aanleveren vaccinaties vanuit HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148841","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148846","dc_title":"Re: Escalatie vanuit werkgroep HIS-leveranciers d.d. 10/2/21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148854","dc_title":"Re: Update vaccinatiestrategie COVID - inzet AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148854","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148855","dc_title":"Vraag voor uitwerking van specificaties COVID-19 vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148855","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148857","dc_title":"FW: Infomatievoorziening vanuit de huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148857","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148872","dc_title":"RE: Verzoek doorrekening extra doses Pfizer - instellingen - graag input om 14.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148872","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148874","dc_title":"RE: Extra Moderna voor Twente komende vrijdag?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148874","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148880","dc_title":"RE: Voorraden vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148880","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148885","dc_title":"RE: Volgende week  PO met dPDC19  URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148885","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148903","dc_title":"RE: Covid-19 onderzoeksprogramma thema 16 - projectplannen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148903","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148910","dc_title":"WVO 18 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148910","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148933","dc_title":"RE: regiegroep GOR ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148933","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148944","dc_title":"20210217 Verslag strategisch overleg vaccinatie met -.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148944","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148949","dc_title":"Re: Antw:  regiegroep GOR ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148949","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148956","dc_title":"Actiepunten.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148956","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148980","dc_title":"Verslag koepeloverleg LZ Corona 1602.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148980","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148983","dc_title":"RE: SLA Movianto - RIVM versie 1 *Graag laatste blik en fiat voor tekenronde* ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1148983","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148985","dc_title":"RE: aandachtspunt voor uitvoering vacc bij BMI>40","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148985","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148992","dc_title":"repack toebehoren en andere acties ivm te snelle afname voorraad ambiente producten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148992","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148997","dc_title":"FW: Sant\ufffd Group Introduction","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1148997","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1148998","dc_title":"Schriftelijke reactie Transavia n.a.v. evaluatie-uitvraag, d.d. 2februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1148998","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149010","dc_title":"FW: -70 leveringen  - ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149010","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149011","dc_title":"mail DPC overzicht covid websites.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149011","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149013","dc_title":"Aanpassen bijlage Goed vaccinbeheer?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149013","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149015","dc_title":"RE: vaccinaties langdurige zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149015","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149016","dc_title":"Bijlage 3 Planning PDC richting 8 maart.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149016","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149018","dc_title":"Re: Nieuw contactformulier","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149018","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149019","dc_title":"Nota ter beslissing 2021-01-27 9_17_39.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149019","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149022","dc_title":"FW: Notulen - Stuurgroep Supplychain Covid Vaccinatie GGD GHOR - RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149025","dc_title":"RE: Antw: Kick off logistiek AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149025","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149027","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx/AZ naar GGD?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149031","dc_title":"Presentatie Handreiking Coronacommunicatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149031","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149038","dc_title":"FW: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149038","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149046","dc_title":"RE: ontdooien Pfizer vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149046","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149057","dc_title":"RE: webminar cold chain en vaccin transport","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149057","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149066","dc_title":"GGD LN_Inzet VS en PA op vaccinatielocatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149066","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149072","dc_title":"RE: HIS planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149072","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149079","dc_title":"FW: Doorst: spoed: AZ leveringen verminderd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1149079","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149081","dc_title":"FW: Doorst: spoed: AZ leveringen verminderd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149081","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149085","dc_title":"RE: Koppeling his en coron-it","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149085","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149091","dc_title":"feedback ICT specs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149091","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149093","dc_title":"Rechttrekken doelgroepen operationeel en tactisch model","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149093","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149108","dc_title":"FW: Movianto klachten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149109","dc_title":"RE: Deze week iig 60-65-jarigen met AZ bij HA voorbereiden.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149109","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149114","dc_title":"FW: restjes van Astra vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149114","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149127","dc_title":"FW: Kernteam  update | Repack Moderna en AstraZeneca | hoogrisico patienten | COA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149127","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149134","dc_title":"RE: Antw:  ondeugdelijk transport Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4696","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149137","dc_title":"FW: Overzicht cold chain incidenten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149137","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4697","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149150","dc_title":"FW: batchreview proces","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149150","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4698","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149153","dc_title":"FW: 2e factsheet vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149153","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149160","dc_title":"FW: dashboard morgen: huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149160","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149162","dc_title":"RE: werkinstructie instellingen eigen medische dienst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149176","dc_title":"FW: Doorst:  Doorst: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149176","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149179","dc_title":"FW: Doorst:  Doorst: Confidential: bevestiging 3e levering AZ vaccin en planning rest Q1 /Q2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149179","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149181","dc_title":"FW: hoeveelheid AZ voor GGZ kleine wijziging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149181","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149186","dc_title":"RE: akkoord op allocatie GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149186","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149188","dc_title":"RE: communicatie frame logistiek tbv video - verzoek MinVWS - input vandaag svp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149188","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149189","dc_title":"FW: Versterking LCC - insteek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149189","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149194","dc_title":"SAMEN KUNNEN WE NIET STUK_Final2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149194","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":18,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149197","dc_title":"FW: Veegactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149197","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149202","dc_title":"FW: vaccinatie 03022021 afgesproken.xlsx | versnelling vaccinatie bewoners zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149202","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149208","dc_title":"RE: transport instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149208","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4712","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149221","dc_title":"RE: Scenario HA'en 63 en 64 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149221","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149233","dc_title":"FW: Doorst:  Pfizer voor HAPs -  input voor analyse","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149233","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149235","dc_title":"FW: Nav versnelling verpleeghuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149235","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4715","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149237","dc_title":"FW: Ter info: call flow 088 nr RIVM COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149237","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149240","dc_title":"FW: juiste aantal bestellende HA praktijken per provincie?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149240","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149243","dc_title":"FW: Spoedvragen voor callcenter - graag uiterlijk 14.00u retour","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149243","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149246","dc_title":"FW: Concept reminderbrief 80/90+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149246","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149248","dc_title":"Re: prioritering van hoogrisicopati\ufffdnten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1149248","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149250","dc_title":"FW: acties op onrust vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149250","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149256","dc_title":"FW: covid vaccinatie prioritering zeer hoog risicogroepen; hart- en longtransplantatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149256","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149263","dc_title":"prioritering hoog risico groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149263","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149264","dc_title":"RE: overleg vaccinatie van neurologische patienten met ademhalingsproblemen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149264","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149266","dc_title":"RE: prioritering covid vaccinatie hoog risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149266","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149270","dc_title":"FW: 20210223 Actielijst COVID-19 vaccinatie Opslag en Transport.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149270","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149271","dc_title":"Re: COVID vaccinatie van orgaantransplantatie patienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149271","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149275","dc_title":"FW: huisartsen vraag hoog risico en nu oproep voor AZ ipv Pfizer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149275","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149276","dc_title":"FW: Levering Moderna Vaccins 17/02/2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149276","foi_groundsOfRefusal":"5.1.2e;5.1.2f","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149291","dc_title":"RE: Inschatting Pfizer bestellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149291","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149298","dc_title":"Antw:  overleg CBG irt EMA, vaccingoedkeuring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149298","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149303","dc_title":"RE: Start regio pfizer- 4000 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149303","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149321","dc_title":"RE: Planning Friese Wadden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149321","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4734","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149325","dc_title":"FW: overleg prioritering covid vaccinatie hoog risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149325","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149328","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx | versnelling vaccinatie bewoners zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149328","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149331","dc_title":"FW: webtekst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149334","dc_title":"RE: Tekst burgers grensgebieden en buitenlandse huisarts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149334","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149337","dc_title":"Voorbereiding debat  wat betreft Reactie op motie SP over stoppenprivatisering Intravacc def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1149337","foi_groundsOfRefusal":"5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149340","dc_title":"werkwijze en uitnodigingspakket 60+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149340","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4740","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149342","dc_title":"RE: Alert SNPG\ufffdWerkwijze uitnodiging door GGD van 85-89 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149342","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149344","dc_title":"agenda operationeel overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149344","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149346","dc_title":"RE: HIS planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149346","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149348","dc_title":"RE: Alert SNPG\ufffdWerkwijze uitnodiging door GGD van 85-89 jarigen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149348","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149357","dc_title":"werkwijze rondsturen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149357","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149359","dc_title":"RE: Doorst: Fwd: copy awb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149359","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149368","dc_title":"Procesplaten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149368","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149381","dc_title":"RE: Adressen en contactpersonen tbv waardebrieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149381","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149382","dc_title":"RE: aantallen verzekerden en begeleiders in NL ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149382","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149387","dc_title":"Nota SG onrechtmatigheden BRBA - Marjoleinversie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149387","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149395","dc_title":"FW: opdrachtbrief 9/2/21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149395","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149398","dc_title":"RE: EPI 2020 12 projectrapportage.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149398","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149400","dc_title":"RE: EPI 2020 12 projectrapportage.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149400","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149441","dc_title":"RE: Vragen vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149441","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149461","dc_title":"RE: Winkelwagen HIS Offertes deel 8/9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149461","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149462","dc_title":"RE: Winkelwagen HIS Offertes deel 7/9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149462","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149464","dc_title":"RE: Winkelwagen HIS Offertes deel 6/9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149464","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149469","dc_title":"Winkelwagen HIS Offertes deel 2/9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149469","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149470","dc_title":"RE: brief aan NFU en NVZ over hoog risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149470","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149475","dc_title":"FW: Winkelwagen HIS Offertes deel 1/9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149475","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149479","dc_title":"FW: Vraag AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149479","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149539","dc_title":"RE: Inschatting I-D-B voor scenario's vaccinatieregistratie/bewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149539","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149546","dc_title":"FW: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149546","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149554","dc_title":"RE: Bijdrage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149554","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149559","dc_title":"Re: DPV_210 Aanlevering geanonimiseerde vaccinatiedata v1.2.2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149559","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149561","dc_title":"Beantwoording brief onderwijsraden.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149561","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149563","dc_title":"RE: Beantwoording diverse juridische vragen en procesverloop","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149563","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149585","dc_title":"Doorst:  Overleg Vaccinatiebeleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149585","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149588","dc_title":"FW: Advies mail Victor Sannes opdracht COVID vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149588","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149589","dc_title":"RE: RIVM-HI overleg (COVID19 vacc. module)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149589","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149609","dc_title":"FW: Advies mail Victor Sannes opdracht COVID vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149609","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149615","dc_title":"RE: onderzoek gebruiksgemak spuiten en naalden COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149615","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149632","dc_title":"RE: onderzoek inzet spuiten en naalden in Covid vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149647","dc_title":"RE: Antw: AW: Delivery 26.01.2021 - SD OFF-004-2021 - BioNTech Europe GmbH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149647","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149649","dc_title":"RE: Artwork & afmetingen en gewicht verpakkingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149649","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149652","dc_title":"RE: nieuwe leverancier opnemen in risico analyse en leverancierslijst - Farkol","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149652","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149662","dc_title":"FW: Invoice - week 04 - RIVM - COVID19 / Movianto Nederland BV ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149662","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149666","dc_title":"FW: Inschatting kosten Movianto tbv VWS 2021 jan-juni_240221.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149666","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149670","dc_title":"RE: onderzoek inzet spuiten en naalden in Covid vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149670","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2c;5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149684","dc_title":"RE: koelbox voor Sint Maarten, urgent","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149684","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149688","dc_title":"kostenraming Movianto","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149688","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149690","dc_title":"controleren facturen Movianto ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149690","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149697","dc_title":"Benaderen zorgverleners wijkverpleging.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149697","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149705","dc_title":"RE: onderzoek gebruiksgemak spuiten en naalden COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149705","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149713","dc_title":"RE: Extra koelboxen voor Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149713","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149714","dc_title":"FW: akkoord allocatie versnelde traject zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149714","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149719","dc_title":"RE: Antw: AW: Delivery 26.01.2021 - SD OFF-004-2021 - BioNTech Europe GmbH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149719","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4787","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149724","dc_title":"RE: Vragen vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149724","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149726","dc_title":"RE: Update Covid-19 producten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149726","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149731","dc_title":"RE: Veegronde","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149731","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149740","dc_title":"Janssen en FDA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149740","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149744","dc_title":"RE: Aanvulling vragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149744","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149748","dc_title":"Bespreeknotitie Samenwerking en taakverdeling PG en PDC-19 op covid-19vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149748","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149754","dc_title":"Vragen week 7_mc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149754","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149772","dc_title":"RE: vragen over uitnodigingen die RIVM verstuurt","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149772","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149790","dc_title":"FW: kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149790","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4799","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149815","dc_title":"FW: Getekend specific contract + order form FFP2 maskers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149815","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149816","dc_title":"FW: COVID programma overleg morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149816","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149817","dc_title":"FW: FINAL VERSION ZonMw Covid19 Call - lifelines","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149817","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149895","dc_title":"RE: Onderwijs subproject COVID19 evaluatie van scenarios ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149895","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149934","dc_title":"Thematische duiding dashboard sociale impact corona.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149934","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149946","dc_title":"RE: check data irt Datakwaliteit barchnummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149946","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149951","dc_title":"RE: check data irt Datakwaliteit barchnummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149951","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149957","dc_title":"RE: [EXT] FW: Vraag over tabel met batchnummers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149957","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149961","dc_title":"RE: DAP Dataverkeer Covid-19 21 02 23","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149961","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149971","dc_title":"RE: Vraag over tabel met batchnummers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149971","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149978","dc_title":"RE: CIMS: Resultaten per leverancier van verwerking op 24-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149978","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149981","dc_title":"RE: check data irt Datakwaliteit barchnummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149981","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149983","dc_title":"RE: Vraag over aantallen in CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149983","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4815","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1149997","dc_title":"RE: Vraag over aantallen in CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1149997","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4816","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150000","dc_title":"RE: CIMS: Resultaten per leverancier van verwerking op 17-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150000","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150003","dc_title":"RE: Inzicht in welke leveranciers (HIS) al aanleveren bij RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150003","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150010","dc_title":"Verzoek om aantallen in CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150010","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150014","dc_title":"RE: Vraag om iets te checken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150014","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150015","dc_title":"RE: Update planning ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150015","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150022","dc_title":"RE: Advisering anonimiteit geanonimiseerde vaccinatie data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150027","dc_title":"Opzet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150043","dc_title":"RE: SPOED Besluit gevraagd over aanpassing in de geanonimiseerde data","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150043","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150045","dc_title":"RE: aanpak datakwaliteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150045","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150083","dc_title":"FW: Vijf doelstellingen vandaag (19-02) 2.5m schaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150083","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150085","dc_title":"RE: vaccinatie acute zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150085","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150087","dc_title":"RE: Prikcapaciteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150087","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150088","dc_title":"Brief CPZ mbt covid vaccinaties 3feb21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150098","dc_title":"FW: Urgente vraag voor 13:00: BRBA koppeling met CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150098","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150105","dc_title":"FW: Agenda en stukken Kernteam 17022021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150105","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150111","dc_title":"Re: verzoek om brief door te geleiden, graag ff naar kijken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150111","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150123","dc_title":"FW: strategie 60+ asielzoekers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150123","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150130","dc_title":"RE: Contactgegevens Nicole","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1150130","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150134","dc_title":"RE: Gesprek VWS over Asielzoekers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150153","dc_title":"RE: Reinier/Zeeland vraag over \"Immuun gecompromitteerden\"","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150153","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150155","dc_title":"RE: Covid Gezondheidseconomie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150155","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150162","dc_title":"RE: Covid Gezondheidseconomie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150162","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150164","dc_title":"RE: Covid Gezondheidseconomie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150164","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150173","dc_title":"RE: Covid Gezondheidseconomie **update 12 december**","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150177","dc_title":"RE: Offerte in word","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150190","dc_title":"RE: Covid Gezondheidseconomie **update 12 december**","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150190","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150194","dc_title":"Burgerportaal Vaccineren communicatie aanpak_25022021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150194","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150196","dc_title":"RE: Begroting COVID-15, 16, 17 2021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150196","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150205","dc_title":"RE: Covid Gezondheidseconomie **update 12 december**","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150205","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150223","dc_title":"RE: covid offerte gezondheidverschillen - optie 1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150223","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150232","dc_title":"FW: COVID-V&Z programma (thema 14 t/m 18)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150232","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150237","dc_title":"LCI_RIVM_COVID_Sitrep_16-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150237","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150243","dc_title":"RE: Covid Gezondheidseconomie **update en vervolg**","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150243","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150255","dc_title":"FW: 012675_A5 Flyer Q&A priklocaties_V4_ TG","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150255","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150295","dc_title":"Re: Scenarioplanning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150295","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150310","dc_title":"FW: Brede blik sessie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150310","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150317","dc_title":"FW: Motie Veldman en uitwerking 2-2,5 mln scenario","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150317","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150325","dc_title":"FW: Scenario's verder uitwerken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150325","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150328","dc_title":"Communicatieadvies  1 jaar Corona.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150328","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150329","dc_title":"RE: Tweede prik voorbereidingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150329","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150353","dc_title":"RE: Antw:  Doorst: Naam vaccin onderdeel van toestemmingsverklaring?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150353","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150364","dc_title":"RE: Antw:  Doorst: Naam vaccin onderdeel van toestemmingsverklaring?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150364","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150381","dc_title":"25022021_Notulen operationeel overleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150381","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150401","dc_title":"Presentatie c-VTV 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":18,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150459","dc_title":"Corona overleg FEZ 9 15-2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150459","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4867","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150463","dc_title":"Uitnodiging Webinar_Goed Vaccinbeheer.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150463","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150468","dc_title":"Monitor Zorgcontinu\ufffdteit week 7 landelijk beeld.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150468","foi_nrPages":12,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150471","dc_title":"RE: COVID Vaccine Reaction Can Mimic Breast Cancer Symptoms","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150477","dc_title":"IIVAC Setup of the study.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150477","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150481","dc_title":"GGD GHOR corona monitor definitief 22-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150481","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":33,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150493","dc_title":"Tekst communicatie PBM's 22-02-2021-.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150493","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150498","dc_title":"GGD GHOR corona monitor definitief 15-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150498","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":33,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150510","dc_title":"FW: Consultatie wetsvoorstel sluitingsbevoegdheid - deadline 4 maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150510","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150518","dc_title":"Dagafsluiting verslag 23-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150533","dc_title":"Bureaukaart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150533","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150534","dc_title":"Dagafsluiting verslag 17-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150534","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150535","dc_title":"20210215 veelgestelde vragen AstraZeneca huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150535","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150537","dc_title":"RE: Bureaukaart HA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150537","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150544","dc_title":"bureaukaart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150544","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150545","dc_title":"RE: microplanning SNPG bestellen Zeeland en Limburg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150545","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150552","dc_title":"Doorst: Info toedieningsnaald op spuit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150552","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150562","dc_title":"RE: Reanimatie en vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150562","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150575","dc_title":"oproepkaart kan zo blijven?!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150575","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150580","dc_title":"RE: Uitzonderingssituaties 1e prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150580","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150582","dc_title":"Organogram datalek V 1.0.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":5,"v2":5},"foi_fileName":"VWS-WOO-17-1150582","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150585","dc_title":"Notitie directeurenoverleg 23 feb Wv testbewijzen (schoon).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150585","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150602","dc_title":"Verslag CCT 17 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150602","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150620","dc_title":"definitiefverslag BR 19 februari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150620","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150626","dc_title":"RE: Antw:  Update COVID-19-vaccinatie medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150626","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150628","dc_title":"RE: communicatie naar huisartsen over Astra Zeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150628","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150638","dc_title":"RE: communicatie naar huisartsen over Astra Zeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150644","dc_title":"RE: communicatie naar huisartsen over Astra Zeneca vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150644","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150658","dc_title":"RE: alarmerend bericht bijwerkingen AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150658","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150659","dc_title":"RE: Contra-indicaties-voorstel Imke 20210219","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150659","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150661","dc_title":"RE: alarmerend bericht bijwerkingen AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150661","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150665","dc_title":"RE: alarmerend bericht bijwerkingen AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150665","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150676","dc_title":"20210216 veelgestelde vragen AstraZeneca huisartsen naar comm","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150676","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4905","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150680","dc_title":"RE: bureaukaart volgende slag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150680","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150682","dc_title":"Document2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150682","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150688","dc_title":"RE: Uitvoeringsrichtlijn huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150688","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150690","dc_title":"RE: vaccinatie: nieuwe groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150690","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4908","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150696","dc_title":"RE: zinnetje perspectief wijkverpleging voor kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150696","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150697","dc_title":"Doorst: Volgorde","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150697","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150702","dc_title":"RE: Planning en link platform vaccinatie VGN","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150702","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150708","dc_title":"RE: start \"GO\"voor medewerkers gehandicaptensector","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150708","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150709","dc_title":"RE: Werkwijze vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150709","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150711","dc_title":"RE: Rev 20210209 Werkwijze vaccinatie zorgmedewerkers versie 2.9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150711","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150712","dc_title":"RE: Werkwijze vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150712","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150713","dc_title":"RE: Bespreekpunten en stukken regiegroep vaccinatie zorgmedewerkers 08-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150713","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4916","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150719","dc_title":"RE: Nav Platform vaccinatie 2 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150719","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150723","dc_title":"Regiegroep vaccinatie zorgmedewerkers | 08-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150723","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150727","dc_title":"RE: [vragen vanuit OCW]: Pilots coronasneltesten in het ho/mbo","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150727","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150741","dc_title":"RE: Invulling Bijsluiter Ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150741","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150746","dc_title":"RE: Drie doelstellingen vandaag 2.5m schaling","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150746","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150750","dc_title":"RE: Leveringen vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150750","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150765","dc_title":"Uitnodigingen & ZKH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150765","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150767","dc_title":"Memo4 CIMS voor BESCAS 2feb2021SOFG.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150767","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150776","dc_title":"Bureaukaart toevoegingen uitz-AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150776","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150778","dc_title":"aanvullingen op aantal docs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150778","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150783","dc_title":"RE: Ter info: aantal punten/aanpassingen ter info voor de praktijkhandleiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150783","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150794","dc_title":"Doorst: Uitwisselen vaccins HA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150794","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150798","dc_title":"FW: 210212 Profielomschrijving Tactische planning team Yorick Wilton","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150798","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150830","dc_title":"RE: VKA - tussenstand procesplaten COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1150830","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150831","dc_title":"RE: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1150831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4933","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150832","dc_title":"FW: Gegevensbeschermings-effectbeoordeling_Selecteren Oproepen Aanleveren CIMS versie0.9","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150832","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150840","dc_title":"FW: Gegevensdeling asielzoekers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150840","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150863","dc_title":"Document2 (Compatibiliteitsmodus).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150863","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150882","dc_title":"RE: Contra-indicaties-voorstel Imke 20210219","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150882","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150897","dc_title":"Nota ter beslissing - beleidsinterventies rondom COVID-19-vaccinatie(versie 22-2-2021).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150897","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150904","dc_title":"RE: [ PROCES SELECTEREN EN OPROEPEN] RE: Aanvullende eisen RIVM bij  verwerkersovereenkomst getekend 502599-003. [Advies over aan Xerox te stellen eisen in verband met verwerken oproepbrieven COVID-19]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150904","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150910","dc_title":"RE: koppeling RIVM-RECOVAC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150910","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150916","dc_title":"E-mail LNAZ aan VWS inz Zwolle [2859190].pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150916","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150947","dc_title":"FW: Geleideformulier aanbiedingsbrief DVP 2021_1 toedieningsmateriaal, transport en transportbeveiliging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1150947","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150950","dc_title":"RE: Offerte beveiliging DVP 2021_2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150950","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150956","dc_title":"FW: Ter bespreking: Hernieuwde uitvraag ondersteuning consultant COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150956","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150958","dc_title":"FW: Voor akkoord: Geleideformulier aanbiedingsbrief DVP 2021_1 toedieningsmateriaal, transport en transportbeveiliging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150958","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150970","dc_title":"FW: Verzoek tot goedkeuring - motivering onderhandse gunning - Aanpassingen HISsen COVID-19 vaccinatieprogramma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150970","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150978","dc_title":"Factsheet Vaccinatie medische risicogroepen en niet mobieleouderen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150978","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1150996","dc_title":"RE: rapportage 2 ter bespreking morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1150996","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151012","dc_title":"Vaccinatie medische risicogroepen en niet mobiele ouderenfactsheet.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151012","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151014","dc_title":"RE: Vaccinatie gebiedsteams Sudwest Fryslan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151014","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151017","dc_title":"RE: Update coronavirus - 108","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151017","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151026","dc_title":"RE: Platform vaccinatie 23 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151026","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151029","dc_title":"FW: DPC ticket EM1775047 : Tekst brief mbt AMO svp aanpassen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151029","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151034","dc_title":"FW: Doorst: vaccinatie corona 60+ COA-bewoners/ mail Rivm","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151034","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151045","dc_title":"RE: En nu de goeie!","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151045","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151051","dc_title":"RE: Webpagina voor werkgevers zorgmedewerkers Reactie op signaal Amarant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151057","dc_title":"RE: prikken van deel huisarts personeel door GGD in maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151057","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151067","dc_title":"RE: Planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151067","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151068","dc_title":"FW: Vaccinatie van medewerkers van klinische MSR-pati\ufffdnten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151068","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151079","dc_title":"factuur Breathomix 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151079","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151083","dc_title":"aangaan contract SJJ Zero Residual producten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151083","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4966","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151092","dc_title":"RE: Privacyverklaring en extra uitleg voor de rechten van betrokkenen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151092","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151095","dc_title":"RE:  dPIA CIMS rapportage - voorgenomen live gang 25.2.2021- Verzoek advies.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151108","dc_title":"RE: Ontsluiting vaccinatie naar PGO's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151120","dc_title":"Antw:  Verminderde levering AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151120","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151123","dc_title":"RE: Antw: Borging platen VKA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151123","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151124","dc_title":"FW: Ter info: call flow 088 nr RIVM COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151124","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151133","dc_title":"RE: COA en Probas - Wil jij hierin meedenken? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151133","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151143","dc_title":"Doorst:  COA en Probas - Wil jij hierin meedenken? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1151143","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151145","dc_title":"FW: Bespreekpunt en mededeling stuurgroep CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151148","dc_title":"Verschil flowcharts.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151148","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151149","dc_title":"RE: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151149","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151153","dc_title":"RE: Doorst:  VKA - tussenstand procesplaten COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151153","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151160","dc_title":"samenvatting afwegingskader_interdepartementale sessiestestbeleid_.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151160","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151162","dc_title":"FW: Vragen nav meeting Calamiteitenprocedure overleg RIVM VZVZ SC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151171","dc_title":"RE: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1151171","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151192","dc_title":"RE: Geleideformulier aanbiedingsbrief DVP 2021_1 toedieningsmateriaal, transport en transportbeveiliging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151200","dc_title":"RE: Operationele planning - urgent ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151200","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151209","dc_title":"RE: Uitnodigingsbrief GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151209","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151211","dc_title":"RE: toch al vaccinatie wmo medewerkers? ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151211","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151219","dc_title":"RE: Vervolg inzet VKA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151219","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151225","dc_title":"FW: Data Platform voor LCC (en programma) - ter bespreking morgen tijdens de lunch ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151225","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151230","dc_title":"RE: [ PROCES SELECTEREN EN OPROEPEN] RE: Aanvullende eisen RIVM bij  verwerkersovereenkomst getekend 502599-003. [Advies over aan Xerox te stellen eisen in verband met verwerken oproepbrieven COVID-19]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151230","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i Concept","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151240","dc_title":"Moties en Toezeggingen COVID-19 debat 24022021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151240","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":18,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151241","dc_title":"RE: Planningsapplicatie vervolg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1151241","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151270","dc_title":"Presentatie VacScanapp.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151270","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151287","dc_title":"RE: Pfizer vaccin - transport condities","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151287","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151293","dc_title":"FW: Waarom BW niet mee met GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151293","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151294","dc_title":"FW: Eerste opzet concept Plan van Aanpak voor Medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1151294","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151299","dc_title":"RE: Vaccineren groepen met sterk verhoogd risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.4999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151326","dc_title":"- presentatie testen en traceren ARK 20210217 11u40.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151326","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151328","dc_title":"vervolgproces: moeilijk bereikbare doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151328","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151333","dc_title":"Doelgroepen - laatste status","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151333","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151335","dc_title":"FW: SPOED Tweede vaccinatie ziekenhuismedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151335","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151339","dc_title":"RE: Antw:  Doorst: Vragen Moderna voor huisartsen voor niet mobiele 65+","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151339","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151345","dc_title":"RE: wanneer is er AZ voor 50-59 --> vraag voor in de kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151345","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151348","dc_title":"RE: Antw: defensie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151348","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151357","dc_title":"20210218 nota moeilijk bereikbare doelgroepen versie 2 (002) (002)_LK_LM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151357","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151373","dc_title":"RE: Vraag voor debat - uitbraken verzorgingshuizen na ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151373","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151376","dc_title":"20210201_Allplex SARS-CoV-2 Variants I assay_Introduction.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151376","foi_nrPages":16,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151378","dc_title":"FW: vaccinatie van neurologische patienten via de huisarts?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151378","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151386","dc_title":"Madurodam plan 20210216 input LCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151394","dc_title":"RE: Beroepenreeks","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151394","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151395","dc_title":"RE: akkoord allocatie versnelde traject zorginstellingen | graag Go of No Go ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151395","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151396","dc_title":"RE: Vaccinatie Beschermd Wonen en GGZ - besluitvorming ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151396","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151397","dc_title":"kunnen we helpen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151397","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151408","dc_title":"FW: Vaccinatie Beschermd Wonen en GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151408","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151413","dc_title":"FW: Ter info: Antwoord op vragen van GL over de vaccinatiestrategie over ongedocumenteerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151413","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151419","dc_title":"Re: Antw: Dringende vraag voor VOICE studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151419","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151421","dc_title":"Re: Antw: Dringende vraag voor VOICE studie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151421","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151427","dc_title":"RE: Doorst:  afstemming huisarts/GGD op de wadden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151431","dc_title":"Re: Vaccin COVID vaccin onderzoek kwetsbare groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151431","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151439","dc_title":"RE: Vaccin ZonMW COVID vaccin onderzoek: voor de VOICE studie/ inclusief correctie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151439","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151441","dc_title":"Re: Vaccin COVID vaccin onderzoek kwetsbare groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151441","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151444","dc_title":"uitsluitsel werkwijze route gemiste vaccinatie via GGD voor medewerkers instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151444","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151449","dc_title":"FW: nota moeilijk bereikbare doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151449","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151453","dc_title":"Motie inzichtelijker maken wanneer mensen aan de beurt zijn voorvaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151453","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151454","dc_title":"RE: Vaccin COVID vaccin onderzoek kwetsbare groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151454","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151455","dc_title":"Re: Vaccin COVID vaccin onderzoek kwetsbare groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151455","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5032","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151466","dc_title":"Vaccination Certificates - Introduction 2021-02-17.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":22,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151471","dc_title":"Overzicht COVID vaccins voor onderzoek in kwetsbare groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151475","dc_title":"RE: Reminder--> Deelname aan vaccinatieprogramma ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151475","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151482","dc_title":"RE: Beslisdocument Veegactie_MM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151482","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151495","dc_title":"FW: Brede blik sessie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151495","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151513","dc_title":"17022021 Notitie vaccineren asielzoekers op locatie.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151513","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151519","dc_title":"16022021 Notitie achterwachtfunctie voor instellingen en uitvoerderstbv 2e prik -.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151519","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151531","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151531","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151538","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151538","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151568","dc_title":"RE: lijst van afspraken van het overleg over dagbesteding op 25februari jl.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151568","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151569","dc_title":"Kinderen met chronisch zieke ouders - Openen onderwijs.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151569","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5045","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151585","dc_title":"RE: Totaal aantallen GGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151585","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5048","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151652","dc_title":"Theo - CE 731248- BSI certificate for FFP2 800-01 .pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151652","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5049","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151682","dc_title":"PLATO-#4189766-v3-COVID-19__Resultaten_peiling_corona_18_februari_2021.DOCX","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151682","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5050","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151683","dc_title":"VS: Request from the Netherlands to eHealth Network Members","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151683","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5051","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151684","dc_title":"preventie pitch versie_def.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151684","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5052","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151689","dc_title":"stavaza vaccin onderzoeken rivm_zonmw_immuungecompromiteerden.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151689","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5053","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151693","dc_title":"voorbereiding 4 landen-HK.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151693","foi_nrPages":13,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5054","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151712","dc_title":"Presentatie - van Delden t.b.v. technische briefing 24 februari2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151712","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":35,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5055","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151726","dc_title":"PPT joint H2020-HE meeting 15-2-2021 final1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151726","foi_nrPages":18,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5056","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151748","dc_title":"20210216 DR nota Jaarrapportages Rijksopdrachtgevers 2020.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151748","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5058","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151780","dc_title":"RE: Zinder introductie n.a.v. uw Linkedin bericht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151780","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5059","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151794","dc_title":"Werking reserveringsmodule coronatest (2).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151794","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5060","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151828","dc_title":"Ketenoverleg 18 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151828","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5061","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151831","dc_title":"Ketenoverleg 11 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5062","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151832","dc_title":"Ketenoverleg 25 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151832","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5064","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151835","dc_title":"Ketenoverleg 28 januari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151835","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5065","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151838","dc_title":"Ketenoverleg 2 februari.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151838","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5066","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151841","dc_title":"-20210212.04 - --raad oplegnotitie - Interne Standpuntbepaling governance infectiecrisis 20210209.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151841","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5067","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151845","dc_title":"RE: Pfizer vaccin - transport condities","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151845","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5068","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151846","dc_title":"Gecombineerde adviesaanvraag GR - Janssen-vaccin en vaccinatiestrategiemiddellange termijn versie 26-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5069","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151847","dc_title":"RE: 25 02 2021 Notitie LHV tweede kwartaal tn MV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151847","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5070","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151848","dc_title":"RE: Doorst:  PDS-ZRS03B-SJJ-v01.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151848","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5071","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151850","dc_title":"FW: extra Moderna voor HAPs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151850","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5072","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151851","dc_title":"Scan_van_een_Xerox_MFA.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151851","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5073","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151856","dc_title":"RE: aanvullingen op notitie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151856","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5074","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151863","dc_title":"FW: Overleg COVID-19 vaccinatiestrategie - 22 februari 15:00-16:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151863","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5075","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151866","dc_title":"20201231 Presentatie Update scenario LOT-C (definitief).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151866","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5076","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151870","dc_title":"20210225 Bijlage BCO bij Kinderen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151870","foi_nrPages":13,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5077","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151873","dc_title":"210202 Epidemiologische status Amsterdam-Amstelland.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151873","foi_nrPages":15,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5078","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151884","dc_title":"FW: allocatie vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151884","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5080","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151903","dc_title":"RE: de professoren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151903","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5081","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151906","dc_title":"RE: Madurodam scenario","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151906","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5082","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151910","dc_title":"RE: Verzoek afspraak met de heer Gerritsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151910","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5083","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151913","dc_title":"RE: Doorst:  Distributie covid vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151913","foi_groundsOfRefusal":"5.1.2e;5.1.2f;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5084","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151923","dc_title":"RE: koppeling RIVM-RECOVAC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151923","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5085","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151924","dc_title":"RE: Start regio pfizer- 4000 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151924","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5086","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151925","dc_title":"RE: Reminder--> Deelname aan vaccinatieprogramma ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151925","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5087","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151927","dc_title":"RE: vaccinatie 03022021 afgesproken.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151927","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5088","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151928","dc_title":"RE: Down","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151928","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5089","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151930","dc_title":"FW: Doorst: Naam vaccin onderdeel van toestemmingsverklaring?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151930","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5090","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151932","dc_title":"RE: 1 miljoen mensen met een medische indicatie tussen 18-59","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5091","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151933","dc_title":"RE: Doorst: 1 miljoen mensen met een medische indicatie tussen 18-59","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151933","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5093","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151945","dc_title":"FW: Healthcare warehouse van Rutges Cargo Europe op Amsterdam Schiphol airport 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5095","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151956","dc_title":"akkoord op allocatie voor versnelle vaccinatie instellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151956","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5096","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151960","dc_title":"FW: uitzonderlijke situatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1151960","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5097","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151961","dc_title":"RE: koppeling RIVM-RECOVAC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151961","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5098","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151980","dc_title":"Rapportage vaccinatiebereidheid huisartsen februari 2021 .pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151980","foi_groundsOfRefusal":"5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5099","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1151983","dc_title":"Veiligheidsberaad 25 januari 2021 - zorgcontinuiteit_ (002).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1151983","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152003","dc_title":"20210211 Verslag Afstemmingsoverleg ICT.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152003","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152007","dc_title":"3c. Course of action -  testbereidheid zelftesten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152007","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152024","dc_title":"3d. Validatie STRIP.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152024","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152028","dc_title":"GGD Groningen Gebruikerservaring Testen bij Kinderen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152028","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152030","dc_title":"Gebruikerservaring Testen bij Kinderen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152030","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152033","dc_title":"4. Course of action vervolg massa spectrometrie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152033","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152035","dc_title":"Presentatie Driehoeksoverleg 26022021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152035","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152038","dc_title":"RE: uitzondering verplichte testen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152038","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152039","dc_title":"Dilemma's nav reacties op afmelding.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152039","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152040","dc_title":"GGD Rotterdam-Rijnmond Gebruikerservaring Testen bij Kinderen 18 Januari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152040","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152041","dc_title":"Definitieve notulen 2021.01.21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152041","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152051","dc_title":"4. Rapid MS-based COVID-19 diagnostic test validation presentation.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152059","dc_title":"Verslag validatie speekseltesten_GGD Amsterdam_2021024-def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152059","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152081","dc_title":"memo ronde tafels leveringszekerheid_Philips_26022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152081","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152090","dc_title":"Presentatie Stavaza kernteam LNAZ.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1152090","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152108","dc_title":"FW: Medewerking BCO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152108","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152113","dc_title":"Invoice 7799.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152113","foi_groundsOfRefusal":"5.1.1c;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152148","dc_title":"VTGM Formulier blanco.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152148","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152160","dc_title":"kerngroep fase 3 lnaz 19 feb 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152160","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152164","dc_title":"Vera Timmermans-Wetten die gelden bij testen in de verschillendesporen-onjuist.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152164","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152191","dc_title":"Gezamenlijke agenda Bestuurlijk Overleg VNO 22 febr.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152191","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152196","dc_title":"210223 brief LNAZ aan VWS verantwoording LCPS en voorschot.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152196","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152223","dc_title":"2021-001 Sion Biotext NL offerte FFP2 maskers-aangepast.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152223","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152241","dc_title":"Voorlichtingsmaterialen Corona versie 28 januari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152241","foi_groundsOfRefusal":"5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152245","dc_title":"UptoDate duur isolatiemaatregelen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152245","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152246","dc_title":"Mededeling HERA incubator  commentaar BO.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152246","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152252","dc_title":"richtlijn corona besmettelijkheid .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152252","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152254","dc_title":"VeiligheidsBeraad01.2.2021.JaapVanDissel.v1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152254","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152290","dc_title":"Protocol voorkomen van Corona 08022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152290","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152330","dc_title":"ISB-tabel VWS Begrotingsonrechtmatigheid_HA_LtH.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1152330","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152340","dc_title":"informatiememo bestuurscommissies OV en PGMZ 19-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152340","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":30,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152369","dc_title":"Vaccinatiestrategie COVID-19.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152369","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152374","dc_title":"Concept-vergaderverslag CvT 25-2-2021_v1.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152374","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152437","dc_title":"annex 5 - 20210218 Aanwezig 18 februari.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152437","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152444","dc_title":"18022021 Nationale crisis staf politie def  CW.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152444","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":22,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152467","dc_title":"Aanbiedingsbrief DVP 2021_2 Extra beveiliging.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152467","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152474","dc_title":"Prof Brug RIVM PPV23 Feb 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152474","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152487","dc_title":"RE: Vaccinaties / PGO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152487","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152495","dc_title":"annex 5 - 20210211 Aanwezig 11 februari.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152495","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152496","dc_title":"RE: Stuurgroep vaccinatieregistratie plannen tussen op 23 of 24 maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152496","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152514","dc_title":"RE: VERTROUWELIJK - conceptbrieven ziekenhuizen IC-opschaling[PRDF-11015018] [Nysingh-238383]","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152514","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152533","dc_title":"Operatie Steepen the Curve - VWS update 26 feb 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152533","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152549","dc_title":"RE: Update m.b.t. privacy advies/besluit geanonimiseerde vaccinatiedata","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152549","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152566","dc_title":"Moties PDC-19 16 feb.rtf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152566","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152567","dc_title":"annex 5 - Aanwezig 26 + 28 januari.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152567","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152578","dc_title":"Persoonlijk verslag van het debat over de ontwikkelingen rondom hetcoronavirus dd. 24 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152578","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152614","dc_title":"Nota ter voorbereiding gesprek goudsmitv3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152614","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152651","dc_title":"vaccinatiebewijzen interdepartementaal vragen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152651","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152666","dc_title":"Logboek AZ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152666","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5170","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152685","dc_title":"response team_0202.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152685","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152686","dc_title":"RT 02022021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152686","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152693","dc_title":"Response team meeting 2-2-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152693","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152708","dc_title":"20210128 Tabellen BCO Fase 2 Risicogestuurd - kopie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152708","foi_nrPages":14,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152709","dc_title":"20210128 Tabellen BCO Fase 1 Volledig - kopie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152709","foi_nrPages":16,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152711","dc_title":"20210128 Tabellen BCO Fase 1B Volledig zonder monitoring - kopie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152711","foi_nrPages":14,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152716","dc_title":"Sant\ufffd - Capability Statement.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1152716","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152721","dc_title":"nota ter beslissing - surplus vaccinatielocaties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152721","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152726","dc_title":"20210128 Bijlage HPZone Registratie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152726","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":29,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152733","dc_title":"20210128 Brieven en bijlagen BCO Fase 1B Volledig zonder monitoring - kopie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152733","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152736","dc_title":"20210128 Brieven en bijlagen BCO Fase 1 - kopie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152736","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152737","dc_title":"20210128 Brieven en bijlagen BCO Fase 2 Risicogestuurd - kopie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152737","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152766","dc_title":"Notulen16022021 Overleg GedragCorona.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152766","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152780","dc_title":"20210128 Bijlage Zorgmedewerkers.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152780","foi_nrPages":7,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152812","dc_title":"overzicht flankerend beleid.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152812","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152822","dc_title":"2020 02 24 Breed Online Onderzoek COVID-19 RIVM - 2 domeinen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152822","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152837","dc_title":"2020 02 16 Breed Online Onderzoek COVID-19 RIVM.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152837","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152842","dc_title":"Overzicht implementatiekosten vaccins.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152842","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5192","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152853","dc_title":"20210128 Werkinstructie BCO Fase 1B Volledig zonder monitoring - kopie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":51,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152862","dc_title":"communicatieaanpak 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152862","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152879","dc_title":"20210128 Werkinstructie BCO Fase 2 Risicogestuurd - kopie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":52,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152881","dc_title":"20210128 Werkinstructie BCO Fase 1 volledig - kopie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152881","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":54,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5196","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152886","dc_title":"AG snelstest kinderen_09-02-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152886","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152909","dc_title":"210201 Narrative aanpak corona nieuw (002).docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152909","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5199","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152914","dc_title":"210203 DEF Visual duurzaam testlandschap.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152914","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152926","dc_title":"20210222 Beslisdocument niet mobiel V2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152926","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152927","dc_title":"210226 Bijlage 1 voor- en nadelen scenario's MKS.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152927","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152934","dc_title":"P15 CIB Jaarrapportage 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152934","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e;buiten verzoek","foi_nrPages":66,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152942","dc_title":"Offerte SEO-RIVM 20210305.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152942","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152947","dc_title":"Re: Locaties en tijdstippen van de vaccinaties (reactie vereist)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152947","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152953","dc_title":"RE: Update Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152953","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152988","dc_title":"110221_Presentatie InEEN_HAPs_Pfizer.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152988","foi_nrPages":8,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1152996","dc_title":"Global Vaccination Overview Deck 1.18.21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1152996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":43,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153012","dc_title":"RE: OPROEP: in aanmerking komen voor BionTechPfizervaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153012","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153036","dc_title":"210203 Aftemmen 1a en 1b.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153036","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153088","dc_title":"Q21111 Aanbieding Cato Composites FFP2 mondmaskers min. VWS.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153088","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153102","dc_title":"Verslag Stuurgroep VGL 4 februari 2021 concept.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153102","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153168","dc_title":"Aanpak RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153168","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153200","dc_title":"Dagafsluiting verslag 16-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153200","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153227","dc_title":"Scenario Analyse - Huisartsen LHV NGH (Normpraktijk).pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153227","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153228","dc_title":"20210222 overleg toekomstbestendige dienstverlening 0.2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153228","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153235","dc_title":"Scenario Analyse - Huisartsen LHV NGH.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153235","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153242","dc_title":"reactie min Van Ark op schriftelijk PO 22 februari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153242","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153245","dc_title":"2021.02.19 Overleg Movinato-LCC -concept.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153245","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153266","dc_title":"advies_vrijstelling_verruiming_pt1_naar_alle_prof.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153266","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153275","dc_title":"Retour 218062 - akkoord - en MVWS.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153275","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153289","dc_title":"Scenario's Corona 2021 d.d. 14.02.2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153289","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153295","dc_title":"Scenario's nieuw.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153295","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153299","dc_title":"Verslag stuurgroep supply chain RIVM-LCC-GGDGHOR 02-03-2021_.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153300","dc_title":"Voorstel hap Moderna en MF_20210202_MV_LK_MBAG.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153300","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153303","dc_title":"DVP_FOR_0018 wijziging voorraad allocatie Covid vaccin orders 210226.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153303","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153313","dc_title":"SAP wijziging voorraad allocatie Covid vaccin orders 210226.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153313","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153316","dc_title":"cut over plan batch allocatie 210226.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153316","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153317","dc_title":"20210216AgendaStuurgroepSC_GGD_LCC.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153317","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153321","dc_title":"2021.02.17 Overleg Movinato-LCC -concept.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153321","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153332","dc_title":"FW: Leveringen tbv zorginstellingen - week 6 | impact weersituatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153332","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153344","dc_title":"d05-15-02-21-1.01-JEST.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153344","foi_nrPages":12,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153347","dc_title":"d02 - Vaccinatieproces Instellingsarts - Instellingsarts d02-25-02-21-1.12-JEST.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153347","foi_nrPages":11,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153358","dc_title":"Restanten instellingen en Haps naar GGD.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153358","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153361","dc_title":"Uitvoeringsoverleg vaccinatie zorgmedewerkers 28-01.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153361","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153365","dc_title":"20210202 Werkwijze 2de prik acute zorgmdw bij GGD v2.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153373","dc_title":"Gesprekspunten RIVM - GGD GHOR logistiek & distributie 20210205.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153373","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153375","dc_title":"Vaccineren zorgmedewerkers Ziekenhuizen en Klinieken 04-02.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153375","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153377","dc_title":"algemene-werkwijze-vaccinatie-covid-19-nvza-ggd.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153377","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153380","dc_title":"2021_02_04-lijst-aandachtspunten-50 openbare farmacie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153380","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153387","dc_title":"vtgm-protocol-covid-19-vaccins-nvza-ggd-comirnaty.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153387","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153441","dc_title":"Selectie_2021-02-27.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153441","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":50,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153492","dc_title":"HA-werkgroep09Feb2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153492","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153493","dc_title":"20210209 Conceptverslag WG uitvoering huisartsen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153493","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153508","dc_title":"Korte samenvatting uit het CO 22 feb van Imke.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153508","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153524","dc_title":"webpagina registreren_KH.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153524","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153544","dc_title":"Vaccinatie medische risicogroepen en niet mobiele ouderenfactsheet.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153544","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153559","dc_title":"Praktisch overleg 18-2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153559","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153577","dc_title":"20210212 Doelgroepbepaling voor op site.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153577","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153586","dc_title":"20210225 Verslag overleg Regiegroep Zorgmedewerkers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153586","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153589","dc_title":"20210222 Notulen overleg Kerngroep DJI.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153589","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153590","dc_title":"Verslag budgethoudergesprek DGCZ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153590","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153595","dc_title":"20210202 Conceptverslag WG uitvoering huisartsen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153595","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153618","dc_title":"Stand-up verslag 18-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153618","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153640","dc_title":"Varianten Caribische regio v. 18-2-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153640","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153646","dc_title":"Dagafsluiting verslag 26-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153646","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153654","dc_title":"Stand-up verslag 26-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153654","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153659","dc_title":"Stand-up verslag 24-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153659","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153678","dc_title":"Korte samenvatting uit het CO 15 feb van Imke.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153683","dc_title":"Dagafsluiting verslag 19-2-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153683","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153719","dc_title":"Handreiking verdeling overblijvende COVID-19-vaccins in huisartspraktijken voor WG 20210202.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153719","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153807","dc_title":"FW: Aantekeningen LHV - VWS - rivm","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153807","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153833","dc_title":"210208_RIVM_Vaccinatie_v10.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153833","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153840","dc_title":"Stand-up verslag 2-3-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153840","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153841","dc_title":"PBCOVV-3_02022021_Uitzonderingsscenarios tweede prik.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153841","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153849","dc_title":"2021-02-17 Projectsstructuur COVID vaccinatieprogramma nw. versie.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153849","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5290","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153868","dc_title":"Aanvulling Imke 2.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153868","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5293","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153880","dc_title":"2_ApplicationReport_AG_PST_Handling.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153880","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153926","dc_title":"aanvraagformulier vaccins GGZ1.2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153926","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5296","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153927","dc_title":"10312020_INV-1177_Aruba_revised.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153927","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5297","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153930","dc_title":"CM_StMaarten_Sep2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153930","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153932","dc_title":"10312020_INV-1178_St.Maarten_Final.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153932","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5299","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153935","dc_title":"Bijsluitervraagstuk.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153935","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153936","dc_title":"FW: Ter info: Antwoord op vragen van GL over de vaccinatiestrategie over ongedocumenteerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153936","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153938","dc_title":"Inv 00949 AMI_CURACAO_COVID19 RELIEF_INITIAL INVOICE_00949.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153938","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153942","dc_title":"overzicht benodigdevaccins VOICEallen12-2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153942","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153945","dc_title":"Factuur - 2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153945","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153948","dc_title":"inv 00966 AMI ST MAARTEN INVOICE 07 JUNE 2020 (1).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153948","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153951","dc_title":"aanvraagformulier vaccins Defensie en BuZa.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153951","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153952","dc_title":"Inv 00960 AMI_CURACAO_INVOICE_11 MAY.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153952","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153955","dc_title":"Inv 00977 AMI ST MAARTEN INVOICE 14 JUNE 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153955","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153960","dc_title":"inv 01033 AMI ARUBA INVOICE 5 JULY 2020 (1).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153960","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153962","dc_title":"Inv 00992 AMI CURACAO INVOICE 15 JUNE 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153962","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153967","dc_title":"Inv 01004 AMI ARUBA INVOICE 21 JUNE 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153967","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153971","dc_title":"INV-01123.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153971","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153984","dc_title":"INV-01213_Aruba_november 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153984","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153987","dc_title":"INV-01125.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1153987","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153990","dc_title":"INV-01124.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153990","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153994","dc_title":"INV-01214_St.Maarten_november 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153994","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153997","dc_title":"Beleid hepatitis-B-vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153997","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1153998","dc_title":"INV-01212_Curacao_november 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1153998","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154002","dc_title":"INV-01235_Aruba_dec 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154002","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154006","dc_title":"INV-01234_Curacao_dec 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154006","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154012","dc_title":"Factuur Hospitainer - 14 april 2020 - IC unit Sint Eustatius.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154012","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154014","dc_title":"Eerste effecten vaccinatie zichtbaar onder bewoners verpleeghuizen_V4.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154014","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154019","dc_title":"INV-1176_Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154019","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154023","dc_title":"INV-01236_St.Maarten_dec 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154023","foi_groundsOfRefusal":"5.1.1c;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154027","dc_title":"Factuur Hospitainer - 14 april 2020 - IC units Sint Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154027","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154044","dc_title":"Factuur Hospitainer - 3 april 2020 - IC unit Sint Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154044","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154047","dc_title":"Factuur Zoll Ventilator.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154047","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5329","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154049","dc_title":"20210216 GGZ overleg verslag.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154049","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154062","dc_title":"20210209 GGZ overleg verslag.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154062","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5331","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154065","dc_title":"20210211 GGZ overleg verslag.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154065","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5332","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154068","dc_title":"20210218_Notitie Operationele Planning Pfizer.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154068","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154073","dc_title":"FW: Besluit livegang Rapportage Tooling  [ Vaccinatieregister fase vi- evaluatie & monitoring  ] ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154073","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154074","dc_title":"PLATO-#4186454-v1-COVID-19__CEO_campagnemonitor_vaccinatiecampagne_nm1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154074","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154079","dc_title":"Factuur - 1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154079","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154095","dc_title":"RE: declaratie per vaccinatietype","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154099","dc_title":"RE: Update verloop COVID-19 vaccinatie bij huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154099","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154103","dc_title":"20210217_Bottlenecks bij opschaling naar 25m.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154103","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":26,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154108","dc_title":"20210215_Bottlenecks bij opschaling naar 2,5m.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154108","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154128","dc_title":"Reactie discussienota de Nederlandse GGZ.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154128","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154136","dc_title":"DPV-232 addendum dPIA CIMS rapportage v1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154136","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154139","dc_title":"Reactie discussienota VGZ.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154139","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154164","dc_title":"Praatplaat operationeel tool afd overleg.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154164","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154168","dc_title":"20210222 overzicht CCI COVID tbv IGJ.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154168","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154173","dc_title":"20210202 RIVM-IGJ overleg covid-vaccin.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154177","dc_title":"20210209 RIVM-IGJ overleg covid-vaccin.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154177","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154201","dc_title":"Scenario Analyse.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154201","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154211","dc_title":"Instructies ontdooien.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154211","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154242","dc_title":"FW: Materiaal zojuist besproken (26-02-2021) - Fransoo/ Enders","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154242","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154244","dc_title":"Beheerplan platform Praeventis en CIMS v1 getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154244","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":31,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154249","dc_title":"RE: Overleg RIVM VWS GGD GHOR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154249","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5356","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154250","dc_title":"Verslag RIVM VWS GGD GHOR 31-3-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154250","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154267","dc_title":"ema-cover-leg002.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154267","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154356","dc_title":"FW: Vraag bevoorraden huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154356","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5360","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154359","dc_title":"RE: Uit de MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154359","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5361","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154360","dc_title":"RE: Uit de MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154364","dc_title":"Uit de MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154364","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5363","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154388","dc_title":"3_ Clientbeheer.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154388","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154396","dc_title":"2_ Uitvoering vaccinatieproces.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154396","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154400","dc_title":"1_ Logistiek.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154400","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154432","dc_title":"maa-m3-18feb21-leg2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154432","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":83,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154483","dc_title":"FW: argumentatie crisisbedden jeugd (max 600 medewerkers)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154483","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154484","dc_title":"FW: belletje door Bart Smit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154488","dc_title":"FW: GGD GHOR - ADR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154488","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154494","dc_title":"FW: Eerste resultaten Gedragsonderzoek ronde 8 (16-22 feb)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154494","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154498","dc_title":"FW: Leverschema incl. Maart 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154498","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154509","dc_title":"FW: Openstaande vragen n.a.v. controle contracten en kamerbrieveninzake vaccins ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154509","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154513","dc_title":"FW: Halma / Advies  (Mondmaskers VWS)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154513","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e;5.1.2i;Wft","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154519","dc_title":"FW: Openstaande vragen n.a.v. controle contracten en kamerbrieveninzake vaccins ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154519","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154537","dc_title":"FW: Tekstvoorstel convenant BuZa naar VKA?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154537","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154541","dc_title":"RE: vragen over vastlegging gegeven bij de Corona vaccinatie; Kenmerk FCC/Privacy: A20210306-01","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154541","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154544","dc_title":"FW: Restitutie 6de dosis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154544","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154547","dc_title":"Bijlage 199.2.1 Presentatie verantwoordelijkheden voor LOI.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154547","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154549","dc_title":"FW: QenA vaccins Wilders - debat avondklok","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154549","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5380","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154550","dc_title":"FW: Ter attendering: Aanpassing interval B/P Sint Maarten (BES/CAS)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154550","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154567","dc_title":"Map1.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154567","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154574","dc_title":"FW: Vaccinatieroute BW - samenvatting ter akkoord - ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154574","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154578","dc_title":"FW: verantwoordelijkheid uitvoering vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154578","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154579","dc_title":"FW: versnellen vaccineren. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154579","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154592","dc_title":"Fwd: Support NPPU evaluatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154601","dc_title":"Toetsingsverslag pandplan L\ufffdbeckplein 34 Zwolle_201127.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154601","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154608","dc_title":"FW: Vraag bevoorraden huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154608","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5388","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154624","dc_title":"FW: Nota vooruitbetaling opties Moderna en volgende nota's hierop","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154624","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154629","dc_title":"C1237_Aanbiedingsbrief Technische realisatie vaccinatiegegevens in PGO.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154629","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154639","dc_title":"C1237_Projectovereenkomst Technische realisatie vaccinatiegegevens in PGO_v1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154639","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154646","dc_title":"Pfizer leveringen incl. Maart 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154646","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154654","dc_title":"Graag even printen op een A4-tje","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154654","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154665","dc_title":"FW: berekeningen middenvariant met nieuwe cijfers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154665","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154707","dc_title":"RE: 2021Z01993 - Bergkamp_VS_AZ_NK_VS_DvB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154707","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5397","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154711","dc_title":"RE: 10e ronde onderzoek gedragsunit, publicatie op 26 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154711","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5398","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154712","dc_title":"RE: Aantal gezette prikken tm 12-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154712","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5399","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154724","dc_title":"RE: Antw: Verdeling van de vaccins over de eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154724","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154731","dc_title":"RE: Bwo sheets","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154731","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154733","dc_title":"RE: BioNTech-Pfizer - Rebate Mechanism ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154733","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154736","dc_title":"RE: Check data ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154736","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154755","dc_title":"RE: concept tekst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154755","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154761","dc_title":"RE: CoronIT Wpg/Wgbo","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154761","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154771","dc_title":"RE: Flowchart ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154771","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154772","dc_title":"RE: Gezondheidsministers VTC 1 maart: deelname en voorbereidingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154772","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154787","dc_title":"RE: input crisisstaf - graag aandacht situatie in de noodopvang","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154787","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154791","dc_title":"RE: ivm briefing morgenavond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154791","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154806","dc_title":"RE: National Helicopters","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154806","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154818","dc_title":"RE: Overzicht aantallen intramurale ggz ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154818","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154821","dc_title":"RE: overgebleven vaccins naar defensie?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154821","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154848","dc_title":"RE: Rectificatie : Verdeling van de vaccins over de eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154848","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154850","dc_title":"RE: Signaal DMO over toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154850","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154862","dc_title":"opdrachtbrief 09022021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154862","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154884","dc_title":"13012021_Opslag en Distributie Overeenkomst met ziekenhuisapotheken  MST Enschede signed sdr.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154884","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154889","dc_title":"beschikbaarheid november 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154889","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154891","dc_title":"Beschikbaarheid december 2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154891","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154916","dc_title":"RE: URGENT graag akkoord van RIVM op spreeklijn AZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154916","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154917","dc_title":"RE: Verklaring opdracht Moderna","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154917","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154930","dc_title":"PLATO-#4189931-v1-Blauw_Research_(25346-1)_Deelofferte_09_Uitnodigingsbrief_vaccinatie_70+.PPTX","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154930","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154934","dc_title":"RE: Verslag crisisoverleg BES/CAS - 9 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154934","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154938","dc_title":"RE: Verklaring van opdracht BioNTech/Pfizer - Initial Contract +opties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154938","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154948","dc_title":"Convenant RIVM - Saba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154948","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154952","dc_title":"Convenant Covid 19 vaccinaties signed Saba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154952","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154956","dc_title":"Convenant RIVM - Bonaire.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154956","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154958","dc_title":"RE: Voorzetje stavaza brief motie dijkhoff - voorzet om te komen totafstemming met EZK, OCW, Sport en NCTV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154958","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154969","dc_title":"Convenant RIVM - St. Eustatius.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154969","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1154990","dc_title":"RE: Stukken debat dossier notaoverleg - initiatiefnota Veldman ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1154990","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155017","dc_title":"Stand van zakenbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155017","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155051","dc_title":"vertrouwelijk: terugkoppeling ACC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155051","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155058","dc_title":"Vaccination Certificates - Introduction 2021-02-18.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155058","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155063","dc_title":"vertrouwelijk: terugkoppeling ACC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155063","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155084","dc_title":"210222 Update figuren berg en staafjes en fysieke voorraad.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155084","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155097","dc_title":"The Vaccine Adverse Event Reporting System (VAERS) Results Form.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":5,"v2":5},"foi_fileName":"VWS-WOO-17-1155097","foi_nrPages":339,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155101","dc_title":"Offerte 94220.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155101","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155114","dc_title":"20210223 Verslag miniwerkgroep geanonimiseerde data DPV 210 v1.0.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155114","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155118","dc_title":"Assessment of VALs - Score added by Marc Sprenger 230221.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155118","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155121","dc_title":"Final_Announcement Webinar Vaccine Development_Section Pharmaceutical Toxicology 04FEB2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155121","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155135","dc_title":"Sint Maarten brief voor M Panneflek ms230221.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155135","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155144","dc_title":"Open_balance_statement_Netherlands.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155144","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155175","dc_title":"02112021_Credit_Note_Letter_Netherlands.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155175","foi_groundsOfRefusal":"5.1.1c;5.1.2c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155199","dc_title":"EC_Estimated_Delivery_Schedule_update_20210208.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155199","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155201","dc_title":"CGM Zorgdossier acceptatierapport.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155201","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155221","dc_title":"Presentatie BWO 16 feb v1718.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155221","foi_nrPages":9,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155242","dc_title":"20210217 Overleg GGD bestelproces.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155242","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155284","dc_title":"2020-01 Cold Chain CN COVID NL sharefile.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":73,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155292","dc_title":"Klachtenregistratie_v2.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155292","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155294","dc_title":"Klachtenregistratie_v2.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155294","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":14,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155303","dc_title":"Overleg prioritering covid19 vaccinatie 15 feb 2021 20u Nefro.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155303","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155304","dc_title":"Versnellen vaccinatie bewoners zorginstellingen 20210203b.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155304","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155309","dc_title":"Overleg prioritering covid19 vaccinatie 17 feb 2021 9.30 Neuro.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155309","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155310","dc_title":"Overleg prioritering covid19 vaccinatie 18 feb 2021 20.30 Immuno.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155310","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155326","dc_title":"Verslag 01-feb-2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155326","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155333","dc_title":"Waardebrief levering aan St. Eustatius.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155333","foi_groundsOfRefusal":"5.1.2a;5.1.2b;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155351","dc_title":"20210201 Concept Verslag VWS BES CAS COVID Vaccinoverleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155351","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155365","dc_title":"ter info: Terugkoppeling DOC-19 15 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155370","dc_title":"Waardebrief PBMs SAB vlucht week 07 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155370","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155373","dc_title":"Waardebrief PBMs SXM vlucht week 07 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155373","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155375","dc_title":"Waardebrief PBMs EUX vlucht week 07 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155375","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155379","dc_title":"Invoice Aruba - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155379","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155382","dc_title":"Waardebrief PBMs AUA vlucht week 07 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155382","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155385","dc_title":"FW: concept rapport modellering COVID-19 vaccinatie strategieen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155385","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155389","dc_title":"Invoice Curacao - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155389","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155393","dc_title":"Invoice Bonaire - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155393","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155397","dc_title":"Invoice Saba - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155397","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155400","dc_title":"Invoice Sint Eustatius - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155400","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155402","dc_title":"Concept Verslag 17-dec-2020 CAS COVID Vaccinoverleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155402","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155403","dc_title":"Waardebrief PBMs BON vlucht week 07 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155403","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5484","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155405","dc_title":"Invoice Sint Maarten - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155405","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155412","dc_title":"2021.02.20 NVZ.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5486","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155414","dc_title":"Concept Verslag 4-jan-2021 BES COVID Vaccinoverleg.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155420","dc_title":"C19 1006 2020 Offerteverzoek HiX voor de huisartsenzorg Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155420","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155424","dc_title":"2021.02.20 NFU.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155424","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155426","dc_title":"Offerte Bricks Huisarts.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155426","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5490","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155437","dc_title":"C19 1004 2020 Offerteverzoek CGM Huisarts Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155437","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155442","dc_title":"C19 1008 2020 Offerteverzoek OmniHisScipio Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155442","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155446","dc_title":"C19 1007 2020 Offerteverzoek MicroHIS Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155446","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155450","dc_title":"C19 1010 2020 Offerteverzoek Promedico ASP Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155450","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155452","dc_title":"object0001.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155452","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155455","dc_title":"C19 1005 2020 Offerteverzoek CGM WebHIS zorgdossier Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155455","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5496","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155457","dc_title":"object0001.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155463","dc_title":"object0001.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155463","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155469","dc_title":"C19 1011 2020 Offerteverzoek Promedico VDF Covid-19 vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155469","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155486","dc_title":"Medimo Handleiding_Covid_19_Vaccinatie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155486","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155501","dc_title":"RE: Status ketentest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155501","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155508","dc_title":"DPV_2xx Datakwaliteit maatregelen v 0.1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155508","foi_groundsOfRefusal":"5.1.1e;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155510","dc_title":"DPV_210 Aanlevering geanonimiseerde vaccinatiedata  v1.2.3.releasenotes.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155510","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155522","dc_title":"Planning COVID19 registratie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155522","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155531","dc_title":"Communicatieplan Vaccinatiebeleid.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155531","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155545","dc_title":"Inschatting kosten Movianto tbv VWS 2021 jan-juni_010321.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155545","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155550","dc_title":"FW: Achtergrond animatievideo 'Uitzondering mondkapjesplicht'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155550","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155558","dc_title":"Verslag_RIVM_spuit_test_dd210217.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155558","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5508","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155565","dc_title":"Testprotocol Prenger 1- spuiten_11feb2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155565","foi_groundsOfRefusal":"5.1.2e;5.1.2f","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155583","dc_title":"Testprotocol Prenger 1- spuiten_11feb2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155583","foi_groundsOfRefusal":"5.1.2e;5.1.2f","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155587","dc_title":"20210147 - RIVM COVID19.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155587","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155633","dc_title":"Inschatting kosten Movianto tbv VWS 2021 jan-juni.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155633","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5512","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155648","dc_title":"20210223 Thema 17 offerte JP.doc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155648","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.5","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5514","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155742","dc_title":"21150210.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155742","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155747","dc_title":"21150211.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155747","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155757","dc_title":"Duiding wekelijkse rapportage_week7_v4.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155757","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155761","dc_title":"check AZ op website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155761","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155791","dc_title":"FW: stuk voor overleg LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155791","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155817","dc_title":"Reactie BZK op vragen vaccinatiebewijzen interdepartementaal.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155817","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155840","dc_title":"RE: wetswijziging wtm ivm quarantaineplicht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155840","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155843","dc_title":"FW: input kosten vaccinaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155843","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5524","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155895","dc_title":"210302 Draaiboek vaccinatie bewoners-def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155895","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":47,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1155926","dc_title":"FW: Kopie van Berekening personeelskosten + inhuur derden + matex(verdeling 2020 + 2021) NRK SN 331471 v201221.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1155926","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156032","dc_title":"RE: uitvoeringsplan testen bij aankomst op Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156032","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156070","dc_title":"curacao veilig.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156070","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156080","dc_title":"FW: rapportage vaccinatiegezant over Aruba","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156080","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156099","dc_title":"Varianten Caribische regio v. 18-2-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156099","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156102","dc_title":"20210210 LCC Varianten.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156102","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156123","dc_title":"Overview DB RIVM 15020221_MH.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156123","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156129","dc_title":"Notulen REC bijeenkomst_04.02.2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156129","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156130","dc_title":"FW: Reactie ZKN aanvullend beleidskader, fase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156130","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156131","dc_title":"Notulen REC bijeenkomst_11.02.2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156131","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156145","dc_title":"Opdrachtbevestiging Quick Scan SFTP koppelvlak CIMS - getekend.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":18,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156150","dc_title":"EPI analyses regionale verheffingen_04.02.2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156150","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156161","dc_title":"Bijlage 199.4 Verzoek tot beantwoording LOI van vragen vanuit programmalijn BCO.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156161","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156172","dc_title":"Bijlage 199.4 Verzoek tot beantwoording LOI van vragen vanuit programmalijn BCO cv3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156172","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156181","dc_title":"EPI analyses regionale verheffingen_28.01.2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156181","foi_nrPages":14,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156185","dc_title":"Bijlage 197.2.1 LOI handreiking.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156185","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156258","dc_title":"20210216  Voorstel Moderna twente.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156258","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156261","dc_title":"Systeemdecompositie SNPG 23-02-2021- JEST.vsd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156265","dc_title":"FW: Input gesprek - Verkenning vaccinatiestelsel voor donderdaga.s.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156265","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156272","dc_title":"Systeemdecompositie Logistieke keten v10-02-2021- JEST.vsd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156272","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156295","dc_title":"d04-19-02-21-1.0-JEST.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156295","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156297","dc_title":"BES-CAS - CONCEPT - V0.83.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156297","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156407","dc_title":"FW: Verschillenanalyse CIMS versus dashboard Rijksoverheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156407","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156415","dc_title":"FW: Willen wij inzicht in call center m.b.t. afspraken van de GGD?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156415","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156427","dc_title":"Re: Financiele vraag m.b.t. vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156437","dc_title":"RE: Doelgroep omvang","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1156437","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156441","dc_title":"FW: Flits IPCR rondetafel, 22 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156441","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156442","dc_title":"FW: Ter info: call flow 088 nr RIVM COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156442","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156458","dc_title":"RE: VERTOUWELIJK - Mogelijk wijziging in vaccinatiestrategie: 1 dosis","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156458","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156469","dc_title":"FW: Vraag voor Dwarsverband: Adviesvragen mbt vanuit VWS voor deze week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156469","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156478","dc_title":"RE: Financiering entvergoedingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1156478","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156496","dc_title":"FW: Spoed: notitie LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156496","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156505","dc_title":"RE: Actie | Veegactie verpleeghuizen met Pfizer | Invullen checklist voor bredere assessment","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156505","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156517","dc_title":"Re: Antw: SPOED, Bevestiging bestelling COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156517","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156522","dc_title":"FW: Locaties en tijdstippen van de vaccinaties (reactie vereist)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156522","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156525","dc_title":"FW: Uitvraag vaccinatie klinische MSR-patienten RIVM.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156525","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156530","dc_title":"RE: Convenant ROAZ apotheken: traject 1b HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156530","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156534","dc_title":"Locaties Revant en Inschatting Surplus Covid 19 Vaccinaties Patienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156534","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156538","dc_title":"RE: Update Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156538","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156548","dc_title":"FW: SPA-NL non-paper - DL 27-01 COB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156548","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156550","dc_title":"FW: Update Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156550","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156569","dc_title":"RE: Extra levering van vaccins Pfizer/BioNTech bij levering op 2 maart a.s ivm tekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156569","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156596","dc_title":"RE: [SNPG] - Bevestiging gewijzigde bestelling COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156596","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156602","dc_title":"RE: Bestelling tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1156602","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156617","dc_title":"Bericht: bijstellen bestelling 2e vaccinatieronde","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156617","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156642","dc_title":"FW: Stukken en bespreekpunten overleg vrijdag 5 feb: pandemicpreparedness: rol FAST en HH plan.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156642","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156648","dc_title":"RE: European Partnership on Pandemic Prepardeness ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156648","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156651","dc_title":"RE: aanmelding BZ voor interdep werkgroep vaccinatie certificaten/verzoek spoedig bijeenkomen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156651","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156663","dc_title":"RE: nog enkele comments bij input VWS  Staat van de Unie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156663","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156693","dc_title":"201215 Rode Kruis Nationaal actieplan covid19staatssteuntoets_WJZ.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156693","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156695","dc_title":"Opmerking Olger_reactie AD.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156695","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156711","dc_title":"FW: AMR internationaal - offerte 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156711","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156717","dc_title":"RE: Antw: Vervolg uitnodigingen 2 prikkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156717","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156731","dc_title":"RE: Dichte vaccinflacons over","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156731","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156733","dc_title":"RE: Extra levering van vaccins Pfizer/BioNTech bij levering op 2 maart a.s ivm tekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156733","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156735","dc_title":"RE: Melding dichte flacons | AGB 41412903","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1156735","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156738","dc_title":"FW: Restanten instellingen en Haps naar GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156738","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156744","dc_title":"Updates from the Commission  (20210223).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156744","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156774","dc_title":"RE: extra vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156774","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156775","dc_title":"RE: VRAAGJE - Overgebleven flacons vaccin pfizer - St. Elisabeth AGB code 47471046 in Ben-Leeuwen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156775","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156776","dc_title":"FW: Overgebleven flacons vaccin pfizer - St. Elisabeth AGB code 47471046 in Ben-Leeuwen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156776","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156782","dc_title":"Aanpassingen nieuwe verordening","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156782","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156783","dc_title":"FW: Overgebleven flacons vaccin pfizer - St. Elisabeth AGB code 47471046 in Ben-Leeuwen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156783","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156794","dc_title":"FW: overgebleven PFizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156794","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156795","dc_title":"RE: vaccins volgende week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156795","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156811","dc_title":"RE: Convenant ROAZ apotheken: traject 1b HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1156811","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156817","dc_title":"RE: Eerste prikken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156817","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156830","dc_title":"RE: [SNPG] - Bevestiging gewijzigde bestelling COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156830","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5596","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156834","dc_title":"RE: Bestelling tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1156834","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156836","dc_title":"RE: 2de COVID-Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156836","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156846","dc_title":"RE: Veegactie vraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156846","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156847","dc_title":"RE: microplanning SNPG bestellen Zeeland en Limburg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156847","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156851","dc_title":"RE: Bestelling tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156851","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156858","dc_title":"RE: vraag overgebleven (geprepareerde) COVID vaccins Pfizer/BioNTech vaccin (Comirnaty)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156858","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156864","dc_title":"RE: signalen vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156864","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156865","dc_title":"RE: Bestelling tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156865","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156866","dc_title":"RE: Notitie ter voorbereiding op het bestuurlijk overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156866","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156870","dc_title":"RE: M2102 2420: MC21018 cold chain incident Noorderzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156870","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156874","dc_title":"Antw:  signalen vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156874","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156880","dc_title":"RE: Uitvoeringsrichtlijn huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156880","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156884","dc_title":"RE: Spillage protocol tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156884","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156899","dc_title":"RE: Vragen vaccinatieproces Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156899","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156905","dc_title":"RE: Eerste versie agenda en nota BO 2-3-2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156905","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156906","dc_title":"RE: flacon Covid vaccin Pfizer over","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156906","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156909","dc_title":"RE: flacons pfizer vaccin over","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156909","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156916","dc_title":"RE: Tweede prik voorbereidingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156916","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156924","dc_title":"FW: Tweede prik voorbereidingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156924","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156929","dc_title":"Agenderen voor MT morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156929","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156957","dc_title":"RE: Algemene spreektekst-skp+mh","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156957","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156966","dc_title":"2021-02-22 Agenda IPCR RT_REV1.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156966","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156968","dc_title":"22022021 IPCR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156968","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156969","dc_title":"RE: wegprikken Pfizer ter voorkoming van spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156969","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156977","dc_title":"RE: VRAAGJE - Overgebleven flacons vaccin pfizer - St. Elisabeth AGB code 47471046 in Ben-Leeuwen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156977","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156978","dc_title":"RE: vragen tav prijs en financiele bepalingen Covid 19 vaccinatie campagne","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156978","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156980","dc_title":"Re: spillage 2e vaccinatie BioNTech/Pfizer van WZH naar GGD","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156980","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156985","dc_title":"FW: AMI contract","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156985","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156987","dc_title":"RE: vaccins volgende week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156987","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156988","dc_title":"RE: Uitvraag voor veegronde - traject 1a","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156988","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156991","dc_title":"2021-02-15 WLRT Agenda.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156991","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1156996","dc_title":"RE: Bestelling tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1156996","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157000","dc_title":"RE: vaccintransport ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157000","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157003","dc_title":"RE: Invloed uitbraak corona op 2e vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157003","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157014","dc_title":"RE: Vraag vanuit Support","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157014","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157019","dc_title":"RE: nieuwe versies nota: moeilijk bereikbare doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157019","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157020","dc_title":"RE: Spillage protocol tweede prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157020","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157021","dc_title":"FW: aantekeningen gesprek Ronnie rivm","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157021","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157022","dc_title":"RE: Gezondheidsverklaring/vragenlijst(en) covid-19 vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157027","dc_title":"RE: DOI agenda 16 februari 2021 + overige stukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157038","dc_title":"RE: optrekspuiten en 7e vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157038","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157039","dc_title":"Briefadvies Planbureaus voor herstelbeleid. Een doorstart van de samenleving ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157039","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157054","dc_title":"FW: Controleren aanmeldingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157054","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157056","dc_title":"FW: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157056","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157061","dc_title":"RE: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1157061","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157067","dc_title":"FW: internet pagina https://www.rivm.nl/covid-19-vaccinatie/professionals/zorginstellingen-vaccinatie-bewoners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157067","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157068","dc_title":"RE: Afspraak inplannen | Doelgroepoverzicht t.b.v. allocatie/planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157068","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157080","dc_title":"FW: mijn laatste actiepunt van vorige week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157080","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157086","dc_title":"FW: Gesprek VWS over Asielzoekers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157086","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157169","dc_title":"Pandemic Preparedness Partnerschap - t.b.v. BO morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157169","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157189","dc_title":"Note from the Presidency 08FEB.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157189","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157200","dc_title":"21_02_08 WLRT COVID-19 - Agenda.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157200","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157208","dc_title":"20210208_Communicatieplan aanvullend beleidskader fase 3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157208","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157213","dc_title":"Stukken n.a.v. de (niet) presentatie vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157213","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157217","dc_title":"RE: OMT Verslag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157217","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157251","dc_title":"20210215_Bottlenecks bij opschaling naar 2,5m.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157251","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157255","dc_title":"210202 Draaiboek vaccinatie bewoners v0.22.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157255","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":42,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157278","dc_title":"bestellen vaccins klinische patienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157278","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157289","dc_title":"218740 akkoord min VWS op nota.pdf.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157289","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157297","dc_title":"Convenant RIVM - Revalidatiecentra DEF.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157297","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157300","dc_title":"D. Brief patienten vaccinatie nieuw opgenomen_v2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157300","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5660","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157311","dc_title":"G. Werkdocument kliniek artsen ten behoeve van covid vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157311","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157313","dc_title":"I. Taakverdeling bij het vaccineren.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157313","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157324","dc_title":"FW: alarmerend bericht bijwerkingen AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157324","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157326","dc_title":"A. algemene verantwoordelijkheden vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157326","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157335","dc_title":"H. Werkwijze overgebleven vaccins COVID-19 Euregio.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157335","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157354","dc_title":"Aantekeningen SdW.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157354","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157361","dc_title":"AOB_Pandemic Preparedness note.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157361","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5669","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157378","dc_title":"FW: besluitvorming doelgroepen 100221 cs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157378","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5670","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157383","dc_title":"FW: Antw: chjeck","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157383","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5671","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157408","dc_title":"FW: Twee non papers (conference Europe + Pandemic Alliance/vaccins)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157408","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5672","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157412","dc_title":"RE: Ter beoordeling: nota EU Gezondheidsraad + bijlagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5673","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157417","dc_title":"FW: Marjolein CC email: Intern of uitgaand stuk betreffende 'Nota terbeslissing M MZS Kamerbrief verslag informele EU gezondheidsministersbijeenkomsten 2 en 3 oktober en 2 december 2020 (zaaknummer: 218036)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157417","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5674","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157418","dc_title":"Motie Segers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157418","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5675","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157429","dc_title":"FW: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157429","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5676","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157434","dc_title":"FW: vervolg overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157434","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5677","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157440","dc_title":"RE: Vragen beantwoorden Public Health England (donderdagochtend)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157440","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157488","dc_title":"FW: Slides new","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157488","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157493","dc_title":"FW: werkinstructie huisarts","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157493","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157498","dc_title":"RE: Marjolein CC email: Intern of uitgaand stuk betreffende'Informeel EU Ministers Volksgezondheid 1 maart 2021 (zaaknummer: 218932)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157498","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157499","dc_title":"RE: Marjolein CC email: Intern of uitgaand stuk betreffende'Informeel EU Ministers Volksgezondheid 1 maart 2021 (zaaknummer: 218932)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157499","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157504","dc_title":"RE: Reinier/Zeeland vraag over \"Immuun gecompromitteerden\"","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157504","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157506","dc_title":"FW: aantallen medisch onderliggend lijden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157506","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157518","dc_title":"RE: Uitvoeringsrichtlijn huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157532","dc_title":"Nav vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157532","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157556","dc_title":"2021 MIRs - Hcare- NL Versie def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157556","foi_nrPages":13,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157558","dc_title":"20210204 Verslag VC Gezaghebbers.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157558","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157559","dc_title":"20210224 Coronavaccinatie inbreng Pati\ufffdnten en Clientenorganisaties BO 2 maart, bijlage bij ....docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157559","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157561","dc_title":"FW; Aansluiten overleg ma 1 maart 11-12 over vaccinatie medische risicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157561","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157569","dc_title":"FW: Definitie hoog risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157569","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157572","dc_title":"RE: Orderbevestiging 130610: 012538 Coronavirus tekeningen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157572","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157583","dc_title":"RE: Naam comirnaty op de verpakking","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157583","foi_groundsOfRefusal":"5.1.2e;5.1.2f;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157592","dc_title":"RE: Orderbevestiging 130610: 012538 Coronavirus tekeningen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5696","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157594","dc_title":"RE: Aantal positieve testen naar leeftijd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157594","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5697","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157596","dc_title":"FW: DBC-codes transplantatiepatienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157596","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5698","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157601","dc_title":"RE: Eerste opzet concept Plan van Aanpak voor Medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157601","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157603","dc_title":"FW: DBC-codes transplantatiepatienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157603","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157608","dc_title":"FW: DBC-codes transplantatiepatienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157608","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157610","dc_title":"FW: DBC-codes transplantatiepatienten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157610","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157614","dc_title":"RE: DBC-codes voor spierziekten patienten met (dreigende) ademhalingsspierzwakte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157614","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157616","dc_title":"FW: DBC-codes voor pt met primaire immuundef.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157616","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157617","dc_title":"FW: RIVM-advies en impact op programma","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157617","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5705","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157619","dc_title":"Antw:  communicatie tav 15 min observatietijd HA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157619","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157626","dc_title":"RE: planningstool huisarts covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157626","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5707","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157630","dc_title":"Bottlenecks opschaling aantal vaccinaties 3 slides.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157630","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5708","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157643","dc_title":"FW: LHV memo ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157643","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157651","dc_title":"RE: Marjolein CC email: Intern of uitgaand stuk betreffende 'Beleidsregel corona Wlz en meerkosten vaccinatie (zaaknummer: 217154)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157651","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157698","dc_title":"RE: 2de COVID-Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157698","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5711","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157722","dc_title":"RE: GGD vangnet - uitzonderingssituaties 2e prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1157722","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5713","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157729","dc_title":"RE: Bestellen vaccins verzorgingshuisbewoners","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157729","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5714","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157733","dc_title":"210129 Nota ter info - stand van zaken testen en vaccineren.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157733","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5716","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157794","dc_title":"Aanvraag modeldoorrekening tbv levering Covid-19 vaccins voor doelgroep.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157794","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5717","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157804","dc_title":"20210219 Voortgang DGSC-19 voorbereid de crisis door - impactanalyse enlessen_AD.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157804","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5718","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157806","dc_title":"RE: DBC-codes voor pt met primaire immuundef.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157806","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5719","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157808","dc_title":"210117_Concept Flowchart Project 1b RIVM v3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157808","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5720","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157810","dc_title":"RE: DBC-codes patienten nefrologen: nabrander","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157810","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5721","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157816","dc_title":"RE: 2 vragen over vaccinaties zorginstellingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157816","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5722","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157837","dc_title":"RE: Def tekst - Desinformatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157837","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5723","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157855","dc_title":"Herziening Covid-19 vaccinatie begroting","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157855","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5724","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157857","dc_title":"012501_Registratiekaart-Coronavaccinatie_V5_TGbev.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157857","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5725","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157875","dc_title":"FW: low dead space naald uitproberen - poolen bij GGD Apeldoorn?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157875","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5726","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157894","dc_title":"Brief inzet AstraZeneca VERSIE 23.00 cs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157894","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5727","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157895","dc_title":"FW: Omega Logistics - GDP transport - vaccin distributie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157895","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5728","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157909","dc_title":"FW: communicatie frame logistiek tbv video - verzoek MinVWS - input vandaag svp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157909","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5729","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157921","dc_title":"RE: Doorrekening extra 10kd doses Pfizer - instellingen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157921","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5730","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157928","dc_title":"FW: Doorst:  New Product Introduction Management","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157928","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5731","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157949","dc_title":"FW: Ter informatie: ACC versie concept Kamerbrief Flankerend beleid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157949","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5732","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157955","dc_title":"minutes joint H2020-HE Health meeting 15-2-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157955","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5733","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1157963","dc_title":"Claim COVID ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1157963","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5735","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158017","dc_title":"FW: Commissiemededeling Verenigd Front","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158017","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5736","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158051","dc_title":"FW: CONCEPT - Accountantsprotocol opschaling IC COVID19 05022021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158051","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5737","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158078","dc_title":"FW: concept kabinetsstandpunt vaccinatiebewijzen versie 12 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158078","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5738","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158079","dc_title":"aantal_meldingen_per_leeftijdsgroep_20210305.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158079","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5739","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158087","dc_title":"Orderbevestiging 130610.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158087","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5741","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158108","dc_title":"20210203 COVID vaccinatie huisartsen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158108","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5742","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158111","dc_title":"210217 Nieuwsbericht interval 1e en 2e vaccinatie[10].pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158111","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5743","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158117","dc_title":"Omega Logistics - Vaccin distributie.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158117","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5744","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158148","dc_title":"FW: ONJUISTHEDEN BESLUITNOTA DPV 198  (en DPV 232)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158148","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5745","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158153","dc_title":"FW: Doorst: 210224 IB analyse koppelpunten aanleverende partijen v1.1 CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158153","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5746","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158166","dc_title":"RE: CRP II // COVID-19 EU coordination: vaccines // woensdag 17februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158166","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5747","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158167","dc_title":"FW: Voorbereidingen DPIA fase vii- monitoring ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158167","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5748","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158169","dc_title":"Presentation MoH Netherlands_20210216.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1158169","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5749","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158183","dc_title":"RE: Voorzet IPCR maandag 8 feb. as. (10:00 uur)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5750","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158184","dc_title":"CRP II instructie COVAX / vaccin donaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1158184","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5751","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158192","dc_title":"Doorst:  IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5752","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158203","dc_title":"FW: IB&P COA & Probas uitvoeren - CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1158203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5753","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158204","dc_title":"Eerste analyse clientportaal + QS AVG (RIVMtoegang, Clientportaal)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158204","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5754","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158209","dc_title":"Coronapersconferentie 2 februari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158209","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5755","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158218","dc_title":"COVID deel GA RAZ en ER feb opm Wilm- HS -","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158218","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5756","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158245","dc_title":"Procesplaten - VKA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158245","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5757","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158269","dc_title":"FW: Email t.b.v. informeren ziekenhuisbestuur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158269","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5758","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158278","dc_title":"FW: Jaargesprek RIVM - NVDA ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158278","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5759","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158281","dc_title":"FW: CRPII geannoteerde draft agenda voorbereiding ER","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5760","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158283","dc_title":"FW: laatste versie presentatie: powerpoint vaccinatiebeleid VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158283","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5761","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158289","dc_title":"FW: DEFINITIEVE instructie Voorbereiding VTC ER //  Coreper II //woensdag 10 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158289","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5762","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158293","dc_title":"RE: Debat voorbereiding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158293","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5763","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158323","dc_title":"Opmerking vraag Actiz ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158323","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5764","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158340","dc_title":"FW: SPOED Concept ER verklaring 25/26 februari - evt input voorCoreper instructie deadline vandaag 14:00u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158340","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5765","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158355","dc_title":"FW: SPOED Concept ER verklaring 25/26 februari - evt input voorCoreper instructie deadline vandaag 14:00u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158355","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5766","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158359","dc_title":"RE: SPOED Concept ER verklaring 25/26 februari - evt input voorCoreper instructie deadline vandaag 14:00u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158359","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5767","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158361","dc_title":"repack details","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158361","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5768","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158365","dc_title":"RE: RIVM (COVID-19) - MOV Operational Framework","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5769","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158367","dc_title":"RE: repack details AZ-Moderna en hulpmiddelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158367","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5770","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158368","dc_title":"RE: onderzoek gebruiksgemak spuiten en naalden COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158368","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5771","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158369","dc_title":"FW: Overzicht GGZ instellingen AZ, wens tot repack ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158369","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5772","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158373","dc_title":"RE: Leveringen vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158373","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5773","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158379","dc_title":"COVID vaccinaties voor ambassadepersoneel 3e wereld","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158379","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5774","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158380","dc_title":"FW: vragen IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158380","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5775","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158381","dc_title":"FW: Aanbiedingsbrief extra beveiliging opslaglocaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158381","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5776","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158383","dc_title":"FW: Extreem weer aanpak","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158383","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5777","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158392","dc_title":"RE: AZ vaccin update eerste leveringen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158392","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5778","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158399","dc_title":"RE: onderzoek gebruiksgemak spuiten en naalden COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158399","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5779","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158413","dc_title":"Doorst:  low dead space naald uitproberen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158413","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5780","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158422","dc_title":"RE: gebruikservaring Prenger spuit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158422","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5781","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158425","dc_title":"FW: Prenger spuiten - testprotocol opzet","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158425","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5782","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158442","dc_title":"FW: Ter info: Vlaams - Nederlandse top 4 november","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158442","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5783","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158443","dc_title":"RE: SPOED Vlaams - Nederlandse top 4 november","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158443","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5784","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158450","dc_title":"Verslag overleg beveiligingsmaatregelen 11-02-2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158450","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5785","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158461","dc_title":"FW: Interdepartementaal directeurenoverleg inz. beveiliging - verslag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158461","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5786","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158463","dc_title":"Vlaams - Nederlandse top 4 november","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158463","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5788","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158494","dc_title":"RE: Uitvraag agendapunten PO -","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158494","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5789","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158495","dc_title":"RE: Besluit vaccinatie huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158495","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5790","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158502","dc_title":"Review privacy verklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158502","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5791","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158512","dc_title":"Privacyverklaring met comments","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158512","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5792","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158527","dc_title":"01 xxx Prov. agenda.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158527","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5793","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158528","dc_title":"02.1 xxx GA ER.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158528","foi_groundsOfRefusal":"buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5794","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158529","dc_title":"02.2 xxx Verslag VTC ER COVID-19 van 21 januari 2021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158529","foi_groundsOfRefusal":"buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5795","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158531","dc_title":"03 xxx REA notitie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158531","foi_groundsOfRefusal":"5.1.2a;5.1.2e;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5796","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158534","dc_title":"02.3 xxx Verslag ER van 10 en 11 december 2020.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158534","foi_groundsOfRefusal":"buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5797","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158537","dc_title":"06.2 xxx Bijlage II - FS CIE-mededeling Hera Incubator.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158537","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5798","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158542","dc_title":"06.4 xxx Bijlage IV - FS non-paper CIE EU Vaccin Sharing Mechanism.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158542","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5800","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158564","dc_title":"06.3 xxx Bijlage III - Non-paper CIE EU Vaccin Sharing Mechanism.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158564","foi_nrPages":4,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5801","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158575","dc_title":"FW: DVP_Motivering directe aankoop extra  spuiten en naalden SJJ Solutions - 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158575","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5802","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158579","dc_title":"De getallen rond vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158579","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5803","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158593","dc_title":"DVP_Motivering directe aankoop extra  spuiten en veiligheidsnaalden Prenger Healthcare dec. 2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158593","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5804","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158609","dc_title":"vaccin voorbereiding Pfizer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158609","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5805","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158653","dc_title":"FW: Vraag website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158653","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5806","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158659","dc_title":"update dossier notaoverleg Veldman","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158659","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5807","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158671","dc_title":"RE: SAGE werkgroep over AstraZeneca ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158671","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5808","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158693","dc_title":"stavaza 3 ontwikkelingen rondom uitz mondkapjes: check MT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158693","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5809","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158705","dc_title":"RE: gewijzigde versie ER conclusies - deadline input Coreperinstructie dinsdag 16/2 11:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158705","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5810","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158727","dc_title":"FW: Vervolgstappen dataplatform en gerelateerde acties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158727","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5811","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158730","dc_title":"FW: Callcenter","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158730","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5812","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158750","dc_title":"FW: 23 02 2021 Notitie LHV tweede kwartaal rev","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158750","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5813","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158763","dc_title":"FW: notitie LHV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158763","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5814","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158777","dc_title":"RE: kamervragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158777","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5817","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158890","dc_title":"Motivering COVID-19 studie v0.3 - juridische toets","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158890","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5818","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158896","dc_title":"RE: Callcenter","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158896","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5819","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158924","dc_title":"RE: ter info: Commissiemededeling ER toelichting John Ryan in HorizonPC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158924","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5820","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158942","dc_title":"Flits IPCR rondetafel, 1 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158942","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5821","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158944","dc_title":"Flits Coreper II - 17 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158944","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5822","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158949","dc_title":"FW: COVID Outbound - levering aan BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158949","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":24,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5823","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158950","dc_title":"flitsen CRP I en CRP II","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158950","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5824","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158952","dc_title":"Flits RWG Pharma 23 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158952","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5825","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158956","dc_title":"Flits VC RWG  HTA 19 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158956","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5826","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158966","dc_title":"RE: Retour transportbox","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158966","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5827","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158969","dc_title":"RE: Opties transport SXM naar Saba/Statia //","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158969","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5828","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158971","dc_title":"RE: Temp deviation BON shipment (074-42488423)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158971","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5829","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158978","dc_title":"FW: 1 februari 2021 / Wekelijkse update Corona in Belgi\ufffd en Luxemburg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158978","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5830","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158987","dc_title":"FW: 5 februari / Update Corona in Belgi\ufffd n.a.v. besluitvorming Overlegcomit\ufffd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158987","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5831","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158990","dc_title":"RE: Opties transport SXM naar Saba/Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158990","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5832","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158991","dc_title":"FW: Aanwijzing IGJ als bevoegde instantie EU exportverbodCovidvaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158991","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5833","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158995","dc_title":"FW: Actielijst n.a.v. overleg Exportauthorisatie Vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158995","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5834","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1158996","dc_title":"RE: begeleiding vluchten Saba Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1158996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5835","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159009","dc_title":"FW: agendapunten  en brief met onderzoeken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159009","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5836","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159010","dc_title":"FW: Agenda werkgroep kwetsbare groepen 4-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159010","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5837","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159015","dc_title":"FW: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1159015","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5838","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159023","dc_title":"FW: Agenda werkgroep kwetsbare groepen 4-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159023","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5839","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159024","dc_title":"RE: Wil je een eerste blik werpen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159024","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5840","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159026","dc_title":"RE: Confirmation of receipt by World Courier agent for vaccine distribution Dutch Caribbean ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159026","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5841","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159032","dc_title":"FW: Opties transport SXM naar Saba/Statia //","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159032","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5842","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159043","dc_title":"RE: ICAO State letter 2021/08: COVID-19 Testing and Cross-border Risk Management Measures + Vragen over vaccin distributie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159043","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5843","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159045","dc_title":"RE: Temp deviation BON shipment (074-42488423)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159045","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5844","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159050","dc_title":"FW: COVID 19 vaccinatie rollout & capacity planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159050","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5845","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159052","dc_title":"Doorst:  aanvullende instructies voor verwerken temploggers Comirnaty ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159052","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5846","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159072","dc_title":"Afmetingen en ontvangstbevestiging transport 19-2-21","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159072","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5847","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159074","dc_title":"FW: COVID Outbound - levering aan BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159074","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5848","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159085","dc_title":"FW: COVID Outbound - levering aan BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159085","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5849","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159096","dc_title":"FW: aanpassing planning v 17","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159096","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5850","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159101","dc_title":"RE: kamervraag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159101","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5851","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159104","dc_title":"FW: Bijkomende kosten inzet Tempo Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159104","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5852","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159120","dc_title":"Doorst:  wanneer is er AZ voor 50-59 --> vraag voor in de kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159120","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5853","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159127","dc_title":"RE: wanneer is er AZ voor 50-59 --> vraag voor in de kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159127","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5854","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159132","dc_title":"FW: Publicatie Vaccinatiecijfers ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159132","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5855","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159140","dc_title":"RE: Call centrum en AstraZeneca.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159140","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5856","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159147","dc_title":"FW: spoed: AZ leveringen verminderd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159147","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5857","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159157","dc_title":"RE: eerste prik AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159157","foi_groundsOfRefusal":"5.1.1d;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5858","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159159","dc_title":"FW: Coreper I flits - 10 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159159","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5859","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159161","dc_title":"FW:  COVID vaccin BES CAS -WEEK 7 // invoices met HS codes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159161","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5860","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159165","dc_title":"FW: Covid update ROM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159165","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5861","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159167","dc_title":"FW: Corona contact tracing and Social distancing tracking","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159167","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5862","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159173","dc_title":"RE: eerste prik AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159173","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5863","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159195","dc_title":"FW: RIVM intern dataoverzicht","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159195","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5864","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159209","dc_title":"Lijst van parameters nu in programma dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159209","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5865","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159218","dc_title":"RE: kiesmenu t.b.v. vaccinatie vragen ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159218","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5866","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159220","dc_title":"Overzicht parameters programma dashboard","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159220","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5868","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159258","dc_title":"No Subject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159258","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5869","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159268","dc_title":"FW: Factsheet LCPS mid term scenario's IC-capaciteit (prognoses)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159268","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5870","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159281","dc_title":"RE: Vraag website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5871","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159287","dc_title":"FW: Follow-up discussion Janssen COVID-19 Vaccine","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159287","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159290","dc_title":"FW: bureaukaart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159290","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5872","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159295","dc_title":"RE: Convenant ROAZ apotheken: traject 1b HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159295","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5873","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159297","dc_title":"FW: HA en ouderen v1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159297","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5874","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159318","dc_title":"FW: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159318","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5875","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159322","dc_title":"FW: HERA - Inception Impact Assessment Consultation - Deadline 24 Feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159322","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5876","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159328","dc_title":"FW: Herverdeling IC-bedden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159328","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5877","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159330","dc_title":"FW: HERA Incubator reactie -","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159330","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5878","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159333","dc_title":"FW: 7-institutenoverleg ma 15 februari a.s. agenda en stukken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159333","foi_groundsOfRefusal":"5.1.2d;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5879","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159337","dc_title":"FW: Grootschalige laboratoria contract VWS / U-Diagnostics factuur21150210 / 21150211","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159337","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5880","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159344","dc_title":"FW: HSC audio meeting","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159344","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2h","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5881","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159360","dc_title":"FW: Vaccinatie Beschermd Wonen en GGZ - besluitvorming ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5882","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159365","dc_title":"RE: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159365","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5883","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159367","dc_title":"RE: Powerpoint presentatie vervolgsessie, exceloverzicht aanleveren aantallen en communicatiebericht toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159367","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5884","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159368","dc_title":"RE: Vervolg BioNTech/Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159368","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5885","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159371","dc_title":"FW: Input standaard burgerbrieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159371","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5886","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159374","dc_title":"PFZIER HAP ALMERE-RE: Powerpoint presentatie vervolgsessie, exceloverzicht aanleveren aantallen en communicatiebericht toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159374","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5887","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159379","dc_title":"RE: Powerpoint presentatie vervolgsessie, exceloverzicht aanleveren aantallen en communicatiebericht toestemmingsverklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159379","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5888","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159395","dc_title":"RE: Startsessie vaccinatietraject covid19 HAPs Moderna","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159395","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5889","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159401","dc_title":"FW: Input stavaza kernteam LNAZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159401","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5890","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159403","dc_title":"HKN HUiSARTSEN VOORKEUR ZIEKENHUISAPOTHEEK PFIZER","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159403","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5891","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159404","dc_title":"RE: Selectie Moderna week 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159404","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5892","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159405","dc_title":"AANVULLING GELDERS RIVIERENLAND RE: Werkinstructie HAP MODERNA- aankondiging startbijeenkomst 9 februari  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159405","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5893","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159412","dc_title":"FW: Tussentijdse bijstelling aantal patienten coronavaccinatie Modernavaccin Huisartsenposten De LIMES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159412","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5894","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159413","dc_title":"MEDRIE Werkinstructie HAP MODERNA- aankondiging startbijeenkomst 9 februari  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159413","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5895","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159415","dc_title":"RE: Werkinstructie HAP PFIZER- aanmelding aantal vaccins en leveringsadres","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159415","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5896","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159419","dc_title":"RE: [SNPG] - Bevestiging bestelling briefpapier met infographic COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159419","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5897","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159422","dc_title":"RE: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159422","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5898","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159426","dc_title":"FW: Planning en link platform vaccinatie VGN","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159426","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5899","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159428","dc_title":"RE: HAP regio's Moderna- 1e prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159428","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5900","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159429","dc_title":"RE: SPOEDZORGNU Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159429","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5901","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159430","dc_title":"FW: IRHP / Instructie vrijwaringscomite","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159430","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5902","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159441","dc_title":"FW: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159441","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5903","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159469","dc_title":"CovidSituation_CountryCriteria_complete_2021-02-18.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159469","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5904","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159471","dc_title":"20210215 IPCR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159471","foi_groundsOfRefusal":"5.1.2i OMT","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5906","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159478","dc_title":"Fw: Koppelvlakken en koppelingen CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159478","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5907","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159493","dc_title":"Ecosysteem COVID 19 vaccinatie.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159493","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":25,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5909","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159505","dc_title":"RE: Werkinstructie HAP MODERNA- aankondiging startbijeenkomst 9 februari  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159505","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5910","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159511","dc_title":"Operational Conclusions - IPCR Roundtable 22 February COVID-19.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159511","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5911","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159513","dc_title":"RE: Vervolg BioNTech/Pfizer ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159513","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5912","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159515","dc_title":"RE: Inzet zorgkantoren overzichtslijsten HAP traject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159515","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5913","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159517","dc_title":"Re: Werkinstructie HAP PFIZER- aankondiging startbijeenkomst 9 februari ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159517","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5914","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159522","dc_title":"FW: Nieuwsbericht en werkinstructie vaccinatie bewoners HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159522","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5915","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159534","dc_title":"FW: mail Ernst BO mmb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159534","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5917","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159551","dc_title":"FW: Medewerkers zorginstellingen met eerste prik","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159551","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159561","dc_title":"RE: Bernadette LeDoux neemt tijdelijk mijn plaats in","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159561","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5918","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159577","dc_title":"FW: Nadere info t.b.v. mondneusmaskers ASML en Chemistry NL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159577","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5919","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159578","dc_title":"FW: Moties en toezeggingen coronadebat 4 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159578","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5920","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159581","dc_title":"RE: 1 miljoen mensen niet vaccineren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159581","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5921","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159584","dc_title":"FW: vragen over stof in vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159584","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5922","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159585","dc_title":"FW: Nieuwe informatie RIVM en NHG vaccinatie wooninitiatieven","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159585","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5923","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159592","dc_title":"RE: Vraag Twentsche Courant Tubantia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5924","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159597","dc_title":"RE: eerste prik AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159597","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5925","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159598","dc_title":"RE: Link vaccinatiestrategie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159598","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5926","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159614","dc_title":"FW: notes 10-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159614","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5927","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159618","dc_title":"FW: NVZ-reactie op VWS-notitie inzake Uitgangspunten beleidskaderfase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159618","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5928","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159627","dc_title":"FW: zuid afrikaanse variant en astrazeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159627","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5929","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159642","dc_title":"annotatie voor het overleg met programmadirectieCOVID op 2 maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159642","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5930","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159643","dc_title":"RE: Brief minister de Jonge: COVID-vaccinatie GGZ-bewoners kleinschalige woonvormen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159643","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5931","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159668","dc_title":"FW: Onderdeel testen en traceren Kamerbrief 02/02/2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159668","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5932","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159683","dc_title":"RE: Link vaccinatiestrategie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159683","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5934","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159692","dc_title":"FW: Overkoepelend uitvoeringsoverleg 18 februari a.s.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159692","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5935","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159696","dc_title":"FW: Overzicht covid (gerelateerde) dossiers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159696","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5936","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159703","dc_title":"RE: Planning communicatie vaccinatie wk 6","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159703","foi_groundsOfRefusal":"5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5937","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159712","dc_title":"RE: nieuwsbericht 80-84-jarigen + huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159712","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5938","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159726","dc_title":"FW: pilot testen voor mantelzorgers mensen die niet gevaccineerdkunnen worden (BO 2 maart)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159726","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5939","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159748","dc_title":"EA_5 v 0.1 27012021.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159748","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":12,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5940","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159750","dc_title":"RE: Notulen werkgroep vaccinatie zorgmedewerkers ziekenhuizen en klinieken ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159750","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5941","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159751","dc_title":"RE: Notulen werkgroep vaccinatie zorgmedewerkers ziekenhuizen en klinieken ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159751","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5942","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159756","dc_title":"RE: [Spam] RE: Bedankt voor uw aanmelding.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159756","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5943","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159757","dc_title":"Fw: Aantekeningen overleg vaccineren ziekenhuismedewerkers en klinieken 11-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159757","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5944","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159777","dc_title":"FW:  Vaccinatieuitvraag hoogrisico-nierpati\ufffdnten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159777","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5945","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159781","dc_title":"RE: COVID vaccinatie pati\ufffdnten uit medische risicogroepen in het ziekenhuis? Ziekenhuis Rijnstate in Arnhem","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159781","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5946","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159784","dc_title":"FW: COVID vaccinatie patienten uit medische risicogroepen in het ziekenhuis?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159784","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5947","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159797","dc_title":"Praktijkhandleiding pagina over komende huisartsen inspanningen COVID-19-vaccinatie o.a. AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159797","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5948","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159839","dc_title":"FW: Handleiding huisartsenposten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159839","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159865","dc_title":"RE: Vaccineren groepen met sterk verhoogd risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159865","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5949","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159886","dc_title":"FW: Graag akkoord tekenen Curacao contract AMI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159886","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5950","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159917","dc_title":"FW: Risicoanalyse en Controleprotocol Regeling IC-opschaling enAanpassing subsidieregime i.r.t. COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5951","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159920","dc_title":"FW: SAGE werkgroep over AstraZeneca ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159920","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5952","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159929","dc_title":"FW: SPOED gewijzigde versie conclusies ER COVID","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159929","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5953","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159931","dc_title":"FW: Signalen/punten Ieder(in) voor Overleg dinsdag 9 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159931","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5954","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159937","dc_title":"RE: Uitleg ontheffingsprocedure voor zelftesten voor publicatie op rijksoverheid.nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159937","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5955","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159938","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159938","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5956","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159939","dc_title":"RE: beoordeling antigeentesters","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159939","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5957","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159941","dc_title":"FW: lukt vandaag het zinnetje mbt vergelijking zelftest vs professionele test?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159941","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5958","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159944","dc_title":"FW: SARS CoV 2 Rapid AG Test zur Eigenanwendung - BfArM Sonderzulassung 5640 - S-025/21- weitere Unterlagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159944","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5959","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159947","dc_title":"RE: Eerste meeting beoordeling antigeentesten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159947","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5960","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159965","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159965","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5961","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159972","dc_title":"210223 Nieuwe figuren v3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159972","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5962","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1159991","dc_title":"FW: Deltaplan beschikbaarheid hulpmiddelen voor de zorg 2.0 2020-10-11.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1159991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5963","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160005","dc_title":"RE: Offerte rioolwatermetingen Covid-19 middelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160005","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5964","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160023","dc_title":"FW: microplanning SNPG bestellen Zeeland en Limburg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160023","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5967","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160054","dc_title":"210218 Update figuren berg en staafjes.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160054","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5968","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160083","dc_title":"Voor Nota passage HERA incubator - PhvD.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160083","foi_groundsOfRefusal":"5.1.2a","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5969","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160091","dc_title":"RE: Email n.a.v. overleg van vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160091","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5970","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160092","dc_title":"FW: Support NPPU evaluatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160092","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5971","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160093","dc_title":"Re: Distributieplan restant Moderna vaccins t.b.v. Onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160093","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5972","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160098","dc_title":"FW: DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160098","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5973","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160100","dc_title":"RE: Overleg Medische Doelgroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160100","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5974","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160103","dc_title":"FW: ter info inbreng Per Saldo, KansPlus en Ieder(in) voorcoronadebat morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160103","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5975","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160108","dc_title":"FW: Signalen over ontvangst brieven perifere ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160108","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5976","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160110","dc_title":"FW: DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160110","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5977","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160113","dc_title":"FW: Ter akkoord: Zinnen over APA in hera incubator kamerbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160113","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5978","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160116","dc_title":"FW: Uitgangspunten beleidskader fase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1160116","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5979","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160118","dc_title":"FW: Signalen over ontvangst brieven perifere ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160118","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5980","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160122","dc_title":"RE: Email t.b.v. informeren ziekenhuisbestuur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160122","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5981","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160124","dc_title":"RE: Mail t.b.v. ziekenhuis bestuur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160124","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5982","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160138","dc_title":"FW: Uitvraag gecertificeerde FFP2-mondneusmaskers, in Nederland/EUgeproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1160138","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5983","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160140","dc_title":"RE: belevering ihk VOICE studie URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160140","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5984","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160143","dc_title":"FW: uitnodiging door gemeente sudwest-fryslan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160143","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5985","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160153","dc_title":"2 Moderna flacons over in Radboud","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160153","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5986","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160159","dc_title":"RE: Berichtgeving aan leden van werkgroep COVID-19-vaccinatie van immuungecompromitteerde pati\ufffdnten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160159","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5987","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160164","dc_title":"RE: Doorst:  belevering ihk VOICE studie URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160164","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5988","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160167","dc_title":"RE: Distributieplan restant Moderna vaccins t.b.v. Onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160167","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5989","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160174","dc_title":"FW: Vaccins EU en NL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160174","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5990","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160183","dc_title":"RE: Distributieplan restant Moderna vaccins t.b.v. Onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160183","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5991","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160189","dc_title":"FW: vaccinatiebewijs planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160189","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5992","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160200","dc_title":"RE: Stavaza","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160200","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5993","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160206","dc_title":"FW: Versnelde aanbestedingsprocedure - richtsnoeren Europese Commissie Covid19-crisis veroorzaakte noodsituatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160206","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5994","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160216","dc_title":"Re: onrust rond naar achter schuiven vaccinatie zorgpersoneel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160216","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5995","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160217","dc_title":"RE: selectie van neurologische patienten voor prioritering covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160217","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5996","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160218","dc_title":"FW: Vervoer Rode Kruis (niet begeleid vervoer)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160218","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5997","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160225","dc_title":"FW: verzoek Dienst Testen aanhaking initiatiefnota groenlinks","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160225","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5998","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160226","dc_title":"RE: Doorst:  afstemming huisarts/GGD op de wadden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160226","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.5999","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160247","dc_title":"RE: 2e vaccinatie acute zorg medewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160247","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6000","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160274","dc_title":"FW: Vaccinatie ZZP\ufffdrs in de Kraamzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160274","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6001","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160285","dc_title":"RE: vraag over vaccinatieschema","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160285","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6002","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160286","dc_title":"Inkoophulpwijzer enkelvoudig en meervoudig inkooptraject - ZKNvaccinatieproject.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160286","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6003","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160299","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6004","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160304","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160304","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6005","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160316","dc_title":"Offerteaanvraag vaccinatieproject zorgkliniekmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160316","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6006","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160319","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160319","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6008","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160349","dc_title":"FW: RIVM persupdate","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160349","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6009","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160378","dc_title":"RE: Distributieplan restant Moderna vaccins t.b.v. Onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160378","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6010","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160381","dc_title":"RE: DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160381","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6011","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160383","dc_title":"Bijlage 2. NOV 5-11-2020 Overzicht anticiperen Corona incl IPSONRK_def.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160383","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":38,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6012","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160405","dc_title":"FW: Goedkeuring voor 3 punten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160405","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6013","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160414","dc_title":"RE: Distributieplan restant Moderna vaccins t.b.v. Onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6014","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160426","dc_title":"FW: DBC-codes voor pt met primaire immuundef.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160426","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6015","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160433","dc_title":"FW: Financi\ufffdle ondersteuning Present","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160433","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6016","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160443","dc_title":"FW: SPOED Tweede vaccinatie ziekenhuismedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160443","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6017","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160462","dc_title":"RE: belevering ihk VOICE studie URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160462","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6018","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160480","dc_title":"RE: belevering ihk VOICE studie URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160480","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6019","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160482","dc_title":"RE: 2de COVID-Vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160482","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6020","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160519","dc_title":"RE: Vaccineren uit spillage","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160519","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6021","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160522","dc_title":"RE: Fvraag: Vaccin COVID vaccin onderzoek kwetsbare groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160522","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i Wetenschappelijk beraad","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6022","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160538","dc_title":"FW: Telco Ernst Kuipers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160538","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6023","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160539","dc_title":"Nota ter beslissing 2021-01-28 12_27_10 -.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160539","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6024","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160545","dc_title":"FW: Dienstverleningsovereenkomst ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160545","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6025","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160563","dc_title":"RE: Logistiek vaccin levering voor onderzoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160563","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6026","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160565","dc_title":"RE: overig HA personeel prikken? Waar? door wie ? En met welk vaccin?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160565","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6027","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160566","dc_title":"FW: Vaccineren groepen met sterk verhoogd risico","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160566","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6028","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160576","dc_title":"FW: Werkwijze vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160576","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6029","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160578","dc_title":"FW: VTC ER 25-26/2 - concept-verklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160578","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6030","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160590","dc_title":"FW: woordvoering export autorisatie vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160590","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6031","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160594","dc_title":"FW: woordvoering export autorisatie vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160594","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6033","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160638","dc_title":"RE: Vaccinatieregistratie kaartjes voor huisartsvaccinatie in de ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6034","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160639","dc_title":"Antw: Definitieve aantallen voor de huisartsen vaccinatie (Moderna)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160639","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6035","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160649","dc_title":"RE: Schriftelijke Curestaf 22 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160649","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6036","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160657","dc_title":"WI NL 7-5-020-XX - RIVM COVID-19 - Inbound Moderna Vaccin - v1.0.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160657","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6037","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160663","dc_title":"Email Eramus oppakken inzake tekort vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160663","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6038","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160668","dc_title":"RE: alarmerend bericht bijwerkingen AstraZeneca","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160668","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6039","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160672","dc_title":"RE: microplanning SNPG bestellen Zeeland en Limburg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160672","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6040","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160678","dc_title":"RE: keuze voor regio's huisartsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6041","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160701","dc_title":"Project opzet Vaccinatie Statia versie 1.1.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160701","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":40,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6042","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160712","dc_title":"RE: Doorst:  AZ maart","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160712","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6043","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160720","dc_title":"RE: IGJoverleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160720","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6044","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160738","dc_title":"RE: wat vanmiddag gebeurde","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160738","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6046","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160785","dc_title":"Invoice Saba - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160785","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6047","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160795","dc_title":"Invoice Sint Eustatius - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160795","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6048","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160800","dc_title":"Instructies ontvangst Moderna vaccin.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160800","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6049","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160803","dc_title":"Waardebrief PBMs CUR vlucht week 16-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160803","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6050","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160809","dc_title":"St. Eustatius.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160809","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6051","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160811","dc_title":"Saba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160811","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6052","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160815","dc_title":"vergat net 1 ding","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160815","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6053","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160818","dc_title":"RE: Bijpraat vaccinatiebewijzen in licht bespreking informele ER","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160818","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6054","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160819","dc_title":"Waardebrief PBMs EUX vlucht week 16-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160819","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6055","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160821","dc_title":"RE: Communication adopted today by the European Commission -  HERAIncubator: Anticipating together the threat of COVID-19 variants","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160821","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6056","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160825","dc_title":"Waardebrief PBMs SXM vlucht week 16-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160825","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6057","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160829","dc_title":"Waardebrief PBMs BON vlucht week 16-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160829","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6058","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160832","dc_title":"Waardebrief PBMs AUA vlucht 16-2-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160832","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6059","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160841","dc_title":"Invoice Aruba - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160841","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6060","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160853","dc_title":"Invoice Saba - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160853","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6061","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160857","dc_title":"Invoice Curacao - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160857","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6062","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160859","dc_title":"Invoice Bonaire - Week 7.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160859","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6063","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160878","dc_title":"Document 1 Ontvangstdocument.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160878","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6065","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160923","dc_title":"210215 Invulformulier HAPs Pfizer BEL.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160923","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6066","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160951","dc_title":"Extreme urgency to vote on batch VACCELERATE.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160951","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6067","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160988","dc_title":"RE: Aanscherping communicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1160988","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6069","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1160994","dc_title":"RE: Agenda koepeloverleg 02/02","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1160994","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6071","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161042","dc_title":"4 ApplicationReport_AG_(Nasal sample)_PST_signed_SDB.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161042","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6072","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161057","dc_title":"Alliade VTGM Instructie Pfizer Covid-19 vaccin - Zero-Residual spuiten vs5.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161057","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":43,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6073","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161060","dc_title":"Deltaplan beschikbaarheid hulpmiddelen voor de zorg 2.0 2020-10-11.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161060","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6074","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161062","dc_title":"RE: Terugkoppeling GR vergadering ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161062","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6075","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161063","dc_title":"EC - Questions production capacity and bottlenecks.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161063","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6076","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161073","dc_title":"FW: overleg PG/GMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161073","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6078","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161081","dc_title":"FW: overleg PG/GMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161081","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6079","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161097","dc_title":"Instructie tbv uitvoeringsvo 2021/111 COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161097","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6081","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161128","dc_title":"jaarplan dienst testen 2021 08022021 schone versie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161128","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6083","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161145","dc_title":"RE: HERA Incubator appreciatie - svp check uiterlijk 17 uur.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161145","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6084","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161170","dc_title":"ROAZ huisartsen moderna 2e levering feb 2021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161170","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6085","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161180","dc_title":"Vaccines COVID vaccin onderzoek per ziekenhuis.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161180","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6086","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161207","dc_title":"Gescand vanaf een multifunctionele printer van Xerox.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161207","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6088","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161217","dc_title":"Laatste check bij ok dan zet ik de mail door AMI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161217","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6089","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161224","dc_title":"20210205110534.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161224","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6090","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161230","dc_title":"Procesbeschrijving t.b.v. convenant.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161230","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6091","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161252","dc_title":"Mail aan Robert de Groot en Anita van de Ende: RolverdelingStuurgroep Vaccins en Coreper","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161252","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6092","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161255","dc_title":"FW: LTT der Kommisson zu Transparenzverordnung","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161255","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6093","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161264","dc_title":"RE: nota + spreektekst 1 maart VTC EU health ministers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161264","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6094","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161291","dc_title":"OESO initiatief inzake reizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161291","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6096","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161310","dc_title":"Mertens memo CRP-I - 9 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161310","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6098","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161315","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161315","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6099","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161320","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161320","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6100","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161322","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161322","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6101","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161325","dc_title":"FW: onderzoek gebruiksgemak spuiten en naalden COVID vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161325","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e","foi_nrPages":11,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6103","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161334","dc_title":"210211 Brief minister VWS 2e ronde adviezen IC opschaling.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161334","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6104","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161337","dc_title":"RE: Verzoek afspraak met de heer Gerritsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6105","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161338","dc_title":"210211 IC advies Catherina zhhs def.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161338","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6106","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161363","dc_title":"210211 IC advies RdGG.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161363","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6107","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161373","dc_title":"Netherlands vote regulation export authorisation COVID19 vaccines","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161373","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6108","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161380","dc_title":"210211 IC Advies Maasstad zkhs.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161380","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6109","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161401","dc_title":"FW: overleg met Vektis - datauitwisseling Vektis- RIVM- ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161401","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6110","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161405","dc_title":"RE: Dienstverleningsovereenkomst ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161405","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i Concept","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6111","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161409","dc_title":"Dienstverleningsovereenkomst RIVM en UMCU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161409","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6112","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161413","dc_title":"FW: Dienstverleningsovereenkomst ziekenhuisapotheken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161413","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6113","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161449","dc_title":"RE: Nota ER 25022021 v2 AR","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161449","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6114","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161457","dc_title":"FW: Sant\ufffd Group Introduction","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6115","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161474","dc_title":"RE: vraag vaccins Mexicaanse griep vs. corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161474","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6116","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161482","dc_title":"RE: Concept beslisnota 'Aanwijzing IGJ exportverbod Covidvaccins(zaaknummer: 217921)'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161482","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6117","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161520","dc_title":"Re: FW: wat is de status van validatie vriezer?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161520","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6118","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161529","dc_title":"RE: Doorst: Refrigerator validation ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161529","foi_groundsOfRefusal":"5.1.1d;5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6119","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161533","dc_title":"RE: bezoek aan priklocaties Amphia Breda en Bergen op Zoom","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161533","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6120","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161538","dc_title":"Re: Melden bijwerkingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161538","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6121","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161550","dc_title":"RE: Formulier bijwerkingen melden Lareb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161550","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6122","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161555","dc_title":"Plan Cura\ufffdao (aanvulling)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161555","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6123","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161570","dc_title":"RE: verzoek CIE extra vaccis Oostenrijk en Tsjechie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161570","foi_groundsOfRefusal":"5.1.1d;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6124","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161575","dc_title":"RE: Status uitvoeringsplan","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161575","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6125","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161588","dc_title":"RE: gewijzigde versie ER conclusies - deadline input Coreperinstructie dinsdag 16/2 11:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1161588","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6126","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161611","dc_title":"FW: Concept uitvoeringsplan (vertrouwelijk!!)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161611","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6127","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161612","dc_title":"Uitvoeringsplannen Curacao","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161612","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6128","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161615","dc_title":"Fwd: FW: Definitieve versie Persbericht vaccinatie Caribisch deel Koninkrijk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161615","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6129","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161618","dc_title":"RE: Definitieve versie Persbericht vaccinatie Caribisch deel Koninkrijk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161618","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6130","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161621","dc_title":"Re: vaccinatie registratie bewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161621","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6131","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161623","dc_title":"RE: wat is de status van validatie vriezer?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161623","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6132","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161633","dc_title":"Re: werkinstructie cold chain","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161633","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6133","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161636","dc_title":"RE: vervolg overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161636","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6134","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161641","dc_title":"Uitvoeringsplannen Aruba","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161641","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6135","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161644","dc_title":"Re: Punten mbt covid vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161644","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6136","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161665","dc_title":"RE: Shipment of first batch of Pfizer vaccine to Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161665","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6137","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161666","dc_title":"RE: Levering COVID vaccin BES CAS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161666","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6138","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161668","dc_title":"Passage Cariben vaccinatie paragraaf brief TK","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161668","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6139","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161696","dc_title":"RE: PHIRI WP8 extended REF meeting 15/02/2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161696","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2h;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6140","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161707","dc_title":"RE: Cov19 vacc Voorbereiding CvT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161707","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6141","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161723","dc_title":"RE: ServiceNow Vaccinatie Management Platform","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161723","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6142","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161729","dc_title":"RE: Verzoek afspraak met de heer Gerritsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161729","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6143","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161740","dc_title":"twee aanbiedingen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161740","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6144","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161741","dc_title":"FW: Reminder--> Deelname aan vaccinatieprogramma ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161741","foi_groundsOfRefusal":"5.1.1c;5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6145","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161744","dc_title":"Re: FW: Reminder--> Deelname aan vaccinatieprogramma  Meldingnummer: M2102 2660","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161744","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6146","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161766","dc_title":"Re: Ontvangst Pfizer vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161766","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6147","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161767","dc_title":"Instructies ontdooien","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161767","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6148","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161780","dc_title":"Operational Conclusions - IPCR Roundtable 15 February COVID-19_.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161780","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6149","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161798","dc_title":"FW: Nieuwsbrief COVID-19-vaccinatie, vragen melding bijwerking Lareb en Webinar door Gwylim","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161798","foi_groundsOfRefusal":"5.1.1d;5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6150","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161808","dc_title":"Jullie input is nodig! dashboard sociale impact corona - slidementale gezondheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161808","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6151","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161833","dc_title":"Doorst:  Bijwerkingenmelding CAS-eilanden COVID","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161833","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6152","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161835","dc_title":"FW:  COVID vaccin BES CAS -WEEK 7","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161835","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6153","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161849","dc_title":"RE: afronden van werkplan vaccinatie Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161849","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6154","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161851","dc_title":"FW: Proces inbound Pfizer vaccin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161851","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6155","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161878","dc_title":"FW: Validatie -80 graden vriezer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161878","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6156","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161879","dc_title":"RE: IOPQ TEMP ULTRA LOW FREEZER","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161879","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6157","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161880","dc_title":"ECDC_COVID-19_IPCR update_20210215.DP.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161880","foi_nrPages":17,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6158","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161882","dc_title":"RE: European Partnership on Pandemic Prepardeness ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161882","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6159","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161889","dc_title":"Re: Agenda werkgroep voor de COVID-19 vaccinatie bij immuungecompromitteerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161889","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6160","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161906","dc_title":"FW: herzien Standpunt Vaccinatie tegen COVID-19 rondom zwangerschap en kraambed ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161906","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6161","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161909","dc_title":"RE: actie lijstje taskforce covid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161909","foi_groundsOfRefusal":"5.1.1d;5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6162","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161914","dc_title":"RE: EWRS: Spain created a new selective exchange","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161914","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.2i;5.1.5;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6163","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161921","dc_title":"Notitie tbv IRF over stavaza maatschappelijk steunpakket v5.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161921","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6164","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161937","dc_title":"RE: overleg prioritering hoog risico groepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161937","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6165","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161946","dc_title":"RE: nu met bijlagen - RE: Uitnodiging en toelichting workshops 'project PGO'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161946","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6167","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161952","dc_title":"Uitnodiging en toelichting workshops 'project PGO'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161952","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6168","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161954","dc_title":"RE: Aanvraagformulier risicoacceptatie 20210225 - definitieve versie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161954","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6169","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1161969","dc_title":"RE: IB risicoanalyse CIMS 2.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1161969","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6171","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162011","dc_title":"RE: DBC-codes patienten nefrologen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162011","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6172","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162020","dc_title":"RE: Update COVID-19-vaccinatie medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162020","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6173","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162023","dc_title":"FW: Update COVID-19-vaccinatie medische hoogrisicogroepen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162023","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6174","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162025","dc_title":"RE: prioritering van hoogrisicopati\ufffdnten ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162025","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6175","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162049","dc_title":"RE: vraag formulier RL input","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162049","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6176","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162053","dc_title":"RE: feedback tekst prioritering website","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162053","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6177","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162059","dc_title":"FW: herzien Standpunt Vaccinatie tegen COVID-19 rondom zwangerschap en kraambed ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162059","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6178","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162065","dc_title":"RE: Gezondheidsraadadvies over prioritering binnen medische indicaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162065","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6179","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162068","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162068","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6180","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162069","dc_title":"Roland Driece overleg vandaag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162069","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6181","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162074","dc_title":"FW: Slides WG Immuungecompromitteerden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162074","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6182","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162078","dc_title":"RE: Datakoppeling tentatief scenario vanuit CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162078","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6183","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162095","dc_title":"RE: vaccinatiebewijs planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6184","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162096","dc_title":"concept kabinetsstandpunt vaccinatiebewijzen versie 9 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162096","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6185","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162105","dc_title":"FW: afstemming communicatie en follow up","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162105","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6186","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162106","dc_title":"RE: Directeurenoverleg/Strategiesessie (on)mogelijkheden en wenselijkheid van vastlegging covid-vrij zijn - 03/02 14.00 - 14.30 uur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162106","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6187","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162115","dc_title":"FW: Doorst:  New Product Introduction Management","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162115","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6188","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162116","dc_title":"FW: Contactgegevens Nicole","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162116","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6189","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162130","dc_title":"FW: Vaccinatiebewijs - discussie document mogelijkheid voor data aanlevering vanuit CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162130","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6190","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162133","dc_title":"DEFINITIEF.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162133","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6191","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162135","dc_title":"FW: 100.000 NPPU gratis ter beschikking voor testen  Meldingnummer:M2010 5157","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162135","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6193","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162162","dc_title":"RE: Urgente vraag voor 13:00: BRBA koppeling met CIMS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6194","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162163","dc_title":"FW: Procesplaten voor rechten van betrokkenen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162163","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6195","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162167","dc_title":"Canceled: Uitnodigingen & printproces - voor scenario 2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162167","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6197","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162193","dc_title":"RE: Vraagje over CIMS - inzage vaccinatiegegevens","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162193","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6198","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162203","dc_title":"RE: Inschatting realisatiegrootte RIVM scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162203","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6200","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162212","dc_title":"RE: Bericht via Vincent Karremans","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162212","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6201","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162214","dc_title":"FW: Korte update vaccinatiebewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162214","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6202","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162218","dc_title":"RE: Berichtenbox - vaccinatiebewijs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162218","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6203","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162219","dc_title":"RE: Dank voor de kennismaking & samenvatting actiepunten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162219","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6204","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162228","dc_title":"RE: Inschatting PDF-PKI aanbieden in clientportaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162228","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6205","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162230","dc_title":"RE: laatste opmerkingen op presentatie ter voorbereiding op sessie vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162230","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6206","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162232","dc_title":"FW: laatste opmerkingen op presentatie ter voorbereiding op sessie vanmiddag","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1162232","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6207","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162238","dc_title":"RE: Informatie website coronavaccinatie n.a.v. afstemmingsoverleginhoud  Q&A's COVID vaccinatie 2/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162238","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6208","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162239","dc_title":"RE: LNAZ opschalen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162239","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6209","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162240","dc_title":"FW: update Vaccinatiebewijs ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162240","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6210","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162241","dc_title":"RE: check op opdrachtbrief, kamerbrief en nieuwsbericht special envoyvaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162241","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6211","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162242","dc_title":"No Subject","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162242","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6212","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162245","dc_title":"RE: Stand-up ochtend schalingsvraagstuk","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162245","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6213","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162254","dc_title":"FW: vaccinatiebewijs planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162254","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6214","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162256","dc_title":"RE: Veegronde instellingen: bestellen en leveren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162256","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6215","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162259","dc_title":"FW: Nieuwsberichten en werkinstructies: vaccinatie bewoners door HAP","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162259","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6216","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162262","dc_title":"FW: Bijbestellingen organisaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162262","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6217","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162270","dc_title":"RE: ZKH - opschaling naar 2.5m","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162270","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6218","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162279","dc_title":"RE: Update Voorstel versoepeling preventieve maatregelen instellingen langdurige zorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162279","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6219","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162281","dc_title":"RBZ handel irt vaccins Covid 19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162281","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6220","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162287","dc_title":"RE: FW: briefnummer","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162287","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6221","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162291","dc_title":"RE: Antw: agenda uitnodiging en deelnemerslijst","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162291","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6222","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162293","dc_title":"FW: Vaccinatiebewijs | Aangepaste plan van aanpak en status update","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162293","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6223","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162314","dc_title":"overleg plannen ==> Vaccinatievragen CoronIT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162314","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6224","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162323","dc_title":"RE: BMC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162323","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6225","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162326","dc_title":"RE: is vaccinatie SARS COV 2 nu agendapunt BMC ?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162326","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6226","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162335","dc_title":"Tweede versie van vaccinatiebeleid & dank voor jullie input! ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162335","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6227","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162337","dc_title":"Leeswerk voor volgende week :-) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6228","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162338","dc_title":"RE: 1e versie notitie ter voorbereiding op BO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162338","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6229","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162348","dc_title":"RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162348","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6230","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162355","dc_title":"Failire Loggers.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162355","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6231","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162358","dc_title":"RE: Vaccinatiebeleid - tekstuele update nav ons overleg op 15-02 (input uiterlijk 19 feb v\ufffd\ufffdr 10u retour spv) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162358","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6232","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162367","dc_title":"20210212 overleg RIVM en IGJ over vaccineren Cariben.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162367","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6233","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162368","dc_title":"presentatie VWS 160221.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162368","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":45,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6234","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162376","dc_title":"VWS - Lijst Spuiten en naalden leveranciers 9-3-2021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162376","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6235","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162392","dc_title":"WI NL 7-5-020-44 - RIVM COVID-19 - Inbound Pfizer Vaccin (Comirnaty) - v1.0 (1).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162392","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6236","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162396","dc_title":"RE: 1e versie notitie ter voorbereiding op BO","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1162396","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6237","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162416","dc_title":"tijdlijnen comm","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162416","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6238","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162427","dc_title":"RE: Aangepaste annotatie vierlandenoverleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1162427","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6239","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162435","dc_title":"RE: overleg RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162435","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6240","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162438","dc_title":"update nertsen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162438","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6241","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162441","dc_title":"RE: Achtergrond animatievideo 'Uitzondering mondkapjesplicht'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162441","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6242","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162468","dc_title":"RE: Actiepunten Voortgangsgesprek Programma Impl. VN Verdrag rechtenpersonen met handicap","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162468","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6243","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162470","dc_title":"RE: alvast een voorzetje voor volgende week","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162470","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6244","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162471","dc_title":"RE: 210204  Taak bevoegdheid en uitvoering crisisorganisatie RIVM voor Rec_concept_v2.2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162471","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6245","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162492","dc_title":"OMT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162492","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6246","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162509","dc_title":"Doorst: the grande excel met leveringswijsheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162509","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6247","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162514","dc_title":"RE: Advies over amvb raadpleging EPD ivm corona","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162514","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6248","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162518","dc_title":"RE: HSC meeting: your replies to question IE (Deadline Friday)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162518","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6249","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162527","dc_title":"Opslag en Distributie Overeenkomst met ziekenhuisapotheek  UMCG - RIVM DEF.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162527","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6250","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162529","dc_title":"FW: Afspraak 11 febr. 13:00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162529","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6251","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162532","dc_title":"RIVM-vaccinatiecampagne.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162532","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6252","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162545","dc_title":"RE: 210204  Taak bevoegdheid en uitvoering crisisorganisatie RIVM voor Rec_concept_80%_vs 4.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162545","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162558","dc_title":"RE: 210112 Taak bevoegdheid en uitvoering crisisorganisatie RIVM voor Rec_concept_v09","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162558","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6253","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162559","dc_title":"Nieuwe opzet deel Overige taken in algemeen fiche","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162559","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6254","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162571","dc_title":"RE: overleg RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162571","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6255","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162572","dc_title":"RE: Agenda REA 23/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162572","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6256","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162575","dc_title":"RE: Agenda Stuurgroep samenwerking farmaceutische industrie enonderzoekscentra ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162575","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6257","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162577","dc_title":"RE: Antw: governance GGD GHOR - MT LCI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162577","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6258","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162585","dc_title":"RE: Agenda vaccinatie overleg MVWS 25 februari 15.45u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162585","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6259","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162611","dc_title":"20210217 Dagafronding PT.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162611","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6260","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162637","dc_title":"RE: akkoord?: geco\ufffdrdineerde factsheets voor ACC en MCC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162637","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6261","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162641","dc_title":"FW: Concept besluitenlijst DR 2 februari 2021 en vastgestelde besluitenlijst DR 26 januari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162641","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6262","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162642","dc_title":"RE: Akkoord nodig op deze offerte (ZKN vaccinatieproject)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162642","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6263","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162646","dc_title":"RE: Retour ontvangen uitnodigingen coronavaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162646","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6264","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162653","dc_title":"Standup_20210215_CONCEPT.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162653","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6265","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162680","dc_title":"COVID-19 uitvoeringsplan vaccinatie gezondheidswerkers locatie - v3.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162680","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6266","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162681","dc_title":"RE: AMI contract","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162681","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6267","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162688","dc_title":"RE: annotatie 4 landen overleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162688","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6268","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162700","dc_title":"07022021 Don Bosco.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162700","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6269","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162703","dc_title":"Strategie-Vaccinatie-COVID19_08-02-2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162703","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":17,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6270","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162705","dc_title":"07022021 TERESITA.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162705","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6271","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162707","dc_title":"07022021 JFK.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162707","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6272","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162712","dc_title":"07022021_Centro Betico Croes.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162712","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6273","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162723","dc_title":"RE: Answer to the Danish questions on Covid and Supply","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162723","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6274","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162726","dc_title":"RE: Annotatie vierlandenoverleg 9 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1162726","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6275","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162752","dc_title":"RE: AP DEF WG5 vergadering van 21 januari / format aanvraag milsteunverlening en doorlooptijd ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162752","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6276","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162759","dc_title":"RE: AP DEF WG5 vergadering van 21 januari / format aanvraag milsteunverlening en doorlooptijd ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162759","foi_groundsOfRefusal":"5.1.1d;5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6277","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162769","dc_title":"Nota ter beslissing 2021-02-15 13_31_36.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162769","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6278","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162773","dc_title":"input mail Liesbeth de Vries.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162773","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6279","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162780","dc_title":"RE: appreciatie onderzoek zorgkosten-eenzaamheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162780","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6280","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162781","dc_title":"input Wolbink uitstel na PCR positief.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162781","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6281","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162788","dc_title":"RIVM Risicoanalyserapportage bestelproces COVID-19 vaccins v0.1.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162788","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":19,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6282","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162798","dc_title":"2020211 Bespreekdocument sessie opschaling vaccinatiecampagne Q2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162798","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6283","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162799","dc_title":"RE: Appreciatie Verenigd Front","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162799","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6284","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162800","dc_title":"210215 Capaciteit uitbreiding scenarios v0.04 (002).xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162800","foi_nrPages":10,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6285","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162803","dc_title":"RE: Appreciatie Verenigd Front","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1162803","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6286","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162807","dc_title":"RE: Appreciatie Verenigd Front","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162807","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6287","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162813","dc_title":"RE: Appreciatie Verenigd Front","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162813","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6288","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162818","dc_title":"Updates from the Commission  (20210205).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162818","foi_groundsOfRefusal":"5.1.2a","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6289","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162824","dc_title":"IPCR 2021 02 08 SANTEC3+JRC_rapid antigen tests.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162824","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":18,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6291","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162832","dc_title":"Concept_20210125 MT-IDS.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162832","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6292","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162877","dc_title":"2021 febr Voorstel vervolg R&V.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162877","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6295","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162900","dc_title":"210211 Verslag van reflectie op eerste producten RV team.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162900","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6298","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162911","dc_title":"9 - iPOP DCA Overview.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162911","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6300","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162932","dc_title":"Kort verslag van het overleg Programmadirectie Nafase Covid.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162932","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6301","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162941","dc_title":"Re: webinar coronacrisis & internationale kerken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162941","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6302","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162964","dc_title":"RE: Artikel clinical severity first / second wave","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162964","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6303","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162967","dc_title":"RE: Arts voor vaccinatie - Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162967","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6304","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162978","dc_title":"RE: AZ levering en aantallen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162978","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6305","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162996","dc_title":"RE: BES CAS - FW: tool 'wanneer ben ik aan de beurt?'","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162996","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6306","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1162999","dc_title":"RE: [External] RE: Longitudinaal cohort onderzoek COVID-19 sneltest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1162999","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6307","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163019","dc_title":"RE: adviserende rol  in het beoordelen van ontheffingsaanvragen antigeentesten als zelftest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163019","foi_groundsOfRefusal":"5.1.2d;5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6308","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163067","dc_title":"Information note.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163067","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163079","dc_title":"RE: Bezoek Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163079","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163081","dc_title":"RE: Bezoek Statia","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163081","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163088","dc_title":"RE: Bijkomende kosten inzet Tempo Sint Maarten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163088","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163094","dc_title":"RE: Bijpraten Covid zaken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163094","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163099","dc_title":"RE: Bilthoven Biologicals en AstraZeneca vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163099","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163103","dc_title":"RE: Brief DK/POL/BEL/LIT/SPA aan PEC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163103","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6315","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163149","dc_title":"RE: Call with Mr Roland Driece and Ambassador Roper (Vaccines)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163149","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163158","dc_title":"RE: CoCo 8 dd 23 februari - brief VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163158","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163170","dc_title":"RE: Communicatie inzet beleidskader fase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163170","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163191","dc_title":"RE: concepttekst hulplijnen kamerbrief ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163191","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163192","dc_title":"RE: Covid vaccinaties en AMI/uitzendpersoneel URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163192","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163193","dc_title":"RE: Covid vaccinaties en AMI/uitzendpersoneel CMC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163193","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163196","dc_title":"RE: contact bij IGJ voor vragen over fill en finish locaties in NL?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163196","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163198","dc_title":"RE: COVID-19-vaccinatie: AstraZeneca-vaccin voor de CAS-landen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163198","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6323","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163203","dc_title":"RE: cross-border request regarding the need for doctors and nurses.Slowakije","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163203","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6324","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163210","dc_title":"RE: Dashboard overzicht voor gesprek met -","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163210","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6325","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163211","dc_title":"RE: Dashboard en ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163211","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6326","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163213","dc_title":"RE: TER INFO: CRP II // Concept geannoteerde agenda speciale EuropeseRaad d.d. 25 en 26 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163213","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6327","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163217","dc_title":"RE: DEBAT uitvraag | deadline maandag 09:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163217","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6328","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163219","dc_title":"RE: DEBAT uitvraag | deadline maandag 09:00","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163219","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6330","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163254","dc_title":"Operational Conclusions - IPCR Roundtable 1 February COVID-19.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163254","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6333","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163275","dc_title":"RE: DEFINITIEVE instructies Coreper II // woensdag 3 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163275","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6334","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163284","dc_title":"RE: Deltaplan Jeugd (deelplan Welzijn Jeugd) - Sociale activiteiten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6335","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163289","dc_title":"RE: Desinformatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163289","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6336","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163299","dc_title":"RE: DOC LT2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163299","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6337","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163307","dc_title":"RE: DPC ticket EM1691118 : Coronavirus COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163307","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6338","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163336","dc_title":"RE: Eigen verklaring Uitzondering mondkapjesplicht_v1.2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163336","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6339","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163337","dc_title":"RE: EHPPA - EC ACTION ON THE PRODCUTION OF VACCINE","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6340","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163347","dc_title":"RE: Europese Raad : lukt het voor 1800 te reageren?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163347","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6341","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163348","dc_title":"RE: Europese Raad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163348","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.309","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163350","dc_title":"RE: Europese Raad vanavond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163350","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6342","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163353","dc_title":"RE: Europese Raad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163353","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6343","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163357","dc_title":"RE: Europese Raad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163357","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6344","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163359","dc_title":"RE: Export authorisation of vaccines -  NL licensing authorities ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163359","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6345","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163361","dc_title":"RE: Exportautorisatieregeling COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163361","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6346","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163362","dc_title":"RE: Export authorisaties Covid vaccins - rol IGJ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163362","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6347","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163370","dc_title":"RE: exportautorisatieregeling COVID-19 vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163370","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6348","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163381","dc_title":"RE: financiering vaccinaties CAS/BES","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163381","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6349","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163383","dc_title":"RE: finetuning GA COVID deel ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163383","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6350","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163386","dc_title":"RE: flankerend beleid op leefstijl 1.0","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6351","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163400","dc_title":"RE: Fwd: PAHO subsidieaanvraag voor de NLD OTCs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163400","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6352","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163403","dc_title":"RE: Fwd: Werkbezoek dinsdag 16 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163403","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6353","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163413","dc_title":"RE: gewijzigde versie ER conclusies - deadline input Coreperinstructie dinsdag 16/2 11:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163413","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6354","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163416","dc_title":"RE: gewijzigde versie ER conclusies - deadline input Coreperinstructie dinsdag 16/2 11:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163416","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6355","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163425","dc_title":"RE: Fwd: PAHO subsidieaanvraag voor de NLD OTCs","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1163425","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6357","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163434","dc_title":"RE: graag reactie voor morgenvroeg 10.00 uur. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163434","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6358","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163445","dc_title":"st05664.en21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163445","foi_nrPages":3,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6359","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163446","dc_title":"OOS posities ter voorbereiding op ER, RBZ en RAZ februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163446","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6362","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163477","dc_title":"Instructie Taskforce Interne-markthandhaving 20210219 def..docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163477","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6364","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163512","dc_title":"RE: Grens","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1163512","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6365","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163517","dc_title":"RE: HCEU/REA notitie ER 25 februari COVID deel - graag nog check opinkortingen en vragen, deadline morgen/vrijdag 11u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163517","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6366","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163520","dc_title":"RE: HCEU/REA notitie ER 25 februari COVID deel - graag nog check opinkortingen en vragen, deadline morgen/vrijdag 11u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163520","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6367","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163523","dc_title":"RE: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163523","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6368","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163527","dc_title":"Offerte Mondneus maskers VWS-Auping 25.02.21.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163527","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.2h","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6369","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163529","dc_title":"RE: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163529","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6370","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163530","dc_title":"RE: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163530","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6371","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163535","dc_title":"RE: HERA Incubator appreciatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163535","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6372","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163552","dc_title":"RE: identificatie van kinderen - afgerond","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163552","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6373","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163565","dc_title":"RE: Ik ben zo benieuwd! Hoe loopt het vaccineren bij jullie?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163565","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6374","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163570","dc_title":"RE: ik meende van de IGJ gehoord te hebben dat jgz-ers niet ingezetgaan worden voor COVID vaccinaties omdat de JGZ doorgang moet vinden. Is datzo?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163570","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6375","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163571","dc_title":"RE: informatie over vaccinatiestrategie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163571","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6376","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163578","dc_title":"RE: inkoop FFP2-maskers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163578","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6377","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163579","dc_title":"RE: Informatie website coronavaccinatie n.a.v. afstemmingsoverleginhoud  Q&A's COVID vaccinatie 2/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163579","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6378","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163580","dc_title":"RE: inkoop FFP2-maskers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163580","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6379","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163587","dc_title":"RE: Input Ieder(in) voor coronadebat 4/2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163587","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6381","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163592","dc_title":"RE: input mail nav gesprek Illya","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6382","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163622","dc_title":"RE: Joint Procurement; juni 2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163622","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6383","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163623","dc_title":"RE: Jetten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163623","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6384","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163628","dc_title":"RE: Kamervragen vaccinaties nav uitzending nieuwsuur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163628","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6385","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163629","dc_title":"RE: kamervragen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163629","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6386","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163631","dc_title":"RE: kennismakingsgesprekken PDC-19 ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163631","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6387","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163632","dc_title":"RE: kamervragen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163632","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6389","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163646","dc_title":"RE: Let op! Deadline vervroegd: CPK-uitzetmail: Commentaar op SO ER>> deadline: vr 19 feb, 10:00 <<","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163646","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6390","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163658","dc_title":"RE: lijn beantwoording vragen Mondkapjes Valys. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163658","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6391","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163666","dc_title":"RE: Mailwisseling met Ernst over BO met cli\ufffdntenorganisaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163666","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5;buiten verzoek","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6392","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163667","dc_title":"RE: Link over effectiviteit vaccins staat online ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163667","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6393","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163683","dc_title":"RE: Meeting DG Sante - follow up email tekstje maken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163683","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6394","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163688","dc_title":"RE: Meeting DG Sante - follow up email tekstje maken","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163688","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6396","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163699","dc_title":"RE: MORGENMIDDAG van 13.15 tot 14.00 uur: overleg over flankerendbeleid ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163699","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6400","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163716","dc_title":"RE: Nadere info t.b.v. mondneusmaskers ASML en Chemistry NL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163716","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6401","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163718","dc_title":"RE: Nationaal onderwijsplan minister Slob met daarin extra inzet (enmiddelen) van de JGZ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163718","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6402","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163723","dc_title":"RE: Nieuw contactpersoon DEIA JenV","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163723","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6403","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163724","dc_title":"RE: nav vanmorgen:","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163724","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6404","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163733","dc_title":"RE: Nieuwe versie passage vaccins voor voortgangsbrief + Planning","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163733","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6405","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163736","dc_title":"RE: nieuwe poging- vragen ivm vervoer naar vaccinatielocaties","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163736","foi_groundsOfRefusal":"5.1.2e;5.1.2i;buiten verzoek","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6406","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163743","dc_title":"RE: Nota Hoekstra over impactanalyse + lessen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163743","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6407","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163777","dc_title":"RE: Onderdeel testen en traceren Kamerbrief 02/02/2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163777","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6408","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163789","dc_title":"RE: Opdrachtenbegroting Dienst Testen 2021 LCH-deel 10022021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163789","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6409","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163790","dc_title":"Re: Opdrachtenbegroting Dienst Testen 2021 LCH-deel 10022021.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163790","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6410","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163796","dc_title":"RE: Opmerking MZS op covidbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163796","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6411","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163798","dc_title":"RE: Opmerkingen feedback MZS - Deadline 12:30 - Stavaza covid 2februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1163798","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6412","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163803","dc_title":"RE: Opmerkingen feedback MZS - Deadline 12:30 - Stavaza covid 2februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163803","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6413","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163809","dc_title":"RE: Overeenkomst AMI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163809","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6414","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163812","dc_title":"RE: Overzicht covid (gerelateerde) dossiers (graag donderdag reactie) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163812","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6415","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163815","dc_title":"RE: Overzicht covid (gerelateerde) dossiers (graag donderdag reactie) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163815","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6416","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163817","dc_title":"RE: Overzicht covid (gerelateerde) dossiers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163817","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6417","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163818","dc_title":"RE: Overzicht covid (gerelateerde) dossiers (graag donderdag reactie) ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163818","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6418","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163837","dc_title":"RE: plan herstelzorg / Steunpakket sociaal en mentaal welzijn enleefstijl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163837","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6419","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163853","dc_title":"RE: positie gezant vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163853","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6420","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163871","dc_title":"RE: processtuk voor DOC 10 feb over vaccinatiebewijzen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163871","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6421","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163873","dc_title":"RE: Proposal Feedback","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163873","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6422","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163877","dc_title":"RE: QA mantelzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163877","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6423","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163880","dc_title":"RE: Question re. export authorisation - URGENT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163880","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6424","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163882","dc_title":"RE: QA voor coronadebat morgen?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163882","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6425","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163888","dc_title":"RE: reactie op uw aanmelding vaccinatie zorgmedewerkers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163888","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6426","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163889","dc_title":"RE: RBZ handel irt vaccins Covid 19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163889","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6427","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163899","dc_title":"RE: Reminder gezamenlijke factsheet: deadline vandaag 15.30uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163899","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6428","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163913","dc_title":"RE: RvC 25 februari AOB TF industrial scale-up of COVID-19 vaccines ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163913","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6429","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163916","dc_title":"RE: Samenvatting Kamerbrief 23022021 stavaza COVID","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1163916","foi_groundsOfRefusal":"5.1.2e;buiten verzoek","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6430","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163917","dc_title":"RE: Safeguarding against falsified COVID-19 vaccines - MOH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163917","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6431","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163918","dc_title":"RE: Shipment Mold Soma AWB 112-84738673","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163918","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6432","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163921","dc_title":"RE: signaal Per Saldo irt zorgbonus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163921","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6433","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163927","dc_title":"RE: Special EUCO 25-26/2/21: ADA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163927","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6434","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163945","dc_title":"RE: Stroomschema afstemmen maatwerk voor CIE voorstellen_VWS tweaks","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6435","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163948","dc_title":"RE: Steunpakket sociaal en mentaal welzijn en leefstijl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163948","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6436","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163954","dc_title":"RE: Stroomschema afstemmen maatwerk voor CIE voorstellen_VWS tweaks","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163954","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6437","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163977","dc_title":"RE: Suriname","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163977","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6438","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163980","dc_title":"RE: SVZ hulplijnen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163980","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6439","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163983","dc_title":"RE: Taken vaccinatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163983","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6440","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163989","dc_title":"RE: Tekst toezegging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163989","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6441","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163992","dc_title":"RE: Ter info: Animatie uitzondering mondkapjes","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163992","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6442","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1163999","dc_title":"RE: TER INFO: CRP II // Concept geannoteerde agenda speciale EuropeseRaad d.d. 25 en 26 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1163999","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6443","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164001","dc_title":"RE: Ter info: Vaccinatiestrategie / medische indicatie / Nieuwsuur ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164001","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6444","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164035","dc_title":"RE: Terugkoppeling REA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164035","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6445","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164041","dc_title":"RE: TKN Vaccin alinea SvdU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164041","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6446","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164052","dc_title":"RE: Uitgangspunten beleidskader fase 3","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164052","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6447","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164053","dc_title":"Re: Uiteenzetting mbt Productie.NL  inzake acocuntantscontrole LCH","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164053","foi_groundsOfRefusal":"5.1.1c;5.1.2a;5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6448","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164064","dc_title":"RE: uitnodiging BO Minister De Jonge/cli\ufffdntenorganisaties/Gezondheidsraad op dinsdagmiddag 2 maart om 16.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164064","foi_groundsOfRefusal":"5.1.2e;5.1.2h;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6449","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164069","dc_title":"RE: Uitvraag FFP2 medische mondmaskers, in Nederland geproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164069","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6450","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164073","dc_title":"RE: Uitvraag BO 25 februari  en Verslag BO PG-CIb 16 november 2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164073","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6451","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164074","dc_title":"RE: Uitvraag FFP2 medische mondmaskers, in Nederland geproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164074","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6452","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164075","dc_title":"RE: Uitvraag FFP2 medische mondmaskers, in Nederland geproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164075","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6453","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164082","dc_title":"RE: Uitvraag FFP2 medische mondmaskers, in Nederland geproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1164082","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6454","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164094","dc_title":"RE: Uitvraag FFP2 medische mondmaskers, in Nederland geproduceerd","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164094","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6455","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164105","dc_title":"RE: Update CRP II punt 29 COVID-19 EU coordination - vaccines","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164105","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6456","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164106","dc_title":"RE: Uitzetmail COVID deel SO RAZ en ER - deadline woensdag 17/210:30u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164106","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6457","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164116","dc_title":"RE: URGENT: Vaccination","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164116","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6458","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164119","dc_title":"RE: Update vaccinatiestrategie 5 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164119","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6459","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164130","dc_title":"RE: Vaccin Gezant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164130","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6460","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164131","dc_title":"RE: Vaccin Gezant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164131","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6461","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164134","dc_title":"RE: Vaccinatie AMI","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164134","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6462","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164137","dc_title":"RE: vaccinatie zorgmedewerkers wijkverpleging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164137","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6463","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164145","dc_title":"RE: vaccinatie zorgmedewerkers wijkverpleging","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164145","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6464","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164153","dc_title":"RE: Verklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164153","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6465","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164156","dc_title":"RE: Vergaderstukken 16 feb - Kennisplatform Preventie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164156","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6466","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164161","dc_title":"RE: Verlenging Tijdelijke wet maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164161","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6467","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164162","dc_title":"RE: Versie 0.7. afwegingskader VVT","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164162","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6468","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164169","dc_title":"RE: Versie 4 stand van zakenbrief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164169","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6469","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164176","dc_title":"RE: verslag startgesprek vaccin gezant","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164176","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6470","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164187","dc_title":"RE: Versnelde aanbestedingsprocedure - richtsnoeren Europese Commissie Covid19-crisis veroorzaakte noodsituatie ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164187","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6471","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164201","dc_title":"RE: Vervoer Rode Kruis (niet begeleid vervoer)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164201","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6472","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164211","dc_title":"RE: Verzoek agendapunten voor PO IZ en PG ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164211","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6473","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164214","dc_title":"RE: Vervolg vaccinatie BW","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164214","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6474","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164216","dc_title":"FW: verzoek CIE extra vaccis Oostenrijk en Tsjechie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164216","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6475","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164218","dc_title":"RE: Verzoek om bestuurlijk overleg ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164218","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6476","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164231","dc_title":"RE: VN - Veiligheidsraad - COVID - eerlijke toegang tot vaccins: \"Noone is safe until we are all safe\"","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164231","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6477","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164234","dc_title":"RE: VNVR covid resolutie - graag instructie voor co-sponsoring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164234","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6478","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164235","dc_title":"RE: Volgorde vaccinatie zorgmedewerkers | Vaccinatie tegen hetcoronavirus | Rijksoverheid.nl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164235","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6479","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164241","dc_title":"RE: voor MT: verzoek om bestuurlijk overleg ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164241","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6480","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164244","dc_title":"RE: voor dagstart. RE: Agenda Co\ufffdrdinatorenoverleg Landen 17 feb + uitvraag stand van zaken Voorwaarden liquiditeitssteun","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164244","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6481","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164248","dc_title":"RE: voorstel duiding cijfers BTC/DOC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164248","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6482","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164277","dc_title":"RE: Voorzet IPCR maandag 22 feb. a.s.","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164277","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6483","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164289","dc_title":"RE: Vraag ANP over exporttoets EU","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164289","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6485","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164308","dc_title":"RE: Vraag over vaccin groep 1","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164308","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6487","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164322","dc_title":"RE: Vragen omtrent Covid-19 Statia ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164322","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.311","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164331","dc_title":"checkvraag nav OMT-advies RE: Advies of Maatregel?","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164331","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6488","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164337","dc_title":"RE: Vragen/opmerkingen COVID deel SO RAZ en ER - deadline vandaag 12u","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6489","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164348","dc_title":"RE: VTC ER 25-26/2 - concept-verklaring","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164348","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6491","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164372","dc_title":"RE: woordvoering export autorisatie vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1164372","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.310","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164374","dc_title":"RE: woordvoering export autorisatie vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164374","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6492","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164379","dc_title":"RE: woordvoering export autorisatie vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164379","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6493","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164386","dc_title":"RE: Zaak aan uw werkvoorraad toegevoegd. Betreft VraaggesprekNederland na de crisis (minVWS).","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6494","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164388","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164388","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6495","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164389","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164389","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6497","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164395","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164395","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6498","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164396","dc_title":"RE: ZJCN vervolgvragen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164396","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6499","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164401","dc_title":"RE: Zorg voor de Jeugd en corona: agenda overleg 18 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164401","foi_groundsOfRefusal":"5.1.2e;5.1.5;buiten verzoek","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6500","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164416","dc_title":"RE: [CONFIDENTIAL] AstraZeneca - Delivery this week (Dispatch 17/02)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164416","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6501","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164419","dc_title":"RE: [UITVRAAG] Annotatie DOC-19 10 feb: deadline wo 14:00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164419","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6502","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164454","dc_title":"Stuurgroep Samenwering farmaceutische industrie 2 maart 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164454","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6503","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164459","dc_title":"FW: toezegging scenario's ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164459","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6504","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164487","dc_title":"RE: ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164487","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6505","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164511","dc_title":"Terugkoppeling HSC","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164511","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6506","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164513","dc_title":"Terugkoppeling overleg CBG - RIVM - IGJ - VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164513","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6507","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164518","dc_title":"Testen ter bescherming van mensen die niet beschermd kunnen worden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164518","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6509","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164554","dc_title":"vaccinatiebereidheid 90-plussers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164554","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6510","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164556","dc_title":"RE: voorstel woordvoering voor vaccinatie dagbestedinggehandicaptenzorg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164556","foi_groundsOfRefusal":"5.1.2e;5.1.2i Concept","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6511","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164557","dc_title":"FW: vraag inzake vaccinatie medewerkers orthopedische hulpmiddelensector","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164557","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6515","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164652","dc_title":"IRHP instructie vrijwaringscomite exportautorisatieregeling covid-19vaccins Rev2.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164652","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6516","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164660","dc_title":"Presentatie Stavaza kernteam LNAZ.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1164660","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6517","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164675","dc_title":"Geachte mevrouw Smitsman.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164675","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6518","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164678","dc_title":"GMT input schriftelijke curestaf 23 november 2020","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164678","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6519","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164729","dc_title":"Nota ter beslissing 2020-10-20 9_01_07.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164729","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6520","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164739","dc_title":"RE: verzoek CIE extra vaccis Oostenrijk en Tsjechie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164739","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6521","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164741","dc_title":"RE: verzoek CIE extra vaccis Oostenrijk en Tsjechie en Slowakije","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164741","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6522","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164774","dc_title":"tekst tb 242 nav ouderen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164774","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6523","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164795","dc_title":"20210210 Gespreksnotitie SXM.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164795","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6525","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164808","dc_title":"RE: vragen Vervoersprotocol","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164808","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6526","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164809","dc_title":"Vaccins NL - EU.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164809","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":13,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6527","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164810","dc_title":"COREPER 19022021  EU sharing mechanisme vaccins derde landen.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164810","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6528","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164814","dc_title":"Vaccins NL - EU - Summary en Acties.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164814","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6529","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164831","dc_title":"Taken vaccinatie.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164831","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6530","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164844","dc_title":"Voorstel DPI - Duurzaam testlandschap voor GGD'en en laboratoria -D3124.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164844","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":16,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6531","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164876","dc_title":"Update CRP II punt 29 COVID-19 EU coordination - vaccines.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164876","foi_groundsOfRefusal":"5.1.1c","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6532","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164913","dc_title":"sn00002.en21.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164913","foi_nrPages":6,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6533","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164926","dc_title":"Ter info: Totaalaantallen te vaccineren personen BW intramuraal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164926","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6534","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164944","dc_title":"FFP2/3M","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164944","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6535","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164952","dc_title":"FW: nieuwsbericht bes en cas eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164952","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6536","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164958","dc_title":"FW: Sneak preview brief initiatief effectieve mondmaskers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1164958","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6537","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164967","dc_title":"FW: Vraag Iederin","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164967","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6538","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164971","dc_title":"Nldse producten FFP2 maskers. ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164971","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6539","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164989","dc_title":"RE: Annotatie gezaghebbersoverleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164989","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6540","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164990","dc_title":"RE: beschikbare testcapaciteit","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164990","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6541","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1164991","dc_title":"RE: CONCEPT: FW: Overleg Bonaire - VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1164991","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6542","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165013","dc_title":"RE: Nota FFP2  versie 1.2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165013","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6543","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165015","dc_title":"Re: opdracht TOMi","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165015","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6544","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165022","dc_title":"Re: PERSVRAGEN - Tros Radar - mensen met een medische indicatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165022","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6545","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165027","dc_title":"RE: overleg plannen over differentiatie/maatwerk voorinreismaatregelen Bonaire","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165027","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6546","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165034","dc_title":"RE: Signaal Per Saldo toestemmingsverklaring ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165034","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6547","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165041","dc_title":"RE: Signaal Per Saldo toestemmingsverklaring ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165041","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6548","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165045","dc_title":"RE: Sneak preview brief initiatief effectieve mondmaskers","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165045","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6549","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165049","dc_title":"RE: Support NPPU evaluatie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165049","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6550","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165062","dc_title":"RE: Voorzet stavaza brief 23/2 mbt motie Dijkhoff","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165062","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6551","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165070","dc_title":"RE: vraag om advies en update export vaccins","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165070","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6552","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165072","dc_title":"RE: Vraag over planning LAMP en ademtest","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165072","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6553","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165079","dc_title":"RE: Wijziging ministeriele regeling - deadline VANDAAG COB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165079","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6554","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165086","dc_title":"RE: WMO ondersteuning versus WMO-huishoudelijke julp","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165086","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6555","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165087","dc_title":"RE: Wijziging ministeriele regeling - deadline VANDAAG COB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165087","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6556","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165095","dc_title":"RE: Brief mbt uitwerking motie Dijkhoff - OCW/Sport/EZK/NCTV ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1165095","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6557","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165116","dc_title":"Afspraken nav overleg BON - RIVM - VWS","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165116","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6558","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165117","dc_title":"Annotatie bij Re Kabinet op initiatiefnota Tijdelijketestsamenleving.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165117","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6559","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165135","dc_title":"RE: Proposal Feedback","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165135","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6560","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165141","dc_title":"RE: Graag reactie op voorstellen lessons learned covid enweerbaarheid vanuit whole of gov approach Navo: deadline 4 maart! ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165141","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6561","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165144","dc_title":"RE: Verzoek tot meelezen van de concept kabinetsbrief over devoortgang toezicht op het gebruik van algoritmen door de overheid","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165144","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6562","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165155","dc_title":"RE: concept fiche vaccinatieplicht kinderopvang","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165155","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6563","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165160","dc_title":"072020_St.Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165160","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6564","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165162","dc_title":"082020_St.Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165162","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6565","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165164","dc_title":"072020A_Aruba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165164","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6566","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165166","dc_title":"082020A_Aruba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165166","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6567","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165168","dc_title":"042020A_Aruba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165168","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6568","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165170","dc_title":"052020_St.Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165170","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6569","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165172","dc_title":"052020A_Aruba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165172","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6570","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165174","dc_title":"062020_St.Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165174","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6571","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165176","dc_title":"042020_St.Maarten.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165176","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6572","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165178","dc_title":"062020A_Aruba.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165178","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6573","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165180","dc_title":"042020C_Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165180","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6574","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165182","dc_title":"052020C_Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165182","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6575","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165184","dc_title":"062020C_Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165184","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6576","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165187","dc_title":"082020C_Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165187","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6577","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165189","dc_title":"072020C_Curacao.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165189","foi_groundsOfRefusal":"5.1.1c;5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.312","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165195","dc_title":"FW: Archivering","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165195","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6578","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165199","dc_title":"RE: Info NATO medische voorraad 2de golf Covid-19  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165199","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6579","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165200","dc_title":"Concept NL standpunt NAVO Med voorraden. Stuurgroepvergadering Inkind   ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165200","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6580","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165208","dc_title":"20210301 Conceptinstructie IPCR.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165208","foi_nrPages":5,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6581","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165218","dc_title":"FW: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165218","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6582","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165223","dc_title":"FW: Hologic","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165223","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6583","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165224","dc_title":"FW: Overzicht en eenduidige lijn tav verkenningen GevolgenCoronapandemie voor Nederland","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165224","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6584","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165253","dc_title":"RE: agenda operationeel overleg + werkwijze","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165253","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6585","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165256","dc_title":"RE: AOB documents for the informal videoconference of internal marketand industry ministers on 25 February","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165256","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6586","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165261","dc_title":"RE: cross-border request regarding the need for doctors and nurses.Slowakije","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165261","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6587","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165265","dc_title":"RE: Dagelijkse update cijfers CAS-BES eilanden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165265","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6588","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165270","dc_title":"RE: Graag reactie op voorstellen lessons learned covid enweerbaarheid vanuit whole of gov approach Navo: deadline 4 maart! ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1165270","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6589","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165275","dc_title":"RE: Graag reactie op voorstellen lessons learned covid enweerbaarheid vanuit whole of gov approach Navo: deadline 4 maart! ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165275","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6590","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165276","dc_title":"RE: ik kan vandaag niet aansluiten bij regiegroep- uitvoering","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165276","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6591","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165279","dc_title":"RE: Re:Invitation to the TCM International Cooperation AgainstCOVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165279","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6592","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165284","dc_title":"RE: Samenvatting Kamerbrief 23022021 stavaza COVID","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165284","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6593","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165286","dc_title":"RE: plan herstelzorg / Steunpakket sociaal en mentaal welzijn enleefstijl","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165286","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6594","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165288","dc_title":"RE: Twee non papers (conference Europe + Pandemic Alliance/vaccins)","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165288","foi_groundsOfRefusal":"5.1.2a;5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6595","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165298","dc_title":"RE: Verslag 4 landenoverleg","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165298","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6597","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165322","dc_title":"Common approach to the Conference on the Future of Europe_08022021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165322","foi_nrPages":2,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6598","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165337","dc_title":"RE: Marcel van Raaij - opvolging telefoon gesprek: Mondkapjes die hetvirus doden en besmettingsmomenten elimineren: Biohazard prevention - Testand Compliance documents","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165337","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6599","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165338","dc_title":"RE: Marcel van Raaij - opvolging telefoon gesprek: Mondkapjes die hetvirus doden en besmettingsmomenten elimineren: Biohazard prevention - Testand Compliance documents","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165338","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6600","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165343","dc_title":"RE: Wijziging ministeriele regeling - deadline VANDAAG COB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165343","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":10,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6601","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165345","dc_title":"RE: Instructie OESO / mobiliteitsinitiatief ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165345","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6602","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165349","dc_title":"FW: Verdeling 200 miljoen flankerend beleid voor ISB","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165349","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6603","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165354","dc_title":"FW: Materiaal zojuist besproken (26-02-2021) - Fransoo/ Enders","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165354","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6604","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165355","dc_title":"RE: Materiaal zojuist besproken (26-02-2021) - Fransoo/ Enders","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165355","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6605","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165359","dc_title":"RE: Antw: Resultaten uitvraag naaldentekort","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165359","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6606","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165360","dc_title":"RE: Communicatie huisartsenbericht positieve testuitslagen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1165360","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6607","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165362","dc_title":"RE: Covid vragen  ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165362","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6608","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165372","dc_title":"RE: SPOED Re: vaccinatie (zorg)personeel IC's - zuurstof, beademing,thuisdialyse etc","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165372","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6609","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165379","dc_title":"20210525_Notitie_Prikken per vial.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165379","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6610","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165382","dc_title":"FW: versterking vaccin NL. EU en Internationaal","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165382","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6611","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165386","dc_title":"020621 Notitie besluit op uitvoering regioplannen cluster 2a .docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165386","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6612","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165405","dc_title":"RE: Definitief BR verslag vrijdag 12 februari 2021","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165405","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6613","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165406","dc_title":"RE: Restanten Veklury bij ziekenhuizen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165406","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6614","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165414","dc_title":"RE: coalitieoverleg en bwo: Plaatjes brief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165414","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6615","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165421","dc_title":"RE: Paragraaf voortgangsbrief over inschalingssystematiek, routekaarten exitstrategie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165421","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6616","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165427","dc_title":"FW: Aanvullingen QenA's voor debat morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165427","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.313","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165430","dc_title":"FW: avondklok","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165430","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6617","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165435","dc_title":"FW: NCTV dagstart terugkoppeling | 9 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165435","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6618","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165446","dc_title":"NCTV dagstart terugkoppeling | 8 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165446","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6619","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165457","dc_title":"RE: Aanvullingen QenA's voor debat morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165457","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6620","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165466","dc_title":"RE: Epi-beeld tbv Catshuis - 19-02-2021.pptx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165466","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6621","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165484","dc_title":"RE: update maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":3,"v2":3},"foi_fileName":"VWS-WOO-17-1165484","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6622","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165523","dc_title":"RE: EK vragen deadline 13.00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165523","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6623","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165527","dc_title":"FW: Verslag - technische briefing - planbureaus","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165527","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6624","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165553","dc_title":"RE: VERTROUWELIJK Brief Veiligheidsberaad over Routekaart en Jongeren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165553","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6625","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165575","dc_title":"delen stukken met RIVM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165575","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6626","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165589","dc_title":"FW: advies voor doc tbv agendapunt noodvoorraad","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165589","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6627","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165592","dc_title":"FW: Afstemmen ijzeren voorraad PBM","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165592","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6628","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165596","dc_title":"FW: Door Scheper, E.Z.G. - 3.0 NSOB - essay Leven in de Curve -versie 30 januari 2021.pdf (gedeeld door Scheper, Eline).pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165596","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6629","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165603","dc_title":"FW: NCTV dagstart terugkoppeling | 3 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165603","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6630","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165610","dc_title":"FW: Scan van een Xerox MFA","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165610","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6631","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165611","dc_title":"FW: notulen 9 en 15 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165611","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6632","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165618","dc_title":"FW: Time artikel: Covid-19 in 2021/2022","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165618","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6633","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165619","dc_title":"FW: Vraag uit debat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165619","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6634","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165620","dc_title":"FW: update SO-vragen inzake uitstel verkiezingen - graag voor 13.00uur reactie","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165620","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6635","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165629","dc_title":"FW: ZonMW  Communicatiecampagne corona - COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165629","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6636","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165636","dc_title":"RE: Offerte aanvraag \"schrijven tekst publieke versie van tijdlijnvaccinatiestrategie\"","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165636","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6637","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165637","dc_title":"RE: 20210209 Lessons learned actiepunten.xlsx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165637","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6638","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165638","dc_title":"Nivel kortje gevolgen van coronapandemie mensen met chronische ziekte","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165638","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6639","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165640","dc_title":"NCTV dagstart terugkoppeling | 15 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165640","foi_groundsOfRefusal":"5.1.2a;5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6640","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165643","dc_title":"NCTV dagstart terugkoppeling |1 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165643","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6641","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165644","dc_title":"NCTV dagstart terugkoppeling | 2 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165644","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6642","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165645","dc_title":"NCTV dagstart terugkoppeling | 17 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165645","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6643","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165648","dc_title":"NCTV dagstart terugkoppeling | 11 februari","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165648","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6644","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165668","dc_title":"RE: beeld tbv debat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165668","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6645","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165678","dc_title":"RE: Spreeklijn v1 - tbv TB Henri","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165678","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6646","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165691","dc_title":"RE: Afspraak met LVNL met betrekking tot Vaccinatiestrategie overheiden effect op LVNL","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165691","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6647","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165705","dc_title":"RE: Binnen vs buiten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165705","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6648","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165712","dc_title":"RE: EK vraag scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165712","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6649","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165714","dc_title":"RE: cijfers avondklok / bezoekregel","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165714","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6650","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165715","dc_title":"RE: Concept PvA VWS project Biociden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165715","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6651","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165723","dc_title":"RE: Maatregelen volhouden","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165723","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6652","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165728","dc_title":"RE: Oplegnotitie rol Veiligheidsberaad witte kolom","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165728","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6653","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165733","dc_title":"RE: namen taskforce leden voor sectoren werkgevers, supermarkten","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165733","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6654","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165743","dc_title":"RE: spoedvraag vanwege hoger beroep avondklok","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165743","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6655","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165747","dc_title":"RE: Q&As Routekaart in voorbereiding op persbriefing,persconferentie, Kamerdebat ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165747","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6656","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165757","dc_title":"RE: Stand van zakenbrief COVID-19 definitief","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165757","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6657","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165762","dc_title":"RE: ter info inbreng Per Saldo, KansPlus en Ieder(in) voorcoronadebat morgen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165762","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6658","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165764","dc_title":"RE: toevoeging Henri mbt tijdspad en aangepaste zin mbt scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165764","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6659","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165773","dc_title":"RE: Vaccinatie en testen in het kader van het slechte weer ditweekend ","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165773","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6661","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165776","dc_title":"RE: update maatregelen","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165776","foi_groundsOfRefusal":"5.1.2e;5.1.2i;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6662","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165782","dc_title":"RE: Voor akkoord: redeneerlijn inleiding kamerbrief 23-2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165782","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6663","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165792","dc_title":"RE: voorbereiding 9 feb 12.30-13.00  opzet taskforce","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165792","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6664","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165797","dc_title":"RE: vraag cijfers IC en ziekenhuizen voorgaande jaren","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165797","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6665","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165827","dc_title":"RE: ZonMW  Communicatiecampagne corona - COVID-19","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165827","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6666","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165829","dc_title":"RE: [UITVRAAG] Annotatie DOC 26 feb: deadline vrijdag 11:00 uur","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165829","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6667","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165830","dc_title":"Scenario's","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165830","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6668","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165840","dc_title":"Terugkoppeling NCTV dagstart 22 feb","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165840","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":1,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6678","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165918","dc_title":"FW: Concept tekst bezoek","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165918","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6679","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165937","dc_title":"Oplegnota 2020-12-17 15_50_43.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165937","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6680","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165942","dc_title":"210106 1e Brief Gedragsreflecties op scenario en maatregelen-def_TK.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165942","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6681","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165945","dc_title":"210129 3e Brief Gedragsreflecties maatregelenpakket_TK_.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165945","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":15,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6682","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1165982","dc_title":"Annotatie ACC  Brief Veiligheidsberaad over Routekaarten en Jongeren.docx","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1165982","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6683","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1166011","dc_title":"FW: Nota FFP2  versie 1.2","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1166011","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6684","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1166028","dc_title":"RE: Meerkosten 2021 Jeugdwet en Wmo: regeling, handreiking,registratieformat","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1166028","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6685","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1205040","dc_title":"FW: bestellen medisch mondkapje t.b.v. de Verkiezingen RAI.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1205040","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6686","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220003","dc_title":"CCD-RIVM-AUG-2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220003","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":81,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6687","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220004","dc_title":"CCD-SEP-RIVM-2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220004","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":80,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6688","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220005","dc_title":"CCD-OKT-RIVM-2020.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220005","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":80,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6689","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220014","dc_title":"Kopie van Totaal voor verwerking ISB.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220014","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":20,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6690","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220015","dc_title":"Kopie van ISB mutaties batch 2.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220015","foi_groundsOfRefusal":"5.1.2b;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6691","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220025","dc_title":"RE aanpassing planning v 17 SPOEDVRAAG.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220025","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6692","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1220026","dc_title":"RE Stuurgroep Supplychain Covid Vaccinatie GGD GHOR - RIVM.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1220026","foi_groundsOfRefusal":"5.1.2e;5.1.2h","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6693","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1225003","dc_title":"RE Bespreekversie Kamerbrief Flankerend Beleid voor 13.15 -14.00  toevoeging.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1225003","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6694","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1225004","dc_title":"RE Ter informatie ACC versie concept Kamerbrief Flankerend beleid.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1225004","foi_groundsOfRefusal":"5.1.2b;5.1.2e;5.1.2i;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6695","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1225005","dc_title":"RE Update steunpakket brief + QA.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1225005","foi_groundsOfRefusal":"5.1.2e;5.1.2i","foi_nrPages":4,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6699","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1293298","dc_title":"FW Aanvullende eisen RIVM bij verwerkersovereenkomst getekend 502599-003.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1293298","foi_groundsOfRefusal":"5.1.1c;5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.314","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1293299","dc_title":"FW Overzicht GGZ Moderna in week 9.docx.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1293299","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6700","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1293311","dc_title":"Copy of 088 678 89 00 01 tm 31 januari 2021.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1293311","foi_nrPages":1,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6701","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1293318","dc_title":"RE Voorraad update Moderna & Pfizer.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1293318","foi_groundsOfRefusal":"5.1.1c;5.1.2c;5.1.2e","foi_nrPages":8,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6702","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1293321","dc_title":"RE Vaccinatie Beschermd Wonen en GGZ - aantallen - update.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1293321","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6703","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1295003","dc_title":"RE 210216 Adresgegevens PFIZER HAP.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1295003","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6704","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1295004","dc_title":"RE 210216 Adresgegevens PFIZER HAP.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1295004","foi_groundsOfRefusal":"5.1.2e;5.1.5","foi_nrPages":7,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6706","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1295012","dc_title":"RE houdbaarheid astrazeneca vaccin na aanprikken.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1295012","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":5,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6709","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1295025","dc_title":"RE verklaring leveringen en uitleveringen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1295025","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.6710","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1295026","dc_title":"RE Doorrekening extra 10kd doses Pfizer - instellingen.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1295026","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":6,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.316","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1300021","dc_title":"20210218 Lessons learned actiepunten.xlsx.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1300021","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":28,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.317","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1300022","dc_title":"20210223 Overzicht financiele regelingen uitvoerders.xlsx.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1300022","foi_groundsOfRefusal":"5.1.2b","foi_nrPages":9,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.318","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1300023","dc_title":"Antwoorden enqu\ufffdte Q4.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1300023","foi_nrPages":95,"foi_valuation":"Openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.319","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1300024","dc_title":"ZINL Rapportage Q4 2020 aan VWS.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1300024","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":44,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.320","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1300035","dc_title":"Actie inzake transport Covid vaccins_final.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1300035","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":2,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.321","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1305013","dc_title":"RE Claims DGLZ kolom ten behoeve van de coronamand.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1305013","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":3,"foi_valuation":"Deels openbaar"},{"dc_format":"application/pdf","dc_identifier":"nl.mnre1025.2i.2022.152.doc.322","dc_source":"https://open.minvws.nl/dossier/3478791-1040904-pdo/download/VWS-WOO-17-1435003","dc_title":"Aansluiting fin - cbs.pdf","dc_type":"bijlage","foi_doc_missing":1,"foi_fairiscoreVersions":{"v1":2,"v2":2},"foi_fileName":"VWS-WOO-17-1435003","foi_groundsOfRefusal":"5.1.2e","foi_nrPages":7,"foi_valuation":"Deels openbaar"}],"foi_isWoo":"Ja","foi_nrDocuments":7044,"foi_nrPagesInDossier":22639,"foi_page_title":"Woo-verzoek en -besluit Ministerie Van Volksgezondheid, Welzijn En Sport","foi_publishedDate":"2023-10-22","foi_retrievedDate":"2024-01-12","tooiwl_type":"c_3baef532"},"resource":"nl.mnre1025.2i.2022.152"}